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ABSTRACT 
Background: Respiratory problems, both acute and chronic, remain an important cause of disease 
burden for children worldwide. Airway clearance techniques, as part of the management of these 
conditions, might influence the course of the disease thereby reducing this burden. 
Objective: This PhD thesis aimed to explore the epidemiology and management of children with 
acute respiratory diseases admitted to a paediatric hospital in Cape Town, South Africa; and to 
determine the usefulness and safety of assisted autogenic drainage in children with an acute 
(pneumonia) or chronic (cystic fibrosis) respiratory disease. In order to do this, several linked studies 
were undertaken including a retrospective folder review, two systematic reviews and two pragmatic 
randomised controlled trials.  
Descriptive retrospective folder review: 
Objectives: The objectives of this study were to identify the nature and magnitude of the problem of 
children hospitalised with lower respiratory tract infections at a tertiary paediatric hospital; and to 
investigate the role of airway clearance therapy in this context. 
Methods: A retrospective descriptive research study was conducted using routinely collected data 
related to the characteristics, management and outcomes of children admitted with acute 
respiratory disease at the primary research site over six months.  
Results: A total of 1357 folders were screened, of which 1208 were eligible for inclusion, accounting 
for 1440 hospitalisations (including readmissions) between January and June 2015. The median age 
of the included children was 7.6 months (IQR 2.8-19.0). The majority of children were hospitalised 
primarily for bronchiolitis (n=662, 46.0%), followed by pneumonia (n=525, 36.5%), unspecified lower 
respiratory tract infection (n=144, 10.0%), and other diseases (n=3, 0.2%). No primary diagnosis was 
available for 106 hospitalisations (7.4%), in whom nosocomial infection was considered likely by the 
researchers.  
Comorbidities were present in 52.6% of the patients during at least one of their hospitalisations. The 
median (IQR) duration of hospitalisation was 2.3 (1.5-5.0) days. The duration of hospitalisation was 
longest in children hospitalised for presumed nosocomial infections, followed by pneumonia. A 
longer hospital length of stay was associated with mechanical ventilation, acute comorbidity or 
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having received airway clearance therapy. The mortality rate was 0.7%, with children hospitalised for 
presumed nosocomial infections or pneumonia at higher risk for dying.  
Airway clearance therapy was given during 83 hospitalisations (5.8%). Four hospitalisations were 
excluded from this analysis as these children were included in the intervention arm of the 
pneumonia research study, which could have introduced bias in reporting standard airway clearance 
therapy practice. Vibrations were the technique most often performed (in 83.1% of the cases who 
received airway clearance therapy), followed by modified postural drainage (55.4%), 
percussions/clapping (38.6%), deep breathing exercises (25.3%), active gross motor exercises 
(20.5%), active cycle of breathing technique (13.3%), thoracic compressions (8.4%), huffing/forced 
expiratory technique (7.2%), bubble positive expiratory pressure technique (7.2%), assisted 
autogenic drainage (6.0%), oscillating positive expiratory pressure technique/flutter (3.6%), blowing 
bubbles (3.6%), and chest wall shaking (1.2%). Treatments were performed daily or bidaily for a 
median duration of 3.0 days (IQR 1.0-6.0). Children with presumed nosocomial infections or 
pneumonia, isolated bacterial organisms and chronic comorbidities were more likely to receive 
airway clearance therapy. Desaturation was reported in six children, three desaturated to levels 
between 85 and 89% and three below 85%; and one child developed lung collapse an hour post 
treatment. No other adverse events were reported.  
Conclusion: This study showed that a relatively small proportion of children received airway 
clearance therapy. The majority of children who received airway clearance therapy were hospitalised 
for pneumonia or acquired an infection while hospitalised for other disorders (presumed nosocomial 
infections. Conventional airway clearance therapy was used most often, most likely due to the young 
age of the hospitalised children, limiting the choice of airway clearance techniques. No major adverse 
events were reported, besides self-limiting desaturation in six children during various techniques; 
and lung collapse an hour post treatment, unlikely related to airway clearance therapy given the time 
delay. This novel research in a South African tertiary paediatric hospital provides a better insight in 
the standard airway clearance therapy used in children with acute respiratory disease. This study 
highlights the need for research on the use of airway clearance techniques in children with lower 
respiratory tract infections other than bronchiolitis, and specifically in children with comorbidities, 
which were highly prevalent in this population group. 
Systematic reviews: 
Two systematic reviews were conducted; one on airway clearance therapy in children hospitalised 
with pneumonia and one on autogenic drainage and assisted autogenic drainage in children with 
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cystic fibrosis; to determine current supportive evidence related to the safety and efficacy of these 
interventions. 
Pneumonia systematic review 
Methods: Pubmed, Medline, the Cochrane library, CINAHL, PEDro and Africa-wide information were 
searched for randomised controlled trials and quasi-randomised controlled trials on airway clearance 
therapy in children under the age of 18 years hospitalised with acute pneumonia. Further, the 
reference lists of relevant articles were screened, together with clinicaltrials.gov and pactr.org for 
ongoing studies. 
Results: In total, 202 articles with duplicates were identified. After removal of duplicates, 129 articles 
remained for further investigation. Seven full text articles were screened, of which two met the 
inclusion criteria of this review. The two included randomised controlled trials reported on a total of 
177 participants between 29 days and 12 years of age. One study compared standard treatment, 
consisting of antibiotic treatment, fluid therapy and oxygen therapy when needed, to standard 
treatment with supplementary airway clearance therapy; while the other study compared 
recommended non-mandatory lateral positioning, cough and diaphragmatic breathing to the use of 
conventional airway clearance therapy and positive expiratory pressure therapy. One study had an 
overall low risk of bias, while the other study had a low or unclear risk of bias. No meta-analysis could 
be performed as data could not able pooled due to the differences in study characteristics and 
outcome measures. Narrative analysis revealed no differences between the control and intervention 
group for this review’s outcome measures, however, one study reported a longer duration of 
coughing (p=0.04) and rhonchi (p=0.03) in the intervention group. 
Conclusion: Due to the limited number of included articles and different presentation of outcome 
measures, it was impossible to reject or accept airway clearance therapy as either an effective or 
harmful treatment option in children hospitalised with pneumonia.  
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Cystic fibrosis systematic review 
Methods: Pubmed, Medline, CINAHL, PEDro, the Cochrane library, Africa-Wide Information and 
clinicaltrials.gov were searched; together with the reference lists of relevant articles. Randomised 
controlled trials, quasi-randomised controlled trials and randomised cross-over trials on autogenic 
drainage and assisted autogenic drainage in children under the age of 18 years diagnosed with cystic 
fibrosis were included.  
Results: A total of 157 articles with duplicates were identified. After removal of duplicates, 126 
references were investigated. Eight abstracts were found potentially relevant and underwent full text 
review. Seven randomised cross-over trials met this review’s inclusion criteria, comparing autogenic 
drainage with another form of airway clearance therapy. No studies evaluating assisted autogenic 
drainage were eligible for inclusion. A total of 129 participants (aged four to 42 years) were 
evaluated in these studies, of which only 47 were younger than 18 years of age. Only one study 
clearly indicated separate results for the different cross-over periods of the study. Hence we were 
unable to pool the data in a meta-analysis. This systematic review revealed a weak positive influence 
of autogenic drainage compared to postural drainage in one paediatric randomised cross-over trial, 
based on one outcome measure, the Huang score. Furthermore, a tendency towards fewer hospital 
admissions during one year favouring autogenic drainage compared to postural drainage was seen. 
This randomised cross-over trial also reported a reluctance of those assigned to the autogenic 
drainage arm of the study to cross over to the control (postural drainage) intervention, suggesting 
patient preference for the former intervention. I was unable to identify any true randomised 
controlled trials evaluating autogenic drainage in the cystic fibrosis population.  
Conclusion: Although one study reported a small benefit of autogenic drainage compared to postural 
drainage; the lack of paediatric-specific randomised controlled trials, the small sample sizes included 
in the cross-over trials and the unclear risk of bias of most of the included studies made it impossible 
to determine the efficacy of autogenic drainage in children with cystic fibrosis. Implementation of 
paediatric-specific randomised controlled trials with adequate sample sizes, appropriate clinical 
outcome measures and analysis of adverse effects within this field of research is recommended. 
Conclusions arising from systematic reviews 
No high-level research studies investigating assisted autogenic drainage could be sourced for either 
systematic review, highlighting the need for well-constructed randomised controlled trials to 
evaluate the impact of this technique in children with both acute and chronic respiratory disease.  
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The impact of assisted autogenic drainage in infants and young children hospitalised with 
pneumonia: 
In response to the identified need for further evidence to support the use of assisted autogenic 
drainage in children with pneumonia, a pragmatic, single-blind, randomised controlled trial was 
performed evaluating the effects of assisted autogenic drainage as an add-on intervention to 
standard care in a convenience sample of children admitted to two tertiary hospitals in South Africa, 
with pneumonia.  
Methods: Clinically stable children hospitalised with a clinical diagnosis and/or radiological 
confirmation of community- or hospital acquired pneumonia, between the ages of one month and 
eight years, were included in the study. Exclusion criteria were: bronchiolitis; Pneumocystis jirovecii 
pneumonia; active tuberculosis; any cardiac or respiratory comorbidities; recent history (<six 
months) of pneumothorax or thoracic/abdominal surgery; increased intracranial pressure; pleural 
effusion with or without intercostal drain; chest deformities; any condition for which mobilisation 
out of bed was contraindicated; osteoporosis; very premature (≤30 weeks) birth; hospitalised for less 
than two days; and marked respiratory distress and/or hypoxia. Children removed from mechanical 
ventilation for more than four days prior to recruitment were also ineligible for the study (for 
baseline data purposes). The primary outcome was duration of hospitalisation expressed in days. 
Results: A total of 896 children were screened for inclusion in the trial. Of these, 862 children were 
excluded owing to comorbid factors listed in the exclusion criteria. Ultimately, 29 children, median 
(IQR) age 3.50 (1.47 – 9.57) months, were included in the study. There were no significant differences 
in pre-specified primary and secondary outcome measures between the intervention and control 
group at conclusion of the study. However, there was a trend towards shorter duration of 
hospitalisation in the intervention group compared to the control group on Kaplan-Meier analysis 
(p=0.06), with medium effect size (d=0.54). Further, there was a significant decrease in respiratory 
rate adjusted for age within the intervention group, from the time of recruitment to discharge. 
Although a statistically significant increase in respiratory rate was found immediately after treatment 
(from 45 to 46 bpm, p=0.03), the clinical relevance of one breath per minute is questionable and the 
values returned to baseline one hour post-intervention. Finally, this study also showed a shorter 
duration of hospitalisation for children with unknown compared to viral and bacterial aetiology in the 
intervention group.  
Conclusion: Although there was a trend towards shorter duration of hospitalisation in the 
intervention group, assisted autogenic drainage was not found to be effective for children with 
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uncomplicated pneumonia. However, the study was limited by the small sample size, owing to the 
high exclusion rate. This study is the first of its kind to prospectively investigate the use of assisted 
autogenic drainage in children with pneumonia. The study highlights the need for future research 
towards the effectiveness and efficacy of assisted autogenic drainage in children hospitalised with 
pneumonia and underlying comorbid conditions. 
The impact of assisted autogenic drainage in children with cystic fibrosis, a pilot study: 
A second pragmatic, single-blind, randomised controlled pilot study was performed evaluating the 
feasibility of a randomised controlled trial on the effects of assisted autogenic drainage compared to 
standard airway clearance therapy. A convenience sample of children with cystic fibrosis, attending 
the outpatient clinic at a tertiary paediatric hospital in Cape Town, South Africa, were enrolled.  
Methods: Children between the age of one and eight years of age, with a proven diagnosis of cystic 
fibrosis, confirmed by sweat testing or genotype analysis, were eligible for the study. Children were 
excluded if they were awaiting lung transplantation, had severe scoliosis or kyphosis, osteoporosis, 
recent pneumothorax, thoracic or abdominal surgery in the preceding six months, emphysema or 
active sarcoidosis, very prematurely born less than 30 weeks of gestation, on TB medication, 
uncontrolled/untreated asthma, or known to be non-compliant to physiotherapy treatment prior to 
recruitment. The primary outcome measures were number of hospitalisations and number of 
pulmonary exacerbations during the one year study. 
Results: A total of 37 children were screened for inclusion, of which 16 were eligible and were 
enrolled in the study (median age 5.75 years, IQR 4.27-6.28). No significant between-group 
differences were found for a number of primary and secondary outcome measures, however the 
number of exacerbations during one year revealed a medium effect size (d=0.55) and the number of 
days receiving antibiotic therapy over one year revealed a small to medium effect size (d=0.48) in 
favour of the intervention group. Within the intervention group, trends towards improvement in 
cystic fibrosis clinical score (subjective subtotal and total scores); and health related quality of life 
visual analogue scale were observed, with large effect sizes (d= 1.07, d= 0.87, and d= 0.86 
respectively). Adherence to bidaily therapy was generally poor during the study period and none of 
the participants in the intervention group solely performed assisted autogenic drainage as per pre-
set methodology.  
Conclusion: This pilot study revealed great insight in the applicability of the protocol for a true 
randomised controlled trial. Conclusions cannot be made regarding the effectiveness and safety of 
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assisted autogenic drainage in children with cystic fibrosis due to the lack of adherence to the 
prescribed intervention and small sample size. The very poor adherence related to airway clearance 
therapy in this population is clearly a major concern. Further research is needed to investigate the 
efficacy and effectiveness of assisted autogenic drainage in children of this population and to tackle 
issues related to treatment adherence. Assisted autogenic drainage might be a useful technique to 
add to the airway clearance ‘toolbox’ for young children with cystic fibrosis as no adverse events 
were reported and a small to medium effect size for number of exacerbations and days on antibiotic 
therapy was found, benefiting the intervention group. This is the first controlled clinical study on the 
use of assisted autogenic drainage in children with cystic fibrosis. 
Conclusion:  
This thesis is a stepping stone, which will add to the currently small body of knowledge on the use of 
assisted autogenic drainage in children with acute and chronic respiratory conditions. Owing to the 
small sample sizes included in the studies presented in this thesis, no definite conclusions can be 
made regarding the effectiveness and safety of assisted autogenic drainage in children with either 
pneumonia or cystic fibrosis. Therefore, assisted autogenic drainage cannot currently be 
recommended as standard clinical practice in children with either of these conditions.  
It is recommended that more research needs to be conducted using larger sample sizes in the same 
population groups, as small benefits of assisted autogenic drainage were noted. Multi-site studies are 
recommended to increase sample size. In children hospitalised with pneumonia a trend towards 
shorter duration of hospitalisations with a medium effect size was observed, whilst in children with 
cystic fibrosis, there was a small to medium effect size in reduced number of exacerbations and days 
on antibiotic treatment in the intervention group. No adverse events or complications were 
reported, suggesting safety of this technique. Research investigating the use of assisted autogenic 
drainage in children hospitalised with pneumonia with underlying comorbid conditions is also 
warranted.  
Notwithstanding the limitations of these studies, the results of this thesis are novel, and will 
contribute to the global body of knowledge in improving our understanding of the utility of different 
airway clearance techniques in young children with acute or chronic pulmonary disease. 
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Chapter 1. INTRODUCTION AND THESIS OUTLINE 
1.1  BACKGROUND 
Respiratory problems, both acute and chronic, remain an important disease burden worldwide;1 
impacting the child, the healthcare system and the community negatively.2 Pneumonia in particular, 
an acute lower respiratory tract infection (LRTI), persists as one of the most common causes of death 
in children younger than five years of age;3–5 with an incidence rate of  0.27 per child-year in Africa, 
the highest globally.6 As children with pneumonia are hospitalised for a significantly longer period of 
time than children admitted with other LRTIs within the context of this thesis (see Chapter 5), and 
length of hospital stay determines the cost of treatment,7 these patients are at risk of increased 
financial and psychosocial cost of care, stressing the family and the health care system.  
It is important to focus on ways to reduce the burden of respiratory disease on the patient,(1) which 
will hopefully reduce the burden on the family, community and healthcare system. It is however, first 
necessary to quantify this burden, at least within an acute hospital setting. Existing epidemiological 
research in the South African context has focussed mainly on children with Human 
Immunodeficiency Virus (HIV),  and the aetiology and length of hospital stay in children admitted for 
treatment of LRTI.8–10 The guidelines for the management of children with community acquired 
pneumonia (CAP) in South Africa do not include recommendations regarding the use of airway 
clearance therapy (ACT) in this population,11 and there have been no investigations into the clinical 
application of this modality in hospitalised South African children with pneumonia. Therefore, it is 
necessary to interrogate current airway clearance practice before introducing new treatment 
modalities. 
Chronic disorders are also burdensome on the patient, their family, and the healthcare system. Cystic 
fibrosis (CF), is a relatively common inherited chronic, life-limiting, multisystem disorder affecting the 
respiratory system.12–16 The management of patients with CF relies on a multidisciplinary approach, 
including treatment for all exocrine systems in the body. This necessitates adherence to a complex 
                                                          
 
(1) 
Burden of disease= the impact of a disease, expressed as the time (in years) lost due to the morbidity and/or 
mortality of the disease. The burden of disease is expressed as disability-adjusted life-years.
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treatment regimen, consisting of a number of oral and inhaled medications (with intravenous 
therapy as required), nutritional supplementation, exercise and regular ACT.17–20  
The burden of potentially spending more than an hour per day on the management of the disorder 
may considerably reduce the quality of life of the patient and his/her family.21,22 Furthermore, these 
patients need regular follow up at a specialist CF clinic; and all these interventions come with a price, 
burdening the health care system and family finances even further.23 
ACT, as part of the management of both acute and chronic respiratory conditions, might influence 
the course of the disease and hopefully reduce the associated burden. Many airway clearance 
techniques (ACTs) have been investigated in different patient population groups and a detailed 
overview of the different ACTs will be presented in Chapter 2. However, as young children cannot 
perform the more independent modern ACTs,24 physiotherapists usually use conventional ACTs, such 
as (modified) postural drainage ((M)PD) in this age group.25 It is important to investigate the 
possibilities of using a more modern, time efficient technique in this young age group. Assisted 
autogenic drainage (AAD), has been suggested as an ACT for use in children with CF.25 This technique 
uses the principles of autogenic drainage (AD), however, it is performed by the physiotherapist or 
caregiver without cooperation or with only minimal cooperation from the child. AD and AAD 
incorporate breathing at different lung volumes to loosen, collect and evacuate secretions from the 
lungs.26,27 During AAD, these different lung volumes are achieved by applying gentle pressure on the 
child’s thorax during inspiration.28 A complete description of the technique can be found in Chapter 
2. As the efficacy of this technique has never been previously investigated, a well-designed research 
study is required. Therefore, this PhD thesis investigated the use of AAD in both an acute 
(pneumonia) and chronic (CF) respiratory condition.  
1.2 GENERAL AIM AND RESEARCH QUESTIONS OF THE THESIS 
This thesis, consisting of several studies, aimed to investigate the usefulness of ACTs, specifically 
AAD, in children with either acute pneumonia or CF.  
The specific research questions addressed in this thesis were:  
1) What is the international body of knowledge on the use of ACT for children hospitalised with 
acute pneumonia? 
2) In children hospitalised for a LRTI at a tertiary paediatric hospital in South Africa:  
- What is the patient profile of children who receive ACT compared to those who do not 
receive ACT? 
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- What is the nature and frequency of ACT?  
- What are predictive factors for receiving ACT?  
- Are adverse events reported during ACT and how frequently did they occur?  
- Can these adverse events be predicted?  
3) Is the use of AAD, as an adjunct to standard nursing care, beneficial for infants and young 
children admitted to hospital with acute, uncomplicated pneumonia? 
4) What is the international body of knowledge on the use of AD and AAD in children with CF? 
5) Is the designed research protocol feasible to identify the effect of AAD compared to other 
ACTs in the home management of children with CF?  
1.3 JUSTIFICATION 
As mentioned above, both acute and chronic respiratory disorders impose substantial burdens on 
the patients, their families and the healthcare system. ACT has shown positive effects on mucus 
clearance in children with CF; however, there is currently insufficient evidence on the use of ACT in 
children hospitalised with pneumonia.  
Damage to the airways and development of chronic lung disease (e.g. bronchiectasis) might occur if 
pneumonia is not treated appropriately. It is important to promote quick resolution of infection in 
order to prevent harmful sequelae. ACT is used in clinical practice to facilitate mucus clearance, with 
potential benefits to pulmonary function, symptoms and disease resolution. By accelerating 
resolution of the infection, duration of hospital stay might be reduced which would benefit the 
patient, family and healthcare system; as well as reducing the risk of acquiring additional nosocomial 
infections and minimising the risk of long-term sequelae. Furthermore, ACT may prevent respiratory 
complications, such as atelectasis. 
Research on the use of ACT in children with CF has shown the importance of the use of ACT as part of 
the standard management of these children. Conventional ACTs and some modern ACTs have been 
shown to be effective in older children and adults without superiority of one technique over the 
other (see Chapter 7). Research on AD in children with CF has also shown small benefits, however, 
most studies included small sample sizes and often subjective outcome measures.  
Unfortunately, in young children, physiotherapists are limited in the number of techniques available. 
AAD, a passive/assisted technique could be useful in the treatment of young children and is assumed 
to have few adverse events. However, no research has investigated the efficacy and safety of this 
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technique. Therefore it is important to provide more evidence-based information on the use of AAD 
in both acute and chronic respiratory conditions. 
1.4  RESEARCH SETTING 
The research studies conducted in this PhD thesis took place in two tertiary hospitals and an 
outpatient clinic of a tertiary hospital in South Africa. Although South Africa is classified as an upper 
middle-income country,29,30 it still faces many challenges of a developing country. The overall post-
apartheid economy has improved, but the socio-economic status of many people living in South 
Africa is still low, with a widening of the gap between rich and poor.31 The country’s healthcare 
system, based on the principles of primary health care, provides free primary care for everyone.32,33 
However, the system is divided into a public and private healthcare sector, with the private sector 
providing services to approximately 25.3% of the population.33 The public sector therefore has to 
cover the majority of the population. With 0.8 physicians per 1000 people, South African doctors are 
struggling to provide appropriate quality health care for all.32,34 Primary health care in South Africa is 
provided by local clinics. District hospitals provide the second line of health care, and finally tertiary 
hospitals provide specialist interventions and are often linked to an academic institution. 
The current studies aimed to reach as many children as possible, by targeting public tertiary hospitals 
to identify children hospitalised with pneumonia, and a multidisciplinary outpatient clinic of a tertiary 
hospital specialised in treating children with CF. 
1.5 THESIS STRUCTURE 
The research questions listed above will be addressed in nine chapters:  
A general background chapter, Chapter 2, will first focus on the development of the lungs and the 
difference in anatomy and physiology of the respiratory system between children and adults, as this 
has direct bearing on the presentation and approach to ACT in young children. As the incidence and 
impact of respiratory disease is highest in younger children,3 the focus of this thesis is mainly on this 
age group. Thereafter, airway clearance mechanisms and the different ACTs currently available for 
the management of respiratory conditions are described. 
Chapter 3 provides a background to the research on pneumonia, explaining the impact of the 
disease, the different aetiologies and underlying pathophysiology, the long term sequelae, the 
impact on health related quality of life (HRQOL) and the management of the disease, including ACT. 
5 
Chapter 4 consists of a systematic review on the use of ACTs in children with acute pneumonia. This 
chapter will therefore address the first research question of this thesis. In the previous chapter, ACT 
in this population was described; and several studies on the use ACT in children with pneumonia 
were identified. However, the majority of these studies included small sample sizes, and the study 
designs lacked rigour. This systematic review therefore aimed to synthesise randomised controlled 
trials (RCTs) to determine the effect of different ACTs compared to no physiotherapy, sham 
physiotherapy or alternative therapy in children hospitalised with acute pneumonia. 
Children with pneumonia may receive ACT in clinical practice; however, there is little documentation 
available on the aetiology of disease; prescription, frequency and nature of ACTs used; and length of 
hospital stay, in the South African context. Most importantly, there is no published data regarding 
adverse events that may be associated with ACTs in children with pneumonia. Therefore, Chapter 5 
presents a descriptive study aimed at gaining a better understanding of the role ACT plays in the 
management of children with LRTIs within a specialised tertiary hospital in the Western Cape region 
of South Africa.  
As the need for a well-designed randomised controlled trial on the use of AAD in children with 
pneumonia became clear, Chapter 6  aimed to formulate an answer to research question three, by 
establishing whether standard nursing care with additional AAD is more effective than standard 
nursing care alone, in the management of children hospitalised with community or hospital acquired 
pneumonia. 
In the following chapters, the focus shifts towards the chronic respiratory condition under 
investigation, CF. Chapter 7 provides a narrative background literature review; explaining CF and its 
impact on the body, the incidence of the disease, the impact on HRQOL and the management of the 
condition, including both medical and ACT.  
Several systematic reviews have been published comparing ACTs to no physiotherapy, and one 
specific ACT with other ACTs, however no systematic reviews have been published on the use of AD 
and AAD. The systematic review presented in Chapter 8 therefore pools the body of knowledge and 
investigates the effects of AD and AAD, compared to no physiotherapy, other types of ACTs or sham 
physiotherapy in children with CF (research question four). 
 This systematic review (Chapter 8) revealed that there was no high-level published research on the 
use of AAD in children with CF, despite this technique being increasingly used in clinical practice. 
Therefore, a pilot RCT was conducted to establish feasibility of the designed research protocol in 
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determining whether AAD is more effective than standard ACT when used as a home program in 
children with CF. This trial is described in Chapter 9. 
Finally, the concluding Chapter 10 summarises the thesis findings and provides recommendations for 
clinical practice and future research. 
An overview of the thesis structure with the different chapters is presented in Figure 1-1. 
 
Figure 1-1. Outline of thesis structure 
 
  
7 
Chapter 2. GENERAL BACKGROUND 
2.1  DEVELOPMENT OF THE LUNGS AND IMPACT OF PREMATURITY 
Lung development starts from the moment of conception, continues throughout the prenatal period 
and persists post-natally.35 Although, lungs of the foetus have a liquid production function and not a 
gas exchange function, the development of the lungs is nearly completed when the child is born at 
term.36 This is to ensure survival of the new-born baby, as the lungs need to take over the role of gas 
exchange from the placenta once the umbilical cord is cut.36,37  
After conception, the cells divide into three germinal layers: the endoderm, mesoderm and 
ectoderm.37,38 The respiratory system derives from the endodermal layer.37,38 However, innervation 
of the respiratory system originates from the ectodermal layer, whereas the muscles supporting the 
respiratory system arise from the mesoderm.37 The development of the lungs commences in the 
embryonic period with the development of the respiratory primordium.37,38 During the embryonic 
period, separation of the foregut into the trachea and the oesophagus; the two main bronchi and the 
segments of the different lung lobes (the lung buds) become visible.39  
Maturation of the lungs occurs in four different phases: 
1) In the pseudo-glandular phase, the bronchial tree to the terminal bronchiole airways are 
partially formed.37,39 In this phase, ciliated epithelial cells and goblet cells appear.37,40 At the 
same time; in the bronchial wall; bronchial glands, cartilage, and smooth muscles cells 
emerge.35–37 Further, the development of the diaphragm is complete.37  
2) In the canalicular phase, the respiratory bronchioles and alveolar ducts are formed.35,37,39 
Vascularisation of the lungs and formation of primitive alveoli or terminal saccules take 
place, which enables the gas exchange function of the lungs.35,37,39. Furthermore, type I and II 
pneumocytes begin to develop.37 Type I pneumocytes are epithelial cells, forming the inside 
lining of the terminal sacs.35,37,39 The type II pneumocytes are secretory cells, responsible for 
surfactant production.35,37,39 Surfactant is a phospholipid which lines the terminal sacs and 
reduces the surface tension.35,37,39 Immature surfactant starts to be produced by the end of 
this stage, however, it is only during the saccular stage that mature surfactant is produced.37 
3) In the saccular stage, an increase in terminal sacs appear; type I pneumocytes reduces in 
thickness, allowing for more efficient gas exchange; and surfactant production increases, 
reducing the surface tension even further.35,37,39 This is of great importance to maintain the 
structure of the small airways and alveoli, which is necessary for gas exchange.35,39 Laplace’s 
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law states that the pressure in the airways and alveoli is inversely proportional to the radius, 
when surface tension is constant.41 Reducing surface tension, by the presence of surfactant, 
will result in a lower pressure needed to maintain the airway/alveoli open, preventing 
collapse of these structures, especially in a state of low lung volumes when the radius of the 
structures will be reduced even further.41,42  
4) The final stage of lung development, the alveolar phase, commences around 32 weeks of 
gestational age.37 During this phase, alveoli are developed.37,39 Further, the trachea and 
airways continue to increase in diameter until about five years of age.36 Postnatally, the lungs 
continue to develop, with further maturation and increased number of alveoli until about the 
age of 8-11 years at which time approximately 480 million alveoli are present.37,43–45 
Prematurely born babies are at risk for developing chronic lung disease, such as respiratory distress 
syndrome or bronchopulmonary dysplasia, due to the underdevelopment of the respiratory system 
in utero.35 
Respiratory distress syndrome, also known as hyaline membrane disease, is caused by 
underproduction of surfactant in the premature lung.46 This can lead to bronchopulmonary dysplasia, 
as children with respiratory distress syndrome are often ventilated for more than 28 days after 
birth.46 Bronchopulmonary dysplasia is mainly seen in babies born younger than 30 weeks of 
gestational age.47 However, it can also be found in term born children.48 Further, in children born 
with low birth weight and/or before 33 weeks of gestational age, recurrent wheezing and asthma is 
common.47,49 Prematurely born children can display respiratory problems throughout their lifespan. 
A decrease in forced expiratory volume in one second (FEV1) and increased airway resistance has 
been reported in adolescents who were born prematurely compared to their term born peers.50 
2.2  PAEDIATRIC VERSUS ADULT ANATOMY AND PHYSIOLOGY OF THE LOWER RESPIRATORY TRACT 
AND THORAX. 
The paediatric respiratory system cannot be seen as just a small version of the adult’s system,40 as it 
differs in both anatomy and physiology. Some important structural and physiological changes occur 
throughout childhood, which are discussed in this section. 
2.2.1 Anatomical changes  
In infants, the ribs are more cartilaginous, making them more pliable and deformable.51 Ossification 
of the ribcage is only completed at the age of 25 years.40 A more horizontal positioning of the ribs is 
found in young children, compared to a more oblique position in children older than 10 years of age 
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and adults.40,51 This leads to a flatter position of the diaphragm in young children, influencing the 
diaphragm’s function (Figure 2-1).40,51 Furthermore, the diameter of the trachea is much narrower in 
infants than in adults as well being more compliant and consequently easy to compress.37,51  
 
[Reproduced with permission; this figure was published in Hicks G. The respiratory system. In: Kacmarek R, Stoller J, Heuer A, 
eds. Egan’s Fundamentals of Respiratory Care. Vol 10th ed. St. Louis: Elsevier Mosby (Copyright); 2013].
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Figure 2-1. Anatomical differences of the thorax between young children (left) and adults (right). 
 
2.2.2 Physiological changes 
These structural differences lead to changes in physiology. Due to the horizontal rib position in 
children, the rib cage expansion during inspiration is limited. This rib cage expansion, also known as 
the bucket handle motion, combined with resistance from the chest wall, which is limited in children, 
is necessary for an effective pump mechanism of the thoracic cage.40 This inefficient pump function 
contributes to the predisposition to atelectasis in new-born babies due to decreased residual lung 
volume, resulting in a decrease in oxygen reserves.40 Children compensate to overcome this 
inefficiency by increasing their respiratory rate (RR), increasing haemoglobin concentration to 
facilitate gas exchange, and increasing expiratory time by laryngeal braking.40 Another important 
difference between infants and adults is the decreased recoil capacity of the lungs in infants due to 
the reduced elastin.36 This also leads to an increased risk of developing atelectasis and problems with 
gas exchange.36 Furthermore, the decreased diameter of the trachea in infants increases the airway 
resistance, resulting in an increased risk of lower airway obstruction and atelectasis.52 Increased 
compliance of the airways due to the increased proportion of airway cartilage in infants and the 
underdevelopment of both the pores of Kohn and Lambert’s channels, resulting in poor or even 
absent collateral ventilation in infants, further increases the risk of atelectasis in infants.53,54  
Horizontally 
positioned ribs 
Incomplete 
ossification 
Less dome-
shaped 
diaphragm 
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Incomplete ossification of the ribs leads to an increase in chest wall compliance.36,40,51 This 
phenomenon, together with decreased lung compliance, influences the level of functional residual 
capacity (FRC) in infants compared to adults. As the FRC in infants is located on a lower lung volume, 
it surpasses the level of the closing capacity (the lung volume at which the small airways and alveoli 
collapse), predisposing infants to airway collapse during normal expiration and increasing the risk of 
atelectasis.54 
The horizontal position of the ribs and the increased compliance of the rib cage, results in infants 
having to rely more on their diaphragm as the major respiratory muscle, rather than the intercostal 
muscles, because the intercostal muscles have taken over the stabilising role of the thorax instead of 
functioning as inspiratory muscles.55 When intercostal muscles fail to support the rib cage, 
paradoxical breathing movement can be seen in babies and infants as the thoracic cage will move 
inwards when muscle forces are applied during inspiration.36 Further, as the muscle tone of the 
intercostal muscles during rapid eye movement sleep is decreased, chest wall retraction will increase 
for which this paradoxical breathing pattern becomes even more apparent.36,51,55 Over time, the 
chest wall becomes more rigid, therefore this breathing pattern is not observed in healthy older 
children and adults.36,40 However, infants struggle to keep up with large workloads on the respiratory 
system, as the proportion of type I and type II muscle fibres of the intercostal muscles and diaphragm 
changes throughout childhood.51,56 Prenatally, 90% of the muscles consist of type II muscle fibres. 
This amount decreases to 75% at birth and 50% in children older than two years of age.51 As type II 
fibres are fast-twitch, highly contractile and low-oxidative, they are more prone to fatigue than type I 
fibres which are slow-twitch, low contractile, high-oxidative and more fatigue-resistant.51,57 This 
predisposes new-borns and infants to diaphragm muscle fatigue, respiratory failure and 
decompensation.51,57,58 Due to the above described change in respiratory muscle function and 
physiology, and the fact that ventilation improves when infants are placed in an upright position,59 it 
could be beneficial to maintain an upright position during any airway clearance interventions in 
infants, to promote optimal diaphragm use and minimise fatigue. 
The development of the respiratory system is completed at the age of 18 years for females and 24-30 
years for males.40 Subsequently, aging has an impact on the respiratory system,60,61 but this is beyond 
the scope of this thesis.  
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2.2.3 Anatomical and physiological changes, and the impact on ACTs in infants and 
young children 
Due to the above anatomical and physiological differences between the paediatric and and adult 
respiratory system, some of the working mechanisms applied during ACTs might be irrelevant in 
young children, reducing the efficacy of the technique and limiting the number of available in this 
population. Furthermore, caution is needed when applying conventional ACT in infants due to the 
above mentioned anatomical and physiological changes. For example, percussions and vibrations 
might cause rib fractures, due to the lack of ossification of the rib cage; and airway collapse, due to 
increased pleural pressure on more compliant airways and absence of collateral ventilation.54  
2.3  AIRWAY CLEARANCE THERAPY 
Respiratory diseases are treated with disease-specific interventions, which may include 
physiotherapy using ACTs to evacuate mucus from the airways and/or to improve ventilation.62 In 
this section, normal mechanisms of airway clearance and different ACTs will be described. 
2.3.1 Airway clearance mechanisms 
2.3.1.1 Mucociliary clearance 
Mucociliary clearance (MCC) protects the lungs by clearing excessive mucus and hazardous micro-
organisms from the bronchial tree.36 The MCC apparatus consist of two layers of fluid, the periciliary 
layer and the mucus layer (Figure 2-2). The thickness of the periciliary layer is approximately the 
length of the cilia in the erect position, therefore, the cilia only penetrate the mucus layer in the 
erect position.63   
In normal MCC, the periciliary layer is watery, allowing a wave-like movement of the cilia to propel 
the mucus from peripheral lung regions towards the pharynx.64,65 The cilia start in the resting 
position, then move sideways and backwards in a recovery phase to make an effective stroke 
forwards (Figure 2-3).66 The mucus is only moved during the effective stroke phase (during which the 
cilia are fully erected),67 which propels the mucus to the pharynx where it is swallowed, often 
unnoticed. Cooperation amongst the cilia is achieved by an almost identical ciliary alignment and 
therefore a similar stroke direction.64,68 
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] 
Figure 2-2. A schematic representation of the mucociliary clearance mechanism 
  
[Reproduced with permission of the European Respiratory Society ©.  European Respiratory Journal Dec 2014, 44(6); DOI: 
10.1183/09031936.00052014]
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Black arrows represent the effective stroke phase, grey arrows represent the recovery phase. 
Figure 2-3. Schematic representation of the movement of the cilia. 
 
2.3.1.2 Shear forces 
In addition to MCC, a gas-liquid interaction between the mucus layer (fluid) and the airflow (gas) 
takes place in the airways.66 This interaction leads to shear forces being applied to the mucus layer.69 
The amount of shear is determined by the airflow velocity, with greater shear forces when air flow 
velocity is high.66,69 The diameter of the airways also has an impact on the amount of shear, because 
the same air flow will create more turbulence if the airways have a narrower diameter.70 Although 
the peripheral airways have a narrower individual diameter, the total peripheral airway diameter is 
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larger than the central airways.66 Therefore, the turbulence is greater in the central airways than in 
the peripheral airways. Shear forces are thus greater in the central airways and are one of the main 
underlying principles of forced expiration and cough.66 The volume of mucus also influences the 
airway diameter. A thicker mucus layer (as seen in patients with CF, for example) will lead to a 
narrowing of the airway diameter, leading to greater shear forces.71–73 
During relaxed breathing, shear forces are small and occur during both in- and expiration.66,70 
However, due to an increase in intrapleural pressure during expiration, the airway diameter is 
smaller during expiration, leading to an increase in velocity of airflow.70,74 Therefore, more shear 
forces are created during expiration,70 moving the mucus from peripheral to central airways.66 In 
addition, the inspired air warms up in the nasal passage and airways, therefore expanding in the 
lungs, leading to a greater expiratory flow, enhancing the shear forces from peripheral to central 
even more.66 
2.3.1.3 Equal pressure point 
Another method by which secretions are moved in the airways is squeezing of the airways. The 
pressure in the airways is determined by the pressure at the mouth and nose (atmospheric pressure) 
and the pressure in the alveoli.66,75 The elastic recoil property of the lungs determines the alveolar 
pressure during relaxed breathing, whereas the alveolar pressure during a forced expiration is 
determined by both the elastic recoil properties and pressures generated by the expiratory muscle 
forces.75,76 As long as the pressure in the alveoli and bronchi is greater than the pressure outside the 
airways (pleural pressure), the airways are able to maintain structure. However, the pressure from 
the alveoli towards the mouth decreases gradually.75 The point where the pressure in the airways 
and the pleural pressure are identical, is called the equal pressure point (EPP) (Figure 2-4).66,76 From 
this point upwards towards the mouth, the airways are dynamically compressed and mucus 
transport is elicited.75,77 The position of the EPP can be changed slightly, by influencing the lung 
volume at which the expiration takes place, influencing the elastic recoil properties of the lung.75 This 
is one of the main principles of mucus transport during forced expiration (see 2.3.2.2 forced 
expiratory technique (FET)).66 Further, compression of the airways will lead to narrowing of the 
airway diameter, increasing shear forces at the point of compression.66 
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Equal pressure point is the point where the pleural pressure (Ppl) equals the pressure in the airways (alveolar pressure (Palv), 
bronchiolar pressure (Pbr), tracheal pressure (Ptr)). Pressure outside the body, measured at the mouth equals the 
atmospheric pressure (Patm). (Self-designed by L. Corten) 
Figure 2-4. Schematic representation of the equal pressure point 
 
2.3.1.4 Cough 
Coughing is a natural airway clearance mechanism. When the glossopharyngeal and vagus nerves are 
stimulated by secretions in the central airways (especially around the carina), a cough is elicited.66 
The cough mechanism consist of three phases: a deep inspiration; glottic closure to build up 
intrapleural pressure; and finally forceful expiration with explosive glottis opening.78,79  Coughing is a 
very effective way to clear secretions in the central airways,70 however, closure of the glottis 
increases intrapleural pressure, changing the pressure on the airways significantly, influencing it EPP 
and increasing airflow,79 which might lead to airway closure during expiration. Furthermore, in 
patients with chronic obstructive lung disease, such as CF, bronchomalacia can be present, increasing 
compliance of the airways, resulting in further risk of collapse of the airways during forceful 
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expiration.70,80 Collapse of the peripheral airways reduces the efficacy of airway clearance due to air 
trapping distally from the collapse.81 
2.3.2 Airway clearance techniques 
In respiratory disease, the above described natural airway clearance mechanisms could be impaired 
due to various reasons (See Chapter 3 and Chapter 7 for the pathophysiology of respectively 
pneumonia and CF). Several ACTs have been developed to remove secretions from the lungs, by 
facilitating the natural airway clearance mechanisms. 
2.3.2.1 Conventional airway clearance techniques 
Postural drainage (PD) 
During this technique, the patient is placed in different positions, depending on the area where 
mucus is present in the lungs in order to facilitate mucus clearance from the lungs using gravity.65,82 
The technique is most useful in the central airways, where the influence of gravity is the greatest.65,82 
In the more peripheral airways, gravity alone is not enough to overcome the adhesive forces 
between mucus and the bronchial wall.82 Furthermore, tenacious secretions are unlikely to be 
drained by gravity alone, unless viscocity of secretions is reduced by mucolytics or other forms of 
ACT.54,64,83 Caution is needed when using PD, as the technique has several adverse events. The side 
lying and head-down positions have been associated with an increase in intracranial pressure, 
bronchospasm, gastro-oesophageal reflux disorder (GORD), hypoxemia, discomfort/pain, 
cardiovascular and hemodynamic instability.66,84–86 These adverse events also contribute to poor 
compliance with home PD therapy, previously advocated for people with CF.87  
During coughing and huffing (FET) in different positions, the lowest peak expiratory flow (PEF) and 
maximal expiratory pressure are reported in the head-down position and the highest in the upright 
position.88 Furthermore, FRC is lower in the head down position and supine compared to a more 
upright position (Figure 2-5).89,90 Therefore, adopting a more upright position during treatment is 
advised, particularly for young children who are more susceptible to airway collapse due to changes 
in FRC and related closing capacity, as mentioned previously.54  As a consequence of the potential 
adverse events of the head-down position, MPD was introduced, which avoids the head-down tilt 
position.91 
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Figure 2-5. Functional residual capacity in different body positions 
 
Percussion, vibration and chest wall shaking 
Percussions and/or vibrations applied either manually or mechanically to the thoracic wall are often 
added to PD treatment to loosen secretions. In the central airways vibrations and percussions may 
have an influence on the mucus transport as these are not surrounded by air containing lung tissue.93  
Contradicting results have been reported in the literature regarding the efficacy of these techniques.  
Vibrations could increase the PEF rate by increasing the pressure in the airways, and altering the 
thixotropic characteristics of mucus.94–96 However, other studies failed to identify additional effect of 
percussion or vibration to PD.97,98 Disadvantages of these techniques are bronchospasm, decreased 
arterial oxygen saturation (SaO2) level and FEV1 in patients with little expectoration. Even serious 
hypoxemia can be caused.99,100  Rib fractures and periosteal reactions may occur in very young 
children which is a serious complication of these techniques.101–103 
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Assisted cough 
When respiratory muscles weakness, e.g. due to neuromuscular disorders (NMDs) or in ventilated 
patients, results in a weak cough, assistance might be needed for an effective cough. This can be 
done either manually or mechanically.104  
During manually assisted cough, a maximal inspiration is followed by a facilitated exhalation 
manoeuvre.105 The therapist administers pressure during the expiration phase, by placing the hands 
on the thorax (thoracic squeeze) and/or abdomen. 105–107 This manoeuvre increases the intrathoracic 
pressure and expiratory airflow, using the elastic recoil properties of the lungs and thoracic 
muscles.105,107  Caution needs to be taken when patients have osteoporosis, due to the risk of rib 
fractures.108 Particularly in children with CF, the malabsorption of fat-soluble vitamin D results in 
vitamin D deficiency, osteopenia, osteoposisis and Rickets disease placing these children at increased 
risk for rib fractures during ACT.16,109 
A newer technique for cough augmentation is mechanical in- and exsufflation. These devices apply 
different pressures to the airways; firstly a positive pressure to insufflate the lungs (imitating 
inspiration) and afterwards a negative pressure to exsufflate the lungs (imitating expiration), 
stimulating a cough.107 An increase in PEF and sniff nasal inspiratory pressure; and a decrease in end 
tidal carbon dioxide pressure was observed after use of a mechanical in-and exsufflation device.110 
Although adverse events were scarce, it is unclear whether or not these devices are safe as the 
limited literature available on this topic presented studies which were underpowered to evaluate this 
outcome measure.111 
2.3.2.2 Modern airway clearance techniques 
Forced expiration technique (FET) 
During the FET, one or two forced expirations (huffs) are performed, followed by controlled 
diaphragmatic breathing.112,113 Huffing is a manoeuvre similar to coughing but without closure of the 
glottis. Therefore, FET is considered to stabilize the airways during forced expiration so that airway 
collapse is prevented and a better airway clearance achieved.24 Based on the theory of EPP (see 
section 2.3.1.3), by performing huffs at different lung volumes, different parts of the lungs can be 
cleared.114 By inspiring to different lung volumes, different pressures are created in the airways, 
changing the EPP along the airway. Inhaling deeply before forcefully exhaling evacuates secretions 
from the central airways, by increasing pressure inside the airways, resulting in the EPP moving more 
centrally as the increased airway pressure equals the pleural pressure at a more central location. 
However, when a forced expiration at lower lung volume is performed, the EPP will move more 
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distally as the pressure in the airways is lower and equals the pleural pressure at a more distal 
level.66,112,114 Furthermore, this technique also uses the principle of applying shear forces within the 
airway through forceful expiration.66 This techniques requires active participation of the patient, 
limiting the use to cooperative older children and adults. 
Active cycle of breathing technique (ACBT) 
The active cycle of breathing technique (ACBT) consists of three components, which affect gas-liquid 
interactions: ‘breathing control’, ‘thoracic expansion exercises’ and ‘FET’. These components are 
repeated several times in a cycle.24,115 This technique manipulates the EPP to vary airflow patterns 
and promote shear forces to remove tenacious mucus.78 ACBT improves ventilation by the use of the 
interdependence principle.116 This principle assumes that alveoli are dependent on one another, as 
they share cell walls. Small pores in the alveolar walls allow for pressure redistribution across 
neighbouring alveoli.41 Therefore, ACBT allows air to be redistributed across neighbouring alveoli, 
improving ventilation.78 Further, collateral ventilation channels may be recruited to increase the 
amount of distal air behind secretions.115 Advantages of the ACBT are the ability to perform the 
technique independently in older children, no desaturation or other adverse effects have been 
reported, and no equipment is needed.117 Unfortunately, though, the patient has to be fully 
cooperative to perform this technique, therefore it is not applicable in uncooperative patients or 
infants.24 Parts of the technique can be performed in children as young as 18 months via fun, playful 
games and the complete ACBT can be taught in children from the age of four years.114  However, the 
efficacy of ACBT in young children might be reduced due to the underdevelopment of collateral 
ventilation channels, as mentioned previously.53,54 
Positive expiratory pressure (PEP) technique  
Positive pressure is created in the airways by breathing out against a resistance.24,118 The technique 
aims to improve mucus clearance by preventing dynamic airway collapse and potentially moving air 
behind the secretions through collateral ventilation, thereby influencing peripheral airway 
clearance.25,66,118,119 Benefits of PEP therapy are no desaturation during low pressure PEP and 
independent use.24 However selection of the appropriate PEP level and the application in young 
children remains unclear and is not well supported by high-level evidence.24 Patients who are 
severely ill and cannot maintain breathing control will not be able to perform this technique.120 In 
addition high pressure PEP can induce bronchospasm in patients with hyper-reactive airways.121 
Complications such as barotrauma, pneumothorax and arterial rupture may occur, especially when 
using high pressure PEP.112,122 Another disadvantage of this technique is the cost of PEP masks. Public 
health facilities in South-Africa do not have access to these masks. Only PEP valves with mouth pieces 
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are available, which are not useful in babies and infants (Prof. B. morrow. Personal communication. 
2013). In addition, children might not tolerate facemasks placed on their face,123  leading to reduced 
adherence with this technique. Furthermore, this technique also relies on the mechanism of 
collateral ventilation, which is underdeveloped in infants and young children (section 2.2.2) 
Oscillating PEP (e.g. Flutter, Acapella, Cornet, Quake) 
These devices combine PEP with airway oscillations.118 Oscillations are thought to change the 
viscoelastic characteristics of mucus so clearance is performed with less effort.124 This technique also 
uses shear forces to remove secretions from the lungs, by creating oscillatory expiratory airflow and 
preventing airway collapse using PEP.125 Advantages of these devices are the independent use in 
older children and adults.125 These techniques have the same limitations for infants and young 
children as described for PEP in the section above. 
Assisted and unassisted autogenic drainage ((A)AD) 
These techniques use breathing at three different lung volumes (Figure 2-6);26,27 and apply the 
principle of shear forces by producing optimal airflow (without forced expiration) in the small airways 
to remove secretions from peripheral to central airways, thereby theoretically preventing collapse of 
the small airways.26–28 Airflow velocity is greatest when a deep breath in is taken and forceful 
expiration is performed. However, due to the risk of airway collapse during forceful expiration, AD 
aims to alter lung volumes rather than using forced expiration to increase airflow velocity. The flow-
volume curves when using AD overlap with the flow-volume curve when performing a forced 
expiratory manouevre.70 Therefore, unforceful breathing during AD can still remove secretions from 
the airways.126 Further, the EPP theory is applied in these techniques.26 The position of the EPP can 
be changed slightly, by influencing the lung volume at which expiration takes place. Hence, lung 
volume and expiratory flow velocity are the main elements in AD and AAD. 
In preparing for the technique, it is important to clear the upper airways, to allow mucus to be 
moved from peripheral to central airways.26,28 This can be done by huffing and rinsing/blowing the 
nose.26 Afterwards, a controlled method of breathing at three different lung volumes is performed 
during AD.24,26,127 At each level of breathing, the patient is instructed to breathe in slowly through the 
nose, hold for 2-3 seconds with an open glottis and then breathe out.26,28 The preferred amount of air 
inhaled and exhaled is the patient’s functional tidal volume (which is slightly more than their normal 
tidal volume), while maintaining the required lung volume level.26,28 Expiration during this technique 
is performed in an active, but gentle way.26–28 Firstly, the secretions are ‘unstuck’ in the peripheral 
airways by breathing at a low lung volume, then secretions are ‘collected’ in the central airways by 
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breathing at mid volume and finally the secretions are 'evacuated' from the lungs by breathing at a 
high volume.24,27,28,127 Cough should be avoided during the technique, to prevent secretions from 
moving back into more peripheral airway generations.26,28 Only at the end of the session, when a 
sufficient amount of secretions has been collected in the central airways, should a cough or FET be 
used to evacuate the secretions from the airways.26,128 
 
[Reprinted from Paediatric Respiratory Reviews, 8 (1), McIlwaine M. Chest physical therapy, breathing techniques and 
exercise in children with CF, Copyright (2007), with permission from Elsevier]
114
  
 
 
AD has potential advantages as it can be independently used, no equipment is needed, it is 
applicable in different settings and in daily life, and it can be combined with MPD.24,114 In order to 
effectively perform AD, however, the patient has to be cooperative, not severely ill and some 
endurance and concentration is needed to learn and apply the technique.24,114 A training period with 
visual feedback is recommended.129  Therefore, the technique is only applicable in children over eight 
years of age.70 
In children under eight years of age or children who are not able to perform AD, AAD may be used as 
it does not require active participation.25,130AAD is a modified form of AD, which uses the same 
principles of airway clearance.28 However, as the patient cannot actively change the lung volumes 
towards the desired level, the physiotherapist manually influences the level of breathing.25,28 In 
children able to partially execute AD, the technique can be performed as an active assisted 
technique. During AAD, the child is placed in an upright position. The caregiver manually increases 
the expiratory flow velocity and prolongs expiration towards residual volume by placing the hands on 
the child’s chest and gently following the breathing of the child while lowering thoracic expansion.25 
The technique may be combined with bouncing to improve loosening of the secretions. Another 
Figure 2-6. Lung volumes during the three phases of autogenic drainage
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reason for bouncing is putting the child at ease. No GORD has been reported during this 
technique.130–132 
2.3.2.3 Equipoise in airway clearance therapy 
The above described ACTs all have advantages and disadvantages, but none of them have been 
found to be superior within the CF population.133–136 In children hospitalised for pneumonia, no 
comparison between ACTs have been reported. Although modern ACTs have not been found to be 
more effective than conventional ACTs, they might be more preferred by patients.134 
Therefore, an individualised ACT program adapted to patient’s preference is recommended, as this 
might increase therapy compliance and adherence.25 
2.3.3 Outcome measures in airway clearance therapy 
Various outcome measures are described in the literature to evaluate ACT.  
Sputum 
Although often used in research, sputum weight and volume are generally considered poor outcome 
measures, due to the addition of saliva to the expectorated sputum or swallowing of some 
secretions.137,138 In addition, daily fluctuations in sputum production influence this outcome 
measure.138,139 The use of sputum rheology could, however, be useful to assess viscoelasticity.124  
Mucus transport by tracer 
Transport rates can be determined by the use of radiolabelled particles (Teflon), radiopaque dust 
(tantalum powder) or radiolabelled aerosol tracer.138,139 Radiopaque dust is an invasive technique 
using high amounts of radiation and therefore often not used.138,139 Radiolabelled aerosol tracer is a 
reliable and sensitive technique to measure mucus clearance, however, regional clearance is difficult 
to assess with this technique, as only two-dimensional pictures are produced. Furthermore, in 
patients with severe obstruction of the airways the tracer will be unable to reach poorly ventilated 
lung regions.139 Although small amounts of radiation are used and half-life is approximately six 
hours,140 suggesting radiolabelled aerosol tracer is safe, caution is needed when repeatedly exposing 
children to radiation. Particularly children with chronic disease who are exposed to a high cumulative 
radiation dose from recurrent imaging through their lives.141 
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Transcutaneous oxygen saturation (SpO2) 
SpO2 can be measured by transcutaneous oximetry. This outcome measure is often used in clinical 
practice and research as it is easy to measure, inexpensive and can be used in acute and chronic 
conditions.137 However, the outcome measure might not be reliable, sensitive or specific when SpO2 
is lower than 83% and not be accurate enough for research due to confounding variables such as 
temperature at the measurement site and haemoglobin levels which can influence the outcome.142  
Arterial blood gas analysis 
The analysis of arterial blood gases, such as oxygen partial pressure and carbon dioxide partial 
pressure, is highly reliable and valid. The removal of secretions from the lungs and improving 
ventilation during and after ACT can result in altered arterial blood gases due to improved 
oxygenation. However, this outcome measure is invasive and therefore not recommended for day to 
day follow up of the effect of ACT.142  
Pulmonary function testing / spirometry 
Pulmonary function testing is one of the most commonly used outcome measures to evaluate the 
effect of ACTs.137 Static and dynamic lung volumes can be influenced by mucus, therefore the 
interpretation of results need to be made carefully.139 This outcome measure is neither sensitive nor 
specific for the evaluation of mucus clearance.139 Spirometry is primarily a tool to evaluate the 
secondary effects of ACT rather than an indicator of mucus clearance.143 Only residual volume 
expressed as percentage of total lung capacity (RV/TLC) is a likely indicator of mucus clearance.144 
Obstruction caused by secretions results in increased RV due to the inability to completely exhale. 
Therefore, RV/TLC is an indicator for pulmonary obstruction.145 Conventional lung function testing is 
only possible in children older than five years of age.137 However, more recent studies have shown 
the possibility of using spirometry lung function testing in children as young as three years of age.146–
148 Spirometry is recommended to be performed at every clinic visit in children with CF, to monitor 
the progression of lung disease.149 
Another pulmonary function test, multiple-breath inert gas washout, investigates FRC and ventilation 
distribution by timing the clearance of a tracer gas from the lungs.150,151 It is less frequently used to 
determine closing volume and capacity.151 This technique is useful in young children as little to no 
active cooperation is required and non-hazardous gases such as nitrogen or sulphur hexafluoride are 
used.152 A mass spectrometer is needed for gas washout analyses, however, specific devices are 
required per age range.153 Although several steps have been undertaken to improve reliability due to 
the high inter- and intra-patient and research site variability;150 validity and standardisation of this 
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outcome measure needs to be further investigated before use in clinical practice.151–153 In infants, the 
use of nitrogen is not preferred due to higher oxygen requirements during the test procedure, 
influencing breathing pattern and therefore the outcome;151,154 the availability of sulphur 
hexafluoride is also limited, resulting in increased costs.151,153 The test procedure is more time 
consuming than spirometry, and normative values still need to be established for each device.153 
Respiratory resistance can be measured by the use of the forced oscillation technique, during which 
the child breathes at tidal volume while oscillatory resistance is applied.152 This technique can also be 
conducted in young children as little to no cooperation is required.152 However, this test procedure 
can also be lengthy, particularly in infants when the child may need to be sedated.155 Although the 
forced oscillation technique is easy to perform, contradictory results regarding reliability have been 
reported. Furthermore, the usefulness of this tool as an outcome measure in infants and young 
children with CF is questionable.156 
Chest X-rays 
Chest radiograph scores could be used to investigate mucus clearance. In patients with CF, chest X-
rays scores are reproducible and can be used as part of the evaluation of patients.157 However, this 
assessment is insensitive for acute studies when subjective interpretations need to be made.137 
Radiation exposure needs to be considered, particularly for children with chronic respiratory 
diseases, where chest X-rays may be taken regularly as part of standard practice.138,141 
Hospitalisation and number of exacerbations, antibiotic treatments or days on antibiotics 
Duration of hospitalisation and number of days on antibiotics or number of exacerbations for 
children with CF could be influenced by the mucus clearance rate, as reduction of infectious 
secretions could reduce the need for health care and result in faster discharge from hospital.138,139 
The limitation of these outcome measures is the sometimes subjective criteria on which the 
outcomes may be based or measured.137 For example, the decision to discharge a patient could be 
based on a range of confounders other than simply the resolution of the primary disease, particularly 
in resource- constrained environments with high demand and limited numbers of paediatric hospital 
beds. 
Health related quality of life (HRQOL) 
Although HRQOL is not clearly defined in literature,158,159 the concept of HRQOL describes the 
perception of quality of life attributed to health status, which includes disease and disability, and the 
effect of treatment.160 Several generic and disease specific tools have been developed to assess this 
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concept. A valid and reliable tool to measure HRQOL in children is the EQ-5D-Y (Appendix 1).161 This 
tool has been found valid for acutely ill children and for the long-term evaluation of HRQOL in 
children with CF.162,163 The EQ-5D-Y has been validated and found responsive to change in the thesis’ 
research context.163 Other valid and reliable tools for evaluating HRQOL in children with acute and 
chronic diseases are the Pediatric Quality of Life Inventory,164–166 the Leicester Cough 
Questionnaire,167 the St George’s respiratory questionnaire,168 and the Cystic Fibrosis 
Questionnaire.169  
Disease severity in patients with CF 
Several tools to assess disease severity in the CF population have been described in the literature.  
The Shwachman-Kulczycki score assesses progression of chronic illness, by assessing the participant 
in four domains: general activity; radiological findings; nutrition; and physical examination. A score 
out of 25 is given for each domain, providing a total possible score of 100. The lower the score, the 
more severely affected the patient is.170 A modified version of this tool is described by Doershuk et 
al.171 Limitations of this score are the subjective items which reduce the tool’s reliability; poor 
sensitivity for mild disease severity; and categories which are intertwined.171,172 
Short-term effects of an intervention on disease severity can be measured using the Huang score. 
This tool consists of three domains: clinical evaluation, radiographic findings, and pulmonary 
function; which are assessed pre- and post-treatment. Further, results at admission and discharge 
are compared and complications are recorded.173 A modified version of this tool was developed by 
Matouk et al., however, the validity of the tool within a paediatric population has not been 
established.172 
The cystic fibrosis clinical score (CFCS) was developed to assess the patient’s current clinical status.174 
The tool consist of five subjective criteria and five objective criteria. Each criterion is given a score 
out of five, resulting in a total possible score of 50.174 The higher the score, the more severely ill the 
patient is at the time of assessment. The CFCS is an easy, low-cost tool; and correlates with FEV1 and 
forced vital capacity (FVC), for which the tool could be useful as a surrogate for spirometry in young 
children.174 This tool has been validated in a paediatric population, however, reliability of the CFCS 
needs further investigation.172,174 
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2.4  SUMMARY 
Respiratory disease can be either congenital or acquired, and the approach to the management of 
these conditions differs from adults owing to the physiological and anatomical changes with 
maturation. ACT might be a valuable addition to the medical treatment of children with different 
respiratory diseases. Several ACTs are available, of which none has been found to be superior to the 
others. Limited techniques are applicable in infants and young children, due to the risk of adverse 
events in this population and the need for active participation in most modern ACTs. A number of 
outcome measures are available to measure the effectiveness of different ACTs, however, some of 
the outcome measures were deemed unreliable or invalid. Therefore, caution is needed when 
selecting appropriate outcome measures. 
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Chapter 3. PNEUMONIA – NARRATIVE BACKGROUND LITERATURE REVIEW  
Pneumonia is an acute LRTI, characterised by painful breathing and limited oxygen intake as a result 
of fluid and suppuration packed in the alveoli.175,176 When the disease is contracted outside a hospital 
setting (within the community), it is classified as CAP.177  Infections contracted within the hospital 
setting are referred to as hospital acquired or nosocomial pneumonia.177  
Pneumonia is a global problem, as it continues to be the single leading cause of under five year 
mortality.5,178 In 2000, the United Nations set up a plan of action to reduce childhood mortality. This 
joint action plan was named Millennium Developmental Goal 4 and aimed to reduce childhood 
mortality by two thirds by 2015.178 Prevention and management of pneumonia were the major focal 
points to achieve this goal,179 however, the decline in mortality was slow and the goal was not 
achieved by 2015.179,180 Although, between 1990 and 2008, no progress towards reduction of 
childhood mortality was seen in South Africa;181,182 a clear decline in under-five mortality was 
observed after introduction of highly active anti-retroviral therapy (ARV therapy) (in 2004). However, 
the mortality rate for children younger than five years of age was still 41 deaths per 1000 live births 
in 2015, which was below the pre-set goal of fewer than 20 deaths per 1000 live births (Figure 3-1). 
The majority of childhood deaths (17%) in South Africa are still attributed to pneumonia (Figure 
3-2).183 
 
[Reprinted with permission from: A Decade of Tracking Progress for Maternal, Newborn and Child Survival. The 2015 Report. 
Geneva: UNICEF and World Health Organization; 2015. Copyright UNICEF and World Health Organization, 2015]
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Figure 3-1. Mortality rate for children younger than five years of age in South Africa between 1990 and 2015.  
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[Reprinted with permission from: A Decade of Tracking Progress for Maternal, Newborn and Child Survival. The 2015 Report. 
Geneva: UNICEF and World Health Organization; 2015. Copyright UNICEF and World Health Organization, 2015]
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Figure 3-2. Causes of death in children under five years of age in South Africa in 2015. 
 
3.1  IMPACT OF THE DISEASE: INCIDENCE AND MORTALITY 
In low-and middle- income countries, an incidence rate of 0.22 episodes per child-years has been 
described for CAP.5 Whereas hospital acquired neonatal infections occur in 20 out of 1000 live births 
in Africa,185 with 40% due to pneumonia.186 The overall incidence rate for pneumonia in Africa is 0.27 
episodes per child-years, the highest rate globally.6 
Although there has been a decrease in pneumonia-related mortality and morbidity over the past 
years;5 pneumonia remains the single leading cause of mortality in children younger than five years 
of age, with a mortality rate of 15-18%.176,187 The mortality rate is age-dependent, with the highest 
rate seen in children younger than two years of age (81% of all pneumonia deaths).6 In South Africa 
(in 2008), respiratory infections led to 88 000 deaths in children aged 0 to 14 years, of which the 
majority was due to LRTIs.188 In 2015, pneumonia (excluding TB) is still the second most common 
cause of death in children younger than the age of 14 years in South Africa, preceeded by intestinal 
infections.189 HIV/AIDS predisposes children to pneumonia, increasing the mortality rate to 37% in 
this population.8,188,190 ARV therapy reduces the incidence of pneumonia, but the incidence rates are 
still higher in the HIV-infected than in the HIV un-infected population.191,192 
3.2  AETIOLOGY  
Pneumonia can be caused by different micro-organisms, either bacterial, viral, or fungal.176,190 In the 
African region, Streptococcus pneumoniae, Haemophilus influenza type b (Hib), and Influenza virus 
are the most common organisms causing severe pneumonia (18.6%, 3.1%, and 4.1% respectively), 
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accounting for 32.7%; 12.9%; and 11.1% of pneumonia-related deaths respectively.6,176,190 In pre-
school children, viral aetiology is most common, whilst there is a higher incidence of bacterial 
pneumonia in older children (10-16 years).193,194 
Other bacterial causes of pneumonia often seen in very young children (from birth to six days) are 
Staphylococcus aureus and Klebsiella pneumoniae.6 Salmonella, Mycoplasma pneumoniae, 
Mycoplasma tuberculosis, Bordetella pertussis and Chlamydia pneumoniae are other less common 
causes of pneumonia.6 Viruses, such as respiratory syncytial virus (RSV),176 para-influenza, bocavirus, 
rhinovirus, coronavirus, human metapneumovirus and adenovirus are also common causes of 
pneumonia in childhood.6,193 
Although a decrease in HIV-prevalence has been reported over the past years in South Africa, the 
HIV-prevalence in children remains relatively high, with a prevalence of 2.4% in children younger 
than 14 years of age and 1.7% in children younger than five years of age in 2012.195 Children with 
HIV/AIDS are more susceptible to the acquisition of bacterial pneumonia due to immune 
compromise.8,196 These children are also more susceptible to infection by opportunistic organisms 
such as Pneumocystis jirovecii and Cytomegalovirus infections.6,176,196 Pneumocystis jirovecii 
pneumonia (PJP) differs from other aetiologies of pneumonia, as it is a fungal infection most often 
found in the alveoli of the lungs, and commonly seen in patients with reduced immune support, e.g. 
HIV-infected and –exposed children or those on immunosuppressive treatment.196–199  
3.3  PATHOPHYSIOLOGY  
Infection with any of the above micro-organisms results in an increase in the thickness of the alveolar 
cell wall, leading to a decrease in gas exchange. Furthermore, an inflammatory process is triggered 
within the lungs.193 This inflammatory process results in an increase in the volume and viscosity of 
pulmonary secretions, ciliary dyskinesia and ineffective cough which may lead to reduced secretions 
clearance.70 Subsequent secretion retention predisposes to airway obstruction, inhomogeneity of 
ventilation and superadded infection.24 In addition, pneumonia pathogens themselves may influence 
MCC, impairing its functioning even further.24,64,200 Pneumonia may influence MCC in two ways: 
firstly, micro-organisms produce substances which impair MCC and secondly cytotoxic effects on the 
airway epithelium may occur.24,64 Reduced MCC may increase the amount of secretions in the lungs, 
with long term airway obstruction potentially leading to bronchiectasis.24 
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Healthy individuals have natural defence mechanisms against potentially pathogenic micro-
organisms. However, children are more vulnerable to respiratory infections due to impaired cough, 
impaired MCC, alveolar macrophage dysfunction, aspiration, and/or immune dysfunction.24,200  
3.4  LONG TERM SEQUELAE 
About 12% of children with pneumonia progress to severe pneumonia, with a mortality rate of 8.9% 
for these cases.6 The risk of long term major respiratory sequelae after childhood pneumonia is 
10.4%, with restrictive lung diseases being the most common.201 Children infected with adenovirus 
pneumonia specifically can suffer from obstructive lung disease in the long term.201 In hospitalised 
children, who are reported to have three times greater risk of sequelae and suffer from more severe 
sequelae, the development of bronchiectasis has been reported.201 Bronchiectasis is often related to 
infection with bacterial agents, such as Streptococcus pneumoniae and Hib, as these pathogens often 
lead to severe pneumonia, causing abnormal clearance or airway damage (Figure 3-3).24,202  
 
 
[Reproduced with permission from: Non-cystic fibrosis bronchiectasis: its diagnosis and management. Stafler P and Carr S. 
Arch Dis Child Educ Pract Ed. 2010, 95] with permission from BMJ Publishing Group Ltd]
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Figure 3-3. Development of bronchiectasis 
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3.5  BURDEN OF DISEASE AND QUALITY OF LIFE 
The burden of pneumonia is the highest in infants, with increased disability-adjusted life-year rates 
compared to other age groups.203 Furthermore, hospitalisations for pneumonia during infancy 
decreases HRQOL later on in life.204  
A study conducted in adults with CAP in the Netherlands, using the CAP score, reported a reduction 
to pre-pneumonia level in respiratory score after 14 days, whereas the well-being score remained 
significantly lower than the pre-pneumonia level after 28 days. This well-being level returned to 
normal after six months. This study also assessed HRQOL, using the Short Form-36, and found that 
HRQOL was still significantly lower in the dimensions of physical functioning and general health 18 
months after enrolment in the study. The presence of comorbid conditions was associated with 
significantly more impairment, especially in the physical functioning, physical role function, general 
health perception and vitality domains.205 
3.6  TREATMENT 
Treatment of pneumonia consists of interventions in three domains: (I) protection; (II) prevention, 
and (III) appropriate treatment.175,176,190,206 
3.6.1 Protection by promoting good health 
Children who do not have strong natural defence mechanisms, due to a weakened immune system, 
are more susceptible to infections.190 It is therefore of utmost importance to ensure healthy 
nutrition.206 In children younger than five years of age, approximately 35% of all deaths worldwide 
are related to malnutrition.206 Children who are underweight have a higher risk of contracting 
pneumonia with a relative risk ratio of 1.9 for children between weight-for-age z-values of -2 and -3.6 
Further, an increased risk for mortality due to pneumonia is seen in underweight children, with odds 
ratios (ORs) of  1.2-6.4 (depending on the severity of malnourishment).6 Therefore, prevention of 
malnutrition and protection against illness should be prioritised. This can primarily be ensured by 
exclusively breast feeding until at least six months of age.6,175,176,206 In 2003, in South Africa, only 8% 
of all children younger than six months were exclusively breast fed and; in 2008, 33% of children 
younger than five years of age were underweight.184 Children who do not receive breastfeeding 
during the first six months of life have a 15 times higher risk of pneumonia-related death than 
children who receive breastfeeding during this time.6,206 Complimentary feeding and nutritional 
supplements in older infants and children are also vital to further decrease the mortality rate, as 
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complimentary feeding between the age of six to 24 months reduces mortality for all child deaths by 
6%, and vitamin A supplements decrease it further by 23%.175,206 
3.6.2 Public health considerations 
Prevention of pneumonia is crucial in the reduction of child morbidity and mortality. This is usually 
achieved by vaccinating children against pertussis, measles, Hib, and Streptococcus 
pneumoniae.5,6,175,176,190,194,207 The implementation of vaccinations has led to a reduction of 15-35% in 
pneumonia incidence and 30% in pneumonia mortality.175,206 In South Africa, the application of the 
pneumococcal conjugate vaccine has led to a vaccine attributable reduction in pneumonia incidence 
of 1.0-9.1 per 1000 child years, and 5% reduction in mortality.207,208 In 2014, in South Africa, 
approximately 70% of children were vaccinated against measles, Hib, pneumococcus, rotavirus, 
diphtheria, pertussis and tetanus.184 
A healthy environment is also vital to protect a child from pneumonia.175 Indoor pollution and 
crowding (more than seven people in one household), have been found to increase the child’s risk of 
pneumonia.6,175,176,190,209 By reducing indoor household pollution, the incidence of severe pneumonia 
decreases by 33%.206 
3.6.3 Appropriate treatment of pneumonia 
Although the reduction of childhood mortality due to pneumonia is one of the worldwide health 
priorities,175,190 only 48-54% of children in developing countries are taken to an appropriate 
healthcare provider.182,190 In South Africa, in 2003, only 65% of children younger than five years of 
age were taken to an appropriate health care professional for the treatment of pneumonia.184 
Delayed referral and management of acutely ill South African children might be a result of the tiered 
health care structure, with limited access to health care facilities.210,211 
3.6.3.1 Medical treatment of pneumonia 
Most children with mild to moderate pneumonia (SpO2 above 92%, no cyanosis, no difficulties with 
breathing, no grunting and no apnoea) can be treated in a home-situation, providing the 
parent/caregiver is able to observe and supervise the child’s disease progression.212 Children with 
severe pneumonia require hospitalisation.194,212 Medical management depends on the aetiology of 
pneumonia, e.g. whether or not to use antimicrobial therapy. 
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Mild to moderate pneumonia: out-patient setting 
The majority of children with pneumonia seen in an out-patient setting present with viral pneumonia 
and are treated using a symptomatic approach.193,194 The symptomatic approach in both viral and 
bacterial pneumonia includes the management of fever by antipyretics.193,212 In children with 
bacterial pneumonia, oral penicillin antibiotics e.g. Amoxicillin, are used as first line treatment in the 
out-patient setting.175,190,194 
Severe pneumonia: in-patient setting 
Hospitalised children with pneumonia, of both viral and bacterial origin, are routinely treated with 
oxygen support and intravenous fluids to maintain oxygen saturation and hydration levels.193,212 In 
addition, antipyretics are used to reduce fever; and mechanical ventilation might be necessary if the 
child suffers from severe respiratory distress which leads to fatigue or respiratory failure.212 In 
addition, children with severe viral pneumonia could be treated with antiviral medication, e.g. 
Amantadine, Rimantidine, Oseltamivir or Zanamivir for pneumonia caused by Influenza.193 However, 
these treatments are only effective when used early in the disease process and are mostly used in 
children with chronic disorders or immune deficiencies owing to the high cost and risk of drug-
resistance.193,213–216 Bacterial pneumonia is treated with antibiotics, however, the correct choice of 
antibiotics is vital in preventing emergence of drug-resistance.212 Identification of pathogens is 
therefore important, in order to use appropriate narrow-spectrum antibiotics.212 
3.6.3.2 Airway clearance therapy in pneumonia 
Based on the fact that pneumonia can adversely influence MCC and bacterial agents such as 
Streptococcus pneumoniae and Hib can lead to the development of bronchiectasis due to abnormal 
clearance and/or airway damage,24 ACT may be an appropriate tool to help evacuate secretions from 
the airways and/or improve ventilation (see section 2.3.2 for an overview of ACTs). ACT is therefore 
sometimes prescribed in patients with pneumonia, although the treatment is not recommended by 
clinical guidelines due to the lack of evidence to support this intervention.217–220 
Limited evidence is available on ACT in children with pneumonia (see Chapter 4 for a systematic 
review). Five RCTs,221–225 two observational studies,226,227 and one non-controlled/non-randomised 
study,228 are available for which the results are presented in Table 3-1. 
There is a lack of clear evidence for the use or rejection of ACT in children with pneumonia. Two RCTs 
and one observational study were published more than 30 years ago, for which the data could be 
outdated.224,225,227 In addition, the study by Levine has poor methodological quality, as it is unclear 
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how randomisation was performed, how allocation concealment was maintained and if outcome 
assessors were blinded to group allocation.224 The study by Britton et al. had a pre-set age range of 
15-75 years of age, including both paediatric and adult population groups, but considering the mean 
age for the control and intervention group were 47.4 and 47.2 years respectively and separate data 
are not available, this study is more relevant to the adult population.225  The study reported by 
Stapleton included children of unknown age, with different diagnoses of LRTIs (26 with pneumonia, 
nine with bronchitis and 20 with bronchiolitis), making it difficult to make conclusions specific to 
paediatric pneumonia.227 The study by Plebani et al. is an observational study in only eight 
patients,226 and Santos et al. reported a non-controlled and non-randomised study;228 these study 
designs are not of sufficiently high quality to make conclusions and generalisability is limited. 
The three RCTs may not have included an adequate sample size to evaluate small differences 
between the groups.221–223 Therefore, a systematic review, aimed to synthesise the results of these 
RCTs, was conducted; to determine the effect of different ACTs compared to no physiotherapy, sham 
physiotherapy or alternative therapy in children hospitalised with acute pneumonia (see Chapter 4). 
Although conventional ACT may not be effective in children with acute pneumonia, many of the 
techniques studied are now outdated. Newer ACTs, including AD and AAD, may be more effective in 
removing secretions from the peripheral airways, but research into these techniques is characterised 
by small sample sizes, and therefore more research is needed to make clear and generalizable 
conclusions. 
3.7  SUMMARY 
Pneumonia remains the single leading cause for mortality in children younger than five years of age. 
The disease can be caused by different micro-organisms, impairing the MCC, thickening the alveolar 
cell wall, and triggering an inflammatory process resulting in an increase in the volume and viscosity 
of pulmonary secretions, ciliary dyskinesia and ineffective cough. ACT is often prescribed in patients 
with pneumonia as it might be beneficial to help evacuate secretions from the airways and/or 
improve ventilation. As contradicting results have been reported in the literature on the use of ACT 
in children with pneumonia, systematical evaluation of the literature is needed. 
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Table 3-1. Airway clearance therapy in children with pneumonia 
Authors Study 
design 
N Age Aetiology Intervention Control Duration of 
treatment 
Outcome 
Britton et 
al. 
(1985)
225
 
RCT 171 15-
75y 
Unknown 
(Primary 
pneumonia) 
PD + vibrations + percussions + 
external help with breathing 
(undefined) 
Advice on deep breathing 
and expectoration of 
secretions + exercises to 
prevent thrombosis 
1x 15-20 
minutes /day 
 Significant longer duration of fever 
in the intervention group 
 No significant difference in 
duration of hospitalisation, healing 
time and FEV1 
Stapleton  
(1985)
227
 
Observa- 
tional 
55 
I= 34 
C= 21 
? Unknown 
(Acute 
uncomplicated 
LRTI) 
Percussions + suctioning Standard care 2-3x 5-15 
minutes /day 
 No significant difference in 
duration of hospitalisation 
 No significant differences in 
duration of cough or coryza 
 No significant differences in 
persistence of rales, wheezes or 
ronchi 
Levine 
(1987)
224
 
RCT 55 
I= 32 
C= 23 
2-
12y 
Presumed viral 
Excluded 
bacterial 
PD + percussions + vibrations Standard care 4x/d  No significant difference in time till 
improvement on chest X-ray  
 Significant longer duration of fever 
in the intervention group 
Plebani 
et al. 
(1997)
226
  
Observa-
tional 
8 HIV  
positive 
? Bacterial PEP Therapy used the previous 
year 
2 x 15 
minutes /d 
Study 
duration= one 
year 
 Significant reduction in the mean 
number of: 
- infections per year 
- antibiotic treatments per year 
and days of antibiotics per year 
 Significant improvement in FVC 
and FEV1 
Paludo et 
al. 
(2008)
221
  
RCT 89  29d-
12y 
Unknown 
(Acute 
pneumonia) 
Standard treatment + PD+ 
percussion + vibrations + thoracic 
squeezing + cough stimulation +  
suctioning 
Standard care consisting of 
oxygen therapy, antibiotics 
and fluid 
 2 x 30 
minutes/d 
 No significant difference in  
duration of hospitalisation and 
clinical  resolution  
 Longer duration of cough and 
rhonchi  in the intervention group 
I: intervention; C: control 
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Table 3-1 continued. Airway clearance therapy in children with pneumonia 
Authors Study 
design 
N Age  Aetiology Intervention Control Duration of 
treatment 
Outcome 
Santos et 
al.
228
 (2009) 
  
  
Non- 
controlled/ 
Non-RCT 
123 
  
0-
11.9y  
  
Unknown (CAP) Expiratory Flow Increase 
Technique 
  
Baseline RR, heart 
rate and SpO2 from 
the child 
1 x /d  
 
 Significant improvement in SpO2 after 
treatment and remained elevated after 
20 minutes of rest. RR and heart rate 
are increased after treatment but 
returned to baseline after rest 
Lukrafa et 
al.
222
 (2012) 
  
  
RCT 72 
  
  
  
1-12y 
  
Unknown 
(Acute CAP) 
Positioning + PEP + thoracic 
vibrations + cough 
simulation + suctioning + 
FET (children 5-12 years) 
Cough + positioning in 
side lying for 5 min + 
deep diaphragmatic 
breathing 
  
3 x 10-12 
minutes /day 
  
  
  
 No significant difference in severity 
score  and duration of hospitalisation 
  
  
Abdelbasset 
& 
Elnegamy
223
 
(2015) 
RCT 50 
I= 25 
C= 25 
29d-
5y 
Unknown PD + percussions + 
vibrations + thoracic 
squeezing + cough 
stimulation 
Standard care 3x 20 
minutes/d 
 Significant shorter time to clinical 
resolution in the intervention group 
 Significant lower RR in the intervention 
group at discharge 
 Significant higher SaO2 in the 
intervention group at discharge 
I: intervention; C: control 
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Chapter 4. IS AIRWAY CLEARANCE THERAPY EFFECTIVE IN CHILDREN WITH PNEUMONIA? A 
SYSTEMATIC REVIEW 
4.1  INTRODUCTION 
In respiratory disease such as pneumonia, increased volume and viscosity of pulmonary secretions, 
ciliary dyskinesia and ineffective cough may lead to reduced secretions clearance.70 This predisposes 
to airway obstruction, inhomogeneity of ventilation and superadded infection.24 ACT is therefore 
often prescribed as part of the treatment of pneumonia, as it might be beneficial for gas exchange, 
to evacuate secretions from the lungs and decrease work of breathing.106,218,229 
A systematic review on ACT in adults with pneumonia concluded that ACT should not be given in 
addition to standard treatment in this population.230 In a recent systematic review on ACT in children 
with pneumonia, there was not enough evidence to make a clear conclusion.231 However, the review 
included an article on continuous positive airway pressure (CPAP), which I would not classify as 
ACT.231,232 Further, one RCT and two non-RCTs did show a positive effect of ACT in children with 
pneumonia.223,226,228 
An article based on this  review has been published in the South African Journal of Physiotherapy.(2) 
4.2  AIMS AND OBJECTIVES 
To determine the effect of different ACTs compared to no physiotherapy, sham physiotherapy or 
alternative therapy in children hospitalised with acute pneumonia.  
The following hypotheses were tested:  
- ACT is more effective than no or sham physiotherapy in improving clinical outcome in children 
hospitalised with acute pneumonia. 
- Certain ACTs are more effective than sham or alternative therapy in improving clinical outcome in 
children hospitalised with pneumonia. 
- ACT is safe to perform in children hospitalised with pneumonia. 
                                                          
 
(2) 
Corten L, Jelsma J, Morrow BM. Chest physiotherapy in children with acute bacterial pneumonia. South 
African J Physiother. 2015;71(1):#256. doi:10.4102/sajp.v71i1.256. 
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4.3  METHODOLOGY 
This systematic review used the Cochrane methodology for systematic reviews and conforms the 
Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) (Appendix 2).233,234 This 
review’s unpublished pre-set protocol described the methodology and inclusion criteria prior to the 
database searches. 
4.3.1 Criteria for considering studies for this review 
Types of studies 
RCTs and quasi-RCTs. 
Types of participants 
Children, under the age of 18 years, hospitalised with acute pneumonia. 
Types of intervention 
Any ACT, as a single technique or in combination with others compared to no physiotherapy, sham 
physiotherapy or alternative therapy. 
Types of outcome measures 
Primary outcome measures: 
 Duration of hospital stay (in days) 
 SaO2 or SpO2 measured before and after intervention 
- transcutaneous 
- arterial blood gas analysis 
Secondary outcome measures:  
 RR measured before and after intervention 
 Duration of oxygen supplementation (in hours) 
 Lung function tests (spirometry): vital capacity (VC), FVC, FEV1, PEF, maximal inspiratory 
pressure and maximal expiratory pressure measured on enrolment and before discharge 
 Any adverse effects 
 Mortality 
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4.3.2 Search methods for identification of studies 
Electronic search 
Online databases PubMed, Medline, Cochrane library, PEDro, Africa-wide information and CINAHL 
were searched using predefined search terms (see Appendix 3 for an overview of the search terms). 
These search terms were also translated into the different included languages. 
Articles were included if they were written in English, Dutch, French, German or Afrikaans. Articles 
were excluded if they were published before 1990 (as the field of ACT has evolved significantly in the 
past 25 years), written in another language than the ones described above or used a cross-over, non-
randomised or pre-experimental design.  
Other resources 
Reference lists of the identified articles were manually checked. Ongoing research was identified by 
exploring clinicaltrial.gov and the Pan African Clinical Trials registry (pactr.org). No grey literature 
was searched due to the problem with reproducibility of this type of literature.235 
4.3.3 Data collection and analysis 
Selection of studies 
One reviewer (LC) searched the databases and collected relevant articles based on title and abstract. 
These were reviewed by a second reviewer (BM). After selection, the full text of each article was 
reviewed independently by these two reviewers to decide whether the articles were eligible for 
inclusion in the review. Any disagreement was resolved by consensus. 
Data extraction and management 
Data extraction was done by two independent reviewers (LC and BM) using a pre-structured data 
extraction form and included information on the participants (age, gender, condition, severity of 
symptoms, inclusion/exclusion criteria, comorbid conditions, setting, number randomised, number 
lost to follow-up); interventions (type of interventions, duration, frequency, intensity, compliance); 
outcome measurements; results (point estimates, precision, measures of variability, frequency 
counts for dichotomous variables, number of participants in each group); and study design 
(randomisation, allocation concealment, blinding) (Appendix 4). 
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Assessing risk of bias in included studies 
The reviewer assessed the following methodological characteristics, based on the Cochrane risk of 
bias assessment:233  
1) Generation of sequence:  
It was considered low risk of bias when a random number table, computer generated list of random 
numbers or any other method of randomisation was used. Studies were considered as having high 
risk of bias when invalid methods of randomisation were used, such as date of birth or allocation by 
the physiotherapist or physician. When the allocation sequence was not identified, the bias was 
judged as unclear. 
2) Allocation concealment 
Low risk was considered when investigators were blinded to group allocation, by the use of coded, 
opaque and sealed envelopes, on site locked computer files or similar valid means. When the 
investigator was able to predict allocation, for example by the use of date of birth, the study was 
classified as high risk of bias. When concealment details were not identified, the bias was considered 
unclear. 
3) Blinding 
It is impossible to blind the participant or clinician to physiotherapy treatment, but the physician and 
data-analyst can be blinded. Therefore the studies were judged as having low risk of bias when 
investigator and data-analyst were blinded to treatment method. High risk of bias was considered 
when no blinding or a limited form of blinding was applied. Unclear risk was considered when no 
information on blinding was available. 
4) Incomplete data outcome and intention-to-treat analysis 
Low risk of bias was considered when an appropriate intention-to-treat analysis was performed on 
incomplete data. When no intention-to-treat analysis was conducted, data were considered as 
having high risk of bias. Risk of bias was considered unclear when no information about intention-to-
treat was given. 
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5) Selective outcome reporting 
When primary and secondary outcome measures were reported, the study was considered to have 
low risk of bias. When no pre-specified outcome measures were identified, the risk of bias was 
considered high. If not enough information was available to consider the study high or low risk of 
bias, then the study was classified as having an unclear risk of bias. 
6) Other potential threats to validity 
When the study was free from other threats, such as baseline imbalance or design-specific risk of 
bias, then the study was considered to have low risk of bias. High risk of bias was present when 
there was a potential threat in the study. Unclear risk of bias was considered when insufficient 
information was available to determine risk of bias. 
Measures of treatment effect 
It was intended that continuous outcomes would be reported by using the mean difference (or 
standardised mean differences) and 95% confidence interval (CI). Where insufficient data were 
provided, or nonparametric measures were reported, the authors were contacted to try and convert 
data into means (95% CI). Where this was not possible, data were reported as in the source article. 
Risk ratio and 95% CI were used to report dichotomous outcomes, where possible. 
Unit of analysis issues 
Long- term studies with repeated measures of outcome were considered eligible for this review, and 
could be included in later versions, in which case the outcomes would be defined according to set 
time periods.236 If studies had more than one intervention group, these groups were planned to be 
included separately in a meta-analysis, with the control group divided in half.237 
Dealing with missing data 
The original authors of the studies with missing data were contacted. If the author could not be 
located, a description of the study was included in the narrative review. Where missing data could 
not be obtained, the studies were considered adequate if more than 85% of participants were 
included in the outcome analysis, or if fewer participants were included but sufficient measures 
were taken to ensure or demonstrate that this did not bias the results. Where this was not clear, an 
intention-to-treat analysis was planned from extrapolated data, where possible. 
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Assessment of heterogeneity 
If different studies measured the same outcome, heterogeneity was planned to be assessed using 
the chi-squared statistic and the I2 statistic. Heterogeneity would have been low if I2 was less than 
30%, moderate when I2 was between 30 and 50% and substantial when it was more than 50%. 
Assessment of reporting bias 
If a sufficient number of studies were included, a funnel plot was planned to identify reporting bias, 
and will be used in future reviews when possible. 
Data synthesis 
If a sufficient number of studies were identified to include in this review, a meta-analysis was 
planned, using a fixed-effects model, unless substantial heterogeneity was present in which case a 
random-effects model was planned to be used. 
Subgroup analysis and investigation of heterogeneity 
The following subgroup analyses would be conducted when applicable: 
1) Age 
2) Gender 
3) Duration of treatment 
4) Frequency of treatment 
5) Severity of the disease 
 
Sensitivity analysis 
If an adequate number of studies were included in the review, sensitivity analysis would be 
performed. 
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4.4  RESULTS 
4.4.1 Results of the search 
On 14 July 2016 we performed electronic database searches which identified 202 articles with 
duplicates (48 in Pubmed, 61 in Medline, 20 in PEDro, 51 in the Cochrane Library, 18 in CINAHL and 
four in African-Wide Information) (Figure 4-1). One article was identified through searching the 
reference lists of relevant articles.225 After removal of duplicates, 129 articles remained for further 
investigation. After inspection of the titles and abstracts, seven titles were found potentially relevant 
and the full text was obtained. Full text analysis revealed two articles which met the inclusion 
criteria.221,222 One RCT was identified on pactr.org (closed to recruitment, follow up completed) and 
could be included in future reviews (PACTR201404000706382) (See Chapter 6 for results of this 
RCT).  
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
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Additional records identified through other 
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Records screened  
(n = 129) 
 
Records screened 
(n = 129) 
Records excluded  
(n = 122) 
 
Records excluded 
(n = 122) 
Full-text articles assessed 
for eligibility  
(n = 7) 
Full-text articles excluded, 
with reasons  
5) 
- Published prior to 
1990 (n= 2) 
- Study design: no 
RCT or quasi-RCT 
(n= 3) 
 
Studies included in 
qualitative synthesis  
(n = 2) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0) 
Figure 4-1. PRISMA study flow chart 
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4.4.2 Included studies 
See Table 4-1 for characteristics of included studies. Both studies included in this review were RCTs 
conducted in a hospital setting in Brazil and written in English.221,222 
Table 4-1. Characteristics of included studies. 
Specific characteristics Paludo et al.
221
 (2008) Lukrafka et al.
222
 (2012) 
Study design RCT RCT 
Withdrawal/drop outs, n 9 7 
Country Brazil Brazil 
Research setting Hospital Hospital 
Health condition Acute pneumonia Acute CAP 
Severity of symptoms Mild to moderate Mild to moderate 
Total sample enrolled, n 98 79 
Total sample analysed, n 89 72 
Age range 29 days - 12 years 1 - 12 years 
Inclusion criteria Acute pneumonia with: presence 
of cough and/or fever; 
tachypnoea; consolidations 
and/or infiltrates on CXR 
Hospitalised with acute CAP (clinically and 
radiologically diagnosed) 
Exclusion criteria Chest drain; haemodynamic 
instability (ND
‡
) bone fragility or 
rib fractures; any other contra- 
indication to ACT (ND
‡
) 
Severely ill patients (ICU
~
); chest drain; 
atelectasis detected by CXR; history of 
pneumonia or pleural effusion in previous 
6 months; other pulmonary disease; heart 
disease; CP or immune deficiency 
Primary outcomes Time to clinical resolution Severity score and RR 
Secondary outcomes Length of hospital stay, 
persistence of respiratory 
symptoms and signs 
Duration of hospitalisation 
CXR= chest X-ray, ‡ND= not defined, ~ICU= intensive care unit 
 
4.4.2.1 Participants 
In total, 177 participants between the age of 29 days and 12 years were enrolled in the two trials. 
Sixteen were lost to follow up, therefore 161 participants were analysed (95 male and 66 females), 
with 82 participants in the intervention groups and 79 in the control groups. The study by Lukrafka 
et al. divided participants in two age groups, children younger than and older than five years of 
age.222 This study included participants with acute CAP,222 while the other study did not specify site 
of acquisition of acute pneumonia.221 Both studies included participants with mild to moderate 
disease, but only one study clearly indicated disease severity in the article text.222 In the other article 
disease severity was deduced as mild to moderate from the baseline characteristics of the 
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participants, as the mean SaO2 was above 95%. However, mean RR at baseline was above 45 breaths 
per minute (bpm) which is higher than normal considering the age (Table 4-2).221 
Table 4-2. Baseline characteristics of included studies 
 Characteristics  Paludo et al.
221
 (2008)                       Lukrafka et al.
222
 (2012)   
Group allocation Intervention Control Intervention Control 
Analysed, n 
 
47 42 35 37 
Male, n (%) 
 
29 (62) 24 (57) 20 (57) 22 (59) 
Age, mean (95%CI) or n (%) 44 months  
(31.6-56.4) 
32.2 months 
(22.5-41.9) 
12-59 months:  
25 (71.4) 
5-12 years:  
10 (28.6) 
 
12-59 months:  
28 (75.7) 
5-12 years:  
9 (24.3) 
Respiratory rate (bpm), mean (SD) (95%CI) 
 
45 (14.3) 
 (40.9-49.1)  
45.8 (14.2) 
 (41.6-50.1)  
39.1 (9.9)  
(35.8-42.4) 
38,3 (9.9) 
(35.1-41.5) 
Fever, n (%) 
 
45 (96) 37 (90) 7 (20) 8 (22) 
SaO2
221
 or SpO2
222
 (%), Mean (SD)  
(95%CI) 
 
95.0 (2.5) 
(94.3-95.7)  
95.7 (2.3) 
(95.0-96.4) 
96.5 (2.5) 
(95.7-97.3) 
97.1 (2.1) 
(96.4-97.8) 
Pleural effusion, n (%) 5/45 (11) 6/39 (15) 10 (29) 4 (11) 
 
4.4.2.2 Intervention 
An overview of the interventions can be found in Table 4-3. One trial compared standard treatment, 
consisting of antibiotic treatment, fluid therapy and oxygen therapy when needed, with ACTs as an 
add-on to standard treatment. ACTs included PD (PD positions were guided by chest X-ray findings), 
thoracic squeezing, percussions, vibrations, cough stimulation and aspiration/suctioning when 
necessary.221 ACTs were given bi-daily for an average of 30 minutes per session.221 The other trial 
compared recommended non-mandatory lateral positioning, cough and the performance of 
diaphragmatic breathing for five minutes per day in the control group, with ACTs in the intervention 
group.222 In the intervention group, treatment depended on the child’s age. Participants younger 
than five years of age were positioned in high side lying or high sitting positions, and manual thoracic 
vibrations, thoracic compressions, PEP technique and artificially stimulated cough or suctioning were 
performed. For participants older than five years of age, the same treatment was applied with the 
addition of breathing exercises and FET. Treatment was given three times a day for 10 to 12 
minutes.222  
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Table 4-3. Description of interventions used in the included studies 
Group 
allocation 
Specific 
characteristics 
Paludo et al.
221
 (2008) Lukrafka et al.
222
 (2012) 
 Intervention  
 
Techniques 
 
 
 
 
Standard treatment and ACT: PD, thoracic 
squeezing, percussions, vibrations, cough 
stimulation, aspiration/suctioning when 
necessary. PD positions guided by CXR 
<5 year: positioned in high side lying 
or high sitting, manual thoracic 
vibrations, thoracic compressions, 
PEP, artificially stimulated cough or 
suctioning 
>5 year: same as above + breathing 
exercises and FET 
 Duration of 
treatment 
±30 minutes/ treatment session 
 
10-12 minutes/ treatment session 
 Frequency of 
treatment 
 
2x/ day until discharge 
 
3x/ day until discharge 
 Intensity of 
treatment 
 
Unclear 
 
Unclear 
 Compliance to 
treatment 
Unclear 
 
Unclear 
Control 
 
Techniques 
 
 
Standard treatment: antibiotics, fluid therapy 
and oxygen therapy as needed 
 
Recommended non-mandatory 
request: lateral positioning, cough, 
perform diaphragmatic breathing 
Duration of 
treatment 
 
Information not available 
 
5 minutes (not mandatory) 
 Frequency of 
treatment 
 
Information not available 
 
1x/ day (not mandatory) 
 Intensity of 
treatment 
 
Unclear 
 
Unclear 
 Compliance to 
treatment 
Unclear Unclear 
CXR= chest X-ray 
 
4.4.2.3 Outcome measures 
The primary outcome measure of this review “duration of hospital stay”, was reported in both trials 
as a secondary outcome measure.221,222 The other primary outcome measure of this review, 
SaO2/SpO2 measured before and after intervention, was not assessed in the included studies. The 
other secondary outcome measures (RR measured before and after intervention, duration of oxygen 
supplementation, lung function tests measured at enrolment and discharge, any adverse effects or 
mortality) identified initially, were not reported in the included trials. 
4.4.3 Excluded studies 
Five articles did not meet the inclusion criteria and were excluded from this review. Two articles 
were outdated, with a publication date prior to 1990.224,225 One of these studies included 55 children 
with presumed viral pneumonia,224 whereas the other study  included 171 participants between the 
ages of 15 and 75 years with acute pneumonia.225 Three studies were excluded because of their 
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study design.227,238,239 Stapleton described a case series of 55 children, in which 34 children with 
acute uncomplicated respiratory tract infections (26 with pneumonia, nine with bronchitis and 20 
with bronchiolitis) received ACTs, compared to 21 children who did not receive ACTs.227 Gilchrist 
performed a database search of the Cochrane Library, PubMed and PEDro for an answer to the 
structured clinical question “In a child with CAP, does chest physiotherapy reduce the length of 
hospital admission?”.238 Finally, Lisy presented a summary of the review by Chaves et al.231,239 
4.4.4 Risk of bias in included studies 
A detailed risk of bias analysis can be found in Table 4-4.  A summary of the findings is presented in 
Figure 4-2. 
 
 
 
 
 
 
 
 
Lukrafka et al.222  
Paludo et al.221 
Red = high risk of bias, yellow = unclear risk of bias and green = low risk of bias. 
Figure 4-2. Risk of bias summary: review author’s judgements about each risk of bias item for each included study 
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Table 4-4. Risk of bias 
 Type of bias              Paludo et al.
221
 
  
                 Lukrafka et al.
222
 
  
   Authors’ 
judgement 
Support for judgement Authors’ 
judgement 
Support for judgement 
Generation of sequence Low risk Simple randomisation  
Table of random numbers 
Low risk Computerised random number 
generator to select blocks of 3 and 
4 
Allocation concealment Unclear risk No specifications on 
concealment 
Low risk Use of sequentially numbered 
opaque envelopes 
Blinding 
 
Participants High risk Participants knew in 
which group they were 
assigned 
High risk Participants knew in which group 
they were assigned 
Outcome 
assessor 
Low risk Investigators, nurses and 
physicians were blinded 
Low risk Study radiologist and 
epidemiologist blinded 
Data-
analysts 
Unclear risk No information on data-
analysts 
Low risk Data-analysts were blinded 
Incomplete data Low risk Intention-to-treat 
principle applied 
Number lost to follow-up 
and reason loss to follow-
up similar for both groups 
Low risk Intention-to-treat analyses 
performed 
Number lost to follow-up and 
reason loss to follow-up similar 
for both groups 
Selective outcome 
reporting 
Low risk Primary and secondary 
outcome measures 
reported 
Low risk Primary and secondary outcome 
measures reported 
Other potential threats Unclear risk Baseline characteristics 
were similar 
Groups were treated 
equally, except for 
treatment  
No other information 
available 
Unclear risk Baseline: tendency of more 
children with pleural effusion in 
intervention group  
Groups were treated equally, 
except for treatment  
No other information available 
 
4.4.4.1 Generation of sequences  
Both included studies were described as RCTs. One study applied simple randomisation by the use of 
a table of random numbers.221 The other study used a computerised random number generator to 
select blocks of three and four.222 Therefore the generation of sequence risk of bias was judged as 
being low for both studies. 
4.4.4.2 Allocation 
In the article by Paludo et al., no information was available on allocation concealment. Therefore the 
risk of bias was judged as being unclear.221 In the article by Lukrafka et al. it is stated that 
sequentially numbered opaque envelopes were used to conceal allocation, therefore allocation 
concealment risk of bias was judged as being low for this study.222 
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4.4.4.3 Blinding 
As it is nearly impossible to blind participants for treatment when performing ACT, both studies have 
a high inherent risk of bias. However, outcome assessors could be blinded to allocation. In one 
study, the investigators, nurses and physicians/paediatricians;221 and in the other study, radiologist 
and epidemiologist;222 were all blinded to allocation, therefore the outcome assessor’s risk for bias 
was judged as being low for both studies. Further, in one study the data-analyst was reported to be 
blinded to allocation for which the risk of bias was judged as being low.222 In the other study no 
information was available on blinding of the data-analyst, so the risk of bias was judged as being 
unclear for this aspect of the trial.221 
4.4.4.4 Incomplete outcome data 
In both studies, withdrawals were reported and the number of participants lost to follow up was 
similar for the intervention and control groups. Therefore the risk of bias was judged as being low for 
both studies. In the study by Paludo et al. nine participants (four in the intervention group and five in 
the control group) were withdrawn from the study.221 Four of them were discharged or transferred 
before the second assessment (two in each group) and five met an exclusion criterion (two in the 
intervention group and three in the control group). Therefore, 89 from the 98 enrolled participants 
were analysed during follow-up (47 in the intervention group and 42 in the control group).221 In the 
other study seven participants were withdrawn from the study (three in the intervention group and 
four in the control group) due to the insertion of a chest drain (in four participants, three in the 
intervention group and one in the control group) or atelectasis detected on the chest X-ray (in three 
participants in the control group).222 Analysis was performed on the remaining 72 participants (35 in 
the intervention group and 37 in the control group).222 Both studies applied intention-to-treat 
analysis. 
4.4.4.5 Selective reporting 
Both studies reported primary and secondary outcome measures, and therefore the risk of reporting 
bias was judged as being low.  
One study selected time to clinical resolution, expressed in days, as their primary outcome 
measure.221 They defined it as the number of days the patient needs to achieve: an afebrile state 
(maximal daily body temperature <37.5°C), absence of severe signs of respiratory distress (chest in-
drawing, nasal flaring, cyanosis), and normal RR and SpO2 ≥95%. The other study chose reduction of 
RR and severity score between baseline and discharge as their primary outcome measures.222 
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Both studies used length of hospital stay, expressed in days, as one of their secondary outcome 
measures.221,222 ‘Persistence of respiratory symptoms and signs’ (cough, tachypnea, chest in-
drawing, wheezing, adventitious sounds on lung auscultation, fever (not further defined), and SaO2 
<95%), expressed in days were the other secondary outcome measures used in the study by Paludo 
et al.221 
4.4.4.6 Other potential sources of bias 
None of the studies reported sufficient information to judge this risk, therefore the risk of bias was 
judged as being unclear. In both studies the groups were treated equally, apart from the ACT 
applied.221,222 In the one study,221 baseline characteristics were similar between both groups, but in 
the other study there was a tendency towards more participants with pleural effusion in the 
intervention group.222 No other information was available. 
4.4.5 Effects of intervention 
No meta-analysis or pooling of data was possible due to different outcome measures used in the two 
included studies. Duration of hospital stay, whilst a common outcome measure in the included 
studies, could also not be pooled owing to the absence of the 95% CI of the data, precluding 
judgement of data spreading. 
4.4.5.1 Primary outcome measures 
Duration of hospital stay (in days) 
Both studies reported length of hospital stay as a secondary outcome measure. In both studies, 
median number of days in hospital was reported and no significant difference between the groups 
was found (p= 0.76 and p= 0.11). In the study by Paludo et al.221 the reported median length of stay 
was six days of hospitalisation for both groups. After consulting the authors of this article, the 
following additional information was made available: mean duration of stay for the intervention 
group was 7.8 days with a 95% CI of 6.6-9.0 days and a mean of 6.8 days for the control group with a 
95% CI of 5.9-7.7 days. The other trial reported a median of 8 days in hospital for the intervention 
group (95% CI 5.1-10.9 days) and 6 days for the control group (95% CI 5.1-6.9 days).222 We were 
unable to obtain mean values or 95%CI of duration of hospitalisation for this trial, therefore we were 
unable to pool data or perform a meta-analysis. 
SaO2/SpO2 measured before and after intervention (transcutaneous or arterial blood gas 
analysis) 
None of the included studies reported on this outcome measure. 
51 
 
4.4.5.2 Secondary outcome measures 
Respiratory rate measured before and after the intervention 
Neither of the studies reported on this outcome measure. 
Duration of oxygen supplementation (in hours) 
Neither study reported data on this outcome measure. 
Lung function tests (spirometry): VC, FVC, FEV1, PEF, maximal inspiratory pressure and 
maximal expiratory pressure measured on enrolment and before discharge 
This outcome measure was not assessed in the included studies. 
Any adverse effects 
None of the included studies reported any adverse effects due to the intervention or disease. 
Mortality 
Neither study included mortality as an outcome measure.  
4.4.5.3 Other outcome measures 
See Table 4-5 and Table 4-6 for an overview of the other outcome measures presented in the two 
included studies. 
Except for duration of hospitalisation (reported as a secondary outcome measure), the studies 
included in this review used different outcome measures in their research. One of the studies 
reported time to clinical resolution, expressed in days, as their primary outcome measure.221 No 
significant difference was seen between the intervention and control group (p= 0.8). The median 
time to clinical resolution was four days in both groups, with an interquartile range (IQR) of 2.0-7.0 
in the intervention group and 3.0-6.0 in the control group. After consulting the authors, mean values 
and 95% CI were made available. The mean time to clinical resolution in the intervention group was 
4.4 days, with a 95% CI of 3.3-5.6 and 4.3 days in the control group, with a 95% CI of 3.4-5.4.221 
The other study used reduction of RR and severity score, comparing baseline with discharge results, 
as their primary outcome measures.222 Both groups showed a significant improvement in outcomes 
between baseline and discharge (p<0.001), but there were no significant between-group differences 
for reduction in RR (p= 0.7) and severity score (p=0.6) (Table 4-5).222  
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The study by Paludo et al. reported ‘persistence of respiratory symptoms’, expressed in days, as 
another secondary outcome measure.221 No significant difference between the intervention and 
control group were reported (Table 4-6), except for a longer duration of coughing (p=0.04) and a 
longer duration of rhonchi (p=0.03) in the intervention group. The median duration of coughing was 
5 days (IQR 4.0-8.0) in the intervention group and 4 days (IQR 3.0-6.0) in the control group. Mean 
(95% CI) values for this outcome measure were 6.1 days (5.1-7.1) for the intervention group and 4.7 
days (3.9-5.6) for the control group. Comparing the duration of rhonchi, the intervention group had 
a median (IQR) duration of 2 days (0.0-4.0) and the control group 0.5 days (0.0-2.0). Authors further 
reported a mean duration of ronchi of 2.8 days with a 95% CI of 1.8-3.8 for the intervention group 
and 1.2 days with a 95% CI of 0.5-1.9 for the control group.221 
Table 4-5. Other primary outcome measures 
Outcome measure Study and number 
of participants 
Data-
presentation 
Intervention Control p-
value 
Time to clinical 
resolution in days 
 Paludo et al.
221
 
n=89 
Median (IQR)  
Mean (95% 
CI) 
4.0 (2.0-7.0)  
4.4 (3.3-5.6) 
4.0 (3.0-6.0) 
4.3 (3.4-5.4) 
 0.84 
Reduction of RR
 
(bpm) Lukrafka et al.
222
  
n= 72 
Mean (SD)
 
(95%CI) 
 
 
p-value within 
group 
Baseline: 39.1 (9.9)  
(35.8-42.4)  
Discharge: 31.6 (6.9) 
(29.3-33.9)  
p<0.001 
Baseline: 38.4 (9.8) 
(35.2-41.6) 
Discharge: 32.5 
(8.3) (29.8-35.2) 
 p<0.001 
0.9 
 
 
 
0.7 
Severity score Lukrafka et al.
222
 
n= 72 
Mean (SD)
 
(95%CI) 
 
p-value within 
group 
Baseline: 2.1 (1.6) 
(1.6-2.6) 
Discharge: 0.6 (0.8) 
(0.3-0.8)  
p<0.001 
Baseline: 1.8 (1.1) 
(1.4-2.1) 
Discharge: 0.4 (0.6) 
(0.2-0.6)  
p<0.001 
0.2 
 
 
 
0.6 
P-values are presented as reported in the original article 
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Table 4-6. Other secondary outcome measures 
Outcome measure Study and 
number of 
participants 
Data 
presentation 
Intervention Control p-
value 
Persistence of 
respiratory 
symptoms (days) 
Time to normal 
RR 
Paludo et al.
221
 
n=89  
Median (IQR) 
Mean (95% CI) 
3.0 (0.0-7.0)  
3.6 (2.4-4.8) 
3.0 (1.0-6.0)  
3.3 (2.2-4.4) 
0.75 
Time to normal 
SaO2 
  1.0 (0.0-2.0)  
1.0 (0.5-1.4) 
0.5 (0.0-2.0)  
0.8 (0.4-1.3) 
0.98 
Time to normal 
lung auscultation 
  4.0 (3.0-6.0)  
4.7 (3.5-5.9) 
4.0 (2.0-6.0)  
4.1 (3.1-5.0) 
0.28 
Duration of fever   2.0 (0.0-2.0)  
1.4 (0.8-1.9) 
1.0 (0.0-3.0)  
1.5 (0.7-2.3) 
0.78 
Duration of 
coughing 
  5.0 (4.0-8.0)  
6.1 (5.1-7.1) 
4.0 (3.0-6.0)  
4.7 (3.9-5.6) 
0.04 
Duration of 
parent's reported 
wheezing 
  1.5 (0.0-5.0)  
2.9 (2.0-3.9) 
 
1.0 (0.0-3.5)  
1.7 (1.0-2.4) 
 
0.29 
Duration of fine 
crackles 
  0.0 (0.0-2.0)  
1.1 (0.6-1.6) 
0.0 (0.0-2.0)  
1.2 (0.5-1.8) 
0.72 
Duration of 
coarse crackles 
  2.0 (0.0-4.0)  
2.1 (1.3-2.7) 
 
1.0 (0.0-3.0)  
2.0 (1.1-2.8) 
0.83 
Duration of 
wheezes 
  0.0 (0.0-5.0) 
1.7 (1.0-2.5) 
0.0 (0.0-4.0)  
1.8 (0.8-2.7) 
0.62 
Duration of 
rhonchi 
  2.0 (0.0-4.0)  
2.8 (1.8-3.8) 
0.5 (0.0-2.0)  
1.2 (0.5-1.9) 
0.03 
Duration of chest 
in-drawing 
  2.0 (0.0-3.0)  
1.8 (1.3-2.4) 
2.0 (0.0-3.0)  
2.0 (1.2-2.8) 
0.75 
P-values are presented as reported in the original article 
4.5  DISCUSSION 
4.5.1 Summary of main results 
This review included two RCTs, one of which compared standard treatment for pneumonia with 
additional conventional ACT,221 and one that compared recommended non-mandatory positioning, 
cough and diaphragmatic breathing with conventional ACT combined with PEP in all children and FET 
in children older than five years of age.222 The latter study did not make a distinction between the 
two age categories (younger and older than five years) with regards to control group 
interventions.222 It is questionable if and how diaphragmatic breathing was achieved with young, 
uncooperative children.  
The intended primary outcome measure of this review, duration of hospitalisation, was investigated 
in both studies and I have to conclude that ACT did not have an influence on the duration of 
hospitalisation. However, the study by Lukrafka et al. did report a two day difference between the 
intervention and control group, with a longer duration of hospitalisation for the intervention 
group.222 This study might have been underpowered to detect a significant difference between the 
two groups. The other outcome measures of this review were not assessed in the included studies, 
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therefore we cannot comment on the effectiveness of ACT with regards to these outcomes. 
Conventional ACT was not found to have an influence on time to clinical resolution.221 There was 
also no influence of conventional ACT combined with PEP (and FET in children older than five years 
of age) on the reduction of RR and severity score.222 Investigation of the outcome measure 
‘persistence of respiratory symptoms’, described in the study by Paludo et al., suggests signs of 
improvement when using ACT.221 However, a longer duration of coughing and rhonchi in the 
participants receiving conventional ACT was also reported.  
4.5.2 Overall completeness and application of evidence 
The included studies were both RCTs,221,222 but only one study reported the method of allocation 
concealment.222 Not all the review’s objectives have been addressed; as the included studies did not 
comment on adverse events or mortality and I was unable to compare one technique to no 
physiotherapy or to another type of ACT. Both studies combined multiple ACTs in their intervention 
group, which makes it impossible to draw conclusions regarding individual techniques. Only one of 
our pre-set outcome measures, duration of hospital stay, was reported in the studies. The other 
primary outcome measures, SaO2/SpO2 measured before and after intervention and the secondary 
outcome measures, RR measured before and after intervention, duration of oxygen 
supplementation (in hours), lung function tests (spirometry): VC, FVC, FEV1, PEF, maximal inspiratory 
pressure and maximal expiratory pressure measured on enrolment and before discharge, any 
adverse effect and mortality were not addressed in the included studies. As different outcome 
measures were use in the studies with different presentation of results, it was not possible to 
compare all the data. The study by Lukrafka et al. used severity scores to express baseline and 
discharge symptoms, but no separate reporting of the symptoms, such as SpO2 and fever, were 
available for analysis.222 The study by Paludo et al. did report the duration of symptoms as median 
and IQRs, and the authors made mean and 95% CI available for analysis.221 But due to the lack of 
comparable data, no meta-analysis was possible in this review. Further, one study described the 
condition as ‘acute pneumonia’,221 while the other study described it as ‘CAP’.222 It is therefore 
unclear whether the studies described the same condition. Lastly, both studies were conducted in 
Brazil, which limits the generalisability of the findings. 
4.5.3 Quality of the evidence 
Two studies, analysing 161 participants who were randomly assigned to the intervention or control 
groups, were included in this review. The weakness of these studies included risk of bias, multiple 
ACTs used in the intervention groups, different definitions of the included disease, differing severity 
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of symptoms and different outcome measures, which makes it difficult to make an overall 
conclusion. Only one study reported allocation concealment in their article.222 Due to the nature of 
the intervention it is impossible to blind the participants of the research, therefore both studies did 
not comment on this in their studies. The outcome assessors were blinded in both trials, as was the 
data-analyser in the study by Lukrafka et al.222 The blinding of data-analysts was not mentioned in 
the study by Paludo et al. (for which the risk of bias was unclear).221 There was inadequate 
information available to eliminate other potential threats to the validity of the studies.  
4.5.4 Potential biases in the review process 
Six different databases were searched, as well as checking the reference lists of all relevant articles 
and searching clinicaltrial.gov and pactr.gov registry to identify potential studies for this review. I 
contacted the authors of the articles to gather more information with regards to mean and 95% CI of 
all included data, but only one author replied.221 No articles were excluded due to language, which 
reduces the risk of selective data reporting. Although, two articles were excluded on the basis of 
publication date, which might have increased the risk of selective data reporting, the major changes 
in the field of ACT ought to justify the exclusion of these studies. I might have missed studies 
reported in non-peer reviewed journals or data-bases, or studies presented at local conferences, 
which may lead to a potential bias. Grey literature was not searched, therefore, one RCT which 
compared PD, vibrations, percussions, thoracic squeezing and cough assist with standard care in 50 
children between the age of 29 days and 5 years was not included in this review (see Table 3-1).223 
The study reported some improvement in the time to clinical resolution, RR and SpO2 in the 
intervention group; however, it is unclear how randomisation was performed and allocation 
concealment was maintained with potential for introduction of bias.223 One important potential bias 
is the identification of the ongoing clinical trial identified through pactr.gov, as this study is one 
conducted towards this degree (Chapter 6). 
4.5.5 Comparison with other studies or reviews 
Although two non-RCTs suggested positive effects of ACT (one in a sample of children with CAP,228 
and one on HIV-infected children receiving ARV therapy)226, a recently published review on ACT for 
pneumonia in children concludes that although some minor improvements can be found in children 
receiving ACT, they were unable to pool the data and make generalisable conclusions.231 However, 
the review by Chaves et al. differs from this review with regards to the included types of pneumonia 
and the definition of ACT, as they included a study which used nasal CPAP, a type of non-invasive 
ventilatory support, and not ACT.231 Another published review on ACT in adults with pneumonia 
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included six trials and concluded that osteopathic manipulations and PEP could reduce the length of 
hospitalisation; PEP might reduce the duration of fever; and osteopathic manipulations could reduce 
duration of antibiotic treatment.230 However, the overall conclusion indicated that there was 
insufficient evidence to support the use of ACT in this population.  
4.6  CONCLUSION 
4.6.1 Implications for practice 
Due to the limited number of included articles and the inability to pool data for meta-analysis, it is 
impossible to make clear, justified recommendations for clinical practice. Therefore we cannot reject 
or recommend ACT as a standard treatment option in children with pneumonia. 
4.6.2 Implications for research 
There is clearly a need for more RCTs in this field of research. The two included RCTs used a 
combination of several conventional ACTs, none investigating the use of AD or AAD in children with 
pneumonia. The use of several different ACTs makes it impossible to make conclusions or 
recommendations on one single treatment. Each treatment should ideally be tested separately, 
rather than using in a multi-modal approach, and standardised, to identify its influence in the 
treatment of pneumonia as each ACT has a different mechanism of action (see section 2.3). 
Furthermore, research is recommended with adequate sample sizes (which could allow sub-analysis 
of different severity levels of pneumonia); clear, standardised control interventions; appropriate 
outcome parameters and clear analysis of adverse events and mortality. This need was attempted to 
be addressed as outlined in Chapter 6. 
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Chapter 5. THE USE OF AIRWAY CLEARANCE THERAPY IN CHILDREN HOSPITALISED WITH 
ACUTE LOWER RESPIRATORY TRACT INFECTIONS IN A SOUTH AFRICAN TERTIARY HOSPITAL 
5.1  INTRODUCTION 
As mentioned previously, ACT is often used in the clinical management of children with LRTI, 
including pneumonia. However, there is little documentation available on the prescription, 
frequency and nature of ACT. Most importantly, there is little published data regarding adverse 
events that may be associated with ACTs in children with LRTI. A better understanding of the use of 
ACT in clinical practice is warranted.  
5.2  AIM AND OBJECTIVES 
The overall aim of the study was to develop a better understanding of the role ACT plays in the 
management of children with LRTI, including pneumonia, admitted to a specialised tertiary 
paediatric hospital in the Western Cape of South Africa. 
The specific objectives were to determine, in children hospitalised with LRTI at a teriary paediatric 
hospital in Cape Town, South Africa, from January 2015 to June 2015 (from mid-summer to mid-
winter): 
1) The demographic details, characteristics, medical diagnoses and comorbid conditions. 
2) The proportion of children receiving mechanical ventilation and the duration of these 
interventions; and the proportion of children receiving supplemental O2 at time of 
admission. 
3) The proportion of children who received ACT during their admission. 
4) The nature, frequency and duration of ACT. 
5) Which variables were associated with receiving ACT, including: 
- disease severity (determined by RR, heart rate (HR), the need for mechanical ventilation 
during hospitalisation and/or O2 supplementation at the time of admission)  
- comorbidities (chronic cardiovascular and lung diseases, prematurity, NMD, cerebral palsy 
(CP), among others) 
6) The incidence and nature of adverse events associated with ACT (these are documented as 
part of standard practice with each physiotherapy treatment) 
7) Which factors are associated with adverse events related to ACT, including: 
- disease severity (determined by RR, HR, the need for mechanical ventilation during 
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hospitalisation and/or O2 supplementation at the time of admission) 
- comorbidities (chronic cardiovascular and lung diseases, prematurity, NMD, CP, among 
others) 
8) Patient outcomes:  
- length of hospital stay  
- mortality 
9) The influence of various variables on these patient outcomes. 
5.3  METHODOLOGY 
5.3.1 Study design and research setting 
A retrospective descriptive study was conducted, based on record review. Folder information of 
children hospitalised at the research site, with a clinical diagnosis of community- or hospital acquired 
LRTI, was extracted. The study period was extended to account for a seasonal change in admissions 
to the institution. 
5.3.2 Participants 
Children hospitalised with community- or hospital acquired LRTI at any ward at the research site 
(Intensive Care Unit, medical, surgical and specialist wards), for which the medical files were 
available, were included in the study. 
Participants in the intervention group of the study on the use of AAD in children with acute 
respiratory disease in South Africa (Chapter 6) were included for research objectives 1) to determine 
the demographic details, medical diagnoses and complications; 2) proportion of children receiving 
mechanical ventilation and the duration of these interventions; and proportion of children receiving 
O2 supplementation at time of admission; 8) patient outcomes and 9) the influence of various 
variables on these patient outcomes. However, as these children received bidaily AAD for research 
purposes, they were excluded from the other analyses. 
The sample was population-based, aimed at including the entire population of children admitted 
with a LRTI during the six-month time frame. 
5.3.3 Outcome measures/instrumentation 
A standard pre-structured data extraction form was developed (Appendix 5). Table 5-1 lists the 
different items with reasons for inclusion in extraction form. 
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Table 5-1. Reason for including items in data extraction form 
Category Item Reason for inclusion 
General 
information 
Folder number To identify which folders have been completed and to be able to return to the 
folder when information was incomplete. This item was removed from the excel 
datasheet after completion of the analyses. 
Date of birth To be able to calculate the child’s age at admission 
Gender For demographic description of the population and to investigate whether gender 
influences the chance of receiving ACT 
Prematurity/gestational age Children born younger than 30 weeks gestational age are more prone to chest 
infections and chronic lung disease. Therefore this item would be added to the 
demographic information and used as a variable for predicting the need for ACT 
HIV status For demographic purposes as the incidence of HIV is still high in South Africa. HIV 
infected and exposed children are also more prone to chest infections. This item 
was therefore intended to be used in the logistic regression for predictors of ACT 
use History of TB For demographic purposes regarding medical history and as an influencing factor 
for receiving ACT 
Asthma For demographic purposes regarding comorbid conditions, and to identify factors 
which could influence: 
- the need for ACT 
- the likelihood for adverse events due to ACT 
- duration of hospital stay 
CF 
Other respiratory disease 
NMD 
CP 
Heart disease 
Chest deformities 
Osteoporosis For analyses of adverse events as this condition can lead to rib fractures during ACT 
History of thoracic or 
abdominal surgery 
ACT could influence the surgical site if the surgery was performed in recent history. 
Therefore this item was included for adverse event purposes 
Current 
admission 
Date of admission To calculate the age at admission 
Age For demographic purposes. Furthermore, age will influence vital signs, especially 
HR and RR, and could influence patient outcomes 
Temperature at admission For determining disease severity and to be included in the analyses of the 
association between ACT and disease severity RR at admission 
HR at admission 
SpO2 at admission 
Signs of respiratory distress 
O2 supplementation on 
admission 
Mechanical ventilation 
Type of organism (bacterial, 
viral, mixed, unknown) 
To determine disease organism which could be influencing the need for ACT, 
adverse events and patient outcomes 
Date of discharge To calculate length of stay 
Days of hospitalisation As this is one of the study’s outcome measures 
Adverse events Pneumothorax To identify any adverse events related to ACT. Data was recorded as presented in 
the medical files. Increased intracranial pressure was based on clinical report  such 
as bulging fontanel and altered mental state. 
Increased intracranial pressure 
Pleural effusion 
Rib fractures 
Lung/lobar collapse 
Atelectasis 
Airway 
clearance 
therapy 
Was ACT prescribed? Not all children who have been prescribed ACT receive it. This item will therefore 
be used to identify for which children ACT is prescribed 
Was ACT given? As above, therefore this item will identify which children are more likely to receive 
ACT 
When was ACT started? To identify the nature and frequency of ACT, as well as to identify when ACT is 
commenced. How often was ACT given? 
Which techniques were used? 
Desaturation To identify this adverse event during ACT 
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This data extraction form was validated for content by two experts, one in the field of epidemiology 
and one in the field of paediatric cardiopulmonary physiotherapy. The following items were added 
to the data extraction form after feedback: 1) history of pneumothorax, 2) other types of LRTI, 3) 
blood pressure, 4) mortality outcome, and 5) whether or not other forms of physiotherapy were 
performed. 
Data were collected from the patients’ medical records. The medical files include all patients’ 
characteristics (e.g. age, gender, disease severity and comorbidit conditions) and whether or not 
physiotherapy (either ACT or other forms of physiotherapy) was given to the child. It is standard 
procedure for physiotherapy staff to document their assessment findings, treatment techniques and 
outcomes of treatment, including adverse events, in the patient’s medical file. The following specific 
adverse events were screened for in the medical files: desaturation during and/or post treatment, 
pneumothorax, pleural effusion, increased intracranial pressure, lung/lobar collapse, rib fractures 
and atelectasis.  
Magpi, a mobile data collection tool (available from home.magpi.com), was used to extract and 
digitalise data. 
5.3.4 Procedure 
Approvals from the Human Research Ethics Committee (HREC) of the University of Cape Town and 
the medical superintendent at the research site were obtained (Appendix 6). A waiver of the need 
for written informed consent was obtained from the HREC, as this study was a retrospective, low risk 
study.  
5.3.4.1 Identification of folders 
After consulting clinical staff, the following method of identifying folders was found most suitable: 
eligible patients were identified via Clinicom, using ICD10-codes of the primary admission diagnosis. 
The folders of patients with the following primary diagnoses were screened: pneumonia, 
bronchiolitis, LRTI and respiratory distress (see Appendix 7 for a complete list of searched ICD 10-
codes). In addition, clinical physiotherapy staff allowed access to their records of patients referred 
for ACT for the period under study.  
5.3.4.2 Quality assurance 
A research assistant assisted with extracting folders from medical records and data collection. She 
received an explanation of the pre-set data extraction form and Magpi data collection tool prior to 
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data collection. For the first hour of data collection, I was in close proximity so the research assistant 
could ask questions when necessary. Further, I was always reachable telephonically if there were 
any queries that needed to be resolved. The research assistant and I both collected data from 
different folders. At the end of data collection, ten folders were randomly selected from the list of 
eligible folders and data were extracted once more, by the other data collector, to ensure data were 
entered consistently. For most cases and outcome measures, 100% agreement was obtained. 
However, it was noted that HIV status was entered inconsistently. In the cases where the child’s HIV 
status was ‘unexposed’ as reported by the parents, the research assistant indicated this as 
‘unknown’ HIV status, whereas I indicated this as ‘unexposed’. In the case of HIV positive, negative 
and exposed, good agreement was obtained. Therefore, caution is needed when interpreting HIV 
unexposed and unknown data. This item has therefore not been used for further analyses in this 
study. 
5.3.4.3 Data capturing 
Medical folders were obtained from the medical records office. All folders remained at the medical 
records office to minimise interference with the daily activities at the research site. Patient details 
were de-identified. All data were immediately entered into Magpi, which is a password protected 
online data capturing system. Data were exported from Magpi into a password protected Excel 
spreadsheet. 
5.3.4.4 Data analysis 
Data were analysed with Statistica Version 13 (Statsoft Inc, USA). Descriptive statistics were 
performed for demographic information; the nature, frequency and duration of treatment; 
incidence and nature of adverse events; and patient outcomes. Proportions were presented as 
percentages. Data were tested for normality using the Lilliefors test. All numerical data were 
presented as either mean (standard deviation (SD)) or median (IQR). Chi-square, Fisher exact and 
Yates test were performed for categorical data. Finally, ORs of various variables for receiving ACT 
and adverse events were calculated and logistic regression analyses were performed. The influence 
of various variables on the patient outcome measures were analysed using multiple regression 
analysis. 
5.4  RESULTS 
In total, 1756 cases were identified based on primary ICD10 codes and the Physiotherapy 
Department’s patients list (Figure 5-1), of which 399 folders were duplicates, leaving 1357 folders for 
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screening for eligibility. Fifty-four folders were excluded as the child did not, in fact, have a LRTI (see 
Table 5-2 for reasons of hospitalisation) and 93 folders were missing or missed the relevant doctors’ 
notes, for which no information could be extracted. Therefore, a total of 1208 patient folders were 
included in this descriptive folder review. Of these, 1038 patients (85.9%) were hospitalised once 
between January and June 2015. The remaining 172 (14.2%) were hospitalised multiple times within 
six months. 
Table 5-2. Reasons for hospitalisation of excluded folders 
Category Reason for hospitalisation N Percentage 
 No LRTI, not further specified 9 16.7 
13. 
 
 
Post-surgery Cardiac surgery 7 13.0 
 Sternotomy 1 1.9 
 Thoracic surgery 1 1.9 
 PEG surgery 1 1.9 
 Hip surgery 1 1.9 
 Gunshot wound 1 1.9 
 Kasai surgery 1 1.9 
Respiratory Bronchospasm, not LRTI induced 3 5.6 
 Chronic lung disease, no acute infection 3 5.6 
 Lung abscess 1 1.9 
 Bronchiolitis obliterans pulsing 1 1.9 
 Upper respiratory tract infection (URTI) 1 1.9 
 Asthma exacerbation due to URTI 1 1.9 
 Pulmonary oedema due to chronic heart disease 1 1.9 
 Trachea stenosis 1 1.9 
 Croup, no other LRTI 1 1.9 
Neurological Meningitis 3 5.6 
 Herpes encephalitis with URTI 1 1.9 
Other Chicken pox 5 9.3 
 Pneumothorax after motor vehicle/pedestrian accident 2 3.7 
 TB pericarditis 1 1.9 
 Erythrodema 1 1.9 
 Follow up kidney transplant 1 1.9 
 Measles without LRTI 1 1.9 
 Neuromuscular chest pain 1 1.9 
 Observation for new treatment technique 1 1.9 
 Admitted before the study period 1 1.9 
 Folder of the mother of one of the hospitalised children 1 1.9 
Total  54 100 
N= 54 excluded folders  
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Figure 5-1. Folder review flow chart 
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5.4.1 Demographic information 
The median age of children hospitalised with a LRTI at the research site within the time frame of 
January to June 2015 was 7.6 months (IQR 2.8-19.0). Frequency distribution in years is presented in 
Figure 5-2. The majority was male (59.6%), confirmed HIV negative (57.9%) and born at term (37 
weeks gestational age (64.2%)). Data were based on the first hospitalisation for each patient in the 
study period (n=1208). 
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Thirty-five children were HIV infected, 29 (82.9%) of whom had received ARV therapy prior to or at 
the time of admission. No information was available regarding ARV therapy for the other six 
patients. The median duration of ARV therapy before admission was 63 days (IQR 0.0-117.0). 
 
 
Figure 5-2. Frequency histogram for age in years 
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5.4.2 Health condition 
5.4.2.1 Primary diagnosis 
Most hospitalisations were primarily for the management of bronchiolitis, followed by pneumonia, 
unspecified acute LRTI, and other conditions (Figure 5-3). No primary diagnosis was available for 106 
(7.4%) hospitalisations, which were presumed to be nosocomial infections by the researchers. An 
overview of the ICD-10 codes for primary diagnosis can be found in Table 5-3. 
 
Table 5-3. Overview of ICD-10 codes for primary diagnosis 
Aetiology ICD-10 code Description N Percentage 
Bronchiolitis 
  
  
  
J21.X Acute bronchiolitis 1 0.1 
J21.0 Acute bronchiolitis due to RSV 3 0.2 
J21.9 Acute bronchiolitis, unspecified 658 45.7 
Total  662 46.0 
Pneumonia 
  
  
  
  
  
  
  
  
  
J12.0 Adenoviral pneumonia 6 0.4 
J12.1 Respiratory syncytial virus pneumonia 2 0.1 
J12.8 Other viral pneumonia 2 0.1 
J12.9 Viral pneumonia, unspecified 1 0.1 
J13.X Pneumonia due to Streptococcus pneumoniae 1 0.1 
J15.9 Bacterial pneumonia, unspecified 1 0.1 
J18.0 Bronchopneumonia, unspecified 137 9.5 
J18.1 Lobar pneumonia, unspecified 14 1.0 
J18.9 Pneumonia, unspecified 361 25.1 
Total  525 36.5 
Unspecified LRTI 
  
J22.X Unspecified acute LRTI 144 10.0 
Total  144 10.0 
Other 
  
  
  
B01.8 Varicella with other complications 1 0.07 
B01.9 Varicella without complications 1 0.07 
B20.7 HIV disease resulting in multiple infections 1 0.07 
Total   3 0.2 
N= 1440 hospitalisations 
Figure 5-3. Primary diagnoses of the included hospitalisations 
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5.4.2.2 Associated organisms 
Positive sputum or blood cultures were available in 245 hospitalisations (17.0%). Figure 5-4 and 
Table 5-4 present the prevalence of associated organisms, for each diagnostic category, as identified 
on sputum or blood culture. One child in the category “other” tested positive for RSV and 
Cytomegalovirus.  
N= 1440 hospitalisations, presented as 100% stacked histograms per diagnostic category  
Figure 5-4. Prevalence of identified organisms per diagnostic category 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
LRTI
Pneumonia
Bronchiolitis
Presumed nosocomial
LRTI Pneumonia Bronchiolitis
Presumed
nosocomial
Unspecified 84,7% 76,4% 92,6% 53,8%
Viral 12,5% 18,3% 6,8% 20,8%
Mixed 0,7% 3,8% 0,0% 17,0%
Bacterial 2,1% 1,5% 0,6% 13,2%
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Table 5-4. Prevalence of viral and bacterial organisms 
Category Organism Total, n(%) Bronchio 
litis, n 
Pneumo 
nia, n 
LRTI, 
n 
Presumed 
nosocomial, 
n 
Viral RSV 108 (44.1%) 27 57 10 13 
Rhinovirus 92 (38.0%) 18 51 7 17 
Adenovirus 79 (32.2%) 19 36 11 12 
Boca virus 32 (13.1%) 9 16 4 3 
Parainfluenza 25 (10.2%) 5 14 5 1 
Influenza 19 (7.8%) 4 7 4 4 
Enterovirus 17 (6.9%) 2 13 1 1 
Human corona virus 15 (6.1%) 1 10 0 4 
Cytomegalovirus 11 (4.5%) 1 7 0 2 
Human metapneumovirus 3 (1.2%) 0 2 0 1 
Parvo virus 1 (0.4%) 1 0 0 0 
Total viral organisms 402 87 213 42 58 
Bacterial Mycobacterium tuberculosis 12 (4.9%) 1 7 1 3 
Klebsiella pneumonia 11 (4.5%) 1 4 1 5 
Pseudomonas aeruginosa 9 (3.7%) 0 2 0 7 
Haemophilus influenzae 8 (3.3%) 1 0 1 6 
Staphylococcus aureus 6 (2.4%) 0 1 0 5 
Streptococcus pneumoniae 4 (1.6%) 0 1 0 3 
PJP  4 (1.6%) 0 4 0 0 
Acinetobacter baumannii 3 (1.2%) 0 1 0 2 
Escherichiac coli 3 (1.2%) 0 2 0 1 
Methicillin-resistant 
Staphylococcus aureus 
2 (0.8%) 0 1 0 1 
Moraxella 2 (0.8%) 0 1 0 1 
Enterobacter cloacae 2 (0.8%) 0 0 0 2 
Serratia marcescens      1 (0.4%) 1 0 0 0 
Stenotrophomonas maltophilia 1 (0.4%) 0 0 0 1 
Unspecified gram positive bacteria 
      
10 (4.1%) 
 
0 7 0 3 
Total bacterial organisms 78 4 31 3 40 
Total  480 91 244 45 98 
N= 245 sputum/blood tests, multiple responses per test possible 
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5.4.2.3 Chest X-rays 
Chest X-ray findings were reported in the medical file in 1010 cases (70.1%). Data were extracted 
from the files as reported by the attending physician and are presented in Table 5-5. 
Table 5-5. Frequency of chest X-ray findings 
Category X-ray finding N Percentage 
Consolidation/infiltrates Right middle lobe 322 31.9 
Bilateral 263 26.0 
Right upper lobe 194 19.2 
Right lower lobe 172 17.0 
Perihilar 152 15.0 
Left lower lobe 134 13.3 
Multilobar 87 8.6 
Left upper lobe 55 5.4 
Left lingual 24 2.4 
Total consolidation/infiltrates 1403  
Other Hyperinflation 429 42.5 
Air bronchogram 36 3.6 
Diffuse opacification 30 3.0 
Air trapping 25 2.5 
Collapse 24 2.4 
Airspace disease 22 2.2 
Nodes 22 2.2 
Pleural effusion 21 2.1 
Diffuse ground glass opacification 12 1.2 
Total other findings 621  
Total  2024  
N= 1010 chest X-rays, multiple findings per X-ray possible 
5.4.2.4 Admission information  
Figure 5-5 presents a scatterplot of the absolute values of RR compared to the norm values per age 
(n= 1237 hospitalisations, n= 203 missing data); and Figure 5-6 presents the HR at admission 
compared to the norm values per age (n= 1092 hospitalisations, n= 348 missing data), based on the 
normative data presented in a systematic review by Fleming et al.240 Signs of respiratory distress 
were seen in 1360 hospitalisations (94.4%), with tachypnoea the most common (n= 1009, 81.6% of 
hospitalisations with recorded RR), followed by recessions (subcostal recession (n= 776, 53.9%), 
unspecified recessions (n= 195, 13.5%) and intercostal recession (n= 167, 11.6%). Other signs of 
distress reported in the medical files were alar flaring (n= 338, 23.5%), tracheal tug (n= 122, 8.5%), 
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head bobbing (n= 69, 4.8%), cyanosis (n= 6, 0.4%) and feeding problems (n= 6, 0.4%). The median 
(IQR) temperature at admission was 37.0 (36.7-38.0)°C (based on n= 1334, n= 106 missing); and the 
median (IQR) SpO2 in room air was 96.0 (94.0-98.0)% (based on n= 1059, n= 381missing). 
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Figure 5-5. RR at admission compared to the RR norm for age. 
 
                                                          
 
(3) The green line indicates where the RR at admission is exactly the same as the normed RR. Data 
points left of this line represents children who have a RR at admission below the norm, whereas data 
points right of the line are children who have a RR at admission above the norm. 
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Figure 5-6. HR at admission compared to the HR norm for age. 
 
5.4.2.5 Mechanical ventilation and oxygen support 
Oxygen support at the time of admission was given in 183 cases (12.7%) and recorded in the medical 
files, (ranging from 1-8 litre/min with 2 litre/min the most frequently applied flow rate (n= 164)). 
However, no information regarding oxygen support at admission was available in 820 cases. 
Information for oxygen support during hospitalisation was not extracted from the files. 
                                                          
 
(4) The green line indicates where the HR at admission is exactly the same as the normed RR. Data 
points left of this line represents children who have a HR at admission below the norm, whereas data 
points right of the line are children who have a HR at admission above the norm. 
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In 258 hospitalisations, children received non-invasive and/or invasive mechanical ventilation 
(17.9%). An overview of the provided modalities is shown in Table 5-6. The median (IQR) number of 
days on mechanical ventilation was 3.0 (2.0-5.0) days.  
Table 5-6. Frequency of invasive and non-invasive mechanical ventilation modalities. 
Mechanical ventilation modality N Percentage 
Continuous positive airway pressure  234 90.7 
Intermittent positive pressure ventilation 62 24.0 
Pressure control ventilation 12 4.7 
High frequency oscillatory ventilation 11 4.3 
Bilevel positive airway pressure 11 4.3 
Synchronised intermittent mandatory ventilation 3 1.2 
Total 333  
N= 258 cases receiving mechanical ventilation during hospitalisation; multiple modalities could have been used in one case. 
5.4.2.6 Medical history 
Twenty-five children (2.1%) had a history of TB; information regarding TB history was missing for 
eight children. The episode of TB occurred a median of 8.2 months (IQR 6.3-45.7) prior to the first 
day of admission in our pre-set timeframe (based on n=15, no information available for 10/25 
children). 
Most children (82.1%) had not been hospitalised for a prior respiratory disease before their first 
admission in this study’s timeframe (Figure 5-7). Information was missing for 14 cases. For the 
children who were hospitalised previously, the most recent hospitalisations occurred a median of 8.9 
months (IQR 4.8-14.6) before the first admission in 2015. 
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Figure 5-7. Frequency and nature of previous hospitalisations due to respiratory disease. 
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Two patients had a history of pneumothorax. The pneumothorax occurred three to six months prior 
to the first hospitalisations within the study period in one child, and six to twelve months in the other 
child. A history of abdominal or thoracic surgery was present in 56 children (4.6%), of which 29 had 
repair of cardiac anomalies (e.g. atrioventricular septal defect repair, ventricular septal defect repair, 
atrial septal defect repair, patent ductus arteriosus ligation, aortic stenosis, coarctation repair, 
anomalous left coronary artery from the pulmonary artery, pacemaker), 20 had a percutaneous 
endoscopic gastrostomy (PEG) inserted, three underwent a laparotomy, two a colostomy, one had an 
appendectomy, one a liver transplant, one a pneumonectomy, and one had a posterior urethral valve 
ablation. Two children had two procedures (PEG cardiac surgery). 
5.4.2.7 Comorbidities  
Of the total sample, 52.6% of the children had one or more clinically significant comorbidity during at 
least one of the hospitalisations in our time frame (n= 1208). See Figure 5-8 for an overview of the 
prevalence of different comorbidity categories. An overview of all comorbidities can be found in 
Appendix 8. The common chronic and acute comorbidities present in ten or more children are 
presented in Table 5-7 and Table 5-8. 
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Figure 5-8. Prevalence of comorbidities. Percentage of children with comorbidities during at least one hospitalisation. 
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Table 5-7. Most common chronic comorbidities seen in children hospitalised with a LRTI. 
Disease 
category 
Comorbidity N Percentage 
Respiratory Asthma 
     Proven 
     Suspected 
 
49 
7 
 
4.1 
0.6 
Upper airway obstruction 27 2.1 
Chronic lung disease, not further specified 11 0.9 
Cardiovascular Patent ductus arteriosus 
     Proven 
     Suspected 
 
23 
1 
 
1.9 
0.1 
Ventricular septal defect 22 1.8 
Atrioventricular septal defect 15 1.2 
Neurological Seizures/epilepsy 35 2.9 
CP 23 1.9 
NMD 13 1.1 
Genetic disorder Trisomy 21 19 1.6 
Musculoskeletal Scoliosis 11 0.9 
Gastrointestinal GORD 51 4.2 
Dermatological Eczema 33 2.7 
Other Developmental delay 45 3.7 
Neonatal jaundice 34 2.8 
Dysmorphic features 14 1.2 
Maternal drug abuse during pregnancy or exposure of the child to toxic fumes 
caused by drugs 
10 0.8 
N= 1208 children, one child could present with multiple comorbid conditions 
 
Table 5-8. Most common acute comorbidities seen in children hospitalised with a LRTI. 
Disease category Comorbidity N Percentage 
Respiratory URTI 47 3.3 
Allergic rhinitis 16 1.1 
Apnoea 16 1.1 
Pertussis 
     Proven 
     Suspected 
 
13 
2 
 
0.9 
0.1 
Bronchospasm 11 0.8 
Cardiovascular Anaemia 107 7.4 
Sepsis 72 5.0 
Neurological Meningitis 10 0.7 
Gastrointestinal Acute gastroenteritis 91 6.3 
ENT Otitis media 24 1.7 
Dermatological Dermatitis 18 1.3 
Candidiasis/fungal rash 11 0.8 
Nutritional/metabolic Failure to thrive 151 10.5 
Hypothyroidism 10 0.7 
Ophthalmological Conjunctivitis 18 1.3 
N= 1440 hospitalisations, multiple comorbid conditions could be present during one hospitalisation 
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A significant association was seen between primary diagnostic category and the presence of at least 
one chronic (Yates X2= 170.5, p<0.001) or acute comorbidity (Yates X2= 55.7, p<0.001), based on the 
most common comorbidities. The proportion of children presenting with a primary clinical diagnosis 
of pneumonia and comorbidities was the highest (Table 5-9 and Table 5-10). 
Table 5-9. Association between the presence of a chronic comorbidity and diagnostic category. 
Primary diagnosis Chronic comorbidity 
 Yes No Total 
Presumed nosocomial 71 35 106 
Column% 23.6 3.1  
LRTI 37 107 144 
Column% 12.3 9.4  
Pneumonia 116 409 525 
Column% 38.5 35.9  
Bronchiolitis 76 586 662 
Column% 25.3 51.5  
Other 1 2 3 
Column% 0.3 0.2  
Total 301 1139 1440 
N=1440 hospitalisations 
Table 5-10. Association between the presence of an acute comorbidity and diagnostic category. 
Primary diagnosis Acute comorbidity 
 Yes No Total 
Presumed nosocomial 42 64 106 
Column% 12.5 5.8  
LRTI 34 110 144 
Column% 10.0 10.0  
Pneumonia 161 364 525 
Column% 47.8 33.0  
Bronchiolitis 99 563 662 
Column% 29.4 51.0  
Other 1 2 3 
Column% 0.3 0.2  
Total 337 1103 1440 
N= 1440 hospitalisations 
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5.4.3 Airway clearance therapy 
Four hospitalisations were excluded for the following analyses as these children were enrolled in the 
intervention arm of the pneumonia RCT, biasing the airway clearance intervention. Therefore, 
analysis is based on 1436 hospitalisations. ACT was given in 83 cases (5.8% of the 1436 
hospitalisations) in the study timeframe.  
5.4.3.1 Description of airway clearance therapy 
The majority of ACT interventions (n=63, 75.9%) were started during the first week of hospitalisation. 
Of these, 17 cases (27.0%) received intervention on the day of admission, 25 (39.7%) on the second 
day of hospitalisation, six on day 3 (9.5%), five (7.9%) at each of day 4 and day 5, three at day 6 
(4.8%) and two at day 7 (3.2%). Twelve interventions (14.5%) were started after one week of 
hospitalisation, and seven (8.4%) after two weeks of hospitalisation (of whom five were hospitalised 
for presumed nosocomial infections, one for pneumonia and one for unspecified LRTI). 
Approximately half of the patients received once daily treatment (n= 41, 49.4%). One received more 
than bidaily ACT (1.2%) and the rest received bidaily treatment (n= 40, 48.2%). In one case, no 
information regarding frequency was available. ACTs were performed for a median (IQR) of 3.0 (1.0-
6.0) days per hospitalisation (n=80). 
Table 5-11 presents an overview of the performed ACT modalities (used at least once during the 
respective hospitalisation). 
Table 5-11. Frequency of performed ACTs. 
Treatment modality  N Percentage 
Vibrations 69 83.1 
MPD 46 55.4 
Percussions/clapping 32 38.6 
Deep breathing exercises 21 25.3 
Active gross motor exercises/mobilisation 17 20.5 
ACBT 11 13.3 
Thoracic compressions 7 8.4 
FET/Huff 6 7.2 
Bubble PEP 6 7.2 
AAD 5 6.0 
Oscillating PEP 3 3.6 
Blowing bubbles 3 3.6 
Chest wall shaking 1 1.2 
PEP 0 0.0 
AD 0 0.0 
Total 227  
N= 83 cases receiving ACT, multiple ACTs could be used per case 
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5.4.3.2 Adverse events 
SpO2 decreased during or immediately after ACT in six cases (7.2%) (three desaturated to levels 
between 85-89% and three to below 85%). Desaturation occurred during side lying on the left side 
(n=2), suctioning (n=1), suctioning and vibrations (n=1), percussions and vibrations (n=1), and 
breathing exercises in the sitting position (n=1). One child presented with lung collapse more than an 
hour after ACT. No other adverse events associated with ACT occurred. 
Due to the small number of children presenting with adverse events, no further analyses of this 
outcome measure was conducted. 
5.4.3.3 Predictors for receiving airway clearance therapy 
A significant association was found between the primary diagnostic category and whether or not ACT 
was given (Yates X²= 319.0, p<0.001). ACT was most often given in children hospitalised with 
presumed nosocomial infections and pneumonia. Children with presumed nosocomial infections 
were most likely to receive ACT, followed by children with pneumonia (Table 5-12). 
Table 5-12. Prevalence of airway clearance therapy based on disease category 
Primary diagnosis Airway clearance therapy 
 No Row% Yes Row% Total 
Presumed nosocomial 58 54.7 48 45.3 106 
Column% 4.3  57.8   
LRTI 140 98.6 2 1.4 142 
Column% 10.4  2.4   
Pneumonia 494 96.1 20 3.9 514 
Column% 36.8  24.1   
Bronchiolitis 647 98.0 13 2.0 660 
Column% 48.2  15.7   
Other 3 100.0 0 0.0 3 
Column% 0.2  0.0   
Total 1342  83  1425 
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Furthermore, a significant association between isolated organisms and receipt of ACT was seen 
(X²=171.2, p<0.001). Children with bacterial organisms were more likely to receive ACT (Table 5-13). 
Table 5-13. Prevalence of airway clearance therapy based on organism associated with LRTI. 
 
 
 
 
The OR was calculated for variables, which might be predictive for receiving ACT (see Table 5-14). 
The likelihood of receiving ACT increased greatly when chronic comorbidities were present; when the 
child had a history of previous TB or was previously hospitalised for a LRTI, when the HR at admission 
was above normal and when the child was managed with either mechanical ventilation or O2 therapy 
on admission. 
The variables which predicted a higher odds of receiving ACT were included in a backward stepwise 
logistic regression model. Those that became non-significant were excluded and the final model is 
depicted in Table 5-15. The likelihood ratio was 150.5 (p<0.001) which reflected a better fit than the 
models that included more or fewer variables.  
  
Organism Airway clearance therapy 
 No Row% Yes Row% Total 
unknown 1147 97.1 34 2.9 1181 
bacterial 16 55.2 13 44.8 29 
viral 157 86.7 24 13.3 181 
mixed 22 64.7 12 35.3 34 
Total 1342  83  1425 
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Table 5-14. Odds ratios for receiving airway clearance therapy for various variables. 
Variable  Airway clearance therapy OR 95% confidence interval 
  No Row% Yes Row% Total  Lower Upper 
Gender Female 542 93.0 41 7.0 583 0.7 0.4 1.1 
Male 800 95.0 42 5.0 842    
Total 1342 94.2 83 5.8 1425    
Gestational age Preterm 246 94.3 15 5.8 261 0.9 0.5 1.6 
Term 871 94.8 48 5.2 919    
Total 1117 94.7 63 5.3 1180    
Chronic cardiovascular disease No 1249 94.8 68 5.2 1317 3.0 1.6 5.4 
Yes 93 86.1 15 13.9 108    
Total 1342 94.2 83 5.8 1425    
Chronic respiratory disease, excluding asthma No 1282 95.8 56 4.2 1338 10.3 6.1 17.5 
Yes 60 69.0 27 31.0 87    
Total 1342 94.2 83 5.8 1425    
CP No 1315 94.5 77 5.5 1392 3.8 1.5 9.5 
Yes 27 81.8 6 18.2 33    
Total 1342 94.2 82 5.8 1425    
Genetic disorders No 1304 94.5 76 5.5 1380 3.2 1.4 7.3 
Yes 38 84.4 7 15.6 45    
Total 1342 94.2 83 5.8 1425    
NMD No 1338 95.4 64 4.6 1402 132.4 38.2 459.0 
Yes 3 13.6 19 83.4 22    
Total 1341 94.2 83 5.8 1424    
Seizures No 1299 94.7 72 5.3 1371 4.7 2.3 9.6 
Yes 42 79.2 11 20.8 53    
Total 1341 94.2 83 5.8 1424    
History of TB No 1313 94.7 74 5.3 1387 5.3 2.3 12.0 
Yes 27 77.1 8 22.9 35    
Total 1340 94.2 82 5.8 1422    
Previously hospitalised for LRTI No 943 96.6 33 3.4 976 3.4 2.1 5.4 
Yes 396 89.4 47 10.6 443    
Total 1339 94.4 80 5.6 1419    
Respiratory rate Normal 215 96.0 9 4.0 224 1.4 0.7 2.9 
Increased 949 94.4 56 5.6 1005    
Total 1164 94.7 65 5.3 1229    
Heart rate Normal 286 96.6 10 3.4 296 2.3 1.1 4.5 
Increased 735 92.7 58 7.3 793    
Total 1021 93.8 68 6.2 1089    
Mechanically ventilated No 1136 97.1 34 2.9 1170 8.0 5.0 12.7 
Yes 205 80.7 47 19.3 254    
Total 1341 94.2 83 5.8 1424    
Oxygen supplementation on admission No 1186 95.3 59 4.7 1245 3.1 1.9 5.1 
Yes 156 86.7 24 13.3 180    
Total 1342 94.2 83 5.8 1425    
N= 1440 hospitalisations 
Significant ORs are presented in red 
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Table 5-15. Final model of logistic regression for predicting variables for receiving airway clearance therapy. 
Term Adjusted OR 95% C.I. Z-Statistic P-Value 
Chronic respiratory disease  6.6 3.5 12.4 5.9 <0.001 
CP   3.9 1.4 10.7 2.6 0.009 
Genetic disorder  2.8 1.0 7.6 2.0 0.042 
Chronic heart disease  2.2 1.0 4.7 2.0 0.042 
NMD 130.8 35.9 476.4
 
7.4 <0.001 
CONSTANT * * * -21.1 <0.001 
N= 1440 hospitalisations 
 
5.4.4 Patient outcomes 
The median (IQR) length of hospitalisation was 2.3 (1.5-5.0) days (Figure 5-9). 
 
N= 1440 hospitalisations 
Figure 5-9. Histogram of duration of hospitalisation 
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A one way ANOVA indicated that there was a significant difference in the mean days of 
hospitalisation amongst the different diagnostic groups (p<0.001) (Figure 5-10). A post-hoc Tukey 
test identified this difference as being between presumed nosocomial infections and all other 
diagnostic categories (Table 5-16). Furthermore children hospitalised for bronchiolitis had a shorter 
hospital stay than children in the other diagnostic categories. 
  
                                             Duration of hospitalisation
                                                       Vertical bars denote 0,95 confidence intervals
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F(3, 1416)=54.7, p<0.001 
Figure 5-10. Days of hospitalisation per diagnostic category. 
 
Table 5-16. Post-hoc Turkey test for diagnostic group and days of hospitalisation 
Primary diagnosis Mean (SD) Presumed nosocomial LRTI Pneumonia Bronchiolitis 
Presumed nosocomial 14.3 (18.5) - <0.001 <0.001 <0.001 
LRTI 5.4 (12.4) <0.001 - 0.884 0.012 
Pneumonia 6.0 (8.9) <0.001 0.884 -            <0.001 
Bronchiolitis 2.9 (4.0) <0.001 0.012 <0.001 - 
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Forward stepwise multiple regression analysis was performed to identify factors which influenced 
the duration of hospitalisation. All relevant factors were entered. After residual analysis was done, 
nine cases were excluded from analysis. The final model accounted for 52% of the variance (Table 
5-17 and Table 5-18). Mechanical ventilation was the factor that influenced the length of hospital 
stay the most, explaining 28% of variance. It is also seen that children who received ACT stayed in 
hospital for longer. Furthermore, acute comorbidities were more predictive of a longer hospital stay 
than chronic comorbidities or disease severity. 
Table 5-17. Multiple regression results for length of hospitalisation 
Factor b* Standard  error of b* b Standard error of b t(232) p-value 
Intercept   9,0 3,6 2,5 0,012 
Mechanical ventilation 0,4 0,1 5,3 0,6 8,5 <0,001 
Acute comorbidity 0,3 0,0 3,1 0,6 5,5 <0,001 
Airway clearance therapy 0,2 0,1 3,0 1,1 2,8 0,006 
CP  0,2 0,0 6,3 1,3 4,8 <0,001 
Chronic heart disease 0,2 0,0 4,7 1,0 4,8 <0,001 
Gestational age 0,1 0,0 1,7 0,6 2,8 0,005 
Tachypnoea -0,1 0,0 -1,4 0,7 -2,0 0,051 
Chronic respiratory disease 0,1 0,0 3,0 1,1 2,8 0,006 
NMD  0,2 0,1 6,5 2,2 2,9 0,004 
Chest deformities -0,1 0,1 -5,7 2,5 -2,3 0,025 
SpO2 on admission -0,1 0,0 -0,1 0,0 -2,0 0,052 
Previously hospitalised -0,1 0,1 -1,2 0,6 -2,0 0,042 
Age in months 0,1 0,1 0,0 0,0 1,2 0,241 
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Table 5-18. Forward stepwise multiple regression for factors influencing length of hospital stay 
Factor Step Multiple R Multiple R² R² change F – to entr/rem p-value Variables 
Mechanical ventilation 1 0,5 0,3 0,3 94,8 <0,001 1 
Acute comorbidity 2 0,6 0,4 0,1 29,9 <0,001 2 
Airway clearance therapy 3 0,6 0,4 0,1 24,1 <0,001 3 
CP 4 0,7 0,5 0,0 15,4 <0,001 4 
Chronic heart disease 5 0,7 0,5 0,0 17,1 <0,001 5 
Gestational age 6 0,7 0,5 0,0 6,1 0,014 6 
Tachypnoea 7 0,7 0,5 0,0 3,9 0,048 7 
Chronic respiratory disease 8 0,7 0,5 0,0 4,2 0,041 8 
NMD 9 0,7 0,5 0,0 3,8 0,054 9 
Chest deformities 10 0,7 0,5 0,0 3,2 0,074 10 
SpO2 on admission  11 0,7 0,5 0,0 2,8 0,095 11 
Previously hospitalised 12 0,7 0,5 0,0 3,5 0,064 12 
Age in months 13 0,7 0,5 0,0 1,4 0,241 13 
 
In total, 10 children (0.7%, n=1424) died while hospitalised during the study period. Information 
regarding mortality status was not available in the folders of 16 hospitalisations. A significant 
association between mortality rate and diagnostic category was found (Yates X2= 45.5, p<0.001). 
Mortality was higher for children who developed presumed nosocomial infections, followed by 
pneumonia, compared to other diagnostic categories (Table 5-19). Table 5-20 presents a description 
of the deceased patients. 
Table 5-19. Mortality status per diagnostic category. 
Primary 
diagnosis 
Presumed 
noso-
comial 
Row% LRTI Row% Pneumo
nia 
Row% Bronchi
olitis 
Row% Other Row 
% 
Total 
Alive 100 7.7 139 9.8 514 36.4 658 46.5 3 0.2 1414 
Column% 94.3  99.3  99.4  100.0  100.0   
Died 6 60.0 1 10.0 3 30.0 0 0.0 0 0.0 10 
Column% 5.7  0.7  0.6  0.0  0.0   
Total 106  140  517  658  3  1424 
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Table 5-20. Description of the deceased patients 
Participant Primary diagnosis Age at time of 
death 
Comorbidities 
1 Pneumonia 16.5 years Liver transplant in 2008: chronic liver reject, 
sepsis, anaemia, acute gastroenteritis 
2 Presumes nosocomial 12.4 years Congenital muscular dystrophy, kyphoscoliosis, 
GORD, developmental delay 
3 LRTI 10.9 years CP (spastic quadriplegia), seizures, scoliosis, 
microcephaly, cortical blindness, GORD, upper 
airway obstruction 
4 Presumed nosocomial 7.5 years CP (spastic quadriplegia), congenital dandy-
walker malformation, hydrocephalus, seizures, 
developmental delay, anaemia, sepsis 
5 Pneumonia 5.0 years Trisomy 21, multiorgan failure, seizures, upper 
airway obstruction, GORD, history of rickets 
6 Presumed nosocomial 4.5 years Traumatic brain injury due to pedestrian-
vehicle-accident, brain stem death 
7 Pneumonia 1.8 years Pulmonary haemorrhage, bronchospasm, 
acute gastroenteritis, sepsis 
8 Presumed nosocomial 3.8 months SMA I, failure to thrive, acute gastroenteritis 
9 Presumed nosocomial 2.8 months Trisomy 21, atrioventricular septal defect, 
chylothorax, developmental delay 
10 Presumed nosocomial 1.9 months Trisomy 13, dysmorphic, polydactaly, bilateral 
cataract, URTI, failure to thrive, 
atrioventricular septal defect 
 
Table 5-21 shows an association between delivery of ACT and mortality (Yates X²= 41.96; p <0.001). 
Table 5-21. Airway clearance therapy and mortality status. 
Mortality status Airway clearance therapy 
 No Row% Yes Row% Total 
Alive 1333 94.3 81 5.7 1414 
Column% 99,7  93,1   
Died 4 40.0 6 60.0 10 
Column% 0,3  6.9   
Total 1337  87  1424 
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5.5  DISCUSSION 
This is the first comprehensive descriptive study of ACT prescription and outcomes in children 
admitted to a South African hospital with a LRTI. 
The majority of children admitted with LRTIs were younger than one year of age, male, HIV 
uninfected, and born at term. These findings are similar to other studies, where the majority of 
children hospitalised for bronchiolitis and viral LRTI were also younger than one year of age.2,241,242 In 
an aetiological study of children younger than five years of age with an acute LRTI in Thailand, 59% of 
the affected children were male;243 and in a study by Foster et al. on children with viral LRTI, 60.8% of 
the inpatients were male.242 These results are similar to the proportion found in this current study 
(59.6%). Other studies have also found that a higher proportion of males were hospitalised for LRTIs 
than females.241,244,245 The disproportion among gender could be caused by differences in sex 
hormones, influencing lymphocyte and macrophage function, hence immune reponse.246,247 In 
females, the production of estradiol enhances the immune system, whereas the production of 
testosterone in males suppresses the immune system.246 These differences in sex hormones are 
already present during infancy, although less distinct.247 Furthermore, male infants have narrower 
peripheral airways compared to their female peers, contributing to the increased risk to LRTIs.248  
HIV occurred more often in this current study (2.9%) than in the study by Hasan et al. (0.2%).243 This 
could be due to a higher HIV prevalence in South Africa (19.2% of adults in 2015) compared to 
Thailand (1.1% of adults in 2015), where the study by Hasan et al. was conducted.249 Although a 
decline in HIV prevalence in South Africa was observed, from 5.6% in 2002 to 2.4% in 2012 for 
children between two and 14 years of age, as a result of the “prevention mother-to-child 
transmission” program;33,195 the HIV prevalence in the current study (reporting on data from 2015) is 
comparable to the prevalence of 2012.195  
The most common primary diagnosis was bronchiolitis, followed by pneumonia and unspecified LRTI. 
In the current study, the primary diagnosis of pneumonia was made in 36.5% of the cases. This is 
similar to results found by Forster et al., who identified 59.6% of the inpatients as having 
bronchiolitis, and 35.1% with pneumonia.242 A study by Hatipoglu et al. diagnosed 55.6% of their 
participants with bronchiolitis, and 44.4% with pneumonia.245  And Wolf et al., investigating children 
hospitalised with viral LRTI, diagnosed 40% with a primary diagnosis of pneumonia and 60% with 
other (not further specified) LRTI.244 Eventually, 53.1% of the children were diagnosed with clinical 
pneumonia and 42.8% with bronchiolitis in that study.244 Unfortunately, as the current study did not 
record discharge diagnoses, no comparison can be made for these latter results.  
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In the current study, children referred to the clinical physiotherapy staff for ACT without a primary 
diagnosis of LRTI were classified as presumed nosocomial infections by the researchers. No 
information regarding LRTI diagnostic category was extracted from the medical files, resulting in the 
inability to further distinct between hospital acquired pneumonia, bronchiolitis or other LRTI; hence 
no separate analyses were possible. 
Microbiological isolates revealed more associated viral organisms than bacterial organisms. In 
children hospitalised for bronchiolitis or pneumonia, RSV was the most common isolated viral 
organism. Adenovirus was most common in children hospitalised for unspecified LRTI; and human 
rhinovirus was the most common isolate associated with presumed nosocomial infection. In South 
Africa, human rhinovirus, RSV and adenovirus are most often identified in children with LRTI,250–252 as 
confirmed by the current study. In the study by Hasan et al., RSV was the most commonly reported 
viral agent, followed by rhinovirus.243 This is the same as the current study’s results, although the 
proportions in the study by Hasan et al. are lower (19.5% and 18.7% respective) than in the current 
study (44.1% and 38.0% respective). A study conducted on Turkish children with viral LRTI also 
indicated RSV as the main pathogen (55.6%) in children younger than one year of age, however, they 
found that parainfluenza was the second most common viral agent in children younger than one year 
of age and the most common viral isolate in older children in their study.245 The discrepancies with 
these viral organisms could be due to the low rate of available sputum/blood cultures, 
overestimating the proportions of organisms in the current sample. A study conducted in Taiwan 
found completely different results, with adenovirus and enterovirus the most common viral 
organisms.253 Although adenovirus was found to be the most common viral organism in children 
hospitalised with unspecified LRTI, the other disagreements could be due to the geographical 
differences in aetiology of disease.  
The current study found Mycobacterium tuberculosis to be the most common bacterial organism 
(4.9%), followed by Klebsiella pneumoniae (4.5%); however, Pseudomonas aeruginosa was more 
commonly associated with presumed nosocomial infection. Another South African study reported 
Acinetobacter Baumannii as the most common bacterial organism, with Klebsiella pneumoniae 
(20.6%) the second most common identified bacterial organism.254 Although the incidence rate of the 
current study for Klebsiella pneumoniae was similar to the study by Hasan et al. (4.1%),  it was only 
the seventh most common  bacterial agent in their study.243 A study conducted in Taiwan reported S. 
Pneumoniae as the most common bacterial organism.253 A limitation of this retrospective study is 
that specimens were not taken on all patients, in a standardised manner, and therefore accurate 
aetiological analysis is not possible. 
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Mechanical ventilation (invasive and non-invasive) was provided for 17.9% of the hospitalisations in 
the current study, with CPAP being the most commonly administered. This proportion is higher than 
results found in two studies, where the proportion of children receiving mechanical ventilation was 
only 1.0-1.7%.241,244 However, one of these studies only included invasive ventilation,241 and the other 
study did not specify the type of mechanical ventilation.244 Another study reported on the need for 
intubation, which was required in 1.1% of children.243 Non-invasive ventilation is used to unload the 
work of breathing and might facilitate airway clearance. This could have influenced the outcome of 
ACT as it might limit complications associated with ACT. Furthermore, oxygen supplementation on 
admission was required in 12.7% of the children hospitalised in the current study. This study did not 
record oxygen supplementation throughout the study period, precluding comparison with other 
studies. It is recommended that this intervention be recorded in future studies. 
The majority of children in the current study were not hospitalised for a LRTI prior to the current 
admission. One or more comorbidities were present in just over half the cases, with respiratory 
problems the most common, followed by cardiovascular disorders. Children admitted for pneumonia 
were most often affected with both chronic and acute comorbidities. In a study by Wang et al. on 
Canadian children hospitalised with RSV LRTI, the proportion of comorbidities (22.6%) was lower 
than that seen in the current study (52.6%).255 This might relate to different methodologies and 
comorbidity selection. The study by Wang et al. recorded chronic lung disease, congenital heart 
disease, immunocompromise, other multisystem diseases, and prematurity;255 whereas the current 
study recorded a wider range of comorbidities but excluded prematurity and postnatal age. 
Furthermore, the current study included any LRTI, not merely RSV LRTI. 
ACT was performed in 5.8% of the hospitalisations. The majority of treatments were commenced in 
the first week of hospitalisation, however seven children only received ACT more than two weeks 
after admission. Five of whom acquired a nosocomial infection during hospitalisation, which could 
explain the timing of commencement of ACT. The other two cases were admitted for either 
pneumonia or LRTI, for which it is unclear why ACT commenced at this time. Vibrations and MPD 
were performed most often, with 49.4% of the children receiving bidaily treatment. AD and PEP were 
never given. ACT is not recommended as routine management for children with bronchiolitis, by the 
American Association for Paediatrics and a South African guideline article by Zar el al., based on the 
results found in a systematic review by Figuls et al.256–258 Although the National Institute for Health 
and Care Excellence agrees with this recommendation for most children, they do specify that ACT can 
be given to children with bronchiolitis with relevant comorbidities, if these comorbidities require ACT 
for facilitation of mucus clearance.259 In the current study, ACT was given less frequently to children 
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with bronchiolitis or unspecified LRTI. This practice therefore conforms to the guidelines for the 
management of children with bronchiolitis.  
In children with pneumonia, little evidence is available regarding the use of ACT as part of the disease 
management. Two systematic reviews have been published, including up to three RCTs on this topic, 
without clear recommendations for or against the use of ACT in these children.231,260 However, small 
benefits have been reported in other studies,223,226,228 indicating the need for further research into 
this matter. As only 5.8% of the children received ACT in the current study, it is apparent that ACT 
does not form part of the standard management of children hospitalised with a LRTI at this study 
site. The children who were most likely to receive ACT were those with bacterial nosocomial 
infections or pneumonia and those with chronic comorbidities. Therefore, it is recommended that 
further research be conducted on the use and safety of ACT in children presenting with these 
conditions. 
In the literature, adverse events are rarely mentioned and described; which was also the case in the 
current study. Six children did however desaturate during ACT. Suctioning was reported to cause 
desaturation in two children, conventional ACT (consisting of vibrations, percussions and MPD) was 
associated with desaturation in three children. One child desaturated whilst performing deep 
breathing exercises in sitting position. One child presented with a lung collapse more than one hour 
after ACT, and given the time delay it is unlikely that this adverse event was directly related to ACT. 
Owing to the observation of desaturation during ACT, monitoring of SpO2 is recommended during the 
performance of ACT. In the literature, adverse events are rarely mentioned and described. One study 
conducted in children with bronchiolitis, comparing nasal suctioning to increased exhalation 
technique with assisted cough, reported a significantly higher rate of children who vomited during 
ACT and who presented with transient respiratory destabilisation (not further specified).229 As these 
two adverse events have not been investigated in the current study and the specific ACT has not 
been used at the research site, no comparison could be made. Another study on the use of ACT in 
children with bronchiolitis did mention that no adverse events occurred, however, it is unclear which 
adverse events were under consideration.261  
As the rate of adverse events was low in the current study and very little literature is available on this 
topic, ACT appears to be safe for use in children with LRTI.  
Logistic regression revealed that chronic comorbidities (chronic respiratory disease, chronic heart 
disease, genetic disorders, NMDs, and CP), were the most likely predictors for receiving ACT during 
hospitalisation. Children with presumed nosocomial infections were more likely to receive ACT, 
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followed by children hospitalised for pneumonia. This data, however, may have been biased because 
the majority of children classified as presumed nosocomial infections were included based on 
physiotherapy referral and not through ICD-10 search identification. Children with nosocomial 
infections who were not referred for ACT might therefore not have been identified for inclusion in 
this folder review. In children hospitalised for pneumonia, multiple comorbidities were identified, for 
which ACT might be indicated. Children with positive bacterial culture were treated more often by 
the physiotherapists than children with viral isolates. No previous studies have investigated the 
association between ACT and isolated organisms, therefore, confirmation of the results in a larger 
prospective study is recommended. 
Obstructive disorders, like bronchiectasis, and chronic lung diseases would likely benefit from 
ACT;136,262but the current study found that 60 of 87 children (69%) with chronic respiratory disease 
(excluding asthma) did not receive any ACT. Unfortunately this study did not gather data to identify 
the reasons for not providing ACT to these children, however in some conditions, particularly upper 
airway obstruction, ACT is not indicated.  
Children were hospitalised for a median of 2.3 days, however, children with presumed nosocomial 
infections were hospitalised for a significantly longer duration (14.3 days), followed by children 
hospitalised for other conditions and pneumonia. Two RCTs on children hospitalised with pneumonia 
reported a median duration of hospital stay of 6 to 8 days,221,222 which is similar to the duration of 
hospitalisation for pneumonia in the current study. A study investigating children hospitalised with 
viral LRTI, found that children admitted with human metapneumovirus and co-infected with other 
viruses were hospitalised for the least amount of time (mean (SD) of 2.1 (2.4) days) whereas children 
with RSV were hospitalised the longest (mean (SD) of 4.6 (5.0)days).244 This is similar to the current 
study’s overall length of hospital stay of a median (IQR) of 2.25 days (1.5-5.0). However, a South 
African study found a longer duration of hospitalisation in children hospitalised with human 
metapneumovirus than RSV (median (IQR) 17 (10.5-33.5) days versus 9.5 (6-17.5) days 
respectively).263 Furthermore, a study by Hatipoglu et al. found a median duration of hospital stay of 
7.9 days for children with a known viral infection, of which RSV was the most common.245 Another 
study, conducted by Wang et al., revealed an overall median duration of hospitalisation of 7 days for 
children with uncomplicated RSV LRTI, whereas the children admitted with underlying disorders were 
found to be hospitalised for longer (median 9.5 days).255 This is shorter than the current study’s 
results, however, hospitalisation was longer for children hospitalised with chronic and acute 
comorbidities (median (IQR) 5.5 (2.3-11.8) days and 6.3 (2.5-12.3) days respectively) than for children 
without comorbidities. The shorter overall duration of hospitalisation in the current study compared 
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to the above mentioned studies might be a result of limited available resources at the research site. 
As mentioned in Chapter 1, South Africa is a middle-income country with associated financial 
struggles and a high burden on the public healthcare sector. In addition to clinical outcomes, cost 
prevention and high demands for hospital beds could be attributing factors for short duration of 
hospital stay.264  
The length of hospital stay was associated with whether or not children received mechanical 
ventilation, had acute comorbidities, received ACT, had CP, NMD, a chronic  heart or respiratory 
disease, a genetic disorder, or tachypnoea on admission. In a study conducted by Rodriguez et al. the 
predictors for disease severity, which was partially based on length of hospital stay, in children with 
RSV LRTI were investigated.265 They found that children younger than six months of age, those born 
prematurely, with a pre-existing lung disease or congenital heart disease, were more likely to have 
severe disease.265 Some of these factors, such as heart disease, prematurity and chronic respiratory 
disease were also identified in the current study’s multiple regression analysis, however, other 
factors might have been identified as the current study only investigated duration of hospitalisation, 
not disease severity. Our finding that receiving ACT was associated with increased duration of 
hospital stay may reflect the increased likelihood of receiving ACT in those who developed 
nosocomial infections (also associated with increased duration of hospital stay).266 However, the RCT 
by Lukrafka et al. also reported a median two days longer hospital stay in children who received ACT, 
compared to controls, which was not statistically significant, possibly owing to insufficient sample 
size.222,267 Therefore, further prospective studies are recommended to confirm these results and to 
determine causality. 
Although very few children in our sample died (mortality rate of 0.7%), children with presumed 
nosocomial infections or pneumonia were more likely to die than children with other clinical 
diagnoses. Pneumonia is still the most common cause for mortality in children younger than five 
years of age worldwide.176,187 In the current study, the overall mortality rate for children with a LRTI 
was low at 0.7%; however, a greater proportion of children with presumed nosocomial infection 
(5.7%) died. The mortality rate for children with a clinical diagnosis of pneumonia was 0.6%. These 
mortality rates, although slightly higher, are comparable to the rates found in children younger than 
five years hospitalised with acute LRTI in rural Thailand, with 0.3% overall mortality rate and 0.8% for 
radiologically confirmed pneumonia compared to 0.2% in children without a confirmed diagnosis of 
pneumonia.243 All children, included in the current study, who died during the study period, 
presented with multiple comorbidities and seven of the ten children were older than four years of 
age. The cause of death could therefore be versatile and not solely attributed to LRTI. ACT was 
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associated with an increased mortality rate, which has not been previously reported. However, 
causality cannot be determined on the basis of this study design. Considering most children admitted 
with pneumonia had comorbidities, this may explain the higher observed mortality in this group.  
A retrospective record review was conducted in the current study, which limited the amount of 
available information to that which was presented in the medical folders. In addition, the quality of 
the information could not be verified and a major limitation of this study was the lack of information 
regarding discharge diagnosis. The reported diagnoses were those made at admission, which are not 
always correct and may be altered as more information becomes available. Exposure to smoke, 
which might influence the disease severity and length of hospital stay,268,269 was not extracted from 
the medical files, as this is not standardly documented. Furthermore, length of stay in the paediatric 
intensive care unit was not recorded, which might have been another influencing factor for length of 
hospital stay. 
5.6  CONCLUSION 
This descriptive study is the first South African study investigating patient characteristics; ACT 
practice and adverse events; and patient outcome measures in children admitted to hospital with a 
LRTI.  
This study revealed that a relatively small proportion of children with LRTI received ACT. ACT was 
mostly applied in children with presumed nosocomial infections, followed by pneumonia, compared 
to other clinical diagnoses. Few children with uncomplicated bronchiolitis were treated with ACT, 
which conforms to the guidelines for bronchiolitis management. There is very little literature 
available on the benefits of ACT in children with pneumonia. Given the paucity of high-level 
evidence, ACT is therefore used in clinical practice based on the physicians’ and physiotherapists’ 
expert opinion. It is therefore recommended that more research regarding ACT in children with 
nosocomial infections and pneumonia be conducted. This is particularly important considering that 
the duration of hospitalisation was longer and mortality rate higher in children with nosocomial 
infections and pneumonia, compared to those admitted with other LRTIs, especially bronchiolitis. 
This could be associated with increased financial cost and burden for these families. The 
identification of modalities which could hasten resolution of the disease, as well as identifying 
interventions which are of no use or harmful, would help to ensure rational and appropriate resource 
allocation and optimal clinical outcomes. 
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This study also found that ACT, as performed at this research site, appears relatively safe to perform 
in children with LRTI, with only six children desaturating and no serious adverse events. However, the 
study was not designed or powered to determine safety, and further prospective, controlled clinical 
trials are recommended to confirm this finding. It is recommended that SpO2 be monitored during 
ACT, so the treatment can be halted when deemed necessary. Conventional ACTs were the most 
commonly used techniques by physiotherapists, possibly related to the large proportion of children 
younger than one year of age, in whom modern ACTs requiring cooperation are more difficult to 
perform. 
As more than half the children included in this study presented with comorbidities, research is 
warranted to investigate the use of ACT in children hospitalised with LRTI and comorbidities, both 
chronic and acute. 
This is a ground-breaking study, describing the patient population, management and outcomes for 
children admitted with LRTIs at a tertiary paediatric hospital in Cape Town, South Africa. It highlights 
the need for more research on ACT especially in children with nosocomial infections and pneumonia. 
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Chapter 6. THE USE OF ASSISTED AUTOGENIC DRAINAGE IN INFANTS AND YOUNG CHILDREN 
WITH ACUTE RESPIRATORY DISEASE IN SOUTH AFRICA 
PACTR201404000706382 
6.1  INTRODUCTION 
ACT is often prescribed for children with acute lung disease to assist in clearance of secretions.143,218 
As mentioned previously in this thesis, several studies with mixed results have been published on the 
use of ACTs in children with pneumonia.221–224,226–228 New ACTs have recently been introduced for 
young children, including AAD;84,121,270–272 but no high-level literature could be found on the use of 
AAD, although it is used clinically, especially in European countries. Therefore, a RCT was conducted 
in children hospitalised with acute uncomplicated pneumonia, to investigate the impact of 
administering AAD as additional treatment to standard care.  
AAD is a passive/assisted technique, which could be useful in the treatment of young children and is 
assumed to have minimal adverse effects.25,131,132 A quick resolution of pneumonia is important to 
prevent further damage to the airways, which could lead to bronchiectasis.201 This could additionally 
benefit the patient, and health sector both psycho-socially and financially. 
6.2  AIMS AND OBJECTIVES 
This study aimed to determine whether standard nursing care with additional AAD was more 
effective than standard nursing care alone in improving clinical outcome measures of children 
between the age of one month and eight years, hospitalised with community- or hospital acquired 
pneumonia.  
The specific objectives were to establish if there were any significant differences between the 
following outcomes in the control and intervention group: 
 Primary outcome: duration of hospital stay, expressed in number of days from admission to 
discharge based on the medical practitioner’s prescription. 
 
 Secondary outcomes:  
-   Short-term outcomes before, during and after treatment: SpO2 using transcutaneous 
oximetry; RR; and signs of respiratory distress.  
- Number of children needing intubation or ventilation. 
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- Number of days to clinical resolution: duration of fever and oxygen supplementation 
expressed in days. 
- Lung function test/spirometry in children older than five years of age. 
- Incidence of complications and adverse events. 
- Mortality rate. 
6.3  METHODOLOGY 
6.3.1 Study hypothesis 
Null hypothesis: There will be no significant difference in duration of hospitalisation, time to 
symptom reduction, incidence of adverse events and mortality rate between the control (standard 
nursing care) and intervention (standard nursing care with additional AAD) groups. 
6.3.2 Study design 
A RCT, single blinded, pragmatic study design was used. RCTs are the gold standard in experimental 
research as they reduce bias (especially allocation bias) and have high internal and external 
validity.273 The term ‘pragmatic’ refers to the comparison between a control and intervention group 
within a real-life setting.274 Blinding refers to masking participants and outcome assessors to group 
allocation. As the intervention in the current trial was a physiotherapy intervention, blinding of the 
participants was impossible, therefore, this study was classified as single blinded.275 Although the 
attending physiotherapist (not blinded to group allocation) gathered information pre-, post- and one 
hour after intervention; the outcome assessor collecting data at admission, recruitment and 
discharge, and the data analyst were blinded to group allocation thoughout the study. 
6.3.3 Research setting 
Children, who were hospitalised at two tertiary hospitals in South Africa, with a clinical diagnosis of 
community- or hospital acquired pneumonia were eligible for the study. The first research site is a 
290-bed, tertiary paediatric hospital to which patients from all over Africa, especially low income 
patients, are referred.276 Two general medical wards admit 80 to 100 patients per month, with 
pneumonia and gastro-enteritis as the most common reason for admission. It is estimated that up to 
70% of the ward admissions are respiratory related (Prof. B. Morrow. Personal communication, 
2013). The second research setting is a 1650-beds tertiary academic hospital associated with Sefako 
Makgatho Health Sciences University (formerly known as the Medical University of South Africa 
(Medunsa)). The study took place in their paediatric wards (wards 19, 22 and 23). 
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6.3.4 Participants 
Spontaneously breathing children with a clinical diagnosis of community- or hospital acquired 
pneumonia and hospitalised at one of the research sites were eligible for enrolment in this study. 
The planned age range for inclusion was one month to eight years of age. 
Inclusion criteria: 
 The diagnosis of pneumonia was made by the attending physician, based on the following 
criteria:  
- tachypnoea defined as a RR ≥20 bpm in children >five years, ≥40 bpm in children between 
one and five years, ≥50 bpm in children between two and 12 months, and ≥60 bpm in 
children <two months.194 
- fever and/or cough. 
- radiological or clinical confirmation of pneumonia. 
 
 Clinically stable on recruitment: i.e. with none of the following: 
- tachycardia defined as a HR 120 beats per min (bpm) in children >five years, 140 bpm in 
children beween three and four years, 150 bpm in children between one and two years, 
and  160 bpm in children <one year .194 
- unstable blood pressure 
- altered mental status 
- SpO2 <90% on oxygen support.
194 
Exclusion criteria: 
 Active TB (to reduce exposure of the research team to active TB; the child was considered for 
inclusion once the TB had been found inactive), 
 Clinical diagnosis of bronchiolitis (a recently updated systematic review concluded that ACTs 
are not beneficial for young children with bronchiolitis)257,  
 PJP, either suspected or proven (PJP is of fungal origin and pathophysiology is different from 
bacterial or viral pneumonia (see section 3.2). Furthermore, PJP is generally an interstitial 
disease without obstructive secretions, resulting in severe hypoxia).277,278  
 Pleural effusion (children with pneumonia-associated pleural effusions are hospitalised for a 
longer duration of time, which could be a threat to this research’s primary outcome 
measure)279,  
 Recent pneumothorax in last three months (to reduce the risk of a new pneumothorax),  
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 Clinical diagnosis or history of asthma (as the pathophysiology of asthma with the presence 
of wheezing and collapse of the airways might influence AAD and the clinical outcome 
measurements),  
 Increased intracranial pressure (as AAD has not been researched previously and conventional 
ACTs have been found to increase intracranial pressure,85 children with an increased 
intracranial pressure were excluded as a safety precaution),  
 Chest deformities (chest deformities could influence the AAD technique, as the lung volumes 
are altered manually, decreasing the lung volume),  
 Osteoporosis (due to the risk of rib fractures)101,  
 Severe hypoxia or respiratory distress on admission and recruitment (SpO2 ≤90% on oxygen 
and clinical signs: cyanosis, weak cry, feeding problems, muscle retraction, head nodding, 
nasal flaring)194,280. If the child had more than three of these signs, he/she was excluded from 
the study. If the child had three or fewer signs, he/she was included in the study (Children 
were excluded if they were severely distressed, as manually influencing the lung volumes and 
level of breathing might increase respiratory distress even further). Children who were in 
severe distress and/or being mechanically ventilated due to pneumonia at the time of 
admission were considered for enrolment in the study once they had been stabilised after 
extubation and transferred to the ward. 
 CF (these children are standardly hospitalised for two weeks for infection eradication, which 
influences the duration of hospitalisation),  
 Presence of an intercostal drain (as AAD is a manual technique, the physiotherapist places 
his/her hands on the chest of the child, which could be influenced by the presence of an 
intercostal drain), 
 Thoracic or abdominal surgery during the preceding six months (during AAD, the chest is 
manually manipulated to reduce lung volumes, which might impact the surgical site and 
could increase pressure in the thorax and abdomen), 
 History of prematurity: ≤30 weeks of gestation (as described in section 2.1, prematurity could 
severely impact the child’s respiratory system for which the outcome measures of the study 
might be influenced), 
 Any other chronic respiratory disease receiving daily physiotherapy as standard practice (as 
these children cannot be included in the control group, random allocation would not be 
possible) 
 Any cardiac defect (as the adverse effects of AAD are unknown, these children were excluded 
to prevent increased stress on the heart as a safety precaution) 
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 Acute or chronic upper airway obstruction and/or stridor (blockage of the upper airways 
could influence the clearance of secretions from the lungs and might increase respiratory 
distress when lung volumes are altered) 
 Children with a medical condition/complication for which they could not be taken out of bed 
and placed on the physiotherapist’s lap (to standardise the AAD intervention, all children 
were placed in sitting on the physiotherapist’s lap to perform the technique. If a child could 
not be taken out of bed, the treatment would not be standardised throughout the study) 
 Any neurological condition, including but not limited to seizures/epilepsy and NMD (this was 
a safety precaution for a novel, untested intervention. For patients with seizures/epilepsy, 
exclusion was based on the risk of inducing a new episode of seizures. Children with NMD 
were excluded as the majority of these children would already have respiratory compromise 
due to respiratory muscle weakness and altered chest wall compliance,281 which could 
influence this research’s outcome measures as well as affect the tolerance towards AAD, 
jeopardising safety.) 
 Hospitalised for less than two days. The study took place in the general wards of the 
hospitals, where the majority of children are hospitalised for more than two days. No 
recruitments were done in the short-stay wards to prevent children being enrolled for less 
than two days of hospitalisation. As the intervention needed to be performed bi-daily for 
several days before changes were expected, this exclusion criteria was added after initiation 
of data collection but prior to unblinding the data analyst (as one child was found to be 
hospitalised for less than two days). 
 
HIV-infected or –exposed children were included in the study. A sub-analysis on this group was 
planned, however, insufficient sample size was obtained for analysis.  
Sample size 
The average duration of hospital stay in children admitted for pneumonia was estimated a priori to 
be 7 days (±1.5) (based on results from section 4.4.5.1 and 5.4.4). To detect a clinical relevant 
difference of one day between control (8 days) and intervention groups (7 days), 49 participants per 
group were calculated as being needed to obtain a two-sided α of 5% with a power of 90%.  
Interim analysis 
After enrolment of 23 participants, an interim analysis was done to determine whether the study 
should continue, with a priori boundaries of p<0.006 to reject the null hypothesis (efficacy boundary; 
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if a large treatment effect is detectable before the end of the study); and p>0.52 to accept the null 
hypothesis (futility boundary, if there is little chance of detecting a significant difference between the 
groups). After interim analysis, data were recoded by an independent researcher to maintain 
blinding.  
The study ran from March 2014 until December 2015. From mid-December 2014 until mid-January 
2015, no new recruitments were done owing to staff shortages during the Christmas holidays. 
6.3.5 Outcome measures/instrumentation 
After considering the benefits and downsides of common outcome measures for the assessment of 
ACTs as described in section 2.3.3, the following were included in the study: 
6.3.5.1 Data collection forms 
During recruitment, the researcher collected general information using a standardised case record 
form (Appendix 9). Information on nursing care was extracted from the child’s medical file after 
discharge. The data on ACT were collected by clinical physiotherapists using a standard evaluation 
form (Appendix 9). All pre-set data extraction forms were self-designed and validated for content by 
an expert in the field of paediatric cardiopulmonary physiotherapy. The clinical physiotherapy staff at 
the research sites provided input regarding applicability of the forms in practice. Research personnel 
received training regarding completion of the forms prior to the study, to establish a better interrater 
reliability (see section 6.3.7).  
6.3.5.2 Duration of hospitalisation 
The length of hospital stay was expressed in number of days from admission to discharge based on 
the medical practitioner’s prescription (who was blinded to group allocation), as recorded in the 
medical files. Although the discharge criteria were not pre-defined, the medical practitioner was 
blinded to group allocation, reducing bias in time of discharge.  
o If the child was admitted to the hospital in the morning, this accounted for a full day. 
When the child was admitted in the afternoon, half a day was taken into account and 
when the child was admitted in the evening, a quarter of a day was noted.  
o If the child remained hospitalised due to other unforeseen problems (e.g. social 
problems), the day that the child was clinically cleared of his/her pneumonia, based 
on the medical practitioner’s discretion, was used as a proxy for the discharge date. 
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6.3.5.3 Days to clinical resolution 
This outcome measure was based on nursing documentation, completed by the nursing staff who 
was blinded to group allocation; and expressed as: 
o Duration of fever (>37 ○C) in days.  
o Days on supplemental oxygen support. 
6.3.5.4 Vital signs and oxygen saturation 
 RR: absolute values and adjusted for age 
o At baseline, after five days and at discharge, as presented in the medical files by 
blinded medical personnel 
o Before, immediately after and one hour after every intervention, assessed by the 
attending physiotherapist (not blinded to group allocation) 
 HR: absolute values and adjusted for age 
o At baseline, after five days and at discharge, as presented in the medical files by 
blinded medical personnel 
 Although SpO2 has been reported as unreliable and insensitive for research purposes (see 
section 2.3.3);142 the assessment of SpO2 was deemed necessary to detect desaturation 
throughout the study period, especially during ACT (see section 5.4.3.2). Therefore, SpO2 in 
room air was measured by transcutaneous oximetry  
o At baseline, after five days and at discharge, as presented in the medical files by 
blinded medical personnel 
o Before; during; immediately after and one hour after treatment, assessed by the 
attending physiotherapist (not blinded to group allocation) 
Vital signs and SaO2 were taken once off, with HR and RR measured for one minute. However, these 
measurements were continuously documented by several members of the medical staff, who flagged 
great changes in these outcome measures. 
6.3.5.5 Lung function testing 
Lung function (spirometry) tests (using American Thoracic Society (ATS) criteria) were planned to be 
performed, assessing RV/TLC, VC, FVC, FEV1, PEF, in children age five to eight years of age at baseline, 
after five days and at discharge. This outcome measure would have been assessed by the research 
assistant or myself (both remained blinded to group allocation throughout the study), using the 
Microloop. 
 99 
 
6.3.5.6 Adverse events and mortality 
 The incidence of adverse events were extracted from either the medical files completed by 
blinded medical personnel or from the physiotherapy data collection form (not blinded to 
group allocation). Adverse events included hypoxia (SpO2 90% on oxygen support), acute 
atelectasis and lung/lobar collapse, based on radiology reports (if available). 
 Mortality rate 
6.3.6 Interventions 
Control group 
The control group received standard nursing care, which typically included antibiotic treatment, 
hydration, oxygen support, regular change of body position and nasopharyngeal or oropharyngeal 
suctioning if necessary. No ACT was performed in the control group, with the proviso that 
‘emergency treatment’ by a physiotherapist could be requested at any time by the attending 
paediatrician or physiotherapist. If emergency physiotherapy was deemed necessary, the 
physiotherapist conducted their treatment of choice. The techniques used, and the duration of the 
treatment(s) were recorded. As clinical guidelines do not recommend ACT as standard practice for 
children with pneumonia;11,217 and a minority of children hospitalised with LRTI at the primary 
research site received ACT (Chapter 5); a control group not receiving ACT was justified. 
Intervention group 
The intervention group received standard nursing care as described above, and AAD performed by a 
physiotherapist, as an adjunct. AAD was planned to be given for five consecutive days, with bi-daily 
treatment for a minimum of 10 (children younger than five years) to a maximum of 30 minutes 
(children older than five years) in order to prevent fatigue. The length of therapy was determined by 
the attending physiotherapist, based on signs of respiratory distress and fatigue, and therefore not 
standardised. However, length of treatment and reason for halting the treatment was documented 
on the physiotherapist’s data collection forms. Intervention, as described in Chapter 2, was done in 
the morning and afternoon at approximately the same time daily. To standardise the treatment, all 
participants were treated in an upright sitting position and no bouncing was performed during AAD 
treatment. The upright sitting position was applied as this position optimises diaphragmatic function, 
improves ventilation and reduces fatigue in infants and young children (see section 2.2).  
At the end of every treatment session, the participant was required to cough. If no spontaneous 
coughing occurred, cough was stimulated. Elicitation of a cough was done firstly through 
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demonstration (mimicking), however, when this was unsuccessful, children younger than nine 
months of age were suctioned nasopharyngeally (as per standard nursing care) and children older 
than nine months underwent tracheal stimulation. If children in the intervention group needed more 
than bi-daily physiotherapy, as determined by the physiotherapist, the additional treatment session 
was classified as ‘emergency treatment’, during which the physiotherapist was allowed to use a 
treatment of choice. The techniques used, and the duration of this additional treatment were 
recorded. All children remained in their allocated study group, and were analysed in that group, 
regardless of whether additional ‘emergency’ physiotherapy treatments were administered or not 
(intention-to-treat analysis). 
6.3.7 Procedure 
Approval 
Ethical approval was granted by the Faculty of Health Sciences HREC (ref 532/2013, Appendix 10), 
University of Cape Town. Furthermore, permission to access the hospitals was obtained from the 
medical superintendent at both research sites (Appendix 10).  
Training of research personnel 
I was trained in AAD during my MSc in Belgium, as well as further educated (self-study) based on a 
course designed by Mr Chevailler.128 A pre-trial workshop was organised and attended by all 
physiotherapists involved in the study (at both research sites). I led the sessions and travelled 
between Cape Town and Pretoria to ensure training was identical between the different research 
sites. The content of the workshop were: explanation of the study protocol, AAD technique as 
described above and the completion of the forms. A PowerPoint presentation and a practical session 
were organised to educate the physiotherapists on how and when to perform the AAD technique 
and how to complete the necessary forms. This workshop was mandatory for all six physiotherapists 
involved in the study and repeated every six months to ensure consistency between therapists. 
Correct performance of the technique was evaluated during the AAD workshop as well as during the 
treatment of a patient, not enrolled in the study. The research assistant who collected baseline and 
discharge data at the second research site received extra training on how to collect the data and how 
to interpret inclusion and exclusion criteria. I remained in close contact with the research personnel, 
for which uncertainties were resolved quickly and did not interfere with the research process. 
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Recruitment 
Recruitment was done on Monday mornings by myself (at the primary research site) and a research 
assistant (at the second research site). As the study protocol described AAD to be performed for five 
consecutive days, recruitment could only occur during this limited time frame, to reduce burden on 
the weekend physiotherapy staff. Eligible participants were identified by screening the patient’s 
medical files or based on the attending medical practitioner’s recommendation. Parents received 
verbal and written explanations of the study procedure and provided written informed consent for 
their child’s participation in the study (Appendix 11). The informed consent form was available in 
three different languages (English, Afrikaans and isiXhosa). When parents and/or child did not 
understand the language presented in the consent/assent form, an interpreter explained the study 
and obtained consent/assent. Parents who were not with their child in hospital on the day of 
recruitment were telephonically contacted to obtain verbal consent prior to their arrival to hospital 
to sign the form. If the child was older than five years of age, assent would have been obtained 
(Appendix 11). After obtaining informed consent, the child was randomly assigned to either the 
intervention or control group by the use of simple randomisation. Randomisation was done by a 
computer generated list of random numbers prior to the start of the study (ratio 1:1) and sealed, 
opaque, sequentially numbered envelopes were created to maintain allocation concealment.  
Baseline data 
The child’s baseline characteristics: day and hour of hospitalisation, RR, HR, SpO2, temperature, 
general descriptive characteristics (gender; age; HIV-infected or –exposed; the presence of NMD) and 
the disease history of the child (including previous episodes of lung infections) were obtained from 
the medical file during recruitment. If the child was older than five years of age, lung function tests 
would have been carried out before group allocation. Data were recorded from admission notes and 
the medical file at the day of recruitment. 
During hospitalisation 
Before AAD treatment, SpO2 was noted and RR measured by the attending physiotherapist. During 
treatment, SpO2 and general clinical signs of distress were monitored in order for distress and 
hypoxemia to be prevented or managed. This was done by stopping the therapy until the child 
recovered, or supplying supplemental oxygen if necessary. Duration of distress or hypoxaemia and 
clinical signs were documented by the attending physiotherapist. The physiotherapist also indicated 
the duration of treatment and the reason(s) for halting the intervention. Post-treatment and one 
hour post treatment assessment of RR and SpO2 was performed by the physiotherapist. Children 
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were permitted to receive other (non-respiratory) forms of physiotherapy (e.g. developmental 
stimulation), which was documented. The number of days the child received oxygen 
supplementation was noted in the medical file by the nursing staff (blinded to group allocation). 
After five days all children were re-evaluated by a blinded outcome assessor. If the child was 
assessed clinically as needing further ACT after the five days of AAD-treatment, any other ACT was 
given except AAD.  
At discharge 
Discharge data were documented at the time of hospital discharge and lung function tests would 
have been taken in children older than five years of age before leaving the hospital. All children 
enrolled in the study were exposed to the same medical team, who were blinded to allocation. The 
date of discharge for all participants was determined by this blinded medical team, therefore, no 
discharge criteria were determined in advance. If the child died, date and time of death were 
documented. When patients were transferred to another hospital, date of transfer was used as 
discharge date from the research site. Discharge data were obtained by blinded medical personnel 
and the research assistant or myself. 
6.3.8 Data-capturing and management 
All data were de-identified and coded by the use of coded computer files and/or coded paper files 
saved in sealed envelopes. Data specific to the intervention group (pre-, post- and one hour post- 
treatment) were recorded on a separate sheet and held by the supervisor in order to maintain the 
blinding of the outcome assessor and data analyst. After data-collection, data were entered into a 
password protected Excel spreadsheet and imported to Statistica (Version 12, StatSoft Inc, Tulsa 
USA) for analysis. Adjustments for age were made for RR and HR by comparing the participant’s RR 
and HR with age norms. The absolute values were divided by the norm values for both outcome 
measures. Norms were based on a review published by Fleming et al.240  
6.3.9 Data-analysis 
Data were analysed using Statistica (Version 12, StatSoft Inc, Tulsa USA) and as the numbers were 
too small for application of the Central Limits Theorem, data were tested for normality using the 
Lilliefors tests. Based on these results, parametric or non-parametric tests were utilised. The Chi 
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square, Fisher exact or Yates test were used to test for association between groups for dichotomous 
data, such as gender. Numeric outcome parameters were analysed using the Student t-test or Mann-
Whitney U test. An intention-to-treat analysis was performed. Effect size (Cohen’s d)(5) was 
calculated for outcome measures which showed a trend towards significant differences between 
groups. For non-parametric data, the effect size r value was calculated with the formula r= z/√N.282 
As the z value is sample size dependent, the r value will eliminate this sample size effect.282 The r 
value was converted into a Cohen’s d value by the formula d= 2r/√(1-r2).282 Interpretation of the 
effect size was based on Cohen’s guidelines for small (d= 0.2), medium (d= 0.5) and large (d= 0.8) 
effect sizes.283 
Within-group analyses were conducted using Dependent Student t-tests or Wilcoxon Matched Pairs 
tests. Change over time analysis was conducted by calculating the difference of the means or 
medians and the 95% confidence intervals of the difference of means/medians. A Kaplan-Meier 
analysis was performed to compare the time to discharge between the groups. 
Repeated measures were analysed using Friedman ANOVA, with further analysis of significant results 
by the use of the Dependent Student t-test or Wilcoxon Matched Pairs tests between two dependent 
groups. Dichotomous repeated data were analysed by the McNemar test. Analysis of the effect of 
the intervention in children with viral, bacterial and mixed aetiology pneumonia was conducted using 
the Kruskal-Wallis test. Post hoc analysis of significant results was done using a multiple comparison 
mean rank test. 
An intention-to-treat analysis was performed. A significance level of 0.05 was chosen to analyse 
differences between and within groups. Dependent variables were the different outcome measures 
as indicated above. The independent variables were age, gender, HIV-infected or –exposed or 
previous episodes of lung infections. 
6.4  INTERIM ANALYSIS AND AMENDMENTS 
Owing to the slow recruitment rates, it was deemed necessary to make amendments to the study 
protocol after six months of commencement. The original protocol only included children admitted 
with bacterial pneumonia, and this resulted in many children being excluded as their aetiology was 
                                                          
 
(5) Cohen’s d= (mean1-mean2)/(standard deviation).283 
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not known on the day of recruitment. Therefore, the inclusion criteria were extended to include 
children with all organisms responsible for pneumonia. Further, the study was expanded to a second 
research setting in order to increase the number of participants. 
An interim analysis was performed after enrolment of 23 participants (13 in the control group and 10 
in the intervention group) at the primary research site. No data from the secondary research site 
were included in the interim analysis. Non-parametric statistics were used for this analysis. 
A significant difference in RR adjusted for age at admission was seen between intervention and 
control groups with p= 0.002 (median (IQR) 1.3 (1.0-1.4) for the control group and median (IQR) 1.5 
(1.4-1.8) for the intervention group). However, this difference was resolved by the time of 
recruitment (p= 0.336).  
When looking at the different outcome measures at interim analysis; no significant difference was 
found for the primary outcome measure, duration of hospitalisation (median (IQR) 7.5 (7.0-11.3) 
versus 7.3 (6.5-8.5) days for control and intervention groups respectively, p= 0.239). Further, no 
significant differences were seen for the secondary outcome measures (respective p-values for RR 
and HR adjusted for age; SpO2; and duration of fever and O2 supplementation were 0.975, 0.575, 
0.214, 0.620 and 0.967). No adverse events nor fatalities were noted within these 23 participants. 
It was decided to continue the study as the significance level of the primary outcome measure was 
within the pre-set boundaries. Furthermore, there were no recordings of adverse events within 
either the control or intervention group; and a significant difference at baseline for admission RR 
adjusted for age was observed, for which continuation of the study was recommended.  
The next interim analysis was planned after enrolment of 50 participants, however, the study was 
halted due to pragmatic considerations prior to achieving this number of participants (see  
Discussion). 
6.5  RESULTS 
6.5.1 Participants 
A total of 896 children were screened, of which 862 were excluded (Figure 6-1 and   
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Table 6-1).  Thirty-four participants (23 male (67.6%), median (IQR) age 3.5 (1.5 – 9.6) months) were 
enrolled in the study. Five participants were excluded after enrolment for various reasons (see Figure 
6-1). One participant’s medical file was missing on the day of enrolment, and only after enrolment a 
recent history of pneumothorax was identified for which the participant was excluded from the 
study. Another participant was hospitalised for fewer than two days. The other three participants 
were excluded owing to the diagnosis of bronchiolitis (n=1) and asthma (n=2) post enrolment. All five 
participants were allocated to the control group, of whom two (both diagnosed with asthma) 
received one day of bi-daily emergency physiotherapy prior to exclusion. No participants were lost to 
follow-up, however, six children were transferred to another hospital (n=2 in the intervention group 
and n= 4 in the control group), for whom the date of transfer was used as discharge date. Therefore, 
29 participants were included in the final analysis (18 male (62.1%), median (IQR) age 3.5 (1.5 – 9.4) 
months). In the control group, one participant received three sessions of emergency physiotherapy, 
consisting of percussions, vibrations and suctioning. All other participants in the control group were 
not exposed to ACT. None of the participants in the intervention group required emergency 
physiotherapy. 
Admission and recruitment characteristics of the analysed participants per group are presented in 
Table 6-2. Data were skewed for all baseline and recruitment characteristics, except for systolic blood 
pressure (d= 0.13, Lilliefors not significant (NS)), diastolic blood pressure (d= 0.15, Lilliefors NS) and 
temperature on admission (d= 0.09, Lilliefors NS); as well as HR adjusted for age at admission (d= 
0.10, Lilliefors NS), and recruitment (d= 0.12, Lilliefors NS). Groups were similar at admission and 
recruitment for all baseline characteristics, except for RR adjusted for age at admission (p=0.013). 
However, this difference was resolved by the time participants were enrolled in the study. This could 
have been due to the number of hospitalised days prior to recruitment, which changed the RR 
adjusted for age at recruitment compared to admission.  
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Screened n= 896 
 
   
  
Excluded prior to enrolment, n= 862 
n= 622 with one exclusion criteria 
n= 199 with two exclusion criteria 
n= 36 with three exclusion criteria 
n= 5 with four exclusion criteria 
           Reasons for exclusion: 
- 414 Other respiratory problems 
- 171 Cardiovascular problems 
- 150 Hospitalised for too long 
- 91 On mechanical ventilation at 
time of recruitment 
- 82 Participants outside age range 
- 55 Neurological problems 
- 50 Premature 
- 40 Other non-medical reasons 
- 28 No consent obtained:  
- 19 parents refused 
- 9 parents  were unreachable 
- 28 Other medical reasons  
- 19 Surgery <6m 
- 15 Orthopaedic problems 
   
 Enrolled and 
randomised  
n= 34 
 
   
  Excluded post enrolment/randomisation, 
n= 5 
(2 asthma, 1 bronchiolitis, 1 history of 
pneumothorax and 1 hospitalised for <two 
days) 
    Analysed n= 29  
   
Control group n= 15  Intervention group n= 14 
   
   
Transferred to another hospital 
n= 4 
   Transferred to another hospital n= 2 
   
 
0 lost to follow-
up 
 
Figure 6-1. Study flow chart 
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Table 6-1. Reason for exclusion of screened children 
Category of exclusion Specific reason for exclusion 
Respiratory problems  - 96 Viral infection prior to expansion of inclusion criteria 
- 54 Bronchiolitis 
- 41 PJP (suspicion (n= 28) + diagnosed (n= 13)) 
- 35 Wheezes + prolonged expiration 
- 35 Other/unspecified chronic lung disease (suspicion (n= 2) + diagnosed (n= 
33)) 
- 32 Pleural effusion 
- 28 Asthma (suspicion (n= 12) + diagnosed (n= 16)) 
- 22 Upper airway obstruction 
- 16 Intercostal drain 
- 13 Resolved pneumonia 
- 11 Pneumothorax 
- 9 CF (suspicion (n= 5) + diagnosed (n= 4)) 
- 8 Pertussis (suspicion (n= 6) + diagnosed (n= 2)) 
- 6 Other unspecified lung disease  
- 3 Croup 
- 1 Chronic airway obstruction 
- 1 Contagious TB 
- 1 Coughing spells 
- 1 Stridor 
- 1 Haemoptysis 
Cardiovascular problems - 40 Patent ductus arteriosus  
- 32 Ventricular septal defect 
- 19 Atrial septal defect 
- 15 Atrioventricular septal defect 
- 13 Pulmonary hypertension 
- 12 Stenosis 
- 11 Tetralogy of Fallot 
- 11 Patent foramen ovale 
- 10 Congenital heart deformities/disorders 
- 9 Cardiomyopathy 
- 7 Heart failure 
- 7 Unspecified heart disease 
- 6 Myocarditis 
- 4 Cardiomegaly 
- 4 Heart lesion 
- 4 Pericardial effusion 
- 4 Atrio-ventricular valve regurgitation 
- 3 Double outlet right ventricle 
- 3 Heart murmur 
- 2 Boot shaped heart 
- 2 Atrial switch/defect 
- 2 Coarctation aorta 
- 2 Mitral valve atresia/regurgitation 
- 2 Dextrocardia 
- 2 Deep venous thrombosis 
- 1 Transposition of the great arteries 
- 1 Cor pulmonale 
- 1 Shone’s syndrome 
- 1 Coronary arterial abnormalities 
- 1 Sinus of Valsalva aneurism 
- 1 Mycotic aneurism 
- 1 Right ventricle outlet tract obstruction 
- 1 Intaventricular septum aneurism 
- 1 Bicuspid aortic valve 
- 1 HR at recruitment above inclusion limit 
- 1 Atrial tachyarrhythmia due to Broviac insertion 
- 1 Cardiac arrest prior to enrolment 
- 1 Blood vessel malformation unspecified 
Orthopaedic disorders  - 3 Pectus carinatum 
- 3 Pectus excavatum 
- 3 Osteoporosis 
- 2 Scoliosis 
- 2 Skeletal dysplasia 
- 1 Gibbus 
- 1 Rib fractures 
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Neurological disorders - 37 Seizures/epilepsy 
- 14 Increased intracranial pressure 
- 3 meningitis 
- 1 Congenital centronuclear myopathy 
Surgery < six months prior to enrolment - 12 Thoracic surgery less than 6 months ago 
- 5 Abdominal surgery less than 6 months ago 
- 1 Unspecified surgery less than 6 months ago 
- 1 Surgery on day of recruitment 
On mechanical ventilation on day of 
recruitment 
- 91 on continues positive airway pressure 
Premature - 50 children with gestational age < 30 weeks 
Other medical reasons - 23 No pneumonia during hospitalisation 
- 4 Unable to be taken out of bed 
- 1 Broncho-oesophageal fistula 
Age range - 42 younger than 1 months 
- 40 older than 8 years 
Hospitalisation reasons - 113 admitted prior to Thursday (without ventilation) 
- 37 off ventilation for too long 
No consent obtained - 15 Parents unreachable 
- 7 Refused 
- 6 No consent on day of recruitment 
Other non-medical reasons - 26 Discharged on day of recruitment 
- 9 Folder missing 
- 3 Transferred on day of recruitment 
- 1 Language barrier 
- 1 Child not in ward 
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Table 6-2. Participants’ baseline characteristics at time of admission and recruitment 
Baseline characteristic Intervention 
(n= 14) 
Control 
(n= 15) 
Statistical value p-
value 
Gender, n (%) males 8 (57) 10 (67)  Fisher exact 0.442 
Age (months), median (IQR) 
- at admission 
- at recruitment 
 
7.7 (2.0 – 12.5) 
7.8 (2.2 –12.7) 
 
3.1 (1.5 – 7.5) 
3.2 (1.7 – 7.6)  
 
z= -1.6 
z= -1.5 
 
0.116 
0.144 
Gestational age (weeks), median (IQR) 39.0 (38.0 – 40.0) 39.0 (35.0 – 40.0) z= -0.4 0.712 
Days on mechanical ventilation prior to 
enrolment, median (IQR) 
3.0 (1.5 – 4.0) 4.0 (3.0 – 5.0) z= -1.2 0.214 
SpO2 (in room air) (%), median (IQR)  
- at admission 
- at recruitment 
 
95.0 (92.0 – 97.0) 
99.5 (96.0- 100.0) 
 
93.0 (90.0 – 97.0) 
100.00 (98.0 – 100.0) 
 
z= -0.2 
z= -1.0 
 
0.817 
0.308 
RR adjusted for age, median (IQR) 
- at admission 
- at recruitment 
 
1.4 (1.3 – 1.7) 
1.1 (0.9 – 1.4) 
 
1.2 (1.0 – 1.4) 
1.1 (1.0 – 1.5) 
 
z= -2.5 
z= -0.7 
 
0.013 
0.499 
 
 
HR adjusted for age, mean (SD)  
- at admission 
- at recruitment 
 
1.2 (0.2) 
1.0 (0.1) 
 
1.1 (0.2) 
1.0 (0.2) 
 
t= -1.4 
t= -0.2 
 
0.171 
0.836 
Systolic blood pressure (mmHg) at 
admission, mean (SD) 
100.3 (10.5) 95.6 (21.2) t= -0.6 0.564 
Diastolic blood pressure
 
(mmHg) at 
admission, mean (SD) 
60.8 (15.9) 55.50 (12.1) t= -0.8 0.457 
Temperature (°C) at admission, mean 
(SD) 
37.8 (0.5) 38.03 (1.3) t= 0.7 0.514 
O2 supplement (l/min) at recruitment, 
median (IQR) 
1.0 (0.0-2.0) 2.0 (0.0-3.5) z= 0.9 0.369 
Signs of distress at admission, n (%) 
- Alar flaring 
- Head nodding  
- ICR 
- SCR 
 
7 (50) 
1   (7) 
3 (21) 
7 (50) 
 
5 (33) 
3 (20) 
5 (33) 
9 (60) 
Yates X²= 0.5
  
0.913 
HIV status, n (%) 
- Negative 
- Exposed 
- Positive 
- Unknown 
 
11 (79) 
1 (7) 
1 (7) 
1 (7) 
 
11 (80) 
1 (6.7) 
1 (6.7) 
1 (6.7) 
Yates X²= 1.3 0.722 
Aetiology, n (%) 
- Viral 
- Bacterial 
- Mixed 
- Unknown 
 
 
5 (36) 
2 (14) 
0   (0) 
7 (50) 
 
4 (27) 
3 (20) 
2 (13) 
6 (40) 
Yates X²= 0.5 0.926 
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6.5.2 Between groups comparison 
All data, except for the outcome measure ‘HR adjusted for age at discharge’ (d= 0.09, Lilliefors NS) 
and ‘days on oxygen supplementation’ (d= 0.13, Lilliefors NS), were skewed. Therefore, non-
parametric tests were used to analyse the data, except for these two normally distributed variables.  
No significant difference was found between the intervention and control groups for the primary 
outcome measure ‘duration of hospitalisation’ (p=0.163) (Table 6-3). Nor was there a significant 
difference between the number of days enrolled in the study (p= 0.760) (Table 6-3). This last 
comparison was made to adjust for the days of hospitalisation prior to enrolment in the study. 
However, Kaplan-Meier analyses of time to discharge revealed a tendency towards a shorter time to 
discharge for the intervention group compared to the control group (Log-Rank Test WW= -4.1, p= 
0,057) (Figure 6-2). A medium effect size was found based on the following calculations: 
r = 1.4/√29 = 0.26 
d = 2x0.26/√(1-0.262) = 0.54 
 Control
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Figure 6-2. Comparison between the intervention and control group for time to discharge, Kaplan-Meier logrank test. 
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 Table 6-3. Comparison between the control and intervention groups for different outcome measures, presented in days. 
 
 
 
 
Only eight participants (six in the control and two in the intervention group) were enrolled for five or 
more consecutive days. Therefore, analyses of results between the control and intervention group 
after five days of enrolment, as planned and mentioned in the methodology, was not possible.  
This study’s secondary outcome measures, ‘days to clinical resolution’ (based on days of fever 
(p=0.854) and days on oxygen support (p= 0.949) during hospitalisation), SpO2 (p=0.364), HR and RR 
adjusted for age (respective p-values 0.941 and 0.585); showed no significant differences between 
the groups (Table 6-3 and Table 6-4). 
No adverse events, mortalities or casualties were reported in either of the groups, therefore no 
between-groups analyses could be performed for these outcome measures. None of the participants 
progressed to being intubated and mechanically ventilated during the course of this study. Finally, 
none of the participants were older than five years of age, therefore, no lung function tests were 
performed during this study. 
No difference in change over time for a number of outcome measures, occurred between the 
intervention and control groups (Table 6-4).
Outcome measure Control group 
(n= 15) 
Intervention group 
(n= 14) 
Statistical value p-value 
Days of hospitalisation, median (IQR) 7.5 (7.0-11.3) 7.0 (6.5-8.5) z= 1.4 0.163 
Days of enrolment 3.0 (2.0-6.0) 3.5 (3.0-5.0) z= 0.3 0.760 
Days of fever during hospitalisation 1.0 (1.0-4.0) 2.0 (1.0-2.0) z= 0.2 0.854 
Days on O2 support during hospitalisation,  
mean (SD) 
4.1 (3.9) 4.2 (2.3) t= -0.1 0.949 
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Table 6-4. Difference within and between groups for all outcome measures assessed at recruitment and discharge. 
Outcome 
measure, data 
presentation 
Control Intervention Change over time: median/mean 
differences (95% CI of the 
difference) 
Difference within group Difference between 
groups 
Group or time Recruitment Discharge Recruitment Discharge Control Intervention Control Intervention Recruitment Discharge 
RR
 
adjusted for 
age, median 
(IQR) 
 
1.1 (0.9-1.4) 
(n= 15) 
1.0 (0.9-1.1) 
(n=15) 
1.1 (1.0-1.5) 
(n= 14) 
1.0 (0.9-1.3) 
(n= 14) 
-0.1 (-0.4 – 0.2) 
 
-0.2 (-0.5-0.2) z= 0.9 
p= 0.382 
z= 2.3 
p= 0.019 
z= -0.7 
p= 0.499 
z= 0.6 
p= 0.585 
SpO2 (%), 
median (IQR) 
 
99.5 
(96.0-100.0) 
(n= 14) 
 
97.0 
(93.0-100.0) 
(n= 14) 
100.0  
(98.0-100.0) 
(n= 13) 
99.0  
(97.0-100.0) 
(n= 10) 
-2.5 (-6.7 – 1.7) 
 
-1.0 (- 1.9-3.9) z= 0.7 
p= 0.508 
z= 0.9 
p= 0.398 
z= -1.0 
p= 0.308 
z= -0.9 
p= 0.364 
HR adjusted 
for age, mean 
(SD) 
1.0 (0.1) 
(n= 13) 
1.0 (0.1) 
(n= 14) 
1.0 (0.2) 
(n= 14) 
1.0 (0.1) 
(n= 14) 
0.0 (-0.1-0.1) 
 
 
0.0 (-0.1-0.1) t= -0.43 
p= 0.675 
t= -0.32 
p= 0.753 
t= -0.21 
p= 0.836 
t= -0.07 
p= 0.941 
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6.5.3 Within groups comparison 
Comparison of the data within intervention and control groups, based on recruitment and 
discharge data, are presented in Table 6-4. 
A significant improvement (decrease) in RR adjusted for age occurred in the intervention 
group (p= 0.019). No statically significant change was seen within the control group for RR, 
nor were there any differences within either group for the other outcome measures. 
6.5.4 Pre-, post- and one hour post- intervention 
When comparing the pre-, post- and one hour post-treatment RR in participants receiving 
AAD, a significant difference was found between the different measures (Friedman ANOVA 
X²= 13.7, p= 0.001) (Table 6-5). 
 
Table 6-5. Comparison within the intervention group between the pre-, post-, and one hour post- AAD 
intervention 
Outcome 
measure 
Pre-treatment Post-treatment 1h Post-treatment Friedman 
X² 
p-
value 
RR median (IQR) 45.0 (40.0-50.0) 
(n=62) 
46.0 (40.0-52.0) 
(n=62) 
43.0 (36.0-50.0)  
(n= 57) 
13.7 0.001 
SpO2, median 
(IQR) 
98.0 (95.0-100.0) 
(n= 51) 
98.0 (97.0-100.0) 
(n=52) 
98.5 (96.0-100.0) 
(n= 50) 
2.7 0.256 
 
Further analysis of the results (Wilcoxon matched pairs test) showed a significant increase 
in RR immediately after treatment (n= 55, z= 2.2, p= 0.029), however the values 
significantly decreased one hour post treatment (n= 55, z= 2.9, p= 0.003) and returned to 
pre-treatment values (n= 49, z= 1.4, p= 0.179) (Figure 6-3).  
No significant change was seen in SpO2 amongst pre-, post- and one hour post- treatment 
measurements in the intervention group (p= 0.256). 
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Figure 6-3. Pre-, post- and 1h post-treatment RR for the participants receiving AAD 
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No significant differences were found for the number of participants presenting with signs 
of respiratory distress (head nodding, alar flaring and muscle retraction) pre- and post-
treatment, in the intervention group (Table 6-6). As none of the participants presented with 
weak cry, feeding problems or cyanosis; no analyses could be performed for these signs of 
respiratory distress. 
Table 6-6. Analyses of the signs of respiratory distress pre-and post-treatment. 
Characteristic 
Pre-treatment 
Post-treatment 
absent 
Post-treatment 
present 
McNemar X²  
for change over time 
p-value 
Head nodding 
- Absent 
- Present 
 
 
56 
3 
 
0 
3 
1.3 0.248 
Alar flaring 
- Absent 
- Present 
 
54 
3 
 
2 
3 
0.0 1.000 
Muscle retraction 
- Absent 
- Present 
 
48 
3 
 
4 
7 
0.0 1.000 
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6.5.5 Post-hoc analyses 
No post-hoc analysis for HIV status could be performed due to the limited number of HIV- 
positive (n=2) and exposed (n= 2) children enrolled in this study.  
Post-hoc analyses between the different aetiology groups for the intervention and control 
group (excluding “mixed” aetiology as only two children, both in the control group, were 
identified as having both a bacterial and a viral pneumonia) are presented in Table 6-7. 
A significant difference was seen between the different aetiology groups in the intervention 
group for days of hospitalisation (p= 0.008). Post hoc analysis showed a significant 
difference between “unknown” and both “bacterial” and “viral” aetiology (p= 0.031 and p= 
0.045 respective), but not between “bacterial” and “viral” aetiology. (Figure 6-4). When 
groups were combined results were similar (p= 0.004 for “unknown” and “viral” aetiology, 
p= 0.018 for “unknown” and “bacterial”, p= 1.000 for “viral” and “bacterial” aetiology). All 
other outcome measures did not show a significant difference among different aetiology 
groups. However in the intervention group, a shorter duration of supplemental oxygen 
support is seen between the different aetiologies, approaching significance (p=0.055). In 
the control group, there was a strong tendency to differences between the different 
aetiology groups for RR adjusted for age (p= 0.050). Except for a trend towards a difference 
between days on oxygen supplementation between children with “viral” and “bacterial” 
pneumonia (p= 0.055), post hoc analysis did not show any significant differences amongst 
the different aetiologies for both time on oxygen supplementation in the intervention 
group and RR adjusted for age in the control group. 
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Table 6-7. Comparison within groups for the different aetiologies of pneumonia (presented as median and IQR) 
 Outcome measure Treatment Viral 
N intervention= 5 
N control= 4 
Bacterial 
N intervention= 2 
N control= 3 
Unknown 
N intervention= 7 
N control= 6 
Statistical value P-value 
 
Days of hospitalisation Intervention 
Control 
Combined  
7.8 (7.5-8.5)  
10.0 (8.0-12.4) 
8.5 (7.5-9.5) 
9.1 (8.8-10.5) 
10.5 (6.3-13.5) 
9.5 (8.8-10.5) 
6.5 (4.5-7.0)  
7.0 (6.8-7.0) 
6.8 (6.0-7.0) 
H= 9.7 
H= 5.0 
H= 13.6 
0.008 
0.083 
0.001 
Days of fever during hospitalisation Intervention 
Control 
Combined  
1.0 (1.0-3.0)  
3.0 (1.0-3.0) 
1.0 (1.0-3.0) 
1.0 (1.0-1.0) 
4.0 (0.0-4.0) 
1.0 (1.0-4.0) 
2.0 (2.0-2.0)  
1.0 (0.0-1.0) 
1.5 (1.0-2.0) 
H= 2.1 
H= 1.1 
H= 0.1 
0.343 
0.573 
0.955 
Days on O2 supplementation during hospitalisation Intervention 
Control 
Combined  
5.0 (5.0-6.0)  
6.0 (0.0-11.0) 
5.0 (5.0-7.0) 
0.0 (0.0-0.0) 
1.0 (0.0-10.0) 
0.0 (0.0-1.0) 
4.0 (4.0-6.0)  
2.0 (1.0-4.0) 
4.0 (2.0-6.0) 
H= 5.8 
H= 0.5 
H= 4.6 
0.055 
0.787 
0.099 
RR adjusted for age at discharge Intervention 
Control 
Combined  
1.3 (1.1-1.3) 
0.9 (0.9-1.1) 
1.1 (0.9-1.3) 
1.0 (0.9-1.0) 
1.0 (0.6-1.0) 
1.0 (0.9-1.0) 
0.9 (0.7-1.0) 
1.1 (1.1-1.3) 
1.0 (0.9-1.1) 
H= 3.3 
H= 6.0 
H= 1.9 
0.194 
0.050 
0.387 
HR adjusted for age at discharge Intervention 
Control 
Combined  
1.0 (0.9-1.0) 
1.0 (0.9-1.1) 
1.0 (0.9-1.1) 
1.0 (0.9-1.1) 
1.0 (0.9-1.2) 
1.0 (0.9-1.1) 
1.0 (0.9-1.2) 
1.0 (1.0-1.0) 
1.0 (0.9-1.0) 
H= 0.3 
H= 0.7 
H= 0.2 
0.873 
0.707 
0.925 
SpO2 at discharge (%) Intervention 
Control 
Combined  
99.0 (98.0-100.0)  
96.0 (95.0-100.0) 
98.0 (95.5-100.0) 
97.0(97.0-97.0) 
98.0 (93.0-100.0) 
97.5 (95.0-99.0) 
100.0 (94.0-100.0)  
99.0 (96.0-100.0) 
99.5 (94.0-100.0) 
H= 1.1 
H= 0.5 
H= 0.1 
0.586 
0.782 
0.931 
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Post-hoc power analysis showed a noticeable under powering of the study, with a power of 
41%. This analysis used the pre-set mean duration of hospitalisation for the control group 
and intervention group (8 and 7 days respective), with α= 0.05, σ= 1.5 and the current 
sample size of 15 and 14 participants in the control and intervention group respectively. As 
the p-value for the primary outcome measure ‘duration of hospitalisation’ was still within 
the pre-set a priori boundaries, the study should have continued until the pre-set sample 
size of 98 participants. However, the study ran from March 2014 until December 2015, 
during which only 29 eligible participants were identified. Therefore, the researchers 
deemed it necessary to halt the study for pragmatic reasons. 
6.6  DISCUSSION 
This study was unable to show significant differences between the intervention group (AAD 
plus standard nursing care) and control group (standard nursing care), for any of its primary 
and secondary outcome measures. However, a strong trend towards a faster time to 
discharge and a significant decrease in RR, adjusted for age, from recruitment to discharge 
was found within the intervention group. This change in RR adjusted for age was not seen 
in the control group, and has also not been reported previously. No other within group 
effects were observed. A statistically significant increase in RR was seen after AAD 
intervention, however, it is questionable if this increase in RR is clinically relevant, as an 
increase of only one breath per minute was observed. Further, the RR values returned to 
Figure 6-4. Boxplot comparison between the different aetiologies within the intervention group for the 
outcome measure ‘days of hospitalisation’. 
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baseline levels one hour post treatment. Finally, a significantly shorter duration of 
hospitalisation was seen in children hospitalised with pneumonia of “unknown” aetiology 
compared to “viral” and “bacterial” pneumonia. The shorter duration of hospitalisation 
might have been the reason for the inability to classify the participants as having either 
“bacterial” or “viral” aetiology, as no sputum and/blood cultures were conducted or 
laboratory results were not reported by the time of discharge. A strong trend for a shorter 
duration of oxygen supplementation in participants with bacterial pneumonia in the 
intervention group, compared to “viral” and “unknown” aetiology, was seen. Further, in the 
control group, a strong tendency for a higher RR adjusted for age for participants with 
“unknown” aetiology was observed. No differences were found for the other outcome 
measures between pneumonia of “viral”, “bacterial” or “unknown” aetiology.  
Although admission parameters showed a significant difference between the intervention 
and control group for RR adjusted for age, this difference was not noticeable by the time of 
recruitment. To compensate for the time without intervention, the data obtained at 
recruitment were used for analyses rather than admission data. However, the difference in 
RR adjusted for age at admission might have influenced the outcome of this study, as the 
children in the intervention group might have been more severely ill on admission.  
Several studies on the use of ACT in children with pneumonia have been published (Table 
3-1).221–223,227,228 However, AAD has never been used in research before, hence no 
comparison of our results with similar research using the same intervention could be made.  
Paludo et al.,221 Lukrafka et al.,222 and Stapleton,227 also reported insignificant differences 
between the control and intervention groups on the duration of hospitalisation in children. 
Duration of hospitalisation in the current study (median of 7.5 days and seven days 
respectively in the control and intervention groups) is in line with the number of 
hospitalisation days reported in the study by Paludo et al.221 (median of six days for both 
groups), who also had a non-intervention control group. However, the study by Lukrafka et 
al.222 (median of six days in the control group and eight days in the intervention group) and 
Stapleton (mean of seven and nine days in control and intervention groups respectively)227 
showed slightly longer duration of stay for the participants receiving physiotherapy 
intervention than the participants in the control group (see Table 3-1 for an overview of the 
techniques used in these respective studies). This could be due to the mixed diagnoses 
included in the study conducted by Stapleton (bronchiolitis, bronchitis and pneumonia)227 
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and the inclusion of participants diagnosed with pleural effusion being enrolled in the 
intervention group in the study by Lukrafka et al.222. This latter study also included a control 
group who received advice on coughing, diaphragmatic deep breathing and positioning in 
side lying; which might have influenced the duration of hospitalisation.222 It is however 
unclear how the recommendations of coughing and diaphragmatic deep breathing were 
executed in babies and young children. 
No differences in HR and RR adjusted for age between the groups were found in this study. 
None of the previously conducted studies used HR or RR adjusted for age, and no 
comparison can therefore be made with this study. However, Lukrafka et al.222  reported no 
significant difference between groups at discharge for absolute RR values at the end of the 
study.  This is in contrast with the study by Abdelbasset and Elnegamy, who found a 
significantly lower RR at discharge in the intervention group compared to the control 
group.223 
This current study showed significant improvement in RR adjusted for age within the 
intervention group, whereas no significant improvement was seen in the control group. On 
the contrary, in the study by Lukrafka et al.,222 which reported absolute values for RR, both 
groups showed a significant improvement in this outcome measure. The improvement of 
this outcome measure in the control group may be partly explained by the endorsement of 
deep breathing exercises, positioning and coughing in the control group, for which their 
outcome measure ‘severity score’ also significantly improved.222 By contrast, the current 
study used a non-treatment control group for which no physiotherapy intervention was 
given in 14 of the 15 participants. Only one child in the control group received three 
sessions of emergency physiotherapy intervention, as prescribed by the physician. Similarly, 
the study by Abdelbasset and Elnegamy, which also compared their intervention with a 
non-treatment control group, found a greater improvement in absolute RR values in the 
intervention group, however, this study did not report a statistical value to compare the 
change over time (mean difference in the intervention and control group was -9.8 and -4.9 
respectively).223 This study also found a significantly quicker resolution of disease; 
determined by time to normal RR, temperature, SpO2 and absence of severe signs of 
respiratory distress; for the intervention group (4 days) compared to the control group (7 
days).223 
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No lung function tests were performed in the current study as all included participants 
were younger than five years of age, which is conventionally used as the cut-off age for 
reliable lung function results.137,284 Therefore we were unable to compare our results with 
the study of Plebani et al.,226 who enrolled eight HIV-infected participants between the age 
of 46-94 months and found a significant improvement in lung function results after 
intervention with a PEP-mask bi-daily for one year. Recent literature does suggest the 
possibility of conducting spirometry tests in preschool children, after practice and/or under 
supervision of trained medical staff.146–148,285 Only one participant in the current study was 
older than three years, hence, this new cut-off age would not have changed the 
presentation of our results. However, in future research, the use of spirometric lung 
function tests could be considered as an outcome measure for children younger than five 
years of age. 
The increase in RR after AAD treatment, which returned to baseline values one hour after 
treatment, are in line with the results reported by Santos et al.,228 who also found an 
increase in RR and HR post-treatment which returned to baseline after rest (see Table 3-1). 
This phenomenon could possibly be explained by the change in oxygen demand during 
ACTs, which alters vital signs during treatment.286 Further, during AAD, airway clearance is 
performed at three different lung volume stages.27 Reducing the lung volumes in children 
might lead to fatigue, which could be the reason for increased RR during and after 
treatment.287 However, RR only increased by one breath per minute and the clinical 
relevance of this small increase is questionable. This current study did not reveal a 
significant improvement in SpO2 after treatment, which was reported by Santos et al.
228 We 
did not record HR before, after and one hour after treatment, as cardiac monitoring is not 
standard practice in the general medical wards. This is a limitation of this study, and should 
be included in future trials. 
The original protocol of this study focused only on children with bacterial pneumonia. 
However, due to the numerous unforeseen exclusions of children with “viral” pneumonia, 
this study’s protocol was amended at the point of interim analysis to include children with 
all isolates resulting in pneumonia. The initial inclusion criteria might have led to the 
inability to enrol the pre-set sample size. However, many children hospitalised with viral 
pneumonia would still have been excluded based on other criteria.  
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The protocol of this study did not include the identification of presence of pulmonary 
secretions. This decision was made as determining the presence of pulmonary secretions is 
largely based on subjective criteria, especially the use of auscultation is unreliable.142,288,289 
Other methods of determining the presence of pulmonary secretions, e.g. chest X-rays, are 
not part of routine practice at the research site. Furthermore, chest X-rays expose the 
children to radiation, for which it was deemed necessary to avert unnecessary 
exposure.138,141 This is a major limitation of this study as AAD is most effective when 
pulmonary secretions are present. Other effects of AAD should be considered in future, 
such as improvement in ventilation, perfusion, and alveolar interdependence. 
No subgroup analysis on participants with pneumonia of mixed aetiology (only two children 
were classified as a combined viral-bacterial pneumonia) could be performed; and 
participants with different HIV status (only one child in each group was HIV-positive, -
exposed and –unknown, majority was HIV-negative) due to the small sample size. 
Owing to the many exclusion criteria to warrant safety whilst performing AAD (a novel 
technique) in this vulnerable participant population, and the limited time for recruitment 
during the week (on Monday mornings), only 29 participants were included in the study, for 
which the study power was merely 41%. Ideally, the study should have continued until the 
pre-specified sample size was reached, as the primary outcome measure ‘duration of 
hospitalisation’ was still within the a priori boundaries. However, the study was halted after 
a trial period of one year and nine months due to the slow rate of enrolment, burdening the 
research personnel. Large amendments would have been necessary, which would have 
been too time consuming for this thesis. Future research should include larger sample sizes 
by considering multi-centre (more than two) trials and recruitment on several days during 
the week. It would be challenging to enrol a larger sample size of children with 
uncomplicated pneumonia at the research site in a similar time period, owing to the many 
comorbidities seen in children hospitalised for an extended period with pneumonia at this 
primary research site (see Chapter 5). Therefore, future research should focus on the use 
and potential benefits of AAD in children with different comorbid conditions, admitted to 
hospital with pneumonia. Considering that this is the first research study of AAD in young 
children, it is recommended that future research be done on the efficacy of this technique 
amongst different respiratory conditions and different age groups. The results of this 
current study provide baseline data against which future studies can be compared. 
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6.7  CONCLUSION 
This current study is a stepping stone, aimed at adding to the body of knowledge and 
addressing the gap in literature on the use of AAD in children with different medical 
conditions. Although a trend to a faster time to discharge and a significant decrease of RR 
within the intervention group was observed, this study was unable to prove the clinical 
usefulness of AAD in children hospitalised with uncomplicated acute pneumonia. No 
clinically or statistically significant differences were seen between intervention and control 
groups, therefore AAD cannot currently be recommended as standard practice in children 
with uncomplicated pneumonia. However, as no adverse events and casualties were 
reported, the road towards further research on the usefulness of AAD is opened. Future 
research needs to be conducted using a larger sample size in the same population group, 
and research investigating the use of AAD in children hospitalised with pneumonia and 
underlying comorbid conditions is also warranted.  
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Chapter 7. CYSTIC FIBROSIS – NARRATIVE BACKGROUND LITERATURE REVIEW 
7.1  DESCRIPTION OF CF AND IMPACT ON BODILY SYSTEMS 
CF is an autosomal recessive hereditary disease (Figure 7-1), affecting the CF 
transmembrane regulator (CFTR) gene.290–292 The CFTR gene is located on the long arm of 
chromosome 7 and contains about 180 000 base pairs of DNA.15,293 This gene produces the 
CFTR protein, which is part of the adenosine triphosphate binding cassette transporters.15 
The CFTR protein is responsible for chloride (Cl-) permeability across the cell wall, by acting 
as an ion transporter channel for Cl- and bicarbonate.15,293 In addition, the protein also 
assists in the transport of other ions across the cell wall, such as sodium (Na+).294 Therefore, 
when the CFTR protein is defective, both Cl- and Na+ conductance will be altered, leading to 
impaired salt absorption of the cells in secretory organs.292,294
 
Figure 7-1. Schematic presentation of inheritance CF 
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Various mutations of the CFTR gene have been linked to CF, with 2009 recorded mutations 
in 2011.295 These mutations can be classified in six classes, based on the mechanism of 
action in the disease process (Figure 7-2).291,293,296,297 The class I mutations causes an 
interruption in the production of the CFTR protein due to nonsense alleles in the DNA, 
leading to incomplete protein production. Class II mutations result in production of the 
protein, however, due to a default in the protein, it will be destroyed before reaching its 
end destination in the epithelial cell wall. Class III mutations do produce proteins which 
reach the epithelial cell wall, however, the protein lacks the Cl- permeability for which it 
was designed. Class IV mutations are similar to class III however they are partially 
functional. Class V mutations causes reduced production of the CFTR protein, whereas class 
VI mutations result in proper protein production and function; however, proteins are 
instable and are destroyed faster than normal.291,293,296,297  
 
[Reproduced with permission from Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19); 
Copyright Massachusetts Medical Society]
293
 
Figure 7-2. Schematic representation of the different classes of CFTR dysfunction. 
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Worldwide, the ∆F508 mutation (class II) is most common, being present in approximately 
70% of European Caucasians and 76% of white South Africans with CF.15,298 It is also found 
in about 53% of patients from mixed ancestry, but is rare in patients from African and Asian 
origin.15,292,299 In native Africans, the 3120 +1G→A mutation has been identified most 
frequently; and was found to be the second most common mutation in patients from mixed 
ancestry in South Africa.15,292  
Because mutation in the CFTR gene may affect all secretory organs throughout the body, CF 
can be seen as a multi-organ disease.290,293 Due to the increased Na+ absorption and 
defective Cl- permeability, secretions are dehydrated, becoming thick and sticky.16,300 Table 
7-1 provides an overview of the different affected systems and common presentations of 
CF disease within these systems.  
7.1.1 Gastrointestinal tract 
7.1.1.1 Pancreas 
Depending on the type of mutation(s), people with CF could be either pancreatic sufficient 
(mostly with Class IV-V-VI mutations) or insufficient (Class I-II-III mutations).291 Pancreatic 
insufficiency is present in approximately 85% of patients with CF and leads to the inability 
to absorb nutrients, particularly fat (resulting in steatorrhea), fat-soluble vitamins and 
protein from food; leading to malnutrition.290,301,302 Further, pancreatic insufficiency could 
result in CF-related diabetes mellitus due to hyperglycaemia and glucosuria. Therefore, 
these patients are also at risk for other vascular complications.301  
7.1.1.2 Intestinal tract 
Viscous secretions in the intestinal tract can result in meconium ileus, inability or delayed 
passing of the first stool, in approximately 10-25% of newborn babies.16,292,297,301 
Furthermore, distal intestinal obstruction syndrome can occur in older patients (4-5%), 
leading to abdominal distention, pain and sometimes vomiting.16,297,301 
Due to malabsorption of food, patients with CF are at risk of vitamin deficiency, particularly 
vitamins D, E and K, resulting in associated conditions such as neuropathies, bleeding 
disorders and osteoporosis.16 
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7.1.1.3 Hepatobiliary tract 
Hepatobiliary tract problems in patients with CF can originate from the defective CFTR 
protein which is involved in the production of ductal bile excretion, but could also be due to 
other factors such as malabsorption of nutrients and/or adverse effects of medication.297,303 
Most patients with CF have some form of asymptomatic liver dysfunction (e.g. liver enzyme 
dysfunction).297,301,303 However, only 5-7% present with symptoms of biliary cirrhosis and 
portal hypertension.16,297,301  Common extra-hepatic complications are gallbladder problems 
such as microgallbladder, present in up to 33% of patients, and distended gallbladder.297,303 
7.1.2 Reproductive system 
In adolescents with CF, puberty is often delayed, mainly due to poor nutritional status. 
Although adult height has normalised in recent years as a result of improved nutritional 
management; peak height velocity remains delayed and decreased in patients with CF.304–
306 Delayed onset of puberty influences the onset of sex hormone production, however, in 
adulthood, normal hormone levels are observed in this population.307 
Due to the increased longevity of patients with CF, questions related to fertility and 
reproductive health have become of greater importance in the past decades. Infertility in 
male patients with CF has been reported in up to 98% of patients, originating prenatally 
due to congenital bilateral absence of the vas deferens or atresia of the ductus leading to 
azoospermia; or due to poor quality of sperm because of dysfunction of the seminal 
vesicles resulting in aqueous ejaculates with high acidity levels.16,308,309 
In women, fertility is less affected; however, increased mucus viscosity of the cervix during 
ovulation, alterations in uterine fluid control and disease progression of other bodily 
systems could prevent women from becoming pregnant.310 For example, deterioration of 
the respiratory system influences the woman’s fertility; female patients with an FEV1 of less 
than 50% predicted struggle to fall pregnant.16,309 Malnutrition can lead to irregular 
menstrual cycles or amenorrhea.310,311 Furthermore, structural changes to the reproductive 
system in women with CF have also been reported. 
7.1.3 Sweat glands 
Due to the altered Na+ and Cl- conductance in the body, patients with CF tend to have 
elevated Cl- levels in their sweat.294,300 This leads to salty tasting sweat, and increased risk of 
dehydration especially during warm weather and gastroenteritis.16,293 This distinct 
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characteristic of CF is used as one of the diagnostic tools for the disease (see section 
7.2).300,312  
7.1.4 Respiratory tract 
In healthy people, the MCC mechanism protects the lungs from infections by trapping 
particles, including potential pathogens, in the mucus layer and evacuating them towards 
the central airways. Optimal functioning of MCC is dependent on the airway surface liquid 
(ASL), consisting of the periciliary layer and mucus layer (see 2.3.1.1).13,63 The thickness of 
the ASL can be influenced by Na+ and Cl- ion transport across the epithelial cell wall.78 In 
patients with CF, the impaired Cl- permeability and Na+ conductance results in increased 
absorption of fluids, dehydrating the ASL and increasing the viscoelasticity of the mucus 
layer.13,78 Another mechanism that might influence the respiratory defence system is the 
inhibition of the bactericidal function of the ASL as a result of increased sodium levels in the 
ASL.313 This altered airway environment in people with CF leads to a vicious cycle of 
reduced MCC, leading to secretion retention, airway obstruction, secondary chest 
infections and inflammation; and can result in irreversible lung damage (bronchiectasis) and 
respiratory failure (Figure 7-3).14,291  
Not only the lower respiratory tract is affected in children with CF. Upper respiratory tract 
manifestations, particularly rhinosinusitis (both chronic and acute) and nasal polyps can 
occur in these patients.292,314,315 URTIs can result in LRTIs, inducing the above mentioned 
vicious cycle.315,316 Furthermore, upper respiratory tract manifestations in children with CF 
can lead to sleep apnoea, disturbing the child’s sleeping pattern.317,318  
Lung function testing is part of routine assessment in children with CF.149 This outcome 
measure is not merely influenced by severity of lung disease, but also by nutritional status.  
Children who are underweight for age present with poorer lung function results than their 
normal weight CF peers,19,319 highlighting the need for multi-disciplinary management of 
patients with CF. 
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[Reprinted with permission from Konstan MW, Berger M. Current understanding of the inflammatory process in 
cystic fibrosis: onset and etiology. Pediatr Pulmonol. 1997;24(2)]
14
 
Figure 7-3. Pathogenic scheme for the respiratory system in CF.  
 
Table 7-1. Overview of affected bodily systems and disease presentation in CF 
Affected bodily system Disease presentation Intervention 
Respiratory tract  - Vicious cycle of mucus 
retention, bronchial 
obstruction, infection, 
inflammation and 
destruction 
- Upper respiratory tract 
manifestations, particularly 
nasal polyps and 
rhinosinusitis which can lead 
to sleep apnoea 
- Ivacaftor/Lumacaftor when 
available 
- Prevention (including 
vaccination) 
- Mucolytics 
- ACTs 
- Antibiotics 
- Anti-inflammatories 
- Bronchodilators 
- Frequent sputum cultures 
- Counselling 
- Nasal irrigation 
- Endoscopic surgery 
Gastrointestinal tract: 
1) Pancreas 
2) Intestinal tract 
3) Hepatobiliary 
tract 
- Malabsorption of nutrients 
- Steatorrhea 
- CF-related diabetes mellitus  
- Meconium ileus 
- Distal intestinal obstruction 
syndrome 
- Fat-soluble vitamin 
deficiency (D,E,K) 
- Liver enzyme dysfunction 
- Biliary cirrhosis  
- Microgallbladder 
- Pancreatic enzyme 
supplements (e.g. Creon®) 
- High energy/fat rich diet 
- Laxatives/bowel washout 
(e.g. Golytely) 
- Hypertonic/ 
hyperosmoloar medium 
e.g. Gastrografin  
- Mucolytics 
- Gastrostomy for 
supplemental feeding 
- Vitamin supplements  
- Ursodeoxycholic acid 
- Liver transplant 
Sweat glands - Risk of hyponatremia 
- Hypochloremic alkalosis 
- Oral hydration 
- IV hydration 
- Salt supplements 
Reproductive system - Decreased fertility in women 
- Infertility in most males 
(azoospermia) 
- Counselling 
- Advice on assisted 
reproductive techniques 
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7.2  SCREENING AND DIAGNOSTIC TESTING 
As CF is a genetic disorder, cascade screening for the carrier gene is recommended in 
prospective parents, especially when a family history of CF is present.292,320 Furthermore, 
blood tests to determine the type of mutation present in the parents is useful to facilitate 
prenatal screening. 292,320 
At specialist centres, pre-implementation diagnosis can be made.292,320 By using in vitro 
fertilisation, embryos can be screened for CF mutations and embryos free of CF can be 
selected and implanted.321 
Prenatal screening for CF in couples with increased risk can be done by using amniocentesis 
or chorionic villus sampling, providing the option to terminate pregnancy when CF is 
diagnosed.292,322 Although the safety of these techniques has improved over the years, 
there is still an increased risk of miscarriage when these invasive techniques are performed 
(0.1-1%).322–324 Chorionic villus sampling, removal of a small part of the placenta for testing, 
is performed early in pregnancy; which may make termination of pregnancy (if that option 
is chosen) easier to perform than following amniocentesis performed later on in the 
pregnancy.292 
Post-natal blood tests for screening of immunoreactive trypsinogen is done in patients with 
a possible diagnosis of CF.292,325,326 Diagnosis of CF needs to be confirmed by further 
diagnostic testing, most commonly done by a sweat test.149,292,325 As mentioned in the 
previous section, sweat glands are often affected in patients with CF, due to the altered Cl- 
and Na+ permeability of the secretory glands. Either a sweat conductivity test or electrolyte 
testing can be performed. The conductivity test is more accessible in South Africa,292 
however, the reliability of this test is lower than the electrolyte test, which analyses the Cl- 
levels in the excreted sweat.292,325 Genetic testing, to identify CFTR mutations, can also be 
used to confirm the diagnosis of CF, particularly in patients with atypical CF presentation.320  
When sweat testing is unavailable, faecal pancreatic elastase testing is a reliable test to 
detect pancreatic insufficiency, in children with positive blood tests.292,327  
7.3  INCIDENCE AND IMPACT ON HRQOL 
CF is most common in the Caucasian population in South Africa, with an incidence of 
approximately one in every 2000 white children born in South Africa.292 For the Western 
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Cape (South Africa), incidence rates up to date until 1996 vary in rural and urban areas. In 
the Cape Metropole area (urban), an incidence of one in every 2843 live births has been 
found for the white population, whereas one in every 9778 live births has been reported for 
non-Cape Metropole areas (rural), resulting in a total incidence of one in every 4007 live 
births in the white Western Cape population.328 The rate of the urban Cape Metropole area 
is in line with an incidence rate of one in 2381 live births in the UK (1947-2003).12 Incidence 
rates for CF in the Black African and mixed ancestry population is lower, with one in every 
32 000 black babies and one in 14 511 babies of mixed ancestry affected.292,328 In one study 
in a Latin-American population, an incidence of one in 11 252 live births was reported.329  
In South Africa, approximately 1 in 20-32 individuals in the white population, 1 in 55-60 in 
the population of mixed ancestry and up to 1 in 90 black Africans carry a known CFTR 
mutation.292,328  
Life-expectancy in people affected by CF is decreased, but the number of adults with the 
disease is increasing due to improvements in management e.g. frequent use of antibiotics 
and more frequent review at multidisciplinary CF clinics.12,292  
In patients with CF, HRQOL is mostly determined by the patients’ personal views on their 
health status, coping strategies and time consumption of therapy; and less influenced by 
disease severity.330,331 However, pulmonary exacerbations do have a clear negative impact 
on physical and psychosocial HRQOL due to the ‘disruptive’ effect of exacerbations on the 
patient’s life.330 Nutritional status has also been found to be associated with HRQOL, as 
children and adolescents with poor nutritional status, based on BMI-for-age z-scores and 
percentiles, scored lower on the CF questionnaire.332 Social stigmatisation can also 
influence the patient’s HRQOL by reducing their positive view on life, therefore leading to 
increased levels of depression and anxiety.333 Increased rates of depression and anxiety are 
reported in patients with CF compared to their healthy peers, with rates of up to 29% for 
depression in children and 33% for both depression and anxiety in adults.334,335 
Management of depression is becoming of greater importance as part of the management 
of CF, as depression has proven to negatively influence patient’s adherence to 
therapy.336,337 The influence of CF on the HRQOL in children living in South-Africa has not 
yet been studied. 
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7.4  TREATMENT 
7.4.1 General management 
As CF is a multi-system disease, a multidisciplinary approach is necessary to tackle all 
aspects of the disease. Many of the clinical features previously thought to be inevitable can 
be prevented, delayed or improved by intensive treatment.292 In this section, a brief 
overview of the management of common disease presentations are presented. Explanation 
of different ACTs used in the management of CF can be found in section 7.4.6. 
7.4.2 Gastrointestinal tract 
7.4.2.1 Pancreas 
When patients present with pancreatic insufficiency, pancreatic enzyme supplements (e.g. 
Creon®, Zenpep) are indicated to facilitate protein and fat absorption.16,338 The dosage 
depends on nutritional intake and weight.339 Normally, this results in an intake with three 
main meals and two to three snacks per day.301 Recent studies have found that the 
previously set limit of 10 000 lipase units/kg/day (to prevent fibrosing colonopathy)301,340 
can be crossed without adverse effect, especially in infants receiving more frequent feeds 
per day.341,342 These patients will also have to consume a high energy, fat rich diet to 
prevent malnutrition.16,343 In South Africa,  Creon® is the sole pancreatic enzyme 
supplement available, which is expensive and cannot always withstand the warm climate of 
some parts of the country.292,344 
Patients with CF related diabetes mellitus need an individually adapted insulin therapy, 
especially patients suffering from fasting hyperglycemia.301,345 Insulin injections are given 
around meals rather than basal insulin injections in patients with CF.346 Because patients 
with pancreatic insufficient CF are recommended to increase their energy intake, dietary 
changes for diabetes are contraindicated.149,345,347 Therefore, insulin is adapted to the 
patient’s diet rather than changing the nutrition.345,346 
7.4.2.2 Intestinal tract 
Babies suffering from simple meconium ileus are treated with an hyperosmolar solution 
e.g. Gastrografin®, to extract fluids from the cells and loosen the stool.16,348–350 However, 
caution needs to be taken as these solutions might lead to perforation, 
dehydration/hypovolemia and/or imbalance in electrolytes and fluid.350–352 Therefore, 
Gastrografin should be diluted with water to prevent dehydration and electrolyte 
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imbalance.351,353 Intravenous fluids might need to be administered during the treatment 
and additional electrolyte therapy could be needed.301 When meconium ileus does not 
respond to these interventions, or the problem is complex, surgery (e.g. enterostomy) 
might be indicated.16,348,351 
The management of distal intestinal obstruction syndrome usually commences with a trial 
of laxatives or bowel washouts.16,301,354,355 In South Africa, Golytely is often prescribed as a 
laxative.292,356  Other options are Gastrografin and/or mucolytics when laxatives are 
insufficient.301,354,357 When these solutions are not sufficient, surgical interventions (e.g. 
gastrostomy or laparotomy) might be indicated.16,301,358  
7.4.2.3 Hepatobiliary tract 
First line treatment of hepatobiliary problems are pharmacological agents, especially 
Ursodeoxycholic acid (UDCA), which impede bile acid, improves bicarbonate excretion, and 
increases bile flow.301,359–361 A recent long term study (at least two years of exposure) found 
UDCA to be safe for administration for a prolonged period of time.362 Another 
pharmacological option is Taurine therapy,363,364 which is often administered in addition to 
UDCA to stabilize the taurine levels in the liver.339,360 However, in South Africa, only UDCA is 
available,292 but is not accessible in all geographic areas of the country. 
Although the administering of fat-soluble vitamins (vitamin A-D-E-K) is recommended by 
most guidelines,149,292,365 limited supportive evidence is available to date.109,366,367 Further, 
the toxic effect of an overdose of vitamins needs to be taken into account when prescribing 
vitamin supplements.302,368  
Finally, when liver failure is present, a liver transplant may be indicated.16,149 In South 
Africa, liver transplant is rarely performed due to the limited access to adequate health 
care, poor socio-economic circumstances, high cost of surgery, and poor outcome as a 
result of poor follow up treatment.369 Both internationally and in South Africa, long waiting 
list for transplants result in a more symptomatic treatment for most patients.149,370 
Eligibility criteria for liver transplant surgery in patients with CF has not been established. 
Early liver transplant, prior to severe deterioration of nutritional status and lung function, 
could be beneficial.371,372 However, recommendations for liver transplant have prioritised 
patients with severe liver complications, and poor nutritional status and pulmonary 
function.373,374  
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7.4.3 Reproductive system 
Females with mild to moderate CF severity can fall pregnant and carry the foetus full term, 
despite potentially decreased fertility. Females with severe disease severity could be 
infertile and/or are at increased risk of pregnancy and childbirth complications.149,375 
Female patients should be referred to appropriate health care professionals to evaluate 
their fertility and to guide pregnancies, which are considered high-risk.149,309  
The majority of males are infertile and should be counselled appropriately and referred for 
alternative reproductive options.149,309,376 
7.4.4 Sweat glands 
As patients with CF are at increased risk of dehydration, particularly during warm weather 
and/or episodes of gastroenteritis, it is of great importance to prevent dehydration by 
increasing oral intake of fluids.377,378 Patients could also take salt supplements, especially 
during warm periods and/or periods of illness.16,378  
7.4.5 Respiratory tract 
Decreased longevity in patients with CF is most often due to respiratory complications. 
Therefore, treatments focused on maintaining or improving respiratory function are of 
great importance.  
To prevent URTIs progressing to LRTIs; nasal irrigation, topical steroids and antibiotic 
therapy is recommended.292,316 Patients with chronic sinusitis might benefit from 
endoscopic surgery.292 Symptomatic nasal polyps can be treated with steroids and/or 
endoscopic surgery.292,309 
An overview of the interventions and where they intervene in the vicious cycle of lung 
pathology is presented in Figure 7-4. 
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[Self-designed by L. Corten] 
Figure 7-4.  Interventions respiratory tract in CF 
 
Newer gene therapies, Ivacaftor and Lumacaftor, are valuable as they target the CFTR 
protein defect itself. Ivacaftor is beneficial for patients with the G551D mutation whereas a 
combination of Lumacaftor/Ivacaftor had been found beneficial for patients with class II  
∆508del homozygous mutations.379–384 Other mutations have not been proven to be 
responsive to these treatments. Unfortunately, these gene therapies are extremely 
expensive and not available in South Africa.385 Therefore, interventions focus on 
symptomatic treatment of the disease:  
1) Prevention of infection 
Prevention of infections is important. This can be done by immunisations for vaccine-
preventable agents, especially for measles and influenza.386,387 Further, decreasing exposure 
to infections is necessary, by e.g. sterilising equipment used at clinics, hand hygiene, and 
maintaining a two meter distance between patients with CF to prevent patient to patient 
transmission.387,388 
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2) Inflammation and infection of the respiratory tract 
When the patient presents with an acute exacerbation of infection, the use of antibiotics is 
indicated.389 When the patient is first infected with CF-related bacteria, particularly 
Pseudomonas aeruginosa, an aggressive eradication regime is required.292,388,389 At the 
outpatient CF clinic of a specialised tertiary paediatric hospital in Cape Town, South Africa, 
the eradication protocol for Pseudomonas aeruginosa usually consists of three months of 
oral antibiotic (usually Cipro), three months of inhaled antibitoic (gentamycin/tobramycin), 
and azithromycin (Prof. B. Morrow. Personal communication, 2017). Standard management 
of acute infections (other than Pseudomonas aeruginosa) in South Africa, is two weeks 
antibiotic treatment, either oral (in mild disease) or intravenous (in more severe disease).292 
Antibiotics should not be used long term for prophylactic purposes,17 however, once a 
patient is colonised, particularly with Pseudomonas aeruginosa, long-term inhaled 
antibiotics are indicated.292 Caution is needed to prevent emergence of antibiotic resistant 
bacteria.17,390Azithromycin is often prescribed as it has an anti-inflammatory function in 
addition to its antibacterial and antiviral effect.391 Other non-steroidal anti-inflammatory 
drugs such as Ibuprofen, and corticosteroids, have been shown to slow down the disease 
progress.17,292,392 However, gastrointestinal adverse events of Ibuprofen have also been 
reported.292 Thus gastrointestinal protective medication will need to be administered in 
adjunction to non-steroidal anti-inflammatory drugs and regular monitoring of the patient’s 
condition is required.392 Inhaled and oral corticosteroids, although effective in children with 
CF accompanied by asthma-induced bronchospasm or allergic bronchopulmonary 
aspergillosis, might not reach the inflammation in the airways due to thick secretions, 
reducing the efficacy.17,292 
3) Inhaled/aerosolised therapy 
Ideally, patients should use daily inhaled mucolytics such as hypertonic saline or DNAse, to 
decrease the viscosity of mucus.17,83 Inhaled hypertonic saline increases the airway surface 
liquid by extracting water from the body to loosen the secretions and improve MCC. 393  It is 
inexpensive and freely available for use in South Africa. DNAse has the added benefit of 
reducing inflammation in the lungs.394 However, DNAse is expensive and only available for 
South African patients on medical aid, unless deemed highly necessary for which 
motivation for reimbursement can be obtained.292 Bronchodilators are also often 
prescribed, to help with mucus clearance by opening the obstructed airways,  caused by 
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hyper-reactive airway bronchoconstriction, resulting in improved penetration of mucolitics, 
MCC and response to ACTs.17,395  
4) Airway clearance therapy 
Regular ACTs are of great importance in patients with CF to facilitate MCC, to clear 
secretions from the lungs and therefore prevent mucus plugging, airway obstruction, 
infection and inflammation, hence slowing the progression to chronic lung disease.18 See 
section 7.4.6 for an overview of ACTs in children with CF. 
Respiratory treatment for patients with CF commences with a bronchodilator, followed by 
hypertonic saline or DNAse. Hypertonic saline is preferably administered prior to or during 
ACT,396 whereas DNAse can either be admistered 30 minutes before ACT or afterwards, 
depending on the patient’s lung function, preference or timing of ACT during the day.397 
Treatment should end with inhaled antibiotics, long acting bronchodilators and 
corticosteroids when indicated.17  
7.4.6 Airway clearance therapy 
An overview of available ACTs is presented in Chapter 2. The majority of paediatric studies 
investigating ACTs in children with CF included children older than six years of age. Very few 
studies included infants and young children. 
7.4.6.1 Postural drainage and modified PD 
PD and MPD are useful in infants and young children with CF as no active participation is 
required.25 
Although one study found no influence of PD combined with or without percussions 
compared to cough alone on clearance of a radiolabelled aerosol tracer in adolescents and 
adults with CF,398  a significant improvement in sputum expectoration and respiratory 
function was found when PD was compared to no ACT in this population.399–402  
A systematic review comparing conventional ACTs (including PD) with other ACTs, did not 
find any superiority of conventional ACTs over other ACTs; however, evidence is limited and 
of poor quality, preventing definite conclusions regarding this technique.134  
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Because PD with head-down position induces more gastroesophageal reflux and results in 
reduced FVC and FEV1 in children with CF, a modified version of PD has been developed, 
which does not include inverted positions.86,91,403,404 Button et al. reported significantly 
fewer days of upper respiratory tract symptoms and lower antibiotic usage in children with 
CF using MPD compared to PD during the first year of study.91 At five years of age, the 
children in the MPD group had better respiratory function and fewer radiological changes.91 
An increase in the number of GORD episodes compared to baseline data was seen during 
either PD and MPD treatment, but the increase was significantly lower in children treated 
with MPD than PD.91 
PD has been the gold standard treatment for children with CF in the past decades and, 
along with MPD, has been compared to other ACTs (FET, PEP, oscillating PEP or AD) in 
children with CF. Results of these studies have been reported below under the respective 
headings. 
7.4.6.2 Forced expiration technique (FET) 
FET is often used as an adjunct to other ACTs. The addition of FET to PD results in better 
clearance of secretions than PD alone;113 and the same amount of secretion clearance as 
FET combined with PEP 30 minutes after treatment.405 In a study by Lannefors and 
Wollmer, in patients age 12 to 36 years, FET was combined with either PD, PEP or physical 
activity and no significant differences between the groups were found.406 Steen et al. 
compared FET alone to combined therapy with FET and PEP, PD and percussion, and PEP 
and PD, in patients between the ages of eight to 21 years. No significant differences were 
seen between the different groups for Chrispin-Norman or Shwachman scores; growth; and 
pulmonary function tests (FEV1, FVC, FEF25-75) after one month of intervention.
407 Although 
FET needs active participation of the patient, it could be implemented in the treatment 
regime at a younger age by using blowing games.25 
7.4.6.3 Active cycle of breathing technique (ACBT) 
To correctly perform ACBT, the patient has to be cooperative and able to follow commands, 
therefore it is not recommended in children younger than the age of two years.24 However, 
parts of the technique can be taught in children from 18 months through blowing games.114 
A recently published systematic review found ACBT to be as effective as other ACTs in the 
treatment of paediatric and adult patients with CF (age six to 63 years).408 In adults 
(patients older than 16 years), mucus clearance was as effective in patients using ACBT 
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compared to PD or Flutter.113,409 Lung function outcome measures were also similar for 
ACBT and Flutter.409 In children with an acute exacerbation, ACBT was shown to be superior 
to high-frequency chest wall oscillation (“Vest” therapy), as it resulted in improved 
secretion clearance and increased lung function outcome measures.410 Miller et al. 
compared ACBT combined with PD with AD in patients between the age of 11 and 32 years; 
and found no significant difference for sputum weight, ventilation distribution, HR and 
patient preference. However, ACBT with PD resulted in a better FVC improvement, whereas 
AD resulted in a greater improvement in FEV1.
270  
7.4.6.4 Positive expiratory pressure (PEP) 
Two reviews on the use of PEP, one in a paediatric (from the age of six years) and one in a 
mixed paediatric and adult population, indicate that, overall, PEP is not superior to other 
ACTs in patients with CF.133,411 However, van der Schans et al. reported an increase in 
thoracic gas volume after PEP compared to baseline coughing in supine in adolescent and 
adult patients with CF.412 In another study, children, aged seven to 17 years, using PEP had 
fewer hospital admissions, maintained or improved spirometry outcome measures 
(significant for FVC and trending for FEV1 (p=0.08)) and had a smaller decline in Huang score 
during a one year trial, compared to patients using Flutter.413 Further, children and adults 
on PEP had fewer exacerbations than patients on high frequency chest wall oscillation 
(“Vest” therapy).414 PEP was found to be superior to PD in a study by McIlwaine et al. who 
found a significant improvement in FEV1 and FVC when using PEP compared to PD in 
children with CF.415 Furthermore, a study by Oberwaldner et al. on the use of high pressure 
PEP compared to PD with percussion found that hyperinflation of the thorax decreased and 
lung functions improved when PEP was used for ten months and a deterioration of function 
was seen when returning to PD with percussion.416 PEP combined with FET was preferred 
over PEP alone or PD combined with FET in one study.407 
In infants and young children PEP could be performed by using a facemask.25 However, 
accessibility to facemasks in South Africa is poor (Chapter 2). 
7.4.6.5 Oscillating PEP (e.g. Flutter, Acapella, Quake, Cornet) 
Again, a systematic review on oscillating PEP, in a mixed paediatric and adult population, 
reports equipoise amongst different ACTs.135 Mixed results on the use of oscillating PEP in 
patients with CF are found in the literature. Gondor et al. found a significant improvement 
in FVC and FEV1 after the use of the Flutter device compared to PD in children age five to 21 
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years with CF.417 Konstan et al. reported greater sputum production with Flutter than with 
PD.418 On the other hand, greater sputum production was seen when ACBT was used alone 
instead of combining Flutter and ACBT,419 and  no difference in sputum production was 
seen when Flutter was compared to PD or intrapulmonary percussive ventilator therapy in 
adolescents and adults with CF.420 McIlwaine et al.  found PEP to be more effective than 
Flutter in maintaining pulmonary function in children with CF in the long term, with a 
greater decline in FVC and FEV1 for patients receiving Flutter.
413 One study compared the 
use of Acapella to PEP mask in children with CF, but found no differences between the two 
techniques.421 
Oscillating PEP devices can be used independently in older children, however, as active 
participation is required to apply the device, these techniques cannot be performed in 
infants and young children. 
7.4.6.6 Assisted and unassisted autogenic drainage((A)AD) 
See Chapter 8 for a systematic review on AD and AAD in children with CF. 
AD may improve pulmonary function,121,422 generate greater mucus clearance,270,271,422 and 
is preferred over PD.272 AD also improves SpO2 and is overall better tolerated by 
participants.84 No literature is available on AAD. 
As mentioned in Chapter 2, AD is a technique that can be independently performed by 
patients older than eight years of age, however, due to the complexity of the technique, 
application in children younger than eight years of age is difficult.24 
7.4.6.7 Adherence and compliance to airway clearance therapy 
In chronic respiratory disease, poor compliance and adherence to ACT is a common 
problem. About 50% of patients with CF are not compliant with their airway clearance 
regimen.423–425 The majority of patients complain about the amount of time that goes into 
these treatments.426 The complexity of the interventions is also an important factor for non-
compliance,426 along with patients’ socioeconomic status.427  
It has been reported that self-reported or proxy-reported adherence rates are higher than 
objectively measured adherence; and adherence to medical interventions is higher than 
non-pharmacological interventions, including ACTs.423,428  
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7.4.6.8 Equipoise in ACTs 
The above described ACTs all have advantages and disadvantages, but none of them have 
been found to be superior or markedly inferior within the CF population.18,133–136 Whilst 
newer, independent ACTs are not better in terms of outcome measures, they may be more 
preferred than conventional ACTs, which could equate to improved compliance with ACT 
regimens.134 
It is recommended, for the standard ACT management of people with CF, that 
individualised airway clearance programs adapted to, for example patient preference and 
age, need to be made.18 This may improve therapy compliance and adherence.25 
7.4.7 Conclusion 
CF is a complex multi-system recessive hereditary disease, requiring a multidisciplinary 
treatment approach. ACTs are recognised as being beneficial in improving outcome in 
people with CF, hence they form an essential part of standard management for this 
population. Comparatively little research has been conducted in the airway clearance 
management of infants and young children with CF and they have been included only in 
research on conventional ACTs, as modern ACTs require active cooperation and the ability 
to follow instructions. AAD is a newer ACT clinically used in infants and young children, 
although no evidence is yet available. There is little data available on the relative safety and 
effectiveness of AD, although small studies have suggested AD is well tolerated and 
effective. As indicated above, no ACT has been found to be superior to others,133–135 
therefore it is plausible that AAD would also be as effective as other treatment options. But 
if preferred by patients it may be beneficial as compliance to treatment could be improved. 
Owing to several disadvantages of PEP and PD (see Chapter 2), AAD may be a useful tool for 
airway clearance in infants and young children.   
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Chapter 8. ARE AUTOGENIC DRAINAGE AND ASSISTED AUTOGENIC DRAINAGE AS 
BENEFICIAL AS OTHER AIRWAY CLEARANCE TECHNIQUES IN CHILDREN WITH CYSTIC 
FIBROSIS? A SYSTEMATIC REVIEW. 
8.1  INTRODUCTION 
As discussed in Chapter 7, CF is a life-threatening genetic disease for which no definitive 
cure is yet available. Therefore a symptomatic approach to management is needed. ACT is 
one component of the multidisciplinary approach in the management of people with CF. 
Many articles and reviews have been published on the use of different types of ACTs in this 
population.24,125,133–136,408,429–431 One recently published review which systematically 
evaluated the effect of AD in patients with CF did not focus on the paediatric population; 
only reported on pulmonary function and sputum recovery; and excluded a 
simplified/modified AD technique.422 No published articles, to the best of my knowledge, 
have systematically evaluated the effects of AAD in the management of children with CF.  
8.2  AIM AND OBJECTIVES 
This systematic review aimed to determine the effect of AD and/or AAD compared to no 
physiotherapy, other types of ACTs or sham physiotherapy in children with CF, based on the 
following outcome measures: number of hospitalisations and exacerbations, HRQOL, 
patient or caregiver preference, adverse effects and mortality. 
The following hypotheses were tested: 
- AD and/or AAD are more effective than other ACTs in children with CF, for number of 
hospitalisations and exacerbations during one year. 
- AD and/or AAD are preferred to other ACTs by children with CF and/or their caregivers. 
8.3  METHODOLOGY 
This systematic review used the Cochrane methodology for systematic reviews and 
conforms to the PRISMA (Appendix 12).233,234 This review’s unpublished pre-set protocol 
described the methodology and inclusion criteria prior to the database searches. 
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8.3.1 Criteria for considering studies for this review 
Types of studies 
RCTs, quasi-RCTs and randomised cross-over trials were included. 
Types of participants 
Children, under the age of 18 years, diagnosed with CF by positive sweat test and/or 
genotype analysis. 
Types of interventions 
AD and/or AAD compared to no physiotherapy, sham physiotherapy or other ACTs. Other 
ACTs included, but were not limited to: 
Conventional ACTs: 
 PD and MPD;  
 percussions/clapping;  
 shaking and vibrations;  
 cough;  
 rib cage compression, thoracic squeezing or manual assisted coughing;  
 a combination of the above techniques.134 
Modern ACTs: 
 ACBT; 
 PEP; 
 High pressure PEP; 
 Oscillating PEP (Flutter, Acapella, Cornet, Quake, Intrapulmonary Percussion 
Ventilation).  
Description of these interventions can be found in section 2.3.1.4 of this thesis. 
Types of outcome measures 
Primary outcome measures: 
 Number of hospitalisations measured at 12 months 
 143 
 
 Number of exacerbations measured at 12 months (determined by number of 
antibiotic treatments per year or diagnosis made by a physician) 
Secondary outcome measures:   
 HRQOL measured at six and 12 months 
 Preference measured at six and 12 months 
 Adverse effects measured at three, six and 12 months 
 Mortality measured at three, six and 12 months 
8.3.2 Search methods for identification of studies 
Electronic search 
Online databases PubMed, Medline, the Cochrane library, Pedro, CINAHL and Africa wide 
information were searched with predefined search terms (see Appendix 13 for overview of 
the search terms). These search terms were translated in the different languages included 
in this review. 
Further, clinicaltrials.gov was searched for ongoing research studies. 
Articles were included if they were written in English, Dutch, French, German or Afrikaans. 
Other languages were excluded. No date limitation was set. Non-randomised cross-over 
trials and pre-experimental trials were excluded. 
Other resources 
Reference lists of identified articles were manually checked for relevant studies. No grey 
literature was searched owing to poor reproducibility of this type of literature.235 
8.3.3 Data collection and management 
Selection of studies 
The databases were searched (by LC) and relevant articles, based on title and abstract, 
were collected. These were reviewed independently by a second reviewer (BM) and articles 
requiring full text review were selected. These two reviewers independently determined 
whether the articles were eligible for inclusion in the review. Any disagreement was 
resolved by discussion and consensus. 
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Data extraction and management 
Data were extracted by two independent reviewers using a pre-structured form including 
information on participants (age, gender, condition, severity of symptoms, 
inclusion/exclusion criteria, comorbid conditions, setting, number randomised, number lost 
to follow-up); interventions (type of interventions, duration, frequency, intensity, 
compliance); outcome measurements and results (point estimates, precision, measures of 
variability, frequency counts for dichotomous variables, number of participants in each 
group); and study design (randomization, allocation concealment, blinding) (Appendix 4). 
Assessing risk of bias in included studies 
The Cochrane Collaboration’s tool for assessing risk of bias was used,432 to assess the 
following methodological characteristics: 
1) Generation of sequence: Studies were considered to have low risk of bias if a random 
number table, computer generated list of random numbers or any other valid method of 
randomisation was used. Studies were considered as having high risk of bias if invalid 
methods of randomisation were used, such as date of birth or allocation by the 
physiotherapist or physician. When the allocation sequence was not identified, the bias was 
judged as unclear. 
2) Allocation concealment: Studies were considered low risk of bias if investigators did not 
know which group allocation was planned. This by the use of coded, opaque and sealed 
envelopes, on sight locked computer files, or similar valid methods of concealment. If the 
investigator was able to predict allocation, for example by the use of date of birth, the 
study was classified as having a high risk of bias. When concealment details were not 
reported, risk of bias was considered unclear. 
3) Blinding: It is usually impossible to blind participants and clinicians to ACT, but the 
physician and data-analyst could be blinded. Therefore studies were considered to have 
low risk of bias if investigator and data-analyst were blinded to treatment method. Studies 
were considered to have high risk of bias if no blinding or a limited form of blinding was 
applied. Studies had unclear risk if no information on blinding was available. 
4) Incomplete data outcome and intention-to-treat analysis: Studies were considered to 
have low risk of bias if an appropriate intention-to-treat analysis was performed on 
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incomplete data. When no intention-to-treat analysis was conducted, data were considered 
to have high risk of bias. Risk of bias was considered unclear if no information about 
intention-to-treat was given. 
5) Selective outcome reporting: When pre-specified (primary and secondary) outcome 
measures were reported, the study was considered to have low risk of bias. When no pre-
specified outcome measures were identified, the risk of bias was considered high. If 
insufficient information was available the study was classified as having unclear risk of bias. 
6) Other potential threats to validity: If the study was free from other threats, such as 
baseline imbalance or design-specific risk of bias, it was considered to have low risk of bias. 
High risk of bias was considered if there was a potential threat in the study. Unclear risk of 
bias was considered if insufficient information was available to determine the risk of bias. 
Measuring of treatment effect 
Continuous outcomes were reported, where possible, using the mean difference (or 
standardised mean differences) and 95% CI. Risk ratio and 95% CI was used, where 
possible, to report dichotomous outcomes. Where insufficient data were available, or data 
conversion was not possible, data were presented as per the original report. The extracted 
data were insufficient to perform a meta-analysis (see 8.4 Results). I have therefore 
described the individual results of included studies in narrative and tabular form, using the 
effect measures described in the original studies. 
Unit of analysis issues 
Long- term studies with repeated measures of outcome were included in the review, 
although none were identified in this version of the review. In future reviews, these 
outcomes will be defined according to set time periods.236 If studies had more than one 
intervention group, it was planned that these groups would be included separately in a 
meta-analysis, with the control group divided in half.237  
Dealing with missing data 
The original authors of the studies with missing data were contacted. If the author could 
not be located, a description of the study was included in the narrative review. Where 
missing data were not obtained, the studies were considered adequate if more than 85% of 
participants were included in the outcome analysis, or if fewer participants were included 
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but sufficient measures were taken to ensure or demonstrate that results were unbiased. 
Where this was not clear, an intention-to-treat analysis was planned for the extrapolated 
data. 
Assessment of heterogeneity 
If different studies measured the same outcome, and if there were sufficient data, 
heterogeneity assessment was planned using the chi-squared statistic and the I2 statistic. 
Heterogeneity would be reported as low when I2 was less than 30%, moderate when I2 was 
between 30 and 50% and substantial when it was more than 50%. However, in this review, 
assessment of heterogeneity was not possible owing to insufficient data. 
Assessment of reporting bias 
If a sufficient number of studies were included, a funnel plot was planned to identify 
reporting bias. 
Data synthesis 
If a sufficient number of studies could be identified to include in this review, a meta-
analysis was planned using a fixed-effect model, unless substantial heterogeneity was 
present in which case a random-effects model was planned. These methods will be 
employed if sufficient data is available in subsequent updates of this review. 
Subgroup analysis and investigation of heterogeneity 
The following subgroup analyses were planned, to be conducted as applicable: 
1) Age 
2) Gender 
3) Duration of treatment 
4) Frequency of treatment 
5) Severity of the disease 
Sensitivity analysis 
A sensitivity analysis was planned if an adequate number of studies were eligible for 
inclusion in the review. 
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8.4  RESULTS 
8.4.1 Results of the search 
This review was up to date as of January 2016.  Electronic database searches were 
conducted, identifying 156 references with duplicates (109 in Pubmed, 21 in Medline, 19 in 
the Cochrane Library, seven in PEDro and none in CINAHL or Africa-Wide Information). One 
abstract was found through manually searching the reference lists of relevant articles, 
however we were unable to obtain the full text of this study.433 Thirty-one duplicates were 
removed, which left 126 references for further investigation. After scanning all titles and 
abstracts, eight abstracts were found potentially relevant and underwent full text review. 
After full text analysis seven articles met the inclusion criteria for the review (Figure 8-1). 
However, only one study was purely focused on the paediatric population, with enrolment 
of children less than 18 years of age.272 One study  included both children and adults, but 
the author made raw data available for which a separation of populations could be 
made.434 The other five studies including mixed population.84,121,124,271,284 
8.4.2 Included studies 
See Table 8-1 for an overview of the included studies. 
All studies included in this review were randomised cross over trials.84,121,124,270–272,434 Six of 
the included studies were short term studies, with a study period of less than six months 
(four two day cross over trials,84,270,271,434 one five day cross over trial,121 and an eight week 
cross over trial with a one week washout period between each four week intervention 
period).124 One long term study was included, a two year cross over trial, only the first year 
of which was reported.272 Three studies were conducted in Germany,124,271,434 and one each 
in the United States of America,84 Canada,272 Austria,121 and the United Kingdom.270 In one 
study the research was done in an outpatient setting,121 and in one other study a home-
program intervention was used.272 In the other five articles, it is unclear which research 
setting was used. One article was written in German,434 all other articles were available in 
English. 
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Figure 8-1. PRISMA study flow chart 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097
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Table 8-1. Description of included studies 
Author 
 
- Country  
- Research 
setting 
Duration of trial n
 
Age 
range 
 
CF diagnosis Severity of symptoms Intervention type Duration and frequency of 
intervention 
App et al.
124 
- Germany 
- Unknown 
8 week cross over; one 
week washout between 4 
weeks of intervention 
Enrolled: 17 
Analysed: 14 
7-41 
years 
Sweat test Mild to moderate:  Mean FEV1 
= 75 (26.5)%  
(rang 29.2-117.3) 
AD in sitting or lying 
versus Flutter 
Duration: 4 weeks, acute 
sessions lasted 30 min 
Frequency: twice a day 
Giles et al.
84 
- USA 
- Unknown 
2 day cross over trial Enrolled: 10 
Analysed: 10 
12-42 
years 
Sweat test Unclear AD by Schöni
127 
versus PD with clapping
 
Duration: 
- AD: unclear duration 
- PD: 3 minutes in 7 positions 
Frequency: once a day 
Lindemann et 
al. (1990)
271
 
- Germany 
- Unknown 
2 day cross over trial Enrolled: 20 
Analysed: 20 
4-26 
years 
Unclear 
 
Unclear AD versus PEP 10-25 cm 
H2O 
Duration: 20-30 min 
Frequency: each treatment 
was performed once a day 
Lindemann 
(1992)
434
 
- Germany 
- Unkown 
2 day cross over trial Enrolled: 20 
Analysed: 20 
<18 years: 11 
≥18years: 9 
7-28 
years 
 
Unclear Unclear AD versus Flutter (VRP1-
Desitin) 
Duration: 20 min 
Frequency: each treatment 
was performed once a day  
McIlwaine et 
al.
272
 
- Canada 
- Home-
based 
2 year cross over trial Enrolled: 36 
Analysed: 33 
12-18 
years 
‘proven 
diagnosis of 
CF’ 
Mean (SD) baseline FEV1 
PD: 73.7 (17.7)%  
AD: 75.9 (19.8)% 
AD in sitting versus PD 
with percussion  
Duration: ± 30 min 
Frequency: twice a day 
Miller et al.
270 
- UK 
- Unknown 
2 day cross over trial Enrolled: 18 
Analysed: 18 
11-32 
years 
Unclear Modified SK scores 34-87, 
clinically stable and not on IV
∆
 
antibiotics 
AD in sitting or supine 
versus ACBT with PD
 
Duration: ± 30 min 
Frequency: twice a day on 
each day (two days of 
treatment one week apart) 
Pfleger et al.
121 
- Austria 
- Outpatient 
5 day cross over trial Enrolled: 15 
Analysed: 14 
9.8-
22.4 
years 
Sweat test Mean clinical score 62.2 points 
(range 26-90) Mean X-ray 
score 3.8 points (range 6-20) 
AD versus high pressure 
PEP versus spontaneous 
cough 
Duration: individually, 50% of 
time needed to clear lungs  
Frequency:  twice during 
outpatient visit 
∆IV = intravenous, SK =  Shwachman-Kulczycki 
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8.4.2.1 Participants 
Overall, 136 participants between the age of four and 42 years were recruited for the seven 
studies.84,121,124,270–272,434 However, only 47 participants could be identified as younger than 
18 years of age: 36 in the study by McIlwaine et al. (18 boys and 18 girls),272 and 11 in the 
study by Lindemann (1992) (no gender information available).434 The other studies did not 
make a distinction between the different age groups.84,121,124,270,271 A description of the 
participant population for each study can be found in Table 8-1. All studies included 
participants with CF, but only three clearly indicated that CF needed to be proven by a 
positive sweat test,84,121,124 whereas in the study by McIlwaine et al. 'proven diagnosis of CF' 
was mentioned.272 In the other three studies it is unclear how the diagnosis of CF was 
made.270,271,434 Participants in the study by App et al. had mild to moderate disease severity, 
with a mean (SD) FEV1 of 75 (26.5)%; ranging from 29.2 to 117.3%,
124 and in the study by 
McIlwaine et al. the mean (SD) baseline FEV1 was 73.7 (17.7)% for the PD group and 75.9 
(19.8)% in the AD group.272 Miller et al. used the modified Shwachman-Kulczycki scores to 
address disease severity, which ranged from 34-87.270 They also mentioned that 
participants were clinically stable and did not receive intravenous antibiotics during the 
study. Finally, Pfleger et al. used the Shwachman-Kulczycki clinical score (mean 62.2 points, 
ranging from 26 to 90) and chest X-ray scores (mean 3.8 points, ranging from 6 to 20) to 
describe severity of disease.121 The other studies did not report disease severity. 
8.4.2.2 Interventions 
Two trials compared AD with PD combined with percussion or clapping.84,272 In the study by 
Giles et al., AD as described by Schoni was used.84,127 PD in this study was done for three 
minutes in seven different positions. In each position, manual vibrations and clapping were 
performed by a therapist. Between each position the participant was instructed to cough or 
huff. Both treatments were done once, on separate days. In the other study, AD was 
performed in a sitting position whereas PD was done in five or six different positions 
depending on the time of the day.272 In each PD position, percussions were given for three 
to five minutes by a second person, followed by deep breathing exercises with expiratory 
vibrations; two or three huffs; encouragement to cough; and finally a short period of 
relaxed controlled breathing. Treatment during this trial was given bi-daily for 30 minutes 
as a home-program. The study by Miller et al. was a two-day cross over trial with one week 
of rest between cross-over periods.270 This study compared AD with PD combined with the 
ACBT. AD was done in sitting or supine, and several ACBT cycles were done in standardised 
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PD positions over a Chesham frame for 7.5 minutes per position. Treatment was given bi-
daily for 30 minutes. Two trials compared AD and PEP.121,271 One of them used a simplified 
method of AD ("AD is based on a deepened breathing which is adjusted to the localization 
and quantity of mucus"), compared to PEP (with a mouth pressure of 10-25 cm H2O) in a 
two-day cross over trial.271 Each treatment was given once a day, in a randomised order, for 
20 to 30 minutes. This order was reversed on the second day. The other study compared 
AD and high pressure PEP using a high pressure Danish PEP mask combined with FET.121 
Intensity and duration of treatment are unclear as they were individually chosen. Finally, 
the last two studies compared AD with Flutter therapy.124,434 In the study by App et al., the 
breathing techniques were performed in a sitting or lying position.124 Each treatment was 
done twice a day for four weeks, with a total of eight weeks of intervention and one week 
of washout between the study periods. Before and after each treatment period, the 
participant received an acute therapy for 30 minutes, which was used to assess the 
participant. The other study which compared AD with the VRP1-Desitin (Flutter),434 used 
the same simplified method of AD as used in the study by Lindemann et al (1990).271 Each 
treatment was done for 20 minutes once a day. The second day, the inverse order of 
treatment was given (two-day cross over trial). 
None of the included studies used AAD. 
8.4.2.3 Outcome measures 
This review's primary outcome measure 'number of hospitalisations measured at 12 
months' was only assessed in one study as a secondary outcome measure.272 This study 
revealed no significant difference in the mean (SD) number of hospitalisations between 
treatments (1.0 (0.3) for the PD group, and 0.8 (0.2) for the AD group) for the first year of 
the study (first period data of the cross-over trial). This study also indicated 16 
hospitalisations due to exacerbations occurring in the PD group, compared to 13 in the AD 
group. This review’s other primary outcome: 'number of exacerbations in 12 months, 
assessed by number of antibiotic treatments or diagnosis of a physician' was not assessed 
by any study included in this review. 
Participant or caregiver preference was only used as an outcome measure in one of the 
included studies.270 In this study, the preference was not described after six or 12 months 
as indicated in this review's outcome measures, but it was assessed after the cross over 
trial, which lasted 14 days. Of 18 participants, nine preferred AD, eight preferred ACBT and 
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one did not have a preference. The study by McIlwaine et al. did not report preference as a 
pre-set outcome measure, however the article could not report results from the second 
year of the trial due to the clear preference towards AD.272 Ten of the 17 participants in the 
AD group refused to cross over to the PD technique during the second year. None of this 
review's other secondary outcome measures, HRQOL, adverse effects or mortality rate 
were assessed in any of the included studies. 
8.4.3 Excluded studies 
One abstract was considered potentially relevant for this review.435 However, it was 
subsequently found to be unsuitable as it did not, in fact, include the AD technique.436 
8.4.4 Risk of bias in included studies 
A risk of bias summary can be found in Table 8-2 and Figure 8-2. 
8.4.4.1 Generation of sequences 
All seven studies were randomised cross over trials. However, only one study specified the 
method of randomisation, which was by computer generation.272 Therefore, this study was 
found to have low risk of bias. The other articles did not specify how the randomisation was 
done and were therefore classified as having unclear risk of bias. 
8.4.4.2 Allocation 
Allocation concealment was not specified in any of the articles and therefore there was an 
unclear risk of bias in this respect. 
8.4.4.3 Blinding 
As it is extremely difficult to blind participants and physiotherapists during ACT, all studies 
had a high risk of performance bias. However, it should be possible to blind the outcome 
assessor in this type of research. Two articles reported blinding of the outcome assessor. In 
the article by McIlwaine et al. both physicians and the pulmonary function technician were 
blinded to allocation.272 In the other study, a blinded investigator weighed the sputum.121 
No information on blinding of the other outcome assessments was reported. Both the 
above studies were considered to have low risk of detection bias, whereas the other studies 
were classified as having unclear risk of detection bias.
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Table 8-2. Risk of bias 
  
Author Study bias Risk Support for judgment 
App et 
al.
124
 
Random sequence 
generation 
Unclear  Random order of treatment, no specifications on sequence generation. 
Allocation 
concealment 
Unclear Not specified 
Blinding participants 
& personnel 
High Both participants and physiotherapist knew in which group the participant was assigned. 
Blinding outcome 
assessment 
Unclear Not specified 
Incomplete outcome 
data 
Unclear Unclear if patients were lost to follow up and if an intention-to-treat analysis was performed on incomplete data. 
Selective reporting Unclear Outcome measures were pre-specified. However, SpO2 was only used to report baseline characteristics. It was not mentioned in the results section of 
the article. 
Other bias Unclear Unclear if groups were similar at the start of the research. Both groups were treated equally except for treatment. Two participants, one in each group, 
were withdrawn for the study due to similar reasons. One other participant dropped out with reason. It is unclear if the other participants were analysed 
in the group they were randomly assigned to. 
Giles et 
al.
84
 
Random sequence 
generation 
Unclear Random order of treatment, no specifications on sequence generation. 
Allocation 
concealment 
Unclear Not specified 
Blinding participants 
& personnel 
High Both participants and physiotherapist knew in which group the participant was assigned. 
Blinding outcome 
assessment 
Unclear Not specified 
Incomplete outcome 
data 
Unclear Unclear if patients were lost to follow up and if an intention-to-treat analysis was performed on incomplete data. 
Selective reporting Unclear Outcome measures were pre-specified, however, FEF at 25%, 50% and 75% of VC, and FEF at midportion of VC were not reported in the results section of 
the article. 
Other bias Unclear It is unclear if groups were similar at start of the study and if the groups were treated equally except for treatment. No withdrawals or drop outs were 
reported, but it is unclear if participants were analyzed in the group they were assigned to. 
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Table 8-2 continued. Risk of bias 
 
  
Author Study bias Risk Support for judgment 
Lindemann 
et al. 
(1990)
271
 
Random sequence 
generation 
Unclear  Random order of treatment, no specifications on sequence generation. 
Allocation 
concealment 
Unclear Not specified 
Blinding 
participants & 
personnel 
High Participants were not blinded to treatment. Unclear if clinicians were blinded to allocation 
 
Blinding outcome 
assessment 
Unclear Not specified 
Incomplete 
outcome data 
Unclear No information available on lost-to-follow up and intention-to-treat analysis 
 Selective reporting Low Primary outcome was pre-specified, no secondary outcome measures reported 
 
Other bias Unclear Unclear if the groups were similar at start of the study, if participants were analyzed in the group they were randomly assigned to and if the groups 
were treated equally except for treatment. 
Lindemann 
(1992)
434
 
Random sequence 
generation 
Unclear Random order of treatment, no specifications on sequence generation. 
Allocation 
concealment 
Unclear Not specified 
Blinding 
participants & 
personnel 
High Participants were not blinded to treatment. Unclear if clinicians were blinded to allocation 
 
Blinding outcome 
assessment 
Unclear Not specified 
Incomplete 
outcome data 
Unclear No information available on lost-to-follow up and intention-to-treat analysis 
 Selective reporting Low Outcome measure was pre-specified 
Other bias Unclear Unclear if the groups were similar at start of the study, if participants were analyzed in the group they were randomly assigned to and if the groups 
were treated equally except for treatment 
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Table 8-2 continued. Risk of bias 
Author Study bias Risk Support for judgment 
McIlwaine 
et al.
272
 
Random sequence 
generation 
Low A computer randomly assigned participants to a certain group 
 Allocation 
concealment 
Unclear Not specified 
Blinding participants 
& personnel 
High Participants and physiotherapist knew in which group the participant was allocated 
 Blinding outcome 
assessment 
Low Both the physicians as the pulmonary function technician were blinded to allocation 
 Incomplete outcome 
data 
Unclear There is no information available on loss-to-follow up and intention-to-treat analysis 
 Selective reporting Low Primary and secondary outcome measures were pre-specified 
 
Other bias Low Groups were similar at start as participants were matched as pairs before random allocation. Also, both groups were treated equally except for the 
treatment. All participants, except for 3 drop outs of which the reason for drop out is clearly indicated, were assessed in the group they were 
assigned to 
Miller et 
al.
270
 
Random sequence 
generation 
Unclear Random order of treatment, no specifications on sequence generation. 
Allocation 
concealment 
Unclear Not specified 
Blinding participants 
& personnel 
High Participants and clinicians knew participant's allocation 
Blinding outcome 
assessment 
Unclear Not specified 
Incomplete outcome 
data 
Unclear There is no information available on loss-to-follow up and intention-to-treat analysis 
Selective reporting Unclear Outcome measures were pre-specified. However VC, FEV1 and PEF were not reported in the results section. Also the reason for preference towards a 
certain treatment option was left out of the article. 
Other bias Unclear Unclear if groups were similar at the start of the study, and if participants were analyzed in the group they were randomly assigned to. However 
groups were treated equally except for treatment. 
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Table 8-2 continued. Risk of bias 
Author Study bias Risk Support for judgment 
Pfleger et 
al.
121
 
Random sequence 
generation 
Unclear Random order of treatment, not specified how sequence generation was done 
 Allocation concealment Unclear Not specified 
Blinding participants & 
personnel 
High Participants and physiotherapist knew participant’s allocated 
 Blinding outcome 
assessment 
Unclear Sputum was weighed by an investigator blinded to treatment, not specified if other outcome assessors were blinded to treatment 
 Incomplete outcome 
data 
Unclear Although mean age and range of the 10 participants was mentioned in the results section, it is unclear if analysis of the outcome measures were 
done on all 10 participants as no information is available on loss-to-follow up and intention-to-treat analysis 
 
Selective reporting Low Outcome measures were pre-specified 
 
Other bias Unclear Groups were treated equally except for treatment. However, it is unclear if groups were similar at the start of the study and if participants were 
analysed in the group they were randomly assigned to 
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App et al.
124
  
Giles et al.
84
 
Lindemann et al. (1990)
271
 
Lindemann (1992)
434
 
McIlwaine et al.
272
 
Miller et al.
270
 
Pfleger et al.
121 
Red= high risk of bias, yellow = unclear risk of bias and green = low risk of bias. 
Figure 8-2. Risk of bias summary: review author’s judgment about each risk of bias item for each included 
study. 
8.4.4.4 Incomplete outcome data 
In three trials participants were withdrawn from the study.121,124,272 In the study by App et 
al., two participants, one in each arm of the study, were excluded due to acute 
bronchopulmonary exacerbation for which intravenous antibiotic therapy was 
prescribed.124 One other participant withdraw from the study due to business-related time 
constraints. It is unclear in which arm of the study this drop-out was assigned. In the study 
by McIlwaine et al., three participants dropped out, two in the PD group (due to pregnancy 
and aspergillosis) and one in the AD group (due to non-compliance).272 Finally in the study 
by Pfleger et al., one participant had an acute respiratory viral infection, for which this 
participant was excluded.121 It is unclear to which group this participant was assigned. 
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None of the trials reported the use of an intention-to-treat analysis for incomplete data. 
Therefore an unclear risk of bias in this respect was attributed to all studies. 
8.4.4.5 Selective reporting 
All included studies reported pre-specified outcome measures. Only one article identified 
both primary and secondary outcome measures.272 Two articles reported only one outcome 
measure.271,434 All other trials had multiple pre-specified outcome measures, but no 
distinction between primary and secondary outcome measures were made.84,121,124,270 The 
risk of bias for four of these studies was classified as being low, because all pre-set outcome 
measures were reported in the results section and if not reported in the results section, a 
reason for omission was provided.121,271,272,434 The other three studies did not report on all 
the pre-specified outcome measures, with no reasons provided.84,124,270 Hence these studies 
were classified as having an unclear risk of reporting bias. 
8.4.4.6 Other potential sources of bias 
Only one trial used matched pairs for their research, which ensures groups were similar at 
the start of the study.272 This study also indicated that the groups were treated equally, 
except for the type of ACT and it is clear that participants were analysed in the group they 
were randomly assigned to. Therefore, this trial was judged to have a low risk of other 
potential sources of bias. For the other studies included in this review, insufficient 
information was given to make a good judgement of bias, although it is noted that three 
studies reported that groups were treated equally except for the physiotherapy 
treatment.121,124,270 
8.4.5 Effects of interventions 
No meta-analysis was possible due to the variable outcome measures used in the studies, 
and insufficient reporting of separate period data for both arms of cross-over trials. 
8.4.5.1 Primary outcome measures 
Number of hospitalisations measured at 12 months 
Only one study (based on a paediatric population), included this outcome measure as one 
of their secondary outcome measures.272 There was no significant difference between PD 
and AD in mean (SD) number of hospital admissions. However, the participants performing 
AD showed a tendency to have fewer hospital admissions during one year (1.0 (0.3) (95%CI 
0.8-1.2) for the PD group, and 0.8 (0.2) (95% CI 0.7-0.8) for the AD group). In total, 16 (PD 
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group) and 13 (AD group) participants were admitted to hospital for pulmonary 
exacerbations. The significance level for this comparison could not be obtained, but the 
95%CIs only overlapped marginally. 
Number of exacerbations measured at 12 months 
No study explicitly used this outcome measure. McIlwaine et al. reported that all hospital 
admissions were due to pulmonary exacerbations, but it is unclear how many exacerbations 
were treated as out-patients.272 
8.4.5.2 Secondary outcome measures 
HRQOL measured at six and 12 months 
No included study reported on this outcome measure. 
Preference measured at six and 12 months 
Although no study reported preference measured at six or 12 months, Miller et al. 
measured patient's preference after completion of a two day cross over trial, using of a 
visual analogue scale.270 Eight participants preferred ACBT, nine preferred AD and one 
patient had no preference. In the study by McIlwaine et al. participants’ preference was not 
reported, however this study did reflect a strong apparent preference for AD, with 10 out of 
17 participants (all younger than 18 years of age) refusing to cross over to PD after one year 
of intervention using AD.272 
Adverse effects measured at three, six and 12 months 
No study reported adverse effects after three, six and 12 months. Nonetheless, mild 
desaturation from 93.3 (0.7)% to 91.2 (0.8)% (p<0.01) occurred during PD in one study, 
which was worse when patients were placed in the head down position.84 Oxygen levels 
returned to normal 15 minutes after the end of treatment. Conversely, AD was associated 
with increased SpO2 levels during treatment (from 93.3 (0.8)% to 94.9 (0.7)%, p<0.01), with 
the higher saturation level maintained at one hour post treatment. 
Mortality measured at three, six and 12 months 
No study reported on mortality. 
8.4.5.3 Other outcome measures 
Lung function tests 
Five of the included studies reported data on lung function tests.84,121,124,270,272 However, it 
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was not possible to pool the data, as they were presented in different ways. McIlwaine et 
al. was the only study reporting clear paediatric data and used decline in % predicted FEV1 
as the primary outcome measure for their study.272 When using the regression slope over 
the first year (lung function test done every three months), there was no significant 
difference between PD (mean (SD) 2.1 (2.2)) and AD (1.0 (2.3)) for FEV1 (p= 0.63). Change in 
FVC and FEF25-75 were reported as secondary outcome measures and both showed no 
significant difference between the groups after one year. The mean (SD) change in FVC and 
FEF25-75 for PD and AD groups respectively were 0.5 (1.7) (PD) versus 2.4 (1.9) (AD) and 5.6 
(4.6) (PD) versus -1.9 (3.8) (AD). 
Four studies combined paediatric and adult data, with separate data not available. A 
summary of the results can be found in Table 8-3.84,121,124,270 
Sputum weight 
Six of the included studies reported sputum weight,84,124,270,434 sputum production,121 or 
elimination of sputum as outcome measures.271 One study reported raw data for each 
participant, making it possible to distinguish between adult and paediatric data.434 
However, it is unclear which data belongs to which cross over period, therefore it is only 
possible to report values for the two cross over periods together. In the paediatric 
population, treatment with the Flutter VRP1-Desitin eliminated a mean (SD) 4.8 (3.5)g of 
sputum (95%CI 3.4 - 6.3) whereas AD eliminated a mean (SD) 4.3 (2.6)g of sputum (95%CI 
3.2 - 5.4). The results for the adult population are given in Table 8-3. No significance levels 
were available for the separate age data. 
For the other five studies, no distinction between adult and paediatric population could be 
made. Two of these studies reported sputum production collected during the separate 
periods of the cross-over,124,271 the other three studies did not make a clear distinction 
between the different periods of the cross-over. These results are also presented in Table 
8-3. 
Shwachman- Kulczycki score 
See section 2.3.3 for a description of this outcome measure.  
Change in Shwachman-Kulczycki score in the paediatric population was reported in one 
included study and did not differ significantly between the use of AD and PD.272 The PD 
group had a mean change in score of 7.5, with a SD of 9.0 and 95% CI 3.1 to 11.9. The AD 
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group had a mean change in score of 3.1 with a SD of 6.2 and 95% CI 0.2 to 6.1 (I was 
unable to obtain a p-value for this outcome measure).  
Huang score 
McIlwaine et al. reported on the change in Huang scores in a paediatric population (see 
section 2.3.3 for a description of the Huang score), which improved significantly in the AD 
group, with a mean (SD) change in score of 2.3 (4.3) (95%CI 0.3-4.4), compared to the PD 
group, which had a mean (SD) change in score of -0.9 (4.9) (95%CI -3.3-1.5)(p= 0.04).272 
The following outcome measures were used in the studies with mixed populations. A 
summary of the results are reported in Table 8-3: 
Quotient of the change in FVC and sputum recovery,121 
SpO2,
84,270 
Time needed to clear the lungs,121 
Rheological analysis,124 
Clearance of radiolabelled aerosol,270 
Ventilation studies.270 
  
 162 
 
 
Table 8-3. Other outcome measures 
Outcome Study, n Data 
presentation 
AD Control Outcome between 
groups  
p-value 
between 
groups 
FEV1 App et 
al.124 
n= 14  
(n=7 per 
group) 
Mean (95%CI) 
(in liter) 
Baseline:  
2.1 
(1.3-2.9) 
After 4 weeks: 
2.0 
(1.3-2.7) 
Baseline:  
2.1 
(1.4-2.8) 
After 4 weeks:  
2.1 
(1.4-2.8) 
No significant 
difference between 
techniques 
Not reported 
(NS) 
Giles et 
al.84  
n= 10 
% predicted, in 
graph format 
Not available Not available No difference 
between techniques 
Not reported 
(NS) 
McIlwaine 
et al.272 
n= 17 (AD) 
n= 16 (PD) 
Mean (95%CI) 
(change in 
pulmonary 
function) 
After 1 year:  
1.0 (-0.1-2.0) 
After 1 year:  
2.1 (1.0-3.2) 
No difference 
between techniques 
Not reported 
(NS) 
Pfleger et 
al.121 
n= 15 
% predicted 
Mean (SD) 
(within group 
p-value) 
Test 1: 54 (20) 
Test 5: 56 (19)  
(p: NS) 
PEP: (p< 0.05) 
Test 1: 52 (21) 
Test 5: 54 (20)  
PEP-AD:  
(p< 0.02) 
Test 1: 51 (18) 
Test 5: 55 (18)  
AD-PEP:  
(p: NS) 
Test 1: 52 (21) 
Test 5: 54 (19)  
No difference 
between AD compared 
to PEP or PEP-AD; 
however, AD was 
better than AD-PEP for 
test 5. 
 
 
 
Not reported 
(NS) for AD 
compared to 
PEP and PEP-
AD 
p< 0.05 for AD 
compared to 
AD-PEP 
 
FEF25-75 McIlwaine 
et al.272 
n= 17 (AD) 
n= 16 (PD) 
Mean (95%CI) 
(change in 
pulmonary 
function) 
After 1 year:  
-1.9  
(-3.7-(-0.1)) 
After 1 year:  
5.6 (3.4-7.9) 
No difference 
between techniques 
Not reported 
(NS) 
Miller et 
al.270 n= 18 
Number of 
tests out of 
36 (18 in the 
morning 
and 18 in the 
afternoon) 
>10% 
improvement: 
17 
>15% 
improvement: 
11 
>20% 
improvement: 
9 
>10% 
improvement: 
10 
>15% 
improvement: 
8 
>20% 
improvement: 
7 
No difference 
between techniques 
Not reported 
(NS) 
P-values are presented as reported in the original article 
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Table 8-3 continued. Other outcome measures 
Outcome Study, n Data presentation AD Control Outcome between 
groups 
p-value 
between 
groups 
FVC App et 
al.124 
n= 14  
(n=7 per 
group) 
Mean (95%CI) 
(in liter) 
baseline:  
2.9 (1.9-3.9) 
After 4 weeks: 
2.9 (1.9-3.9) 
baseline:  
3.2 (2.8-3.6) 
After 4 weeks: 
3.2 (2.8-3.6) 
No difference 
between ACTs 
Not reported 
(NS) 
Giles et 
al.84  
n= 10 
 
% predicted, in 
graph format 
Not available Not available No difference 
between ACTs 
Not reported 
(NS) 
McIlwaine 
et al.272 
n= 17 (AD) 
n= 16 (PD) 
Mean (95%CI) 
(change in 
pulmonary 
function) 
After 1 year:  
2.4 (1.5-3.2) 
After 1 year:  
0.5 (-0.3-1.3) 
No difference 
between ACTs 
Not reported 
(NS) 
Miller et 
al.270 
n= 18 
Number of tests 
out of 36 (18 in 
the morning and 
18 in the 
afternoon) 
>10% 
improvement: 
15 
>15% 
improvement: 
10 
>20% 
improvement: 
4 
>10% 
improvement: 
17 
>15% 
improvement: 
11 
>20% 
improvement: 
8 
No difference 
between ACTs 
Not reported 
(NS) 
Pfleger et 
al.121 
n= 15 
% predicted Mean 
(SD)  
(p-value within 
groups) 
Test 1: 69 (21) 
Test 5: 74 (19) 
(p< 0.05) 
PEP: (p< 0.01) 
Test 1: 66 (21) 
Test 5: 73 (20)  
PEP-AD:  
(p< 0.01) 
Test 1: 68 (21) 
Test 5: 73 (20)  
AD-PEP: (p: 
NS†) 
Test 1: 69 (22) 
Test 5: 71 (21) 
No difference 
between AD 
compared to PEP or 
PEP-AD; however, 
AD was better than 
AD-PEP for test 5. 
 
 
 
 
 
Not reported 
(NS†) for AD 
compared to 
PEP and PEP-
AD 
p< 0.05 for AD 
compared to 
AD-PEP 
 Peak 
flow 
Giles et 
al.84  
n= 10 
%predicted, in 
graph format 
Not available Not available No difference 
between techniques 
Not reported 
(NS) 
RV/TLC 
 
Pfleger et 
al.121 
 n= 15 
% predicted Mean 
(SD) 
(p-value within 
groups) 
Test 1: 51 (14) 
Test 5: 49 (14)  
(p: NS) 
PEP: (p< 0.05) 
Test 1: 52 (15) 
Test 5: 50 (14)  
PEP-AD:  
(p< 0.05) 
Test 1: 52 (15) 
Test 5: 50 (13)  
AD-PEP: (p: NS) 
Test 1: 51 (15) 
Test 5: 51 (14)  
No difference 
between AD 
compared to PEP or 
PEP-AD; however, 
AD was better than 
AD-PEP for test 5. 
Not reported 
(NS) for AD 
compared to 
PEP and PEP-
AD 
p< 0.01 for AD 
compared to 
AD-PEP 
 
P-values are presented as reported in the original article 
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Table 8-3 continued. Other outcome measures 
P-values are presented as reported in the original article  
Outcome Study, n Data 
presentation 
AD Control Outcome 
between 
groups 
p-value 
between 
groups 
Airway 
resistance 
Pfleger et 
al.121  
n= 15 
% predicted 
Mean (SD) 
Test 1: 225 
(108) 
Test 5: 212 
(93)  
(p: NS) 
PEP: (p: NS) 
Test 1: 241 (117) 
Test 5: 211 (113)  
PEP-AD: (p: NS) 
Test 1: 240 (128) 
Test 5: 216 (91)  
AD-PEP: (p: NS) 
Test 1: 239 (141) 
Test 5: 219 (97)  
No difference 
between ACTs 
Not reported 
(NS) 
∆FVC/ 
sputum 
Pfleger et 
al.121 
n= 15 
∆FVC (% 
predicted/ 
sputum weight 
in gram).  
Mean (SD) 
0.5 (0.8) PEP:  
0.3 (0.6) 
No difference 
between ACTs 
Not reported 
(NS) 
Sputum 
weight 
(in gram) 
App et al.124 
n= 14  
(n=7 per 
group) 
Mean  
(95% CI) 
Baseline:  
2.7 (1.1-4.3) 
After 4 
weeks: 3.6 
(1.8-5.5) 
 
Baseline:  
2.9 (1.3-4.5) 
After 4 weeks: 4.5 
(2.7-6.4) 
No difference 
between ACTs 
Not reported 
(NS) 
Giles et al.84  
n= 10 
Mean  
(95% CI) 
Both arms of
the study 
together: 
14.0  
(12.1-15.9) 
 
Both arms of the 
study added 
up:10.4 (8.5-12.3) 
No difference 
between ACTs 
Not reported 
(NS) 
Lindemann 
et al 
(1990)271 
n= 20 
Mean (SD)  
(range) 
Day 1: 13.7 
(7.1)  
(4.0-32.0) 
Day 2: 10.6 
(6.4) (0-26) 
Day 1: 6.8 (3.9)  
(0.0-14.0) 
Day 2: 6.2 (3.4) 
(1-12) 
AD more 
effective  than 
PEP 
Not reported 
(significant) 
Lindemann 
(1992)434 
n= 20 
n <18 years = 
11 
n ≥18 years = 
9 
Total = Mean 
(range) 
Pediatric and 
adults = Mean 
(SD) (95%CI), 
in gram 
Both arms of 
the study 
together: 
Total: 4.8  
(0.0-11.7) 
Paediatric:  
4.3 (2.6)  
(3.2-5.4) 
Adults:  
5.4 (3.7)  
(3.8-7.2) 
Both arms of the 
study together: 
Total: 5.0  
(0.0-12.0) 
Paediatric:  
4.8 (3.5)  
(3.4-6.3) 
Adults:  
5.1 (3.4)  
(3.5-6.7) 
No difference 
between ACTs 
p> 0.05 
Miller et 
al.270 
n= 18 
Mean (SD) difference: -0.4g (1.8)g  No difference 
between ACTs 
Not reported 
(NS) 
Pfleger et 
al.121 
n= 15 
Means and SD, 
shown in graph 
format 
AD > cough 
< PEP 
< PEP-AD 
< AD-PEP 
AD produced 
more sputum 
than cough, but 
less then the 
other ACTs 
p< 0.001 
p< 0.001 
p< 0.02 
p< 0.001 
Change in 
Shwachman 
score 
McIlwaine et 
al.272 
n= 17 (AD) 
n= 16 (PD)  
 
Mean  
(95% CI) 
3.1 (0.2-6.1) 7.5 (3.1-12.0) No difference 
between ACTs 
Not reported 
(NS) 
Change in 
Huang score 
McIlwaine et 
al.272 
n= 17 (AD) 
n= 16 (PD) 
Mean  
(95% CI) 
2.3 (0.3-4.4) -0.9 (-3.3-1.5) AD had a better 
outcome than 
PD with 
clapping 
p= 0.04 
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Table 8-3 continued. Other outcome measures 
Outcome Study, n Data 
presentation 
AD Control Outcome between 
groups 
P-value 
SpO2 Giles et 
al.84 
 n= 10 
Mean (95% 
CI) (in %) (p-
value within 
groups) 
Both arms of the 
study together: 
Baseline:  
93.3 
(92.8-93.8) 
During:  
94.9 
(94.5-95.3) 
(p< 0.001) 
1h post:  
94.5 
(94.1-94.9) 
(p< 0.001) 
Both arms of 
the study 
together: 
Baseline:  
93.3 
(92.9-93.7) 
During:  
91.2 
(90.7-91.7) 
(p< 0.001) 
15 min post: 
return to 
baseline 
No comparison 
between groups 
reported 
Not 
available 
Miller et 
al.270  n= 18 
n 
desaturated 
0 Morning: 4 
Afternoon: 1 
No difference 
between ACTs 
p> 0.05 
Time 
needed to 
clear lungs 
Pfleger et 
al.121 
n= 15 
Means and 
SD, shown in 
graph 
format 
AD >PEP 
=PEP-AD 
=AD-PEP 
PEP cleared the lungs 
faster than AD; 
however PEP-AD and 
AD-PEP did not differ 
from AD 
p< 0.05 
for PEP 
compared 
to AD  
Other p-
values 
not 
reported 
(NS) 
Rheologic 
analysis 
App et al.124 data in 
graph 
format 
Not available Not available Flutter better than AD  
     a) viscoelasticity  AD >Flutter p< 0.01 
     b) MCI╖  AD <Flutter p= 0.01 
     c) CCI╓  AD <Flutter p= 0.04 
Clearance 
radiolabeled 
aerosol 
Miller et 
al.270 
n= 18 
(whole 
lung) 
n= 18 
(central) 
n= 18 
(peripheral) 
n= 6 
(mild) 
n= 7 
(moderate) 
n= 5 
(severe) 
Mean (SD)  
(in %/hour) 
Whole lung:  
3.9 (1.4) 
Central lung 
region: 3.6 (1.4) 
Peripheral lung 
region: 5.5 (2.2) 
Mild disease 
severity: 3.8 (2.0) 
Moderate 
disease severity: 
3.3 (0.3) 
Severe disease 
severity: 4.7 (1.3) 
Whole lung:  
3.2 (1.4) 
Central lung 
region: 2.9 
(1.3) 
Peripheral 
lung region: 
4.7 (2.0) 
Mild disease 
severity: 2.7 
(1.2) 
Moderate 
disease 
severity: 2.8 
(1.0) 
Severe 
disease 
severity: 4.3 
(1.5) 
AD cleared the whole 
lung and central lung 
regions faster than 
ACBT, no differences 
for peripheral lung 
regions or disease 
severity 
p< 0.05 
for both 
whole 
lung and 
central 
lung 
regions 
 
Other p-
values 
not 
reported 
(NS) 
Ventilation 
studies 
Miller et 
al.270 
n=9 
n Improvement 
first breath: 5 
No improvement 
first breath: 4 
Faster washout 
rate: 6 
Slower washout 
rate: 3 
 
Improvement first breath: 5 
No improvement first breath: 4 
Faster washout rate: 4 
Slower washout rate: 3 
No change washout rate: 2 
Not 
available 
╖MCI= mucociliary clearability index, ╓CCI= cough clearability index 
P-values are presented as reported in the original article 
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8.5  DISCUSSION 
8.5.1 Summary of main results 
No RCTs were identified for inclusion; however, this review included seven randomised 
cross-over trials which compared AD with Flutter,124,434 PEP,271 high pressure PEP,121 PD 
(combined with percussions or clapping)84,272 or ACBT (combined with PD).270 Although all 
seven included studies were randomised cross-over trials,84,121,124,270–272,434 none was bias-
free. Further, separation of paediatric and adult data was only possible in two studies. 
There is therefore insufficient evidence to accept or reject AD as a safe or effective 
treatment option in children with CF.  
Number of hospitalisations measured at 12 months, one of the intended primary outcome 
measures of this review, was only reported in one of the included studies.272 Although this 
study found no difference between AD and PD in a paediatric population, there was a trend 
towards fewer hospitalisations in the AD group. However, the small sample size prevents 
any conclusions being made in this regard. The other primary outcome measure of this 
review, number of exacerbations during 12 months, was not analysed in any of the included 
studies. 
Even though none of this review's secondary outcome measures were assessed in the 
included studies, two studies did mention participant preference in their research.270,272 
One study in the paediatric population indicated preference towards AD when compared to 
PD, with the majority of participants assigned to AD during the first period of a randomised 
cross-over trial refusing to revert to conventional ACTs after completing the first period of 
cross-over.272 Miller et al. (adult and paediatric data combined) did not report a clear 
preference towards either AD or ACBT combined with PD.270 
Other outcome measures, with various results, were reported in the included studies. 
Within the paediatric population, a significant improvement in Huang scores was reported 
when AD was compared to PD as a one year home program.272 However, the other 
outcome measures from this study (lung function tests presented as %predicted FEV1, FVC 
and FEF25-75; and Shwachman-Kulczycki scores) did not show significant differences between 
AD and PD after a one year home program.272 Sputum weight in the paediatric population 
was reported in one study, but no significance levels were available for the separate (adult 
versus paediatric) data.434 
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All other included studies combined paediatric and adult data, therefore no conclusions can 
be made for the paediatric population.84,121,124,270,271  
8.5.2 Overall completeness and application of evidence 
Not all the review's pre-set objectives were addressed, as no studies on AAD were 
identified, and patient/caregiver preference was only reported in two of the included 
studies but was not assessed as an outcome measure.270,272 The majority of studies did not 
analyse paediatric and adult data separately, and only one study reported on any pre-set 
primary or secondary outcome measures of this review.272 Therefore it is impossible to 
make justified conclusions with regards to this review's objectives. Most of the included 
articles reported lung function tests,84,121,124,270,272 and sputum 
weight/production,84,121,124,270,271,434 however, most studies did not report data on the 
different periods of the cross-over trials or used different ways to report outcome 
measures, which made pooling of the data impossible. Other outcome measures used in 
the included studies were: SpO2,
84,270 quotient change in FVC and sputum recovery,121 time 
needed to clear the lungs,121 rheological analysis,124 clearance of radiolabelled aerosol,270 
ventilation studies,270 Shwachman-Kulczycki score,272 and Huang score.272 Research was 
conducted in Germany,124,271,434 Austria,121 USA,84 Canada,272 and the UK,270 which limits 
generalisability to developed countries. All but one of the included studies was published 
more than ten years ago.272 All other articles were published in the 1990s, which might 
make the studies less relevant as the management of CF has changed over the past decades 
towards a multidisciplinary intensive management approach, associated with improved 
longevity and quality of life.292  
8.5.3 Quality of the evidence 
All seven included studies were randomised cross-over trials,84,121,124,270–272,434 however, only 
one study clearly indicated the method of randomisation and none of the studies reported 
how allocation concealment was maintained.272 The major problem with the included 
studies is the risk of bias and the publication date. Lack of blinding was present in all 
studies. Participants and clinicians are difficult to blind due to the nature of the 
intervention, however, blinding of the outcome assessors should ideally be reported. This 
was only the case in two studies.121,272 No information was available on incomplete data 
analysis and most studies also did not provide sufficient information to make a clear risk of 
bias analysis of other potential threats, except for the study by McIlwaine et al. which had a 
low risk of bias for other potential threats.272 Selective reporting was found to have unclear 
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risk of bias in most studies, only those by Pfleger et al. and McIlwaine et al. were judged to 
have a low risk of bias.121,272 Overall, risk of bias is questionable and therefore no justifiable 
conclusions can be made. 
8.5.4 Potential biases in the review process 
Six different data bases were searched, as well as the reference lists of all relevant articles 
and clinicaltrial.gov for ongoing clinical trials. Attempts were made to contact the authors 
of the included articles, however not all authors were contactable or responded and due to 
the old publication dates, most of the raw data was unavailable. The review included 
studies that were published in English, Dutch, French, German and Afrikaans. No articles 
needed to be excluded due to language restrictions. No data limitation was set. All these 
precautions were set to limit the risk of selective data reporting. It is possible that studies 
published in non-peer reviewed journals, presented at local conferences or non-published 
research dissertations were missed, leading to potential bias. 
8.5.5 Comparison with other studies or reviews 
This systematic review agrees with the conclusion of a previous systematic review on AD in 
patients with CF, which found a lack of evidence that AD improves lung functions but did 
find that AD cleared more secretions than spontaneous coughing based on one study.422 
However, the current systematic review reveals that AD clears less or similar amounts of 
sputum than other techniques based on five studies.84,121,124,270,434 No reviews on the use of 
AAD in children with CF are available. Systematic reviews comparing no ACT with any form 
of ACT,430,431 and reviews comparing different treatment options in patients with CF,133–
135,429 do include AD as one of the treatment options and reveal similar outcomes for the 
comparison between different forms of ACT and AD. 
8.6  CONCLUSION 
8.6.1 Implications for practice 
Due to the small sample sizes, the overall unclear risk of bias and the inability to pool data 
and therefore to perform a meta-analysis, no clear, generalisable conclusions with regards 
to the use of AD or AAD in children with CF can be made. This treatment modality cannot 
be accepted nor rejected as either safe or effective for use in clinical practice. 
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8.6.2 Implications for research 
The implementation of paediatric-specific RCTs with adequate sample sizes (to reduce type 
II error), appropriate clinical outcome measures and analysis of adverse effects (including 
mortality) is recommended within this field of research. Outcome measures of participant 
preference, HRQOL and adherence to treatment should be considered. As no research is 
available on the use of AAD within this population, RCTs should be designed to assess the 
appropriateness of this technique. 
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Chapter 9. THE USE OF ASSISTED AUTOGENIC DRAINAGE IN SOUTH AFRICAN 
CHILDREN WITH CYSTIC FIBROSIS, A PILOT STUDY. 
PACTR201501001016415 
9.1  INTRODUCTION  
ACTs have been shown to have positive effects on mucus clearance in children with CF (see 
section 7.4.6). However, studies are limited by the small sample sizes and, in many cases, 
subjective outcome measures. Furthermore, little evidence is available on the use of ACTs 
in children younger than eight years of age. Development of evidence-based information is 
a priority for this group of children. As no RCTs have been published on AD or AAD in 
children with CF (see Chapter 8), this chapter described a pilot study for an RCT on AAD in 
this population. 
9.2  AIMS AND OBJECTIVES 
This pragmatic pilot study aimed to assess the feasibility of an RCT protocol, comparing the 
effect of AAD to standard ACT as a home program in children between the age of one and 
eight years with CF on: number of hospitalisations and respiratory exacerbations; disease 
severity; preference by parents and children; HRQOL; weight-, height- and BMI-for-age z-
score; lung function tests; and neurodevelopmental level.  
The specific objectives of the RCT were to establish differences between the control and 
intervention group for the following outcome measures: 
A) Primary outcome measures:  
- Number of hospitalisations, during one year. 
- Number of respiratory exacerbations, measured by antibiotic prescription during 
one year. 
B) Secondary outcome measure:  
- Preference by the participants and parents/caregivers 
- Parental proxy HRQOL scores  
- Disease severity 
- Weight-, height- and BMI-for-age between start and end of study 
- Quarterly lung function measurements (if applicable) 
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- Mortality rate 
- Relationship between respiratory symptoms and neurodevelopmental level. 
9.3  METHODOLOGY 
9.3.1 Study hypothesis 
There will be no significant difference in number of hospitalisation and exacerbations 
during one year, HRQOL, lung function tests, preference and mortality rate between the 
control (standard ACT) and intervention (AAD) groups. It is hypothesised that AAD is as 
effective as other ACTs in the management of children with CF. 
9.3.2 Study design 
A pilot RCT, single blinded, pragmatic study design was used. RCTs are the gold standard in 
performing experimental research as this study design reduces bias (particularly allocation 
bias) and has high internal and external validity.273 No RCTs  on the use of AAD or AD in 
children with CF are available, therefore, the current study tested the feasibility of the 
proposed protocol, for which it is classified as a pilot study.437 The term ‘pragmatic’ refers 
to the comparison between a control and intervention group within a real-life setting.274 
Blinding refers to masking participants and outcome assessors to group allocation. As the 
intervention in the current trial is a physiotherapy intervention, blinding of the participants 
is impossible, therefore, this study was classified as single blinded, blinding the outcome 
assessor and data analyst.275 Treatment consisted of a taught home-program, executed by 
the parents during the one year follow up period. The study ran from 15 January 2015 until 
30 September 2016. The CF Clinic was closed from mid-December until mid-January, but 
children still had access to CF care at the hospital in the event of infection, and were able to 
contact one of the investigators during this period if an adverse event occurred. 
9.3.3 Research setting 
The study was conducted at a 290-bedded, tertiary paediatric hospital. Patients from all 
over Africa, especially low income patients, are referred to this institution.276 The hospital 
outpatients department runs a weekly multidisciplinary CF Clinic, which manages about 90 
children with CF from birth to 18 years of age, resided in the Western Cape of South Africa 
(Prof. B. Morrow. Personal communication, 2013). 
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Children with CF who were being followed up at the research site during the study period 
and met the inclusion criteria were enrolled in this home-based research study. The 
parent(s) and/or caregiver(s) of the children were taught standard ACT or AAD during 
routine clinical visits, to be conducted at home, by the parent/caregiver on a bi-daily basis. 
The children returned to the CF clinic for follow up visits at the discretion of the physician. 
9.3.4 Participants 
Children diagnosed with CF between the age of one and eight years of age, who were 
followed up at the research site, were considered for inclusion in the study. Investigation of 
existing hospital records identified participants suitable to enrol in the study. 
Children were included if they had a diagnosis of CF confirmed by sweat testing or genotype 
analysis. Children were excluded when they had the following: 
 awaiting a lung transplant (this intervention is only conducted in severely affected 
patients, therefore, it might influence this study’s outcome measure of disease 
severity),  
 severe scoliosis or kyphosis (as this will influence lung volumes, impacting the 
ability to perform AAD as well as lung function testing),438  
 osteoporosis (due to the increased risk of rib fractures during ACTs),101  
 recent pneumothorax (to prevent a new episode as patients with CF are already at 
increased risk of recurrent pneumothorax. Furthermore, lung function tests, one of 
this study’s outcome measures, are contraindicated in patients with 
pneumothorax),439 
 thoracic or abdominal surgery in the preceding six months (as ACTs will increase 
pressure in the thorax and/or abdomen, influencing the surgical site),  
 emphysema or active sarcoidosis.  
 prematurely born at less than 30 weeks of gestation (see section 2.1, prematurity 
can negatively influence the respiratory system),  
 on TB medication (to limit the impact of TB on the study’s outcome measures),  
 untreated asthma (the pathophysiology of asthma with wheezing and airway 
collapse, might influence ACTs),  
 known to be non-compliant to physiotherapy treatment prior to recruitment (as 
these patients would not be compliant with either arm of the study) 
 
 173 
 
Children who were not on a physiotherapy regime prior to the study were not eligible until 
they had received at least two months of standard ACT (to be able to compare standard 
ACT to AAD in the intervention arm of the study). 
Children who had TB in the past but were not on TB medication during the time of the 
study and children who received asthma medication, such as β2-antagonists or steroids but 
with the disease under control, were considered for inclusion in the study.  
Sample size: due to the small number of children available between the age of one and 
eight years of age with CF at the research site, this pragmatic pilot study aimed to enrol 30 
children (estimated population at the research site) to be randomly assigned to the 
intervention (n=15) or control (n=15) group. The sample size was limited by the availability 
of suitable participants within the 18 month time frame of the study. 
9.3.5 Outcome measures/instrumentation 
After considering the benefits and downsides of common outcome measures for the 
assessment of ACTs as described in section 2.3.3, the following were included in the study: 
9.3.5.1 Data collection forms 
Self-designed standardised data collection forms were used throughout the study 
(Appendix 17). All pre-set data extraction forms were validated for content by an expert in 
the field of paediatric cardiopulmonary physiotherapy. On day of recruitment, a form 
regarding general information on the child was completed, using a combination of data 
from the medical file and oral history from the parent. If data were found to be missing 
from the medical notes, the necessary information was added to the file. At the end of the 
study period, another form regarding the participants’ health status was completed by a 
blinded outcome assessor. These forms also included a summary of this study’s outcome 
measures: neurodevelopmental screening, EQ-5D-Y, number of hospitalisations and 
exacerbations during the one year study period, weight and height. 
9.3.5.2 Number of hospitalisation and exacerbations in one year 
All exacerbations and hospitalisations were assessed by the attending physician, who 
remained blinded to group allocation throughout the study period. The physician reported 
any exacerbation or hospitalisation to the research team and the information was added to 
the patient’s case report file. Number of exacerbations in one year was furthermore 
determined by days on antibiotic treatment. 
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9.3.5.3 Parental proxy-HRQOL scores 
HRQOL was measured by the use of the EQ-5D-Y, completed by the parent/caregiver of the 
child, at the start and end of the study. The questionnaire is available in English, Afrikaans 
and isiXhosa. (Appendix 1).440 This outcome measure has been validated in the South 
African context and found valid for children with CF.162,163 As the parents conducted the 
interventions as a home-program, they were not blinded to group allocation. The 
questionnaire was completed at the CF clinic, either in the waiting room or the 
physiotherapy gym, while awaiting further testing or doctor’s appointment.  
9.3.5.4 Current clinical status 
Current clinical status of the child was assessed by the CFCS, measured at start and end of 
the study by the attending physiotherapist (not blinded to group allocation). This outcome 
measure was not assessed by the blinded outcome assessor as the first section of the tool, 
subjective assessment, was mainly based on parental report who were not blinded to group 
allocation and increased the risk of unblinding the outcome assessor. A description of the 
CFCS score can be found in section 2.3.3 of this thesis.174 This tool has been validated in a 
paediatric population.172,174 
9.3.5.5 Neurodevelopmental test 
The clearance of pulmonary secretions could improve lung function, resulting in the child 
being more active during the day, hence improve their motor development. 
Neurodevelopmental level was assessed by either the Peabody Developmental Motor Scale 
2nd edition (PDMS) for children less than five years of age,441,442 or the Movement 
Assessment Battery for Children 2nd edition (MABC) for children older than five years of 
age.443,444 Both assessment tools are valid and reliable for assessing motor delay in 
children.442,445 The MABC consists of eight items in three domains: manual dexterity, aiming 
and catching, and balance; and has normative values for UK and Dutch children between 
the ages of three and 16 years.443,444 The PDMS assesses fine motor and gross motor skills in 
children younger than 83 months of age, based on five different domains.441,442 The current 
study did not apply the visual-motor domain due to time constrains in administering the 
test. Unfortunately, no developmental screening tool has been validated in the South 
African context, and no normative values are available for South African children. However, 
the MABC has been used in research on developmental coordination disorder in South 
African children.446–448 These studies applied the Dutch normative values, therefore, the 
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current study also used the Dutch values. The PDMS only reports American normative 
values, therefore these normative values were applied in the study. Testing was conducted 
by a blinded outcome assessor and took place at the physiotherapy gym. 
9.3.5.6 Lung function tests (spirometry) 
The quarterly spirometry lung function tests in children older than five years of age (FVC, 
FEV1, PEF, FEF25-75) were compared. Lung function tests, using the Microloop, were done at 
every clinic visit, as per standard practice. The best pulmonary function test scores, which 
adhered to the ATS/European Respiratory Society (ERS) criteria for each quarter was used 
for analysis. The ATS/ERS criteria for an acceptable blow entail the absence of: cough 
during the first second or at any time of the measurement when it interferes with the 
accuracy of the measure; an obstructive mouth piece; leakage; an extra breath during the 
measurement; an extrapolated volume more than 5% of FVC or 0.150 litre or an 
unsatisfactory start of the blow; early termination of the blow; or a hesitation or Valsalva 
manoeuvre. To have a valid lung function test, three acceptable blows should be registered, 
of which the largest two values for both the FEV1 and FVC are within 0.150 litre of each 
other.284 Lung function tests were conducted by the CF clinic’s lung function technologist, 
who was blinded to group allocation and recorded the results of the test and the quality of 
the blow in the patients’ medical files. These results were extracted from the medical files 
at the end of the study by a blinded outcome collector. 
9.3.5.7 Heigth-, weight- and BMI-for age 
Height-, weight- and BMI-for-age z-scores between the start and end of study were 
determined by weight (fully clothed, excluding winter jackets and shoes) and height (in 
standing, barefoot) of the participant at time of recruitment and end of study (measured by 
the assessment tools available at the CF clinic). These measurements are part of standard 
follow up at the clinic and were obtained by the clinic nurse, who remained blinded to 
group allocation throughout the study period. Z-scores were calculated by the use of the 
WHO AnthroPlus software (available from http://www.who.int/childgrowth/software/en/). 
9.3.5.8 Preference 
Patient’s and/or parent’s preference of participants in the intervention group was 
investigated during the second CF-clinic (approximately one to three months after 
initialising AAD), to prevent recall bias of standard ACT, using an adapted version (to reflect 
AAD intervention) of a standardized questionnaire designed by Jarad et al.,449which was 
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made available in three languages (English, Afrikaans and isiXhosa). This questionnaire was 
complete by the parents while waiting for further testing or the doctor appointment in the 
waiting area or physiotherapy gym. The forms were distributed and collected by the 
attending physiotherapist, to maintain blinding of the outcome assessor (only one arm of 
the study completed this questionnaire). At the end of the study, a semi-structured 
interview was conducted by the clinic social worker (blinded to group allocation) to assess 
preference and adherence to the study interventions (Appendix 14). The decision to involve 
the social worker to conduct these end of study interviews was made based on large 
discrepancies between information gathered by the research staff and other medical 
personnel. It was considered more objective when personnel not involved in the study 
collected this information as parents were made aware that this information remained 
completely anonymous The social worker was found most suitable as she had an 
established trust relationship with the knew the participants and their parents, and was 
used to conduct sensitive interviews related to her job. 
9.3.5.9 Adherence 
All parents and participants were asked to keep a record of their adherence to treatment by 
the use of a calendar and sticker system, to indicate when treatments took place. Parents 
were asked to record any adverse events on the backside of the calendar. 
9.3.5.10 Mortality rate 
Mortality rate was based on notes in the medical file, completed by a blinded medical 
personnel and extracted by a blinded data collector. 
9.3.6 Interventions 
It is ethically impossible to withhold treatment to children with CF. Therefore, standard 
treatment, consisting of conventional ACT (MPD, percussion and vibration) and the use of a 
PEP or Flutter device and/or components of the ACBT, was given to children in the control 
group. The intervention group received AAD ( Table 9-1). There is no literature available on 
the use of AAD, but the use of AD in children with CF might be beneficial.272 
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 Table 9-1. Airway clearance techniques performed during the CF trial 
Intervention group Control group 
AAD MPD + percussion and/or vibration 
 (+) ACBT 
 (+) PEP device 
 (+) Flutter 
 
Control group 
The parents of the control group received training and education on bi-daily standard ACT, 
consisting of MPD (excluding the head-down position), percussions or vibrations. Older 
children were taught ACBT, and may have been given a Flutter or PEP device, to be done 
under parental supervision/guidance. The type of control intervention was based on the 
decision of the physician and physiotherapists of the research site, who follow the South 
African consensus statement guidelines (which state that “physiotherapy does not just refer 
to airway clearance techniques. It involves education and practical application with regard 
to the holistic assessment and management of the patient both at the time of diagnosis and 
subsequently as an evolving process throughout the patient’s life […] Airway clearance 
techniques form an integral part of the treatment of CF. This facilitates the loosening, 
mobilisation and clearance of the often thick and tenacious sputum to prevent airway 
obstruction and respiratory complications, and to maintain or improve pulmonary function 
and ventilation. Lung hygiene can be boring, time-consuming and tedious. Therefore it must 
be effective, efficient, specifically designed for each individual and constantly modified and 
adjusted. […] In infants, modified postural drainage, percussion and thoracic compressions 
remain widely used, but other techniques such as infant positive expiratory pressure therapy 
and assisted autogenic drainage along with physical activity have emerged as feasible 
alternatives […] From early on in life, components of the active airway clearance techniques 
should be encouraged[…]”).292 Training and education of all parents is standard practice 
during the CF clinic visits, reinforcing ACT and hopefully optimising compliance to therapy. 
For standard ACT, the child was placed in the correct position, as determined by the 
physician/head physiotherapist and percussions and/or vibrations were performed on the 
chest wall. If PEP or Flutter was used, again a correct positioning of the child was needed 
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(usually in sitting) and correct usage of the device was assessed. If ACBT was used, a clear 
difference between relaxed breathing, thoracic expansion exercises and FET needed to be 
seen. During FET, the glottis needed to stay open; therefore it was important to teach the 
parent how to hear when the child closes his glottis.  
Intervention group 
For AAD, the child was placed in an upright sitting position on the lap of the parent or in 
front of the parent on a chair. The hands of the parent were placed on the chest of the child 
and the parent instructed to follow the breathing pattern of the child with his/her hands. 
When the child breaths out, the parent was told to give light pressure to keep the lung 
volume to this lower level. This was repeated until secretions are heard or felt. Then the 
parent should keep the same pressure on the child’s chest so that the child keeps breathing 
on this level until the secretions were gone. If the secretions were moved more centrally, 
the parent slightly loosened his grip so that the child was able to breathe on a higher lung 
volume, where the secretions were again felt or heard. Finally the parent let go of the chest 
wall so that the child could take a deep breath and cough up the secretions. 
Training of parents/caregivers 
The parents received information on the disease and the importance of physiotherapy. 
Afterwards the therapist explained the principle(s) of the used technique(s) at the 
appropriate language level, he/she demonstrated the technique(s) and then the parents 
showed the therapist how they would perform the technique. The therapist made 
corrections to the parent’s handling if necessary. The parents were allowed to ask 
questions during the entire teaching session and afterwards time was given to reflect on 
the handling and asking questions. Finally the parents were asked to demonstrate the 
technique without feedback from the physiotherapist to make sure they understood it 
entirely. When the performance was inadequate, the physiotherapist gave more feedback 
to make sure the parents knew how to perform the treatment. Only when an adequate 
level of performance (without feedback) was achieved by the parents, they were included 
in the study.450–452 
The level of teaching was adapted to the level of education of the parents. The therapy was 
written down for the parents, with diagrams where necessary. Also the parents were told 
that they could contact the physiotherapist (BM) when they were not sure how to perform 
the technique correctly.  
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Frequency and duration of ACT 
Therapy, standard ACT or AAD, was carried out bi-daily, duration depending on the child’s 
age and tolerability (parents were taught how to identify signs of respiratory distress and 
hypoxaemia and infection). The parents were asked to carry out the intervention every day 
around the same time, once in the morning and once in the afternoon or evening. This was 
a one year follow up study. 
9.3.7 Procedure 
9.3.7.1 Approval 
Permission to carry out the study was granted by the Faculty of Health Sciences HREC, 
University of Cape Town and approval from the medical superintendent at the research site 
was obtained (Appendix 15). I recruited participants during the weekly CF-clinic, which 
takes place on Tuesday afternoons. Eligibility of children was determined by screening the 
patients’ medical files or on physician’s recommendation. Written informed consent was 
obtained from the parent(s) and assent was obtained from children older than five years of 
age (Appendix 16). These forms were available in English, Afrikaans and isiXhosa, and 
interpreters were used as required.  
9.3.7.2 Recruitment 
After obtaining permission from the parents (and children), the recruitment data collection 
form was completed, the CFCS score was assessed by clinic physiotherapist, and the EQ-5D-
Y was completed by the parents. Neurodevelopmental tests, done by myself, and lung 
function tests, performed by the lung function technologist, were then performed. 
Afterwards the child was randomly assigned to the intervention or control group. Simple 
randomisation was done prior to commencement of the study, by the use of a computer 
generated list of random numbers, which randomly assigned the participants to one of two 
parallel groups (randomisation ratio 1:1). Sealed, opaque, sequentially numbered 
envelopes were prepared, to conceal group allocation. Once a child was enrolled, the clinic 
physiotherapist would open an envelope to reveal group allocation. The outcome assessor 
and data analyst remained blinded throughtout the study period. Patient’s information was 
de-identified and coded by the use of coded computer files and/or coded paper files held in 
sealed envelopes.  
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Parents who did not consent on the day of recruitment, preferring to have additional time 
to consider participation, received the researchers’ contact details to obtain more 
information when required as well as to provide the opportunity for telephonic consent. If 
the researchers did not get a response prior to the next follow up visit approximately three 
months later, parents were approached during this follow up appointment.’ 
Once all this information was obtained and the clinic physiotherapist knew group 
allocation, this physiotherapist taught the parents how to perform the necessary 
technique(s) as indicated above.  
9.3.7.3 During the study period 
Parents and participants in the intervention group were asked to complete a questionnaire 
regarding therapy preference at the first follow-up visit. At each CF-clinic visit, the parents 
were asked to hand in their calendar so data could be stored and checked if adherence to 
treatment was appropriate. If adherence and compliance was poor, the parent was asked 
to explain why. Concerns raised by the parents were discussed and the importance of ACT 
was emphasised. 
The child was followed up at the CF clinic at the discretion of the physician. During each 
follow-up visit in the CF-clinic, lung function tests were performed by the lung function 
technologist. The parents of both control and intervention group were then seen by the 
physiotherapist and asked to demonstrate the physiotherapy technique(s) to ensure they 
were well executed and faulty implementation could be corrected. Parents could also ask 
for more explanation or extra demonstrations when necessary. If the child had an 
exacerbation, this was reported by the pulmonologist and the information was added to 
the patient’s case report file.  
9.3.7.4 End of study 
After one year of follow up, lung function tests were repeated and the parents were asked 
to complete the EQ-5D-Y again.161,162,440 The PDMS or MABC were used to reassess the 
neurodevelopment of the children and the CFCS was measured again. Further, the CF 
clinic’s social worker, who was blinded to group allocation, conducted a subjective semi-
structured interview with the parent(s)/caregiver(s) regarding physiotherapy management 
during the study period and the likes and dislikes of the different techniques used during 
the study period.  
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9.3.8 Data-capturing and management 
During recruitment, the researcher collected general information by the use of a general 
information sheet (Appendix 17). The child’s case report file contained a form with medical 
information, including weight, height and the results on the PDMS or the MABC. A calendar 
was used to record the adherence/compliance to therapy, and any adverse events. This 
data was also used to analyse safety of the technique. All data were de-identified and 
coded by the use of coded computer files and/or coded paper files.  
9.3.9 Data-analysis 
All data were entered into an Excel spread sheet and analysed with Statistica (Version 12, 
StatSoft Inc, Tulsa USA). The data were tested for normality with the Lilliefors test. As the 
majority of data were skewed and the sample size was small, non-parametric tests were 
performed. Comparison between the control group and intervention groups on 
dichotomous data were done using the chi square test and Fisher exact or Yates correction; 
and numeric outcome parameters were analysed using the Mann-Whitney U test. Effect 
size was calculated for outcome measures which showed, on initial univariate analysis, to 
have either a significant difference or a trend towards significant between-groups 
differences. For parametric data, the Cohen’s d value was calculated.283 For non-parametric 
data, the r value was calculated with the formula r= z/√N.282 As the z value is sample size 
dependent, the r value will eliminate this sample size effect.282 The r value was converted 
into a Cohen’s d value by using the formula d= 2r/√(1-r2).282 Interpretation of the effect size 
was based on Cohen’s guidelines for small (d= 0.2), medium (d= 0.5) and large (d= 0.8) 
effect sizes.283 
A regression analysis was planned, to compare the relationship between the different 
variables (use of simple, logistic and forward stepwise analysis), however, due to the small 
sample size this analysis was not completed. An intention-to-treat analysis was performed. 
Dependent variables were the different outcome measures as indicated above. The 
independent variables were age, gender, HIV-infected or –exposed, history of TB, 
Pseudomonas aeruginosa or Staph. aureus colonisation, and pancreatic 
sufficient/insufficient. Chi square tests were used to calculate the patient’s or parent’s 
preference.  
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9.4  AMENDMENTS 
In the original protocol, parents and children were asked to complete a diary, indicating 
when, how long, and which ACTs were given; and what the reason was for terminating the 
intervention. However, due to the lack of compliance to this diary, evident at the first 
follow up visit, changes were made. The parents and patients were then asked to adhere to 
a monthly calendar and sticker system. For each completed treatment, the child was 
allowed to place a sticker on the calendar, both of which I provided.  
Furthermore, an end of study interview was added to the protocol. This interview was 
performed by the social worker employed at the CF clinic, who was blinded to group 
allocation. The interview answers were written down by the social worker. No identifying 
information was available on the documents, in the hope that parents and patients would 
answer honestly. It was emphasised that the information provided to the social worker 
would be used for research purposes only and not for patient management. 
9.5  RESULTS 
9.5.1 Participants 
A total of 36 children were screened. Nineteen children were excluded prior to enrolment 
due to various reasons (see Figure 9-1). One child, allocated to the control group, was 
excluded post-enrolment as the diagnosis of CF was questioned by the attending physician. 
Therefore, 16 participants were included in the study (median 5.8 years, IQR 4.3-6.3), of 
which seven were in the intervention group and nine in the control group. All participants 
completed the one year clinical trial. None of the participants were lost to follow up. 
Baseline characteristics of the participants were similar between groups and can be found 
in Table 9-2. The median duration of enrolment in the study was 359.0 days (IQR 326.0-
359.0) for the control group and 360.0 days (IQR 351.0-366.0) for the intervention group (z= 
1.3, p= 0.186). 
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Screened n= 36 
 
   
  
 
 
Excluded prior to enrolment, n= 19  
(n= 17 with one exclusion criteria; n= 2 with two 
exclusion criteria) 
Reasons for exclusion: 
- Non-compliance prior to enrolment, n= 
8 
- No consent obtained, n= 6 
- No proven diagnosis of CF, n= 4 
- Younger than one year of age, n=1 
- Surgery in the past six months, n=1 
- Uncontrolled asthma, n=1 
   
 
Enrolled and 
randomised, n= 17 
 
   
  
Excluded post enrolment/randomisation, n=1 
   
 
Analysed n= 16 
 
   
 
Control group n= 7 
 
Intervention group n= 9 
   
   
   
0 lost to follow-up 
 
0 lost to follow-up 
 
Figure 9-1. Study flow diagram CF pilot study 
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Table 9-2. Baseline characteristics of participants 
Characteristic Control group, 
n= 7 
Intervention 
group, n= 9 
Statistical value p-value 
Gender, Male (n) 4 5 Fisher exact p= 0.671 
Age (years), median (IQR) 5.7  
(3.0-6.0) 
5.8  
(5.5-6.6) 
Z= -1.1 p= 0.266 
Age diagnosis (months), median 
(IQR) 
3.0 
(0.0-6.0) 
3.0 
(1.0-6.0) 
Z= 0.0 p= 1.000 
Age start physio (months), median 
(IQR) 
4.0 
(3.0-6.0) 
6.0 
(2.5-10.5) 
Z= -0.6 p= 0.563 
Gestation 
- Term (n) 
- Preterm (n) 
- Unknown (n) 
 
7 
0 
0 
 
7 
1 
1 
Yates X²= 0.1 p= 0.964 
History of TB (n) 0 1 Fisher exact p= 0.563 
Asthma (n) 1 3 Fisher exact p= 0.392 
Pancreas insufficient (n) 7 9 X²= 0.0 P= 1.000 
HIV status 
- Negative (n) 
- Exposed (n) 
- Positive (n) 
- Unknown (n) 
 
6 
1 
0 
0 
 
7 
1 
0 
1 
Yates X²= 0.3 p= 0.958 
Genotype 
- ∆F508 (n) 
   ∆F508/E585X 
   ∆F508/G542X 
   ∆F508 homozygous 
   ∆F508/unknown 
   ∆F508/394delTT 
- 3120 (n) 
   3120/HG A homozygous 
   3120/G A homozygous 
   3120/G A heterozygous 
- Unknown (n) 
 
5 
     0 
     0 
     3 
     1 
     1 
0 
     0 
     0 
     0 
2 
 
6 
     1 
     1 
     3 
     1 
     0 
3 
     1 
     1 
     1 
0 
Yates X²= 1.7 p= 0.422 
Colonisation/ 
infection 
- St. Aureus (n) 
- MRSA (n) 
- Pseudomonas (n) 
- None (n) 
 
4 
1 
0 
2 
 
8 
0 
1 
0 
Yates X²= 1.0 p= 0.797 
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9.5.2 Results between groups at 12 months 
No significant differences were seen for the primary outcome measures, number of 
hospitalisations and number of exacerbations, between the intervention and control group 
(Table 9-3). Nor were there any significant differences between the groups for the other 
outcome measures (Table 9-3, Table 9-4 and Table 9-5). Although the outcome measures 
‘number of exacerbations during one year’ and ‘days on antibiotic therapy during one year’ 
were not significantly different between both groups, the IQRs were only marginally 
overlapping. Therefore, the effect size was calculated, revealing a medium effect size for 
the outcome measure ‘number of exacerbations during one year’ (d= 0.55), with fewer 
exacerbation during one year in the intervention group and a small to medium effect size 
for ‘days on antibiotic therapy during one year’(d= 0.48), for fewer days on antibiotic 
therapy in the intervention group.  
Due to the small sample of participants performing acceptable lung function tests, based on 
the quality criteria set by the ATS/ERS,284 the data of only five participants (of which three 
were allocated to the intervention group) could be presented in this thesis. Therefore, no 
statistical analyses were performed for this outcome measure. Data are presented in Figure 
9-2 and Figure 9-3. One participant had a clear decrease in both FEV1 and FVC between the 
start of the study and lung functions performed three months later; and another participant 
improved greatly after three months of enrolment in the study. Both participants were 
enrolled in the intervention arm of the study. The lung function tests of the other 
participants did not show large changes over time. 
Furthermore, only four participants were tested with the PDMS-2, two in each arm of the 
study. Again no statistical analyses were therefore possible. Data are presented in Figure 
9-4. The histograms do not reveal clear differences between the two groups. 
All participants were alive at the end of the study period (100% survival rate). 
Table 9-3. Primary outcome measures, presented as median (IQR), between the control and intervention 
group. 
Outcome measure Control (n=7) Intervention (n=9) Statistics (z-value) p-value 
Number of hospitalisations 0.0 (0.0-1.0) 0.0 (0.0-0.0) -0.3 0.791 
Days of hospitalisation 0.0 (0.0-7.0) 0.0 (0.0-7.0) -0.2 0.832 
Number of exacerbations 2.0 (1.0-3.0) 1.0 (1.0-1.0) -1.1 0.290 
Days on antibiotic therapy 20.0 (10.0-97.0) 10.0 (5.0-15.0) 
(n= 8) 
-0.9 0.355 
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Table 9-4. Movement assessment battery for children 2nd edition results presented as median (IQR) 
   
Motor function 
outcome 
Control Intervention Change over time: median differences 
(95%CI) 
Between group at baseline 
and end of study 
Within group from 
baseline to end 
 Baseline 
n= 5 
End 
n= 5 
Baseline 
n= 7 
End 
n= 7 
Control Intervention Baseline End Control Intervention 
MABC Fine 
motor % 
37.0 
(5.0-37.0) 
37.0 
(25.0-50.0) 
50.0 
(0.1-98.0) 
50.0 
(1.0-91.0) 
0.0 (-60.0-60.0) 0.0 (-55.6-55.6) z= 0.4 
p= 0.685 
z= 0.7 
p= 0.516 
z= 0.1 
p= 0.893 
z= 0.1 
p= 0.917 
MABC Catching 
and throwing % 
16.0  
(16.0-63.0) 
25.0  
(9.0-37.0) 
37.0 
(25.0-75.0) 
16.0  
(5.0-50.0) 
9.0 (-46.5-64.5) -21.0 (-66.4,24.4) z= 0.3 
p= 0.745 
z= 0.0 
p= 1.000 
z= 0.7 
p= 0.500 
z= 0.4 
p= 0.675 
MABC Balance % 5.0 
(5.0-16.0) 
25.0 
(5.0-25.0) 
9.0  
(0.5-75.0) 
5.0 
(0.5-75.0) 
20.0 (-21.2-61.2) -4.0 (-58.0-50.0) z= 0.2 
p= 0.808 
z= -0.6 
p= 0.570 
z= 0.1 
p= 0.893 
z= 0.5 
p= 0.600 
MABC Total % 9.0  
(5.0-37.0) 
16.0  
(16.0-16.0) 
25.0 
(0.5-95.0) 
16.0  
(0.1-91.0) 
7.0 (-43.5-57.5) -9.0 (-64.3-46.3) z= 0.2 
p= 0.808 
z= 0.0 
p= 1.000 
z= 0.7 
p= 0.500 
z= 0.9 
p= 0.345 
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start quarter 1 quarter 2 quarter 3 end
Participant 1 110 99 89 101 94
Participant 6 113 116 106
Participant 7 104 103 105
Participant 8 105 103 113 117 102
Participant 11 110 113 91
0
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FEV1/FVC 
        
         
Figure 9-2. FEV1, FVC and FEV1/FVC presented as %predicted of the five participants  
who met the quality criteria for lung function tests. 
Dotted lines represent the intervention group and solid lines represent the control group. 
 
start quarter 1 quarter 2 quarter 3 end
Participant 1 83 97 101 93 91
Participant 6 109 108 117
Participant 7 116 114 116
Participant 8 128 65 64 96 102
Participant 11 61 55 63
0
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Forced vital capacity 
start quarter 1 quarter 2 quarter 3 end
participant 1 88 93 88 91 83
participant 6 119 122 122
participant 7 121 116 122
participant 8 130 65 70 109 100
participant 11 66 60 55
0
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80
100
120
140
%
p
re
d
 
Forced expiratory volume in 1 second 
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Dotted lines represent the intervention group and solid lines represent the control group. 
start quarter 1 quarter 2 quarter 3 end
Participant 1 69 65 47 64 52
Participant 6 78 142 118
Participant 7 101 88 100
Participant 8 98 71 128 67
Participant 11 60 73 31
0
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%
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FEF 25-75 
start quarter 1 quarter 2 quarter 3 end
Participant 1 60 61 65 61 66
Participant 6 74 109 106
Participant 7 83 86 80
Participant 8 104 56 81 76
Participant 11 86
0
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100
120
%
p
re
d
 
Peak expiratory flow 
Figure 9-3. FEF25-75 and PEF presented as %predicted of the five participants who met the quality criteria for lung function tests. 
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Dotted bars represent the participants allocated to the intervention group and solid bars represent the control 
group. 
 
37 
63 
50 
37 
63 
37 
63 63 
Participant 5 Participant 10 Participant 12 Participant 16
Locomotion 
start end
84 
75 
63 
37 
63 
16 
95 
84 
Participant 5 Participant 10 Participant 12 Participant 16
Stationary 
start end
16 
37 
16 
25 
16 16 
25 25 
Participant 5 Participant 10 Participant 12 Participant 16
Object manipulation 
start end
45 
61 
39 
27 
45 
16 
98 
61 
Participant 5 Participant 10 Participant 12 Participant 16
Gross motor subtotal 
start end
75 
84 
75 75 
91 95 
63 
84 
Participant 5 Participant 10 Participant 12 Participant 16
Grasping 
start end
Figure 9-4. Peabody Developmental Motor Scale 2nd edition results, presented as percentage.  
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Table 9-5. Other outcome measures between and within the control and intervention group, presented as median (IQR). 
Outcome measure Control 
 
Intervention Change over time: Median 
differences (95%CI) 
Between group at 
baseline and end of 
study 
Within group from baseline to 
end of study 
 Baseline 
(n= 7) 
End 
(n= 7) 
Baseline 
(n= 9) 
End 
(n= 9) 
Control Intervention Baseline End Control Intervention 
CFCS subjective 8.0  
(7.0-11.0) 
8.0 
(6.0-12.0) 
11.0 
(10.0-12.0) 
8.0  
(6.0-11.0) 
0.0 (-4.2-4.2) -3.0 (-6.0-0.0) z= 7.8 
p= 0.072 
z= 0.2 
p= 0.832 
z= 0.3 
p= 0.753 
z= 1.7 
p= 0.091 
CFCS objective 6.0  
(6.0-8.0) 
7.0 
(5.0-8.0) 
6.0 
(6.0-7.0) 
6.0 
(5.0-6.0) 
1.0 (-1.9-3.9) 0.0 (-1.3-1.3) z= 0.0 
p= 1.000 
z= -1.0 
p= 0.341 
z= 0.3 
p= 0.787 
z= 0.8 
p= 0.418 
CFCS total 13.0 
(13.0-19.0) 
14.0 
(11.0-22.0) 
17.0  
(17.0-18.0) 
14.0 
(12.0-16.0) 
1.0 (-5.1-7.1) -3.0 (-6.7-0.7) z= 1.3 
p= 0.204 
z= 0.1 
p= 0.958 
z= 0.0 
p= 1.000 
z= 1.7 
p= 0.093 
EQ-5D-Y VAS score 91.0 
(90.0-99.0) 
95.0 
(75.0-100.0) 
85.0 
(80.0-95.0) 
92.5 
(90.0-10.00) 
n= 6 
4.0 (-19.6-27.6) 7.5 (-6.4-21.4) z= -1.0 
p= 0.315 
z= 0.4 
p= 0.721 
z= 0.1 
p= 0.917 
z= 1.8 
p= 0.068 
BMI-for-age z-
score 
0.3 
(-1.0-2.3) 
-0.7 
(-1.4-1.8) 
0.1 
(-0.2-0.4) 
-0.3 
(-0.5-0.1) 
-1.0 (-3.9-1.95) -0.4 (-0.9-0.2) z= -0.3 
p= 0.751 
z= 0.4 
p= 0.672 
z= 0.3 
p= 0.735 
z= 1.5 
p= 0.139 
Weight-for-age z-
score 
-1.2 
(-1.5-0.4) 
-1.0 
(-1.5-1.5) 
-1.0 
(-1.1-(-0.5)) 
-0.8 
(-1.4-(-0.1)) 
0.2 (-2.7-3.1) 0.2 (-1.0-1.4) z= 0.2 
p= 0.832 
z= 0.0 
p= 1.000 
.000 
z= 0.5 
p= 0.612 
z= 0.3 
p= 0.767 
Height-for-age z-
score 
-0.6 
(-1.9-0.2) 
-0.3 
(-1.6-(-0.1)) 
-1.3 
(-1.5-(-0.8)) 
-1.0 
(-1.6-0.2) 
0.3 (-2.-3.2) 0.3 (-1.0-1.6) z= -0.6 
p= 0.525 
z= -0.1 
p= 0.916 
z= 1.2 
p= 0.237 
z= 1.1 
p= 0.260 
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Table 9-6. EQ-5D-Y dimension 
 
 
 
 
 
 
In the intervention group, the number of children who had some problems with the EQ-5D-
Y dimensions remained the same or decreased (for the dimension ‘having pain/discomfort’) 
throughout the study. Whereas in the control group a slight increase in children with some 
problems on the dimensions ‘looking after myself’, ‘doing usual activities’ and ‘feeling 
worried/sad/unhappy’ was seen (Table 9-6). 
9.5.3 Results within groups 
Within the control group, no significant changes were seen between baseline and end of 
study for any of the outcome measures (Table 9-4 and Table 9-5). In the intervention group, 
a trend towards an increase in the EQ-5D-Y visual analogue scale score (p=0.067), and an 
improvement in CFCS subjective subtotal (p= 0.091) and total score (p= 0.093) were 
observed. Large effect sizes for these outcome measures were observed in favour of the 
intervention group (d= 1.07, d= 0.87, and d= 0.86 respectively). 
9.5.4 Subjective questionnaires 
9.5.4.1 After one month 
Parents and children were asked to complete a written questionnaire with regards to their 
experience and preference of AAD compared to their previous ACT regime (prior to the 
study). Seven of the nine participants in the intervention group completed the 
questionnaire. Results are presented in Table 9-7. 
 
EQ-5D-Y dimension  Control Intervention 
 n/ntotal Baseline End Baseline End 
Mobility No problems 7/7 7/7 9/9 6/6 
Looking after myself No problems 6/7 5/7 6/9 3/6 
Some problems 1/7 2/7 3/9 3/6 
Doing usual activities No problems 7/7 6/7 7/9 4/6 
Some problems 0/7 1/7 2/9 2/6 
Having pain/discomfort No problems 5/7 5/7 7/9 6/6 
Some problems 2/7 2/7 2/9 0/6 
Feeling worried/sad/unhappy No problems 7/7 5/7 8/9 5/6 
Some problems 0/7 2/7 1/9 1/6 
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Table 9-7. Experience and preference of the intervention group after one month. Table should be read as 
follows: “AAD is … than my previous physiotherapy regime”. 
Participant Breathlessness Secretion clearance Relaxation Overall experience Preference 
1 Unanswered Similar Slightly better Similar Previous ACTs 
2 Much better Slightly worse Slightly worse Similar Previous ACTs 
3 Similar Similar Similar Similar Previous ACTs 
4 Similar Slightly better Similar Similar AAD 
5 Similar Slightly better Slightly worse Similar Both techniques 
6 Similar Slightly worse Slightly worse Slightly worse Previous ACTs 
7 Similar Much better Slightly better Much better AAD 
 
Although AAD was not experienced as worse than the previously used ACTs for most 
aspects of the questionnaire, four of the seven participants would prefer to return to their 
previously used ACT. The two participants who would prefer to use AAD instead of their 
previous ACT indicated that AAD was similar or better on all aspects of the questionnaire. 
One participant would prefer to combine AAD with their previous ACT. 
9.5.4.2 End of study interview 
An overview of the used techniques, frequency and duration is presented in Table 9-8. 
Furthermore, likes and dislikes per technique are listed in Table 9-9. 
It is clear that, for both groups, percussions and active play were the most preferred 
techniques during the study period, as they were performed most often, had most likes and 
least dislikes. 
Intervention group 
Two participants were not interviewed at the end of the study, as their primary caregivers 
were not present at the visit. Telephonic follow up calls were inappropriate due to social 
reasons. Therefore, we can only present the information on seven of the nine participants 
in the intervention group.  
Four of the seven participants used AAD during the trial. The other three did not indicate 
they used AAD throughout the study period. Further, each of the following techniques was 
used by one participant: Flutter, vibrations, ACBT, and blowing water; and five of the 
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participants used additional percussions and active play. Frequency and duration for each 
technique are presented in Table 9-8. 
Non-adherence to ACTs in the intervention group was because the treatment regime was 
time consuming (n=3) and the child resisted treatment (n=2). One participant indicated that 
there was no reason for non-adherence. And one participant declined to answer this 
question. 
Control group 
In the control group, all participants conducted percussions, two did Flutter, two performed 
vibrations and one did ACBT. Further, six were engaged in active play/exercise during the 
day. See Table 9-8 for an overview of frequency and duration of treatment techniques. 
Reasons for non-adherence in this group were: treatment regime is time consuming (n=3), 
child is not productive/ill therefore no treatment was given (n=2), child vomits after 
treatment (n=1). Three participants did not provide a reason for non-adherence. 
Table 9-8. ACTs used during the study period, providing frequency and duration per technique 
Technique Intervention (n=7) Control (n= 7) 
 n  Frequency Median time, in 
minutes, per session 
(IQR) 
n Frequency Median time, in 
minutes, per session 
(IQR) 
AAD 4 Daily (n=3) 
Not daily 
(n=1) 
7.0 (1.0-15.0) 0 - - 
Flutter 1 Daily 10.0 2 Daily (n=1) 
3x/w (n=1) 
3.0 (2.0-15.0) 
Percussions 5 Daily (n=1) 
Bidaily (n=1) 
3x/d (n=1) 
Not daily 
(n=1) 
When sick 
(n=1) 
10.0 (5.0-16.0) 
(n=4) 
7 Daily (n=1) 
Bidaily (n=3) 
3x/w (n=1) 
4-5x/w 
(n=1) 
When sick 
(n=1) 
15.0 (5.0-15.0) 
Vibrations 1 Not daily N/A 2 Bidaily 2.0 (2.0-2.0) 
ACBT 1 Not daily N/A 1 Daily 1.0 
Active play 5 Daily 105.0 (45.0-180.0) 
(n=4) 
6 Daily 75.0 (60.0-75.0) 
Other: blowing 
water (bubble PEP) 
1 Bidaily N/A 0 - - 
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Table 9-9. Likes and dislikes for each ACT used during the study period. 
Technique Likes Dislikes 
AAD - It works (n=2) 
- Easy (n=1) 
- Active technique (n=1) 
- Difficult technique (n=2):  
didn’t get it right (n=1) + unsure 
when to stop (n=1) 
- Not easy to distract the child (n=1) 
- Less cough production (n=1) 
- Child tires easily (n=1) 
- Child needs to actively cooperate 
(n=1) 
- Nothing (n=1) 
Flutter - It works (n=2) 
- Easy (n=1) 
- Feel the vibration/feel that is 
does something (n=1) 
- Feels like a duty (n=1) 
- Child vomits after the technique, 
especially in the morning (n=1) 
- Nothing (n=1) 
Percussions - Easy (n=6) 
- It works (n=2) 
- Routine/been doing it from the 
beginning (n=2) 
- Parent feels what he/she is doing 
(n=1) 
- Bonding and adaptable (n=1) 
- Cough augmentation (n=1) 
- Sleeps better (n=1) 
- Relaxing (n=1) 
- Nothing (n=6) 
- Time consuming (n=2) 
- Scared to hurt the child (n=2) 
- Feels like a duty (n=1) 
- Needs to convince child (n=2) 
- Painful hands (n=1) 
Vibrations - Effective (n=1) 
- Easy (n=1) 
- Time consuming (n=1) 
- Feels like a duty (n=1) 
- Not sure how to perform 
technique (n=1) 
ACBT - It works (n=1) 
- Easy to motivate the child (n=1) 
- Feels like a duty (n=1) 
- Nothing (n=1) 
Active play - Active (n=3) 
- Parents are happy when child 
tires (n=2) 
- Fun (n=1) 
- Gets out frustrations (n=1) 
- No extra effort (n=1) 
- Independent (n=1) 
- Clears secretions (n=1) 
- Keeps child busy (n=1) 
- Parent can see that the child is 
healthy (n=1) 
- Child can be him/herself (n=1) 
- Nothing (n=5) 
- Needs to observe the child (n=1) 
- Fear of dehydration (n=1) 
- Child destroys furniture (n=1) 
Blowing water 
(bubble PEP) 
- It works (n=1) - None (n=1) 
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9.6  DISCUSSION 
This study did not reveal any significant differences between the intervention (AAD) and 
control group (standard ACT) for any of its primary and secondary outcome measures.  It 
did however, give some indication of positive trends in favour of the intervention group. In 
addition, interesting insights were gained with regard to the outcome measures and the 
methodology, which can be used to inform the development of protocols which could 
entail multi-centre implementation. 
A small to medium effect of AAD on required antibiotic therapy during one year and a 
medium effect of AAD on number of exacerbations during one year was seen. Due to the 
small sample of participants who were able to perform good quality lung function tests, no 
comparison could be made between or within both groups. Analysis of the raw data did not 
reveal a clear difference between the intervention and control group. Similarly, no analyses 
could be performed for the neurodevelopmental outcome measure PDMS-2 due to the 
limited number of children younger than five years of age. Again, narrative analyses did not 
reveal a clear difference between both groups. A tendency and large effect sizes for 
improvement in CFCS subjective and total scores were observed in the intervention group. 
Although a trend towards a better HRQOL was found within the intervention group, based 
on the EQ-5D-Y visual analogue scale (with a large effect size) and the EQ-5D-Y dimensions; 
AAD was not preferred over standard ACT. An important finding of this study, although this 
was not one of the study’s intended outcome measures, was the finding of poor adherence 
to the study protocol in the intervention arm of the study, as well as poor general 
adherence to ACT regimens. 
As no literature is available on AAD in patients with CF, no comparison can be made with 
the current study’s results. However, several studies have been published on the use of AD 
in children with CF.84,121,124,270–272,434 Only one study was purely focused on a paediatric 
population and compared AD with PD and percussions in a long term randomised cross-
over study.272 The other studies were all randomised cross-over studies, performed in a 
mixed paediatric-adult CF population. Two of which compared AD with flutter;124,434 one 
each compared AD with PD and clapping,84ACBT and PD,270 PEP,271 and high pressure PEP.121 
For a complete overview of these studies, refer to Chapter 8. 
The current study did not find any differences between AAD and standard ACT for the 
primary outcome measure ‘number of hospitalisations in one year’. This is in line with the 
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results found in a study by McIlwaine et al.272 This outcome measure might be confounded 
by other non-pulmonary related variables, resulting in a low hospitalisation rate.The other 
primary outcome measure of the current study, number of exacerbations during one year, 
has not been reported in any of the studies on AD in children with CF. However, the study 
by McIlwaine et al. did mention that more hospitalisations for pulmonary exacerbations 
were required for participants in the PD with percussions arm of the study, compared to 
the AD arm.272 The current study found a small to medium effect size of fewer days on 
antibiotic therapy in the intervention group. This could suggest that AAD might clear 
infectious secretions from the lungs, therefore, influencing antibiotic needs. This requires 
confirmation in controlled trials with larger sample sizes.  
Only four of the included participants were hospitalised during the study period, however, 
13 participants did experience a pulmonary exacerbation during the study period. Hence 
‘number of exacerbations’ might be a more appropriate outcome measure than ‘number of 
hospitalisations in one year’. Furthermore, it would appear that AAD might have an impact 
on antibiotic use; therefore ‘number of exacerbations’ and ‘days on antibiotic therapy’ 
might be more responsive measures to use as primary outcomes in future studies. 
Lung function testing is often used as an outcome measure for patients with CF, to 
objectively measure lung disease progression and to guide therapy.137,149 It is therefore 
important to take into consideration the quality of the blows, to prevent other variables to 
interfere with the outcome. Unfortunately in the current study, several participants had at 
least one lung function test (at start or end of the study) that was of unsatisfactory quality, 
for which the test scores had to be removed from the analyses. The remaining five 
participants’ results were analysed narratively. One participant had a clear decrease in lung 
function results after three months of enrolment in the study, which might be attributed to 
a Pseudomonas aeruginosa infection requiring eradication regimen at that time; and one 
participant improved greatly after three months of enrolment in the study, which might be 
due to the eradication of Staph. aureus which was present at enrolment of the study. No 
other clear differences between or within the groups were observed. This again is in line 
with findings of several other studies.  FEV1 was not found significantly different between 
the intervention and control group in four studies.84,124,270,272 FVC was investigated in five 
studies, of which four did not find significant differences between groups.84,124,270,272 In a 
study by Pfleger et al., a better % predicted FVC was found for the AD arm of the study 
when compared to AD followed by high pressure PEP. However, no differences were found 
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for FVC when AD was compared to high pressure PEP, or high pressure PEP followed by AD 
in this study.121 Two studies included FEF25-75 as an outcome measure, showing no 
significant differences between the control and intervention groups.270,272 None of the 
studies included PEF as their outcome measures. Therefore, no comparisons of the current 
study’s PEF results can be made. For future research, it is of utmost importance that the 
quality of the lung function tests is on par with the pre-set criteria of the ATS/ERS. 
Otherwise, comparison between and within groups will be impossible as the lung function 
tests could have been influenced by other variables than the participant’s lung function. 
The underlying reason for the current study’s invalid measurements is unclear, as this 
outcome measure was evaluated by a blinded, trained lung function technologist. In 
literature, the use of spirometry lung function tests in children as young as three years of 
age has been described and found to be valid.146,453 Hence, expansion of the lung function 
testing protocol to younger children might be appropriate for future research. However, 
caution is needed as it is unclear whether the above mentioned invalid lung function tests 
could be due to the young age of included children, who might have been unable to 
perform the test adequately, for which an even younger age category might be 
inappropriate.  
Another outcome measure used in the current study was the EQ-5D-Y to assess the 
participant’s HRQOL by proxy report. The majority of parents reported no problems on the 
EQ-5D-Y dimensions. No severe problems were reported on any of the items. Parents 
scored the current health of their children high on the visual analogue scale (medians above 
85/100). This could be a result of the chronic nature of the disease, for which coping 
mechanisms might have led to adaptations in lifestyle and disease perceptions.163,454 None 
of the studies investigating AD compared to other ACTs in children with CF reported on 
HRQOL outcome measures. Therefore, no comparisons can be made with our results. 
However, HRQOL is affected in patients and parents of patients with CF, as they face many 
challenges throughout their life. These challenges entail, but are not limited to: 
stigmatisation; time consuming treatments; increased health care costs; and disrupting 
effect of a pulmonary exacerbation.21,22,333 These lead to increased depression and anxiety, 
which is frequently found in both patient and caregivers lives; and influences adherence to 
treatment.334,455 Therefore, the International Committee on Mental Health in Cystic Fibrosis 
recommends that annual screening for these symptoms should be implemented in routine 
follow up, so an appropriate intervention can be applied when needed.337 Hence, it is 
recommended that in future research, HRQOL tools for both the patient and the caregiver 
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emerge in research protocols. As proxy-report has not been found to be a valid 
representation of the child’s HRQOL for some assessment tools;456–458 the child him/herself 
should complete a questionnaire where possible. The EQ-5D-Y is valid and reliable for 
children older than eight years of age, and the Pediatric Quality of Life Inventory has been 
found valid and reliable when completed by children older than five years of age.161,459 
Unfortunately, no tool is available currently for assessing HRQOL in children younger than 
the age of five years; therefore it is recommended that research is conducted towards 
developing an easy, valid, child-friendly HRQOL tool which is usable in a younger age group 
and responsive to small changes in chronic disease.  
The current study also used the CFCS, as an outcome measure. This tool has not been 
reported in any of the studies investigating AD in children with CF. However, one study did 
report on the Huang and Shwachman-Kulczycki score after one year of intervention in a 
paediatric CF population.272 No significant differences for the Shwachman-Kulczycki score 
were found between the intervention arm receiving AD and the control arm receiving PD 
with percussions. The Huang score, on the other hand, did differ significantly between both 
groups, with a better Huang score reported in the AD arm of the study.272 Although the 
current study did not find any significant differences between the intervention group 
receiving AAD and the control group receiving standard ACTs, baseline characteristics show 
a trend towards more children with an acute illness based on the subjective CFCS results, in 
the intervention arm of the study. Although all three scores are clinical scores, assessing 
disease severity, used in patients with CF, the CFCS score has a different content validity 
than the Huang and Shwachman-Kulczycki score. The CFCS was developed to assess the 
patient’s current clinical status, whereas the Shwachman-Kulczycki score assess the 
progression of chronic illness and the Huang score the short term effects of an 
intervention.170,172–174 Description of the Huang and Shwachman-Kulczycki score can be 
found in section 2.3.3. The CFCS might not have been the most appropriate outcome 
measure for a one year intervention, as the current state of the child could be influenced by 
an acute exacerbation at the time of assessment. However, the current study did find large 
effect sizes within the intervention group from baseline to end of the study. Future 
research could therefore opt to use the modified Shwachman score as described by 
Doershuk et al. in addition to the CFCS, to assess both acute health status and long term 
chronic disease progression.171 However, this tool also has flaws such as subjective items 
reducing the test’s reliability, poor sensitivity for mild disease severity, and categories 
which are intertwined.171,172 Furthermore, the CFCS score can be used on a more routine 
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basis, e.g. during each follow up visit, to assess the presence of an exacerbation. 
Maintaining the score below 25 points or not exceeding five points of the last calculation 
might provide a more reliable outcome to control exacerbation during ACT. 
The median BMI for age z-scores in the current study were within the normal boundaries 
(z>0) and no significant difference between and within groups were seen. None of the 
studies investigating AD in children with CF included BMI-for-age z-scores as one of their 
outcome measures. Therefore, no comparison with the current study can be made. BMI-
for-age has been recommended as the preferred method to assess children’s growth and 
nutritional status.19,365 Children should obtain and maintain a BMI above the 50th 
percentile,19 which correlates with a z-score of zero. However, BMI-for-age is unable to 
identify stunting, therefore, weight-for-age and height-for-age measures are relevant.460 In 
the current study, the majority of children were underweight for age, with median z-values 
>-1. Shorter stature for age was also found, particularly in the intervention group. As the 
BMI-for-age z-scores were within normal range but reduced weight- and height-for-age z-
scores were observed, this study emphasises the importance of including  outcome 
measures focussing on stunting and malnutrition, hence weight-for age and height-for-age, 
rather than BMI-for-age z-scores. 
No severe adverse events or casualties were reported, and the current study had a 
mortality rate of zero. Again, mortality was not included as an outcome measure in any of 
the studies on AD in children with CF, for which no comparison could be made. As the 
current study included a young age range, mortality rate might not have been an 
appropriate outcome measure as mortality at such a young age is not common; especially 
considering the increasing life expectancy of people with CF.12 Adverse events on the other 
hand are more appropriate in assessing a new intervention in this population. Although this 
was not an intended outcome measure, no adverse events were reported in either arm of 
the current study. 
Finally, the current study revealed a higher preference for standard ACTs (4/7 participants) 
than AAD (2/7) in the participants in the intervention group after one month in the study. 
This is in contrast with the study by McIlwaine et al, where 10 of the 17 participants did not 
want to return to PD with percussions after completion of the AD arm of the study.272 In the 
study by Miller et al, preference was equally divided for AD and ACBT in their two day cross 
over trial.270 The discrepancy of the current study’s results with these two studies could be 
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due to the difference in application of the techniques. AD and ACBT are known to be 
techniques that can be performed independently at any time of the day as no equipment is 
needed.24 However, AAD is a passive/assisted technique which requires the caregiver to 
actively participate in applying the technique.25,28 Two of the four caregivers who reported 
to use AAD at the end of the study period did mention that AAD was difficult to administer: 
they ‘did not know how to get it right’ or were ‘unsure when to stop’. AAD might therefore 
require more training of the caregiver, which is similar to AD, where the patient also 
requires multiple training session before effectively being able to apply the technique.24 For 
future research, a more intense and comprehensive training program might be needed to 
train the caregivers in applying AAD. One session with three monthly follow up might not 
be sufficient to master this more complex technique. AAD could be integrated in the ACT 
toolkit from an early age, so caregivers and children get used to the technique and might be 
more comfortable in its application. 
As mentioned above, AAD was less preferred than other ACTs such as percussions and 
vibrations in the current study. However, the adherence to these more preferred ACTs was 
generally poor, with only four of the 13 participants interviewed at the end of the study 
performing bidaily ACTs as recommended. Studies on adherence to ACT and general 
medical treatment in children with CF reported an overall poor adherence to therapy (less 
than 50%).423,461 Factors influencing treatment adherence of children with CF and their 
caregivers include: socio-economic status (with maternal education and income higher than 
$50 000 identified as positive influencers for adherence);424,427 mental health (depression 
and anxiety, in both the child and the caregiver, negatively influencing treatment 
adherence);334,336,462 family relationships (supportive parents and a good child-parent 
relationship positively influencing adherence, whereas oppositional behaviour reduces 
adherence);334,426 time-consuming therapy;426,463 and understanding of the disease 
progression and necessity of therapy. In the current study, the main reason for non-
adherence to ACT was the time consuming nature of the intervention. Furthermore, 
resistance from the child and the lack of physical signs of illness were indicated as being 
barriers to adherence. Adherence was intended to be monitored by the use of a diary, 
however, poor adherence to completion of the diary led to discarding this form of 
adherence control. Afterwards a less time consuming, more enteraining method of 
adherence monitoring was applied, using a calendar and sticker method. Unfortunately, 
even this form of adherence monitoring was not completed by the majority of children and 
parents. Therefore, information in the current study regarding adherence was obtained via 
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a subjective interview, performed by a social worker who was not involved in the study but 
who did know the children and their parents. As this method of data gathering is not 
objective (self-reported adherence is found to be higher than objectively measured 
adherence),423,464 the adherence rates provided in this current study cannot be used for 
generalisation to a broader population. However, if self-reported treatment adherence is 
higher than the actual adherence, the rates of adherence to bidaily ACTs in the current 
study are worrisome; highlighting the need for the use of an objective adherence 
monitoring tool to objectively quantify the problem in future studies. Several options have 
been reported in literature, such as telephone calls on a daily basis and electronic devices 
to monitor adherence.423,424,464 However, these are not always feasible due to high cost and 
time constraints.465 In future research, improving adherence to therapy is essential, which 
may be obtained by improving training of parents and through more intensive follow up. 
Cost-effective methods of adherence follow-up should be explored, such as the use of sms, 
email or online messaging. 
9.7  CONCLUSION 
This study was the first pilot RCT on the use of AAD in children with CF, which aimed to 
explore the feasibility of the study protocol. The results of this study can be used as 
baseline, to which other studies can be compared, adding to the body of knowledge on AAD 
as an ACT in this population. Conclusions cannot be made regarding the effectiveness and 
safety of AAD in children with CF due to the small sample size included in this study, and 
the lack of adherence to the prescribed intervention. However, the magnitude of 
adherence problems related to ACT in this population is clear. Further research is needed to 
investigate the usefulness of AAD in children of this population and to tackle issues related 
to treatment adherence. AAD might be a useful technique to add to the airway clearance 
‘toolbox’ for children with CF as no adverse events were reported and a small to medium 
effect size for number of days on antibiotic therapy was found, benefiting the intervention 
group.  
Future research should explore multi-center research to increase the study’s sample size. 
Improving the training of the parents/caregivers is required, with a more intensive training 
session, aiming to increase adherence to therapy. Primary outcome measures such as 
‘number of exacerbations’ and ‘days on antibiotic therapy’ during one year could be used 
rather than ‘number of hospitalisations’; as they are more responsive to change. Quality of 
spirometry should be monitored closely, to obtain reliable and valid measures. The use of 
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lung function testing in children younger than five years of age could be applied, however, 
training on performance of this outcome measure prior to the study period is 
recommended. Spirometry results should not be obtained for children unable to perform 
good quality blows. Disease severity could be measured using the CFCS, for acute health 
status, and the modified Shwachman score, for chronic disease progress. Furthermore, the 
use of weight-for-age and height-for-age z-scores could be more responsive than BMI-for-
age scores. Adherence to therapy may improve when monitored on a daily basis, using 
cost-effective alternatives. Furthermore, research towards an easy, valid, child-friendly 
HRQOL tool which is usable in a younger age group and responsive to small changes in 
chronic disease should be conducted. The Pediatric Quality of Life Inventory could be useful 
in children ages five years and older.  
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Chapter 10. CONCLUSION 
10.1 SUMMARY OF RESULTS 
Respiratory problems, both acute and chronic, remain an important disease burden 
worldwide; negatively impacting the child, the healthcare system and the community. 
Pneumonia in particular persists as one of the most common causes of death in children 
younger than five years of age; and CF is a relatively common chronic multisystem disorder 
affecting the respiratory system and reducing life expectancy. ACTs, as part of the 
management of these conditions, might influence the course of the disease and hopefully 
reduce the associated burden. Many ACTs have been investigated in different patient 
population groups, however, very few are useful in infants and young children, as they 
require active participation. AAD, a modified version of AD, has been used in clinical 
settings to facilitate airway clearance in infants and young children, however, the efficacy 
and safety of this technique has not been investigated before.  
The first part of this thesis investigated ACTs, including AAD, in an acute respiratory disease, 
pneumonia. The current body of knowledge on the use of ACTs, including AAD, in children 
hospitalised with pneumonia was investigated (Chapter 4), to assess the need for future 
research. Chapter 4 therefore aimed to address the research question: 
What is the international body of knowledge on the use of ACTs for children 
hospitalised with pneumonia? 
Only two RCTs were included in this systematic review, revealing no significant differences 
between the intervention and control groups for length of hospitalisation, time to clinical 
resolution, reduction of RR and severity score, and persistence of respiratory symptoms. 
However, this review was unable to pool data for meta-analysis and included only a limited 
number of articles. Furthermore, positive influences of ACTs in children with pneumonia 
were shown by one RCT and several non-randomised trials, which were not included in the 
review; highlighting the need for more evidence-based research within this field. Hence, no 
clear recommendations can be made for the use of ACTs in the clinical management of 
children with pneumonia.  
Although ACTs are used in the clinical management of children with LRTIs, there is little 
documentation available on the prescription, frequency and nature of ACTs, particularly in 
a South African context. Most importantly, there is little published data regarding adverse 
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events that may be associated with ACTs in children with LRTI. Therefore, a retrospective 
folder review investigating the patient characteristics and ACT management in a tertiary 
hospital in Cape Town, South Africa was conducted (Chapter 5), to answer the second 
research question: 
In children hospitalised for LRTI in South Africa: what is the patient profile of children 
receiving ACT, what is the nature and frequency of ACT, what are the predictive factors 
for receiving ACT, what are the adverse events associated with ACT and could these 
adverse events be predicted? 
This folder review showed that ACT was only given in 5.8% of the hospitalisations, with 
conventional ACTs the most frequently used (vibrations (83.1%), MPD (55.4%), 
percussions/clapping (38.6%), thoracic compressions (8.4%) and chest wall shaking (1.2%). 
This might be due to the large proportion of infants and young children hospitalised for 
LRTIs at the hospital, for whom newer ACTs could be challenging due to the need for active 
cooperation. Other techniques used clinically were deep breathing exercises (25.3%, active 
gross motor exercises (20.5%), ACBT (13.3%), FET/huff (7.2%), bubble PEP (7.2%), AAD 
(6.0%), oscillating PEP (3.6%) and blowing bubbles (1.2%). PEP and AD were not performed 
during the study period. The majority of ACT interventions were commenced during the 
first week of hospitalisation (75.9%), were performed once or twice per day (49.4% and 
48.2% respective), and were carried out for a median of 3.0 days. Children hospitalised for 
presumed nosocomial infections and pneumonia, with isolated bacterial organisms and a 
chronic comorbidity (CP, NMD, chronic respiratory disease or genetic disorder), were most 
likely to receive ACT. Desaturation was reported as an adverse event of ACT in six children 
during various techniques, particularly conventional ACTs. One child developed lung 
collapse an hour post treatment. Predictive factors for adverse events could not be 
analysed due to the small number of children presenting with adverse events. 
Only a few children with bronchiolitis received ACT during the study period, which 
conforms to recommendations made in the literature. However, the folder review did 
confirm that ACTs are still used in children with pneumonia, particularly the children with 
associated comorbidities. Furthermore, these children are hospitalised for a longer period 
than children with bronchiolitis; and have a higher mortality rate. 
As mentioned before, no conclusive evidence-based guidelines are available for the use of 
ACTs in children hospitalised for pneumonia due to the conflicting results in previously 
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published literature. The folder review suggests that ACTs are probably safe to perform in 
these children, if SpO2 is monitored during therapy. Currently, conventional ACTs are most 
often used to treat infants and young children as other techniques require active 
cooperation and the ability to follow instructions. AAD has been reported in the literature 
as a technique that could be used in this population; however, this technique has not been 
investigated before.  
Therefore, Chapter 6 addressed the third research question of this thesis: 
Is the use of AAD as an addition to standard care beneficial in children hospitalised 
with pneumonia? 
Due to ethical reasons, children with chronic comorbidities were excluded from the study, 
as the safety of AAD had not been investigated before. This RCT therefore only included 
children with uncomplicated pneumonia; and was unable to show any significant difference 
between the intervention and control groups for length of hospitalisation. However, a trend 
towards faster time to discharge with a medium effect size for days of hospitalisation 
favouring the intervention group was seen. Furthermore, a significant decrease in RR within 
the intervention group was observed. Although a statistically significant increase in RR 
immediately after AAD was observed in the intervention group, the clinical significance of 
an increase by one breath per minute is questionable, and the RR returned to baseline 
within an hour after treatment. Unfortunately, due to the high number of excluded 
patients, as a result of the strict exclusion criteria, the study was underpowered to make 
clear conclusions regarding AAD in children with uncomplicated pneumonia. 
For the chronic arm of this thesis, CF was the disease of choice as it is a common disorder 
affecting the respiratory system. ACTs have been found to be beneficial in this population, 
however, in infants and young children, the number of useful and available tools are 
limited. The majority of available literature investigates ACTs in children over the age of six 
years as they are cooperative and able to follow instructions. Again, AAD has been 
described in this population and is used in clinical practice but needs further investigation 
to determine effectiveness and safety. As no systematic review was published at the time 
of commencement of this thesis, Chapter 8 described a systematic review on AD and AAD 
in children with CF, to address research question four of this thesis: 
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What is the international body of knowledge on the use of AD and AAD in children with 
CF? 
This systematic review was unable to identify any RCTs for inclusion, however, seven 
randomised cross-over trials were included. Separation of paediatric and adult data was 
only possible in two studies. Although there was a trend towards fewer hospitalisations and 
improvement in Huang score for children performing AD compared to PD, there was 
insufficient evidence to accept or reject AD as a safe or effective treatment option in 
children with CF. AD was preferred over PD in one of the paediatric studies, with the 
majority of participants assigned to AD during the first period of a randomised cross-over 
trial refusing to revert to conventional ACTs after completing the first period of cross-over. 
This systematic review was unable to identify any research studies on the use of AAD in 
children with CF. As no RCTs are available on AD, and AAD has never been researched 
before, the need for well-designed studies in a paediatric population were recommended.  
Therefore, Chapter 9 of this thesis described a pilot RCT in children with CF, to provide an 
answer to the final research question: 
Is the designed research protocol feasible to identify the effect of AAD compared to 
other ACTs in the home management of children with CF?  
A pragmatic pilot study was conducted, the first true RCT, piloting the feasibility of a 
protocol on the use of AAD in children with CF, aiming at increasing the body of knowledge 
on AAD as an ACT in this population. No significant differences between the control and 
intervention groups were observed, although a medium effect size for ‘number of 
exacerbations per year’ and a small to medium effect size for ‘days on antibiotic treatment 
during one year’ were seen, favouring the intervention group. Within the intervention 
group trends towards improvement in EQ-5D-Y visual analogue scale and CFCS subjective 
and total score were observed (large effect sizes). AAD was not preferred over other ACTs 
used prior to the study period. AAD might be a useful technique to add to the airway 
clearance ‘toolbox’ for children with CF; unfortunately, conclusions cannot be made 
regarding the effectiveness and safety of AAD in children with CF due to the small sample 
size included in this study, and the lack of adherence to the prescribed intervention. The 
magnitude of adherence problems related to ACT in this population is clear. Further 
research is needed to investigate the usefulness of AAD in children of this population and to 
tackle issues related to treatment adherence. Future research should explore multi-center 
research to increase the study’s sample size.  
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10.2 RECOMMENDATIONS 
Although small benefits of AAD were observed in both children with pneumonia and CF, 
this thesis cannot recommend the use of AAD as standard practice in these children, based 
on the findings of this thesis. However, several practical recommendations arise from this 
thesis: 
- In children with LRTI, ACTs seem safe to be administered. 
- It is recommended that SpO2 be monitored during ACT, particularly in infants and 
young children, so the treatment can be halted when deemed necessary.  
- As no adverse events and casualties were reported, AAD could be considered as 
part of the ACT toolbox for patients with CF. An additional ACT creates more 
options and hopefully increases adherence to therapy when AAD is more preferred 
over other techniques. 
- Spirometry could be incorporated in the follow up of children with CF from the age 
of three years onwards, however, it is important that the quality of the spirometry 
performance is on par with ATS/ERS criteria, producing valid results. 
- Weight-for-age and height-for-age needs to be monitored during the routine follow 
visits for children with CF. BMI-for-age is insufficient to identify stunting and 
malnutrition in this population. 
- More attention towards caregiver training is recommended, ensuring the parent 
understands the importance of ACT in children with CF, and increase proficiency to 
optimise adherence to home ACT programs. 
This thesis aimed to investigate the effectiveness of AAD in children with pneumonia and 
CF. Efficacy of AAD could not be established, owing to the small sample sizes and poor 
adherence to study protocol in the CF study. Therefore, AAD is currently not recommended 
as standard practice in children with either pneumonia or CF. However, the road towards 
further research on the usefulness of AAD is opened.  
The following recommendations for research are proposed: 
- More research regarding ACTs in children with nosocomial infections and 
pneumonia is warranted; as the duration of hospitalisation was longer and 
mortality rate higher for these children. The identification of modalities which 
could hasten resolution of the disease, as well as identifying interventions which 
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are of no use or harmful, would help to ensure rational and appropriate resource 
allocation and optimise clinical outcomes.  
- Further prospective, controlled clinical trials on the safety of ACTs in children with 
LRTIs are proposed. Although ACT, as performed at this research site, is relatively 
safe to perform in children with LRTI; the study was not designed or powered to 
determine safety. 
- As more than half the children included in the descriptive folder review study 
presented with comorbidities, research is warranted to investigate the use of ACT 
in children hospitalised with LRTI and comorbidities, both chronic and acute. 
- Future RCTs on AAD in the same population groups need to include larger sample 
size, as small benefits of AAD were noted. Multi-site studies are recommended to 
increase sample size.  
- Inclusion of appropriate clinical outcome measures and analysis of adverse effects 
(including mortality) is recommended within this field of research. Therefore, 
following outcome measures are proposed: 
1) ‘Number of exacerbations’ and ‘days on antibiotic therapy’ during one year; as 
they are more responsive to change than ‘number of hospitalisations’. 
2) Combination of the CFCS and modified Shwachman score for assessing current 
health status and chronic disease progression. 
3) Preference of both the parents and child, aimed at improving adherence to 
treatment 
4) Lung function testing in children younger than five years of age could be 
applied, however, training on performance of this outcome measure prior to 
the study period is recommended. Spirometry results should not be obtained 
for children unable to perform good quality blows. 
5) The Pediatric Quality of Life Inventory might be a better tool to assess HRQOL, 
as it is valid and reliable in children from the age of five years, and might be 
more sensitive to small changes in chronic disorders. 
- Research towards an easy to administer, child-friendly HRQOL tool for children 
younger than the age of five years; which is sensitive for change in chronic 
conditions; is recommended. 
- The use of SpO2 as an outcome measure in a research study, which compares two 
groups, is not recommended. The outcome might not be reliable and is most likely 
insensitive to small changes. However, as stated in the clinical recommendations, it 
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is important to measure SpO2 during ACT to identify desaturation and halt 
treatment when necessary. 
- Research into treatment adherence and how to tackle the issue in participants with 
CF is recommended, due to the magnitude of adherence problems related to ACT in 
this population. Investigation into adherence monitoring tools such as sms, email 
and online messaging tools are recommended. 
Notwithstanding the limitations of the studies presented in this thesis, the results are 
novel, and will contribute to the global body of knowledge in improving our understanding 
of the utility of different ACTs in young children with acute or chronic pulmonary disease.  
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APPENDICES 
Appendix 1. EQ-5D-Y 
Describing your health TODAY 
Under each heading, please tick the ONE box that best describes your health TODAY 
Mobility (walking about) 
I have no problems walking about    
I have some problems walking about    
I have a lot of problems walking about    
Looking after myself 
I have no problems washing or dressing myself   
I have some problems washing or dressing myself  
I have a lot of problems washing or dressing myself  
Doing usual activities (for example, going to school, hobbies, sports, playing, doing things 
with family or friends) 
I have no problems doing my usual activities   
I have some problems doing my usual activities   
I have a lot of problems doing my usual activities  
Having pain or discomfort 
I have no pain or discomfort     
I have some pain or discomfort     
I have a lot of pain or discomfort    
Feeling worried, sad or unhappy 
I am not worried, sad or unhappy    
I am a bit worried, sad or unhappy    
I am very worried, sad or unhappy    
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How good is your health TODAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We would like to know how good or bad your health  
is TODAY. 
This line is numbered from 0 to 100. 
100 means the best health you can imagine. 
0 means the worst health you can imagine. 
Please mark with an X on the line to show how good or bad  
your health is TODAY. 
 
 
 
The best health 
you can imagine 
10 
0 
20 
30 
40 
50 
60 
80 
70 
90 
100 
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35 
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The worst health 
you can imagine 
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Appendix 2. PRISMA checklist for the systematic review on the use of ACTs in children with pneumonia 
Section/topic  # Checklist item  Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  P36 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
P V 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  P36 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
P36 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
P37 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
P37 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
P38 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  P38 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
P38 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
P38 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
P38 
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Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
P39 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  P40-41 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2
) for 
each meta-analysis.  
P41 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
P41 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
P42-43 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
P44-46 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  P47-50 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
P50-53 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
P 53-54 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
P 54-55 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  P56 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
P ii 
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Appendix 3. Search term used in the systematic review on the use of ACTs in children with pneumonia 
 
Intervention Population Disease 
chest physiotherapy child* pneumonia 
chest physical therapy infant* lung infection 
respiratory physiotherapy baby lower respiratory tract infection 
respiratory physical therapy babies chest infection 
airway clearance techniques toddler* Pulmonary infection 
airway clearance therapy paediatric*  
breathing therapy pediatric*  
 
Search terms between columns were combined with ‘AND’ 
Search terms within one column were combined with ‘OR’  
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Appendix 4. Data extraction form for the systematic reviews  
Name investigator: ………………………………. Date: ……………… 
Title: ……………………………………………………………………………. 
Author(s):  ……………………………………………………………………….. 
Source:  …………………………………………………………………………… 
Study design: 
1. Where the patients random assigned to the different groups? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
2. The person who recruited the patients did  not know in which group the patient is 
randomly assigned? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
3. Where patients blind to treatment? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
4. Where the clinicians blind to treatment? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
5. Where the investigators blind to treatment? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
6. Where the data-analysts blind to treatment? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
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7. Where the groups similar at start of the study? 
[   ]  Yes 
[   ]  No, but this is corrected during analysis 
[   ]  No, and no correction was done during analysis 
[   ]  No information available 
 
8. Is data available about follow-up? 
[   ]  Yes 
[   ]  No 
 
Is selective loss-to-follow-up excluded? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
9. Was intention-to-treat analysis performed on incomplete data? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
10. Which outcome measures are reported? 
[   ]  Primary 
[   ]  Primary and secondary 
[   ]  Non pre-specified outcome measures 
[   ]  Not enough information available 
 
11. Are all included patients analysed in the group they were randomly assigned to? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
 
12. Are the groups equally treated, except for treatment? 
[   ]  Yes 
[   ]  No 
[   ]  No information available 
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Participants: 
 
1. Condition: ……………………………………………………………………. 
 
2. Severity of symptoms: …………………………………………………………… 
 
3. Inclusion criteria: ………………………………………………………………… 
          ………………………………………………………………… 
          ………………………………………………………………... 
 
4. Exclusion criteria: …………………………………………………………………. 
          …………………………………………………………………. 
          ………………………………………………………………….. 
 
5. Comorbid conditions: ………………………………………………………………. 
               ………………………………………………………………... 
 
6. Setting: ……………………………………………………………………………….. 
 
 
 
  
  Intervention group Control group Total 
Number of subjects Male  
 
  
 Female    
 Total 
 
   
Age Mean 
 
   
 SD 
 
   
Number lost to follow-up     
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Intervention: 
 Intervention group Control group 
Treatment description 
 
 
 
 
  
Duration of treatment   
Frequency of treatment   
Intensity of treatment   
Compliance to treatment   
 
Results: 
DICHOTOMOUS OUTCOMES: 
Outcome: ………………………………………………………………………………. 
Follow-up:  ……….. weeks / months / years 
Group Outcome present Outcome absent Total 
Intervention    
Control    
 
Chance that event occurs in intervention group  
Chance that event occurs in control group  
Absolute risk reduction (ARR)  
Number needed to treat (NNT)  
Relative risk (RR)  
Relative risk reduction (RRR)  
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 CONTINUOUS OUTCOMES: 
 Outcome 1: …………………………………………………………………………….. 
 Follow-up:  ……….. weeks / months / years 
Group Mean (SD) baseline Mean (SD) discharge Range Number (n) 
Intervention     
Control     
Difference between groups: 
 
    
 
Difference within groups:     
95% CI 
Baseline: 
Discharge: 
  
 
  
 
Outcome 2: …………………………………………………………………………….. 
 Follow-up:  ……….. weeks / months / years 
Group Mean (SD) baseline Mean (SD) discharge  Range Number (n) 
Intervention     
Control     
Difference between 
groups: 
 
    
 
Difference within 
groups: 
    
95% CI 
Baseline: 
Discharge: 
  
 
  
 
 
 271 
 
Outcome 3: …………………………………………………………………………….. 
 Follow-up:  ……….. weeks / months / year 
Group Mean (SD) baseline Mean (SD) discharge Range Number (n) 
Intervention     
Control     
Difference between groups: 
 
    
 
Difference within groups:     
95% CI 
Baseline: 
Discharge: 
  
 
  
 
Outcome 4: …………………………………………………………………………….. 
 Follow-up:  ……….. weeks / months / years 
Group Mean (SD) baseline  Mean (SD) discharge Range Number (n) 
Intervention     
Control     
Difference between groups: 
 
    
 
Difference within groups:     
95% CI 
Baseline: 
Discharge: 
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Appendix 5. Data extraction form for the descriptive folder review 
A. General information 
1. Folder number    …………………………………… 
2. Date of birth    …../……/…….. 
3. Gender     M  F 
4. Gestational age?   …………………………………… 
5. HIV status:    Positive  Negative Exposed 
If positive, when diagnosed?  ………………………………….. 
If positive, since when HAART?  ………………………………….. 
6. History of TB:    Y  N 
If yes, when?    ………………………………….. 
7. Asthma:    Y  N 
If yes, since when medication:  …………………………………. 
Which medication?   …………………………………. 
8. Cystic fibrosis:    Y  N 
9. Chronic respiratory disease?  Y  N 
If yes, which disease?   …………………………………. 
10. Neuromuscular disorder:  Y  N 
Type?  
Muscular Peripheral Motor neuron Others 
Duchenne Charcot-Marie-
Tooth 
SMA I Myastenia 
gravis 
Becker Dejerine-Sottas SMA II ………………………. 
Congenital Freidreich’s ataxia SMA III ……………………….. 
Emery-Dreifuss  Spinal-bulbar muscular atrophy (Kennedy 
disease) 
………………………. 
Limb girdle   ……………………….. 
Myotonic 
(Steinerd) 
  ……………………….. 
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11. Cerebral palsy:    Y  N 
Type:    Spastic      Ataxic     Dystonic     Choreo-athetoid 
     Hemiplegia: R or  L    Diplegia Quadriplegia 
12. Heart disease:    Y  N 
If yes, which one?   ………………………………………. 
13. Osteoporosis:    Y  N 
14. History of Tx or abdominal surgery: Y  N When? ……. 
15. Chest deformities:   Excavatum Carinatum None 
16. Other comorbidities:   Y  N 
If yes, which ones?   ………………………………………… 
B. Information with regards to hospitalisation 
1. Date of admission:   ……………………………………….. 
2. Temperature at admission  ………….°C 
3. Respiratory rate at admission:  ……….bpm 
4. Heart rate at admission:  ……….bpm 
5. Blood pressure at admission:  ……/……. 
6. Oxygen saturation at admission: …………..% 
7. Signs of respiratory distress at admission: circle which are present 
Cyanosis Alar flaring Head bobbing  SCR    ICR    
Tracheal tug Feeding problem Weak cry 
8. Oxygen support at admission:  Y  N ……….l/min 
9. Ventilation required during admission: Y  N 
10. Type of ventilation:  CPAP BiPap IPPV HFOV SIMV PCV     ……. 
11. Days on ventilation:   …………………………………………… 
12. Date of discharge/death:  ……/……/………. 
13. Days of hospitalisation   …………………………………………… 
14. Mortality (circle):    alive   /    died 
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15. Organism of LRTI:   
Viral Bacterial Unknown 
RSV Staph. aureus  
Influenza Pseudomonas aureginosa  
Parainfluenza      Streptococcus pneumoniae  
Metapneumo Other Streptococcus  
Adeno PJP  
Boca Mycobacter tuberculosis  
Rhino    Bordetella pertussis  
Entero Other Gram +  
Parvo Other Gram-  
Human corona Klebsiella  
CMV   
 
C. Complications/adverse events during hospitalisation (Y = yes, N = no, N/A = info not 
available) 
1. Pneumothorax:    Y N N/A When? ……………… 
2. Increased intracranial pressure:  Y N N/A When? ……………… 
3. Pleural effusion:   Y N N/A When? ……………… 
4. Lung/lobe collapse?   Y N N/A When? ……………… 
Which lung/lobe?    ………………………………..………... 
5. Atelectasis?    Y N N/A When? ………………. 
D. Chest physiotherapy 
1. Was chest physiotherapy prescribed? Y N N/A When? …………… 
2. Reason?    ……………………………………………… 
3. Was chest physiotherapy given? Y N N/A 
4. When did treatment start?  …………………………………………….. 
5. How often was physio given?  Daily  Bidaily  >2x/d 
6. Techniques used? (M)PD Percussion/clapping Vibrations PEP 
   ACBT Oscillating PEP Bubble   PEP    AD     AAD 
Others/specify:    …………………………………………….. 
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E. Adverse events during or immediately post chest physiotherapy 
1. Desaturation during chest physiotherapy?    Y   N N/A SpO2: ……… % 
2. Pneumothorax:           Y   N N/A When? ……….. 
3. Increased intracranial pressure:         Y   N N/A When? ………… 
4. Pleural effusion:          Y   N N/A When?…………. 
5. Rib fracture:           Y   N N/A When?…………. 
Location?           …………………………… 
6. Lung/lobe collapse?          Y   N N/A When?………… 
Which lung/lobe?          ……….................... 
7. Atelectasis?           Y   N N/A When?………… 
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Appendix 6. Approval forms to conduct the descriptive folder review 
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Appendix 7. ICD-10 codes for identification of patients for the descriptive folder review 
(as found on http://www.health.gov.za/icddoc.php under section ICD-10_MIT_2014 Changes Add Delete Modify 
1 Jan 2014) 
 Chapter 
description 
Group 
code 
Group 
descripti
on 
ICD 
10_3 
code 
ICD 10 code 
description 
ICD 10 
code 
WHO 
description 
VIRAL 
PNEUMONIA 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J10 Influenza due to 
other identified 
influenza virus 
J10.0 Influenza with 
pneumonia, 
other influenza 
virus identified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J11 Influenza, virus not 
identified 
J11.0 Influenza with 
pneumonia, 
virus not 
identified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J12 Viral pneumonia, not 
elsewhere classified 
J12 Viral pneumonia, 
not elsewhere 
classified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J12 Viral pneumonia, not 
elsewhere classified 
J12.0 Adenoviral 
pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J12 Viral pneumonia, not 
elsewhere classified 
J12.1 Respiratory 
syncytial virus 
pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J12 Viral pneumonia, not 
elsewhere classified 
J12.2 Parainfluenza 
virus pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J12 Viral pneumonia, not 
elsewhere classified 
J12.3 Human 
metapneumovir
us pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J12 Viral pneumonia, not 
elsewhere classified 
J12.8 Other viral 
pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J12 Viral pneumonia, not 
elsewhere classified 
J12.9 Viral pneumonia, 
unspecified 
BACTERIAL 
PNEUMONIA 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J13 Pneumonia due to 
Streptococcus 
pneumoniae 
J13 Pneumonia due 
to Streptococcus 
pneumoniae 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J14 Pneumonia due to 
Haemophilus 
influenzae 
J14 Pneumonia due 
to Haemophilus 
influenzae 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15 Bacterial 
pneumonia, not 
elsewhere 
classified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.0 Pneumonia due 
to Klebsiella 
pneumoniae 
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Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.1 Pneumonia due 
to Pseudomonas 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.2 Pneumonia due 
to 
Staphylococcus 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.3 Pneumonia due 
to 
Streptococcus, 
Group B 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.4 Pneumonia due 
to other 
streptococci 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.5 Pneumonia due 
to Escherichia 
coli 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.6 Pneumonia due 
to other aerobic 
Gram-negative 
bacteria 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.7 Pneumonia due 
to Mycoplasma 
pneumoniae 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.8 Other bacterial 
pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J15 Bacterial pneumonia, 
not elsewhere 
classified 
J15.9 Bacterial 
pneumonia, 
unspecified 
PNEUMONIA 
OTHER 
AETIOLOGY 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J16 Pneumonia due to 
other infectious 
organisms, not 
elsewhere classified 
J16 Pneumonia due 
to other 
infectious 
organisms, not 
elsewhere 
classified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J16 Pneumonia due to 
other infectious 
organisms, not 
elsewhere classified 
J16.0 Chlamydial 
pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J16 Pneumonia due to 
other infectious 
organisms, not 
elsewhere classified 
J16.8 Pneumonia due 
to other 
specified 
infectious 
organisms Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J17 Pneumonia in 
diseases classified 
elsewhere 
J17 Pneumonia in 
diseases 
classified 
elsewhere 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J17 Pneumonia in 
diseases classified 
elsewhere 
J17.0 Pneumonia in 
bacterial 
diseases 
classified 
elsewhere Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J17 Pneumonia in 
diseases classified 
elsewhere 
J17.1 Pneumonia in 
viral diseases 
classified 
elsewhere 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J17 Pneumonia in 
diseases classified 
elsewhere 
J17.2 Pneumonia in 
mycoses 
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Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J17 Pneumonia in 
diseases classified 
elsewhere 
J17.3 Pneumonia in 
parasitic 
diseases 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J17 Pneumonia in 
diseases classified 
elsewhere 
J17.8 Pneumonia in 
other diseases 
classified 
elsewhere 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J18 Pneumonia, 
organism unspecified 
J18 Pneumonia, 
organism 
unspecified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J18 Pneumonia, 
organism unspecified 
J18.0 Bronchopneumo
nia, unspecified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J18 Pneumonia, 
organism unspecified 
J18.1 Lobar 
pneumonia, 
unspecified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J18 Pneumonia, 
organism unspecified 
J18.2 Hypostatic 
pneumonia, 
unspecified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J18 Pneumonia, 
organism unspecified 
J18.8 Other 
pneumonia, 
organism 
unspecified 
Diseases of the 
respiratory 
system (J00-J99) 
102 
(J09-
J18) 
Influenza 
and 
pneumon
ia 
J18 Pneumonia, 
organism unspecified 
J18.9 Pneumonia, 
unspecified 
BRONCHIOLITIS Diseases of the 
respiratory 
system (J00-J99) 
103 
(J20-
J22) 
Other 
acute 
lower 
respirato
ry 
infection
s 
J21 Acute bronchiolitis J21 Acute 
bronchiolitis 
Diseases of the 
respiratory 
system (J00-J99) 
103 
(J20-
J22) 
Other 
acute 
lower 
respirato
ry 
infection
s 
J21 Acute bronchiolitis J21.0 Acute 
bronchiolitis due 
to respiratory 
syncytial virus 
Diseases of the 
respiratory 
system (J00-J99) 
103 
(J20-
J22) 
Other 
acute 
lower 
respirato
ry 
infection
s 
J21 Acute bronchiolitis J21.1 Acute 
bronchiolitis due 
to human 
metapneumovir
us 
Diseases of the 
respiratory 
system (J00-J99) 
103 
(J20-
J22) 
Other 
acute 
lower 
respirato
ry 
infection
s 
J21 Acute bronchiolitis J21.8 Acute 
bronchiolitis due 
to other 
specified 
organisms 
Diseases of the 
respiratory 
system (J00-J99) 
103 
(J20-
J22) 
Other 
acute 
lower 
respirato
ry 
infection
s 
J21 Acute bronchiolitis J21.9 Acute 
bronchiolitis, 
unspecified 
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ACUTE LRTI  Diseases of the 
respiratory 
system (J00-J99) 
103 
(J20-
J22) 
Other 
acute 
lower 
respirato
ry 
infection
s 
J22 Unspecified acute 
lower respiratory 
infection 
J22 Unspecified 
acute lower 
respiratory 
infection 
RESPIRATORY 
DISTRESS AND 
PNEUMONIA IN 
NEWBORNS 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P22 Respiratory distress 
of newborn 
P22 Respiratory 
distress of 
newborn 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P22 Respiratory distress 
of newborn 
P22.0 Respiratory 
distress 
syndrome of 
newborn 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P22 Respiratory distress 
of newborn 
P22.1 Transient 
tachypnoea of 
newborn 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P22 Respiratory distress 
of newborn 
P22.8 Other 
respiratory 
distress of 
newborn 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P22 Respiratory distress 
of newborn 
P22.9 Respiratory 
distress of 
newborn, 
unspecified 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23 Congenital 
pneumonia 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.0 Congenital 
pneumonia due 
to viral agent 
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Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.1 Congenital 
pneumonia due 
to Chlamydia 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.2 Congenital 
pneumonia due 
to 
Staphylococcus 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.3 Congenital 
pneumonia due 
to 
Streptococcus, 
Group B 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.4 Congenital 
pneumonia due 
to Escherichia 
coli 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.5 Congenital 
pneumonia due 
to Pseudomonas 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
 
 
P23 Congenital 
pneumonia 
P23.6 Congenital 
pneumonia due 
to other 
bacterial agents 
Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.8 Congenital 
pneumonia due 
to other 
organisms 
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Certain conditions 
originating in the 
perinatal period 
(P00-P96) 
167 
(P20-
P29) 
Respirato
ry and 
cardiovas
cular 
disorders 
specific 
to the 
perinatal 
period 
P23 Congenital 
pneumonia 
P23.9 Congenital 
pneumonia, 
unspecified 
OTHERS Certain infectious 
and parasitic 
diseases (A00-
B99) 
011 
(B00-
B09) 
Viral 
infection
s 
character
ized by 
skin and 
mucous 
membra
ne 
lesions 
B01 Varicella 
[chickenpox] 
B01.2 Varicella 
pneumonia 
(J17.1*) 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
011 
(B00-
B09) 
Viral 
infection
s 
character
ized by 
skin and 
mucous 
membra
ne 
lesions 
B05 Measles B05.2 Measles 
complicated by 
pneumonia 
(J17.1*) 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
013 
(B20-
B24) 
Human 
immunod
eficiency 
virus 
[HIV] 
disease 
B20 Human 
immunodeficiency 
virus [HIV] disease 
resulting in 
infectious and 
parasitic diseases 
B20.6 HIV disease 
resulting in 
Pneumocystis 
jirovecii 
pneumonia 
Diseases of the 
respiratory 
system (J00-J99) 
108 
(J85-
J94) 
Suppurati
ve and 
necrotic 
condition
s of 
lower 
respirato
ry tract 
J85 Abscess of lung and 
mediastinum 
J85.1 Abscess of lung 
with pneumonia 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95 Streptococcus 
and 
staphylococcus 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.0 Streptococcus, 
group A, as the 
cause of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.1 Streptococcus, 
group B, as the 
cause of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.2 Streptococcus, 
group D, as the 
cause of diseases 
classified to 
other chapters 
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Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.3 Streptococcus 
pneumoniae as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.4 Other 
streptococcus as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.5 Unspecified 
streptococcus as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.6 Staphylococcus 
aureus as the 
cause of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
B95.7 Other 
staphylococcus 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B95 Streptococcus and 
staphylococcus as 
the cause of diseases 
classified to other 
chapters 
 
 
B95.8 Unspecified 
staphylococcus 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96 Other specified 
bacterial agents 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.0 Mycoplasma 
pneumoniae [M. 
pneumoniae] as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.1 Klebsiella 
pneumoniae [K. 
pneumoniae] as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.2 Escherichia coli 
[E. coli] as the 
cause of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.3 Haemophilus 
influenzae [H. 
influenzae] as 
the cause of 
diseases 
classified to 
other chapters 
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Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.4 Proteus 
(mirabilis)(morg
anii) as the cause 
of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.5 Pseudomonas 
(aeruginosa)as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
 
 
B96.6 Bacillus fragilis 
[B. fragilis] as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.7 Clostridium 
perfringens [C. 
perfringens] as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B96 Other specified 
bacterial agents as 
the cause of diseases 
classified to other 
chapters 
B96.8 Other specified 
bacterial agents 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97 Viral agents as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.0 Adenovirus as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.1 Enterovirus as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.2 Coronavirus as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.3 Retrovirus as the 
cause of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.4 Respiratory 
syncytial virus as 
the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.5 Reovirus as the 
cause of diseases 
classified to 
other chapters 
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Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
 
 
 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.6 Parvovirus as the 
cause of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.7 Papillomavirus 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B97 Viral agents as the 
cause of diseases 
classified to other 
chapters 
B97.8 Other viral 
agents as the 
cause of diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B98 Other specified 
infectious agents as 
the cause of disease 
classified to other 
chapters 
B98 Other specified 
infectious agents 
as the cause of 
disease classified 
to other 
chapters Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B98 Other specified 
infectious agents as 
the cause of disease 
classified to other 
chapters 
B98.0 Helicobacter 
pylori [H.pylori] 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
020 
(B95-
B98) 
Bacterial, 
viral and 
other 
infectiou
s agents 
B98 Other specified 
infectious agents as 
the cause of disease 
classified to other 
chapters 
B98.1 Vibrio vulnifucus 
as the cause of 
diseases 
classified to 
other chapters 
Certain infectious 
and parasitic 
diseases (A00-
B99) 
021 
(B99) 
Other 
infectiou
s 
diseases 
B99 Other infectious 
disease 
B99 Other infectious 
disease 
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Appendix 8. Comorbidities seen in children hospitalised with a LRTI 
1) Respiratory comorbidities 
Chronic respiratory comorbidities 
Chronic comorbidity N Percentage  
Asthma: proven 
                suspected  
49 
7 
4.1 
0.6 
Upper airway obstruction 27 2.2 
Chronic lung disease, not further specified 11 0.9 
Bronchiolitis obliterans 8 0.7 
Hyaline membrane disease 7 0.6 
Bronchiectasis 6 0.5 
CF 5 0.4 
Chronic obstructive pulmonary disease 4 0.3 
Obstructive sleep apnoea 4 0.3 
Recurrent LRTI 4 0.3 
Chronic respiratory failure, requiring nocturnal BiPap 3 0.2 
Chronic cough 2 0.2 
Pulmonary haemorrhage 2 0.2 
Colonised with Staph. Aureus 2 0.2 
Congenital lung disease 2 0.2 
Left sided empyema 1 0.1 
Atelectasis 1 0.1 
Elevated right hemidiaphragm 1 0.1 
Diffuse lung disease 1 0.1 
Colonised with MRSA 1 0.1 
Bronchopulmonary dysplasia 1 0.1 
Restrictive lung disease 1 0.1 
Destroyed right lung 1 0.1 
Total 151  
N= 1208 children, multiple comorbidities could be present in one child 
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Acute respiratory comorbidities 
Acute comorbidity N Percentage 
URTI 47 3.3 
Allergic rhinitis 16 1.1 
Apnoea 16 1.1 
Pertussis: proven 
                   suspected 
13 
2 
0.9 
0.1 
Bronchospasm 11 0.8 
Croup 2 0.1 
Aspiration 2 0.1 
Sinusitis 2 0.1 
Respiratory acidosis 1 0.1 
Respiratory arrest 1 0.1 
Pneumonitis 1 0.1 
Coryza 1 0.1 
Acute respiratory distress syndrome 1 0.1 
Compression bronchus intermedius 1 0.1 
Persistent left upper lobe collapse 1 0.1 
Pneumatocele 1 0.1 
Total 119  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
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2) Cardiovascular comorbidities 
Chronic cardiovascular comorbidities 
 Chronic comorbidity N Percentage 
Chronic cardiac  Patent ductus arteriosus: proven 
                                              suspected 
23 
1 
            1.9 
0.1 
Ventricular septal defect 22 1.8 
Atrioventricular septal defect 15 1.2 
Patent foramen ovale 8 0.7 
Cardiac failure 8 0.7 
Cardiomyopathy 4 0.3 
Atrial septal defect 4 0.3 
Tetralogy of Fallot 3 0.2 
Heart murmur  3 0.2 
Pulmonary hypertension 3 0.2 
Double outlet right ventricle 2 0.2 
Cor pulmonale 2 0.2 
Shone syndrome 1 0.1 
Dextrocardia 1 0.1 
Congenital cardiac block 1 0.1 
Cyanotic heart lesion 1 0.1 
Cardiomegaly 1 0.1 
Acyanotic heart lesion 1 0.1 
Barth syndrome 1 0.1 
Severe dilated left atrium and ventricle 1 0.1 
Right ventricular outflow tract problems  1 0.1 
Total 107  
Chronic valvar  
 
Pulmonary stenosis 5 0.4 
Mitral valve abnormalities/regurgitation 2 0.2 
Pulmonary atresia 2 0.2 
Bicuspid atrioventricular valve 1 0.1 
Atrioventricular valve regurgitation 1 0.1 
Total 11  
Chronic vascular  
 
Coarctation aorta 3 0.2 
Anomalous left coronary artery from the pulmonary artery 2 0.2 
Truncus arteriosus 1 0.1 
Interrupted inferior vena cava 1 0.1 
Transposition great arteries 1 0.1 
Lymphatic venous malformation 1 0.1 
Total 9  
Chronic blood disorders 
 
Sickle cell anaemia 3 0.2 
Microcystosis 2 0.2 
Acute lymphoblastic leukemia (acute or history)  2 0.2 
Acute non-lymphoblastic leukemia 1 0.1 
Idiopathic thrombocytopenic purpura 1 0.1 
Total 9  
Other chronic disorders 
 
Pulmonary hypertension 4 0.3 
Left isomerism 1 0.1 
Total 5  
Total  141  
N= 1208 children, multiple comorbidities could be present in one child 
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Acute cardiovascular comorbidities 
Acute cardiovascular problems N Percentage 
Anaemia 107 7.4 
Sepsis 72 5.0 
Pericardial effusion 6 0.4 
Deep venous thrombosis 3 0.2 
Hypotension 1 0.1 
Total 189  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
3) Neuromuscular disorders 
Chronic neuromuscular comorbidities 
 Chronic Comorbidity N Percentage 
Neuromuscular disorders  
 
SMA (I – II) 7  
(4 – 3) 
0.6 
Congenital myopathy 5 0.4 
Congenital muscular dystrophy 1 0.1 
Total 13  
Cerebral Palsy  Spastic  
(quadriplegic – unknown distribution) 
15  
(10 – 5) 
1.2 
Spastic dystonic quadriplegic 3 0.2 
Hypotonic 3 0.2 
Dystonic hypotonic (unknown distribution) 1 0.1 
Hemiplegic (left) 1 0.1 
Total 23  
Other chronic neurological condition  
 
Seizures/epilepsy 35 2.9 
Hydrocephalus 5 0.4 
Dandy walker malformation 4 0.3 
Intraventricular haemorrhage 4 0.3 
Hypoxic brain injury 3 0.2 
Hypoxic ischemic encephalopathy 3 0.2 
Traumatic brain injury 3 0.2 
HIV encephalopathy 3 0.2 
Microcephaly 2 0.2 
Agenesis corpus callosum  2 0.2 
Cortical blindness 2 0.2 
Leukencephalopathy 1 0.1 
Neurofibromatosis 1 0.1 
Othara syndrome 1 0.1 
Ataxia 1 0.1 
Hypotonia 1 0.1 
Chronic periventricular leukomalacia 1 0.1 
Colpocephaly 1 0.1 
Total 73  
Total  109  
N= 1208 children, multiple comorbidities could be present in one child 
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Acute neuromuscular comorbidities 
Acute neurological comorbidities N Percentage 
Meningitis 10 0.7 
Febrile seizures/seizures due to acute illness 5 0.3 
Change in tone due to acute illness 2 0.1 
Benign extra cranial hydrocephalus of infancy 1 0.1 
Guillain Barre Syndrome 1 0.1 
Occipital abscess 1 0.1 
Total 20  
N= 1440 hospitalisations, multiple comorbidities could be present in one hospitalisation 
 
4) Genetic disorders 
Comorbidity N Percentage 
Trisomy 21 19 1.6 
Cystinosis 1 0.1 
Goldernhar syndrome 1 0.1 
Klinefelter syndrome 1 0.1 
Wolf-Hirsschorn syndrome 1 0.1 
Prader-Willi syndrome 1 0.1 
Achondroplasia 1 0.1 
Barth syndrome 1 0.1 
Trisomy 13 1 0.1 
Neurofibromatosis 1 0.1 
Total 28  
N= 1208 children 
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5) Musculoskeletal comorbidities 
Chronic musculoskeletal comorbidities 
 Chronic comorbidity N Percentage 
Chronic skeletal comorbidities  
 
Scoliosis 11 0.9 
Pectus carinatum 3 0.2 
Pectus excavatum 3 0.2 
Kyphoscoliosis 3 0.2 
Polydactyly (n=1 digit removed as neonate) 2 0.2 
Spina bifida occulta 1 0.1 
Vertical talus 1 0.1 
Hemivertebra 1 0.1 
Narrowed craniocervical junction 1 0.1 
Congenital missing ribs 1 0.1 
Limb reduction, defect left forearm 1 0.1 
Valgus deformity knees 1 0.1 
Flattened chest, barrel shaped on left side 1 0.1 
Total 30  
Soft tissue/muscular comorbidities  Burns 5 0.4 
Muscle wasting 2 0.2 
Fixed flexion deformity right index finger 1 0.1 
Absent left pectoralis major 1 0.1 
Contractures 1 0.1 
Clubfoot 1 0.1 
Total 11  
Total  41  
N= 1208 children, multiple comorbidities could be present in one child 
Acute musculoskeletal comorbidities 
Acute comorbidities  N Percentage 
Rickets 4 0.3 
Femur fractures 3 0.2 
Hip dislocation 3 0.2 
Rib fractures 1 0.1 
Osteoporosis 1 0.1 
Staph. aureus septic arthritis left shoulder 1 0.1 
Total 13  
N= 1440 hospitalisations 
  
 293 
 
6) Gastrointestinal comorbidities 
Chronic gastrointestinal comorbidities 
Chronic comorbidity N Percentage 
Gastro-oesophageal reflux disorder 51 4.2 
Hepato(spleno)megaly 5 0.4 
Chronic gastroenteritis 2 0.2 
Pancreas insufficiency 2 0.2 
Short bowel syndrome 1 0.1 
Chronic liver rejection 1 0.1 
Central liver placement 1 0.1 
Total 63  
N= 1208 children, multiple comorbidities could be present in one child 
Acute comorbidities N Percentage 
Acute gastroenteritis 91 6.3 
Constipation 2 0.1 
Blood in stool 1 0.1 
Hepatitis 1 0.1 
Multiple bowel perforations 1 0.1 
Total 96  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
7) Ear, nose and throat (ENT) comorbidities 
Chronic ENT comorbidities 
Chronic comorbidities N Percentage 
Hearing impairment/loss/deafness 7 0.6 
Chronic otitis media 3 0.2 
Subglottic stenosis 2 0.2 
Vocal cord paresis 1 0.1 
Laryngomalacia 1 0.1 
Pinna malformation grade 1 1 0.1 
Peri-auricular tag 1 0.1 
Total 16  
N= 1208 children, multiple comorbidities could be present in one child 
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Acute ENT comorbidities 
Acute comorbidities N Percentage 
Otitis media 24 1.7 
Pharyngitis 8 0.6 
Enlarged adenoids/adenoidectomy 7 0.5 
Tonsillitis 6 0.4 
Tympanic membrane perforation 1 0.1 
Enlarged adenoids 1 0.1 
Otitis externa 1 0.1 
Total 48  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
8) Dermatological and facial comorbidities 
Chronic dermatological/facial comorbidities 
Chronic comorbidities N Percentage 
Eczema 33 2.7 
Cleft lip/palate 3 0.2 
Seborrhic dermatitis 2 0.2 
Chronic dermatitis 1 0.1 
Total 39  
N= 1208 children 
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Acute dermatological/facial comorbidities 
Acute comorbidities  N Percentage 
Dermatitis 18 1.3 
Candidiasis/fungal rash 11 0.8 
Scabies 8 0.6 
Erythema 3 0.2 
Varicella 3 0.2 
Tinea Capitis 3 0.2 
Undefined rash 2 0.1 
Urticaria 2 0.1 
Molluscum face 2 0.1 
Cellulitis 2 0.1 
Genital warts 1 0.1 
Axilliary abscess 1 0.1 
Syphillis 1 0.1 
Petechiae due to viral infection 1 0.1 
Vesicles on legs 1 0.1 
Post inflammation hyperpigmented macules  1 0.1 
Mongolian spots 1 0.1 
Measles 1 0.1 
Herpes gingiro-stomatitis 1 0.1 
Haemanglioma 1 0.1 
Occipital blisters 1 0.1 
Dermoid mass 1 0.1 
Pityriassis sicca alba  1 0.1 
Breast abscess 1 0.1 
Impetigo 1 0.1 
Rubella 1 0.1 
Total 70  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
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9) Nutritional and metabolic comorbidities 
Chronic nutritional/metabolic comorbidities 
Chronic comorbidity N Percentage 
Growth faltering/slow weight gain 10 0.8 
Overweight/obesity 9 0.7 
Malnutrition 6 0.5 
Food allergies 6 0.5 
Diabetes 4 0.3 
Metabolic acidosis 1 0.1 
Hyperparathyroidism 1 0.1 
Total 37  
N= 1208 children, multiple comorbidities could be present in one child 
Acute nutritional/metabolic comorbidities 
Acute comorbidity N Percentage 
Failure to thrive 151 10.5 
Hypothyroidism 10 0.7 
Total 161  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
 
10) Ophthalmological comorbidities 
Chronic ophthalmological comorbidities 
Chronic comorbidity N Percentage 
Strabismus 8 0.7 
Visual impairment/blind 4 0.3 
Cataract 3 0.2 
Ptosis 2 0.2 
Chronic dry eye 1 0.1 
Total 18  
N= 1208 children, multiple comorbidities could be present in one child 
Acute ophthalmological comorbidities 
Acute comorbidity N Percentage 
Conjunctivitis 18 1.3 
Eye discharge 2 0.1 
Retinal haemorrhages 1 0.1 
Total 21  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
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11) Urinary comorbidities 
Chronic urinary comorbidities 
Chronic comorbidity N Percentage 
End stage renal disease 2 0.2 
Dysplastic kidneys 2 0.2 
Vesilo-ureteric reflux 1 0.1 
Neuropathic bladder 1 0.1 
Total 6  
N= 1208 children 
Acute urinary comorbidities 
acute comorbidity N Percentage 
Urinary tract infection 3 0.2 
Hydronephrosis 2 0.1 
Renal cyst 1 0.1 
Nephrotic syndrome 1 0.1 
Total 7  
N= 1440 hospitalisations 
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12) Other comorbidities 
Chronic other comorbidities 
Chronic comorbidities N Percentage 
Developmental delay 45 3.7 
Neonatal jaundice 34 2.8 
Dysmorphism 14 1.2 
Maternal drug abuse during pregnancy or exposing the child to toxic drug fumes 10 0.8 
Umbilical hernia 5 0.4 
Allergies 3 0.2 
Lymphadenopathy 3 0.2 
Hypospadias 2 0.2 
Rapid plasma regain (RPR) exposed 2 0.2 
Lympho(histio)cystosis 2 0.2 
Asplenia 2 0.2 
Immunodeficiency 2 0.2 
Foetal alcohol syndrome 2 0.2 
Intellectually impaired 2 0.2 
Sexual assault 1 0.1 
Multi organ failure 1 0.1 
Autism spectrum disorder 1 0.1 
Mitochondrial disease 1 0.1 
Insomnia 1 0.1 
Anorectal malformation 1 0.1 
Speech delay 1 0.1 
Hypoalbuminaemia 1 0.1 
Sacral dimple 1 0.1 
Haemophagocytosis 1 0.1 
Cortes syndrome 1 0.1 
Vestibular anus 1 0.1 
Chylothorax 1 0.1 
Blind ending sacral sinus 1 0.1 
Total 142  
N= 1208 children, multiple comorbidities could be present in one child 
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Acute other comorbidities 
Acute comorbidities N Percentage 
Hyponatraemia  6 0.4 
Hypokalaemia 4 0.3 
Disseminated TB 3 0.2 
Inguinal hernia 2 0.1 
Dehydration 2 0.1 
Dental caries 2 0.1 
Undescended testes 2 0.1 
Electrolyte disturbance 2 0.1 
Hypophosphatemia 1 0.1 
Hypocalcaemia 1 0.1 
Hypoglycaemia 1 0.1 
Submandibular lymph nodes 1 0.1 
Headache 1 0.1 
Elevated auto-antibodies 1 0.1 
Ulcer tongue 1 0.1 
Disseminated cytomegalovirus 1 0.1 
Acute transaminitis 1 0.1 
Distended abdomen 1 0.1 
Cryptorchidism 1 0.1 
Oedematous legs 1 0.1 
Poisoning (salicylate and toxic levels ibuprofen/paracetamol) 1 0.1 
Total 36  
N= 1440 hospitalisations, multiple comorbidities could be present during one hospitalisation 
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Appendix 9. Data extraction forms used in the study on AAD in children hospitalised with pneumonia 
Recruitment form 
1) Name:     ……………………………………………….. 
 
2) Date of birth:    …../.…./…… 
 
3) Date of admission:   …../…../…… 
 
4) Age at admission:   ………………………………………………… 
 
5) Gender:    M F 
 
6) Prematurity:    Y N 
 
Gestational age?   ………………………………………………… 
 
7) Acute TB:    Y N 
 
If yes, since when medication?  ………………………………………………… 
Which medication?   ………………………………………………… 
 
8) History of TB:    Y N 
 
If yes, when?    ……………………………………………….. 
 
9) Previous episodes of lung disease: Y N 
 
If yes, when?    ………………………………………………… 
 
10) HIV-infected:    Y N 
 
If yes, when diagnosed?   ………………………………………………. 
If yes, since when HAART?  ………………………………………………. 
 
11) HIV-exposed:    Y N 
 
12) Asthma:    Y N 
If yes, since when medication:  ……………………………………………… 
Which medication?   ……………………………………………… 
 
13) Cystic fibrosis:    Y N 
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14) Other respiratory disease?  Y N 
If yes, which disease?   …………………………………………….. 
 
15) Neuromuscular disorder:  Y N 
If yes, which one?   ……………………………………………. 
 
16) Chest deformities:   Y N 
If yes, which one?   …………………………………………… 
 
17) Recent pneumothorax (≤3m):  Y N 
 
18) Thoracic or abdominal surgery:  Y N 
(≤6m) 
 
19) Severe heart disease?   Y N 
Type of heart disease?   ……………………………………………. 
 
20) Osteoporosis:    Y N 
Medical record baseline 
1) Increased intracranial pressure:  Y N 
 
2) Intercostal drain:   Y N 
 
3) Pleural effusion:   Y N 
 
4) Mechanical ventilation:   Y N 
Type of mechanical Ve?   ………………………………….. 
 
5) Previously on mechanical Ve?  Y N 
Type of mechanical Ve?   ………………………………. 
Days on mechanical Ve:   …………………days 
Hours on mechanical Ve:  …………………hours 
 
6) O2 supplement:  
on admission    Y N  l/min: …………. 
on recruitment    Y N      l/min:  …………. 
 
7) Oxygen saturation   Admission:……….%  Recruitment:……% 
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8) Distress/hypoxia:   Admission          Recruitment 
Oxygen saturation ≤ 90% on O2: Y N          Y         N 
Cyanosis:    Y N          Y         N 
Weak cry:    Y N          Y         N 
Feeding problems:   Y N          Y         N 
Head nodding:    Y N          Y            N 
Nasal flaring:    Y N          Y         N  
Muscle retraction in neck:  Y N          Y         N 
 
9) Respiratory rate at admission  ………breaths per minute ….. bpm 
 
10) Heart rate at admission:  ……….beats/min  …..bpm 
 
11) Blood pressure    normal  elevated  decreased 
Blood pressure    ………/……….. 
 
12) Mental status    normal  abnormal 
  
13) X-ray:     lobar diffuse 
 
14) Osteoporosis on X-ray:   Score? ……. 
 
15) Sputum/blood culture:   positive  negative 
 
16) Organism of infection:   ………………………………………….. 
  
17) Fever     Y N 
Temperature at admission:  ……………°C 
Temperature site   anal  axillar 
 
18) Lung function tests 
RV/TLC     ………………………………………….. 
VC     ………………………………………….. 
FVC     ………………………………………….. 
FEV1     ………………………………………….. 
PEF     ………………………………………….. 
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Physiotherapy form 
Pre-treatment (for every treatment! = for each AAD, emergency physio and standard physio 
treatment): 
1) Treatment date:   …./….../…….. 
 
2) Treatment hour:   …………………………………………. 
 
3) Respiratory rate:   ……breaths per minute 
 
4) Oxygen saturation   …………………………………………. 
 
5) Distress/hypoxia: 
Oxygen saturation ≤ 90% on O2: Y N 
Cyanosis:    Y N 
Weak cry:    Y N 
Feeding problems:   Y N 
Head nodding:    Y N 
Nasal flaring:    Y N 
Muscle retraction   Y N 
 
6) O2 supplement:   Y N         l/min? ............................ 
 
7) Palpation of secretions:   Y N 
Region (top, mid, base, left, right)? …………………………………………… 
 
8) Auscultation of secretions:  Y N 
Region (top, mid, base, left, right)? ………………….......................... 
 
9) Spontaneous cough:   Y N 
If yes, productive cough?  Y N 
 
10) Wheezing:    Y N 
 
Treatment: 
1) Emergency physio:   Y N Standard physio:   Y N 
If yes, which technique is used?  ……………………………………………. 
 
2) Duration of treatment:   ……………………………………………. 
Reason for stop?   ……………………………………………. 
 
3) Oxygen saturation   between (min)…………and (max)……………… 
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Post-treatment, immediately after: 
1) Respiratory rate:   ……breaths per min 
 
2) Oxygen saturation   ……………………% 
 
3) Distress/hypoxia: 
Oxygen saturation ≤ 90% on O2: Y N 
Cyanosis:    Y N 
Weak cry:    Y N 
Feeding problems:   Y N 
Head nodding:    Y N 
Nasal flaring:    Y N 
Muscle retraction   Y N 
 
4) O2 supplement:   Y N 
l/min?     ...................................................... 
 
5) Palpation of secretions:   Y N 
Region (top, mid, base, left, right)? ……………………………………………………. 
 
6) Auscultation of secretions:  Y N 
Region (top, mid, base, left, right)? …………………................................... 
 
7) Spontaneous cough:   Y N 
If yes, productive cough?  Y N 
 
8) Wheezing:    Y N 
 
Post-treatment, after 1h: 
1) Respiratory rate:   ……….breaths per minute 
 
2) Oxygen saturation:   ……………………% 
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Other physiotherapy treatment sessions: 
1) Reason for treatment:   ………………………………………… 
2) Type of treatment:   ………………………………………… 
3) Start date treatment:   …………………………………………. 
4) Frequency of treatment:  …………………………………………. 
5) Duration of treatment session:  ………………………………………… 
6) End date treatment:   ………………………………………… 
 
After 5 days 
1) Days of fever:    ……………….. 
 
2) Respiratory rate:   ……..breaths per minute 
 
3) Lung function tests 
RV/TLC     ……………………………………………. 
VC     ……………………………………………. 
FVC     …………………………………………... 
FEV1     …………………………………………… 
PEF     …………………………………………... 
 
4) Oxygen saturation   …………………….% 
 
5) Duration of O2 supplement  ……………………(hours) 
 
6) Atelectasis/collapse:   Y N 
If yes, when?    …………………………………………… 
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Discharge information Pneumonia 
1) Date of discharge:   ……/……/…….. 
 
2) Days of hospitalisation:    …………………………………….. 
 
3) Days of fever:    ……………………………………. 
 
4) Respiratory rate:   ……..breaths per minute 
 
5) Lung function tests 
RV/TLC     ……………………………………… 
VC     ……………………………………… 
FVC     ……………………………………… 
FEV1     ……………………………………… 
PEF     ……………………………………… 
 
6) Oxygen saturation   …………………….% 
 
7) Duration of O2 supplement  ……………………(hours) 
 
8) Atelectasis/collapse:   Y N 
If yes, when?    ………………………………………. 
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Appendix 10. Approval documents for the study on the use of AAD in children hospitalised with pneumonia 
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Appendix 11. Informed consent and assent forms used during the study on the use of AAD in children 
hospitalised with pneumonia 
Informed Consent Form for the parent(s)/guardian(s) of children between the ages of 0 
and 8 years with acute pneumonia, hospitalised in Red Cross Children’s hospital, Cape 
Town. 
This Informed Consent Form has two parts: 
 Part I: Information Sheet (to share information about the study with you) 
 Part II: Certificate of Consent (for signatures if you agree that your child may 
participate) 
You will be given a copy of the full Informed Consent Form. 
PART I: Information sheet 
I, Lieselotte Corten (PhD- student at the University of Cape Town), am doing research on 
different breathing techniques in children with lung disease. One of my research topics is 
the use of “Assisted Autogenic Drainage” in children hospitalised with acute pneumonia. 
What is the reason for the study and how will it be done? 
Pneumonia is a disease of the lungs which is usually treated by giving antibiotics and 
oxygen and/or suctioning of phlegm if necessary. Sometimes, physiotherapy is used to clear 
phlegm from the lungs to help the child breathe easier. A new physiotherapy technique, 
called Assisted Autogenic Drainage, may help children to breathe better and get the phlegm 
out of their lungs. This technique uses deepening of breathing to loosen up and remove the 
phlegm from the lungs. During the physiotherapy session, your child will be put on the 
physiotherapist’s lap while the therapist places his/her hands on the child’s chest and gives 
light pressure. We selected this technique because children do not have to actively help 
during the treatment and therefore it can be a useful tool for young children. The aim of 
this research is to test if using this technique can shorten the length of the hospital stay and 
resolve the pneumonia more quickly. We cannot assume that this technique will be 
effective in children with pneumonia unless we test it on children with this disease. We 
therefore invite your child to take part in this research because he/she has pneumonia and 
is less than 8 years old. 
What does the study mean for your child? 
The study will take place during the time your child is in the hospital. While your child is 
hospitalised in Red Cross War Memorial Children’s Hospital, he/she will receive standard 
care given by the nurses in the ward (this means he/she will get oxygen support, his/her 
position will be changed regularly and suction of phlegm will be done if necessary), or 
standard nursing care plus physiotherapy twice a day for 5 days, using Assisted Autogenic 
Drainage, for up to 10 to 30 minutes. As we do not know if the physiotherapy is better than 
the standard nursing care, we need to make a comparison. Children taking part in this 
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research will be put in one of the two groups by chance. This is like flipping a coin: e.g. with 
heads the child will be placed in group 1 and tails in group 2. Only the physiotherapist 
knows if your child will receive physiotherapy or not. All the other healthcare workers 
should not know which treatment your child is given. It is important not to tell the doctors 
which treatment your child is getting.  This is the best way to test treatments without being 
influenced by what we think or hope might happen. We will then compare which of the two 
treatments has the best results. You may stay with your child during the procedures. During 
your child’s hospital stay, we will do some tests to follow up your child’s disease status. 
Your child’s body temperature will be measured daily by the nurses. This is routine practice 
in the hospital. Also an X-ray of your child’s chest will be taken when he is admitted to 
hospital. This is again standard practice for children with pneumonia. We will use these X-
rays to make some observations. We will also count how many times your child breathes 
per minute (the physiotherapist or nurse will watch your child and count the number of 
breaths your child takes during one minute) and we will test the level of oxygen in your 
child’s body by putting a small device on your child’s finger or ear, which will than give a 
number that we will write down in your child’s file. These tests will be done at admission, 
after 5 days and at discharge from the hospital and before, during and after each treatment 
session. The test won’t take longer than five minutes. If your child is between 5 and 8 years 
of age, we will also conduct lung function tests. This means that your child will need to do 
some breathing exercises while breathing through a small tube into a machine, which gives 
us an idea of how well your child’s lungs are working. This test will be done at admission, 
after 5 days and at discharge. The test will take 15 minutes on average. None of the tests 
used in our research are painful for your child. These tests will be done on a regular basis as 
long as your child stays in the hospital.  
What are the possible benefits and/or risks to your child? 
It is unknown which risks/benefits are related to physiotherapy in children with bacterial 
pneumonia. We do not know which complications are associated with Assisted Autogenic 
Drainage, but the technique is adapted to the child’s tolerance. Physiotherapy can lead to 
some distress, but we will watch your child closely for any signs of distress. (We will look if 
your child his/her lips or nails become blue, if he/she is starting to have a weak cry, if 
he/she gets tired, if his/her head is starting to wobble, if your child is breathing with a 
widened nose or if we see that your child has overworked muscles in his/her neck) 
Suctioning may be necessary if the child cannot clear their phlegm by coughing alone. We 
will only use suctioning when it is really necessary, as this is uncomfortable and can damage 
the lungs or increase blood pressure.  
At the start and end of the study, your child may be asked to do a lung function test. Your 
child may experience some light-headedness or fatigue, but the test is not harmful. The 
other tests in this study are not harmful. 
We do not know the benefits of Assisted Autogenic Drainage, but Autogenic Drainage 
which is used in older children and adults works well in clearing the lungs. At the moment, 
we do not know if the children receiving physiotherapy will benefit from this treatment. 
Therefore, there are no direct benefits to participate in the study. 
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Voluntary participation 
Your decision to have your child participate in this study is entirely voluntary. It is your 
choice whether to have your child participate or not. If you choose not to consent, all the 
services you and your child receive will continue and nothing will change, except your child 
will definitely not receive Assisted Autogenic Drainage. You may also choose to change your 
mind later and stop participating, even if you agreed earlier. The services you and/or your 
child receive at the clinic will continue.  
Confidentiality 
The information that we collect from this research project will be kept confidential. Any 
information about your child will have a number on it instead of his/her name. Only the 
physiotherapists will know what information belongs to your child. Participation in this 
research does not involve extra costs for you. No compensations for travel costs will be 
given. 
Insurance 
If you took part in study procedures exactly as the investigator told you to and as a result 
you become ill or are injured as part of the research, you may need to receive medical 
treatment. If this happens, the costs of any reasonable and necessary medical treatment 
will be covered by insurance held by the University of Cape Town through its no fault 
insurance policy, which covers this study, provided you have followed the directions of the 
investigator and her staff. You are not giving up any of your legal rights by participating in 
this study. When you sign this form, you only indicate that your study investigator has 
informed you about this research study and that you agree to take part in it. 
Contact 
If you have any questions or worries after reading this form or at any other time during or 
after the study, please do not hesitate to contact us. You may contact the University of 
Cape Town Faculty of Health Sciences Human Ethics Committee (HREC) if you have any 
questions or concerns regarding your child’s rights or welfare as a research participant.  
Lieselotte Corten      Brenda Morrow 
071 588 37 29       021 658 5074 
crtlie001@myuct.ac.za            Brenda.Morrow@uct.ac.za   
Human Research Ethic Committee (HREC)  
Prof Marc Blockman, Chair   
Old Main Building, Groote Schuur Hospital    
021 406 6338  
Marc.Blockman@uct.ac.za 
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PART II: Certificate of consent 
If you consent, we ask you to sign this letter. 
I have read the above information, or it has been read to me. I have had the opportunity to 
ask questions about it and any questions that I have asked have been answered to my 
satisfaction. I consent voluntarily for my child to participate as a participant in this study. 
Print Name of Participant__________________ 
Print Name of Parent or Guardian_______________      
Signature of Parent or Guardian ___________________ 
Date ___________________________  
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Assent form for children older than 5 years of age, hospitalised with bacterial pneumonia. 
PART I: information sheet 
My name is Lieselotte Corten and I am studying at the University of Cape Town. I am doing 
an investigation into the use of physiotherapy in children with who are hospitalised with 
pneumonia (a lung infection). 
I am trying to find out more about the use of physiotherapy compared to only the care that 
nurses give to you. You are being asked to join this study because you have pneumonia and 
because you are younger than 8 years of age. The study will take place during the time you 
are in the hospital. You can be put in the group of children who only receive the care from 
the nurses, or you can be put in the group of children who will get physiotherapy. We don’t 
know yet in which group you will be placed in. 
But if you decide you want to be in this study, this is what will happen: 
If you are in the group that will only get the care from the nurses, the nurses can give you 
oxygen so you will be able to breathe better and they will change your position (side lying 
on the left or the right or sitting upright). It is also possible that they will need to help you 
with getting the phlegm out of your lungs, this they will do with a small tube which they put 
in your mouth. This is not pleasant and we will only do that when you need it. 
If you are in the group that also gets physiotherapy, you will get the same care by the 
nurses as described above and you will also get 5 days of physiotherapy by a 
physiotherapist. The physiotherapist will come twice a day, once in the morning and once 
in the afternoon or evening to give the therapy. During this therapy, you will be sitting on 
his/her lap. The physiotherapist will place his/her hands on your chest and will give some 
pressure. This does not hurt but it is necessary to perform the treatment correct. You don’t 
have to do anything. The physiotherapist does everything for you. So he/she will give some 
pressure so you will not be able to take a deep breath. The physiotherapist will do this until 
he/she feels or hears your phlegm. If he/she hears or feels them, the physiotherapist will 
hold the pressure on your chest until the phlegm is gone. Then he/she will let go the 
pressure a little bit until he/she feels or hears the phlegm again. Then he/she will hold the 
pressure again until the phlegm is gone. This is repeated three times. Eventually the 
physiotherapist is going to let go of your chest so you can take a deep breath and maybe 
cough the phlegm out. The physiotherapist is going to repeat this a few times, for about 10 
to 30 minutes. 
We will also have to do some tests on you. The nurses will take your temperature every 
day. They will use a thermometer and they will put it under your arm or sometimes we 
need to put it in your bottom.  Also an X-ray of your chest will be taken when you enter the 
hospital. This is done to all children with pneumonia. We will use these X-rays to make 
some observations We will also have to measure the oxygen in your body, this we do by 
placing a small device on your finger or ear. This little device will show us a number which 
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we will write down in your file. And we will also count how many times per minute you 
breathe. For this test you don’t have to do anything, you probably won’t even know the 
nurse or physiotherapist is counting how many times you breath per minute. These tests 
will be done when you are admitted to the hospital, and then before, during and after each 
physiotherapy treatment and again after 5 days in the hospital and before you go home. 
These tests will not take more than 5 minutes. And you will also have to do some lung tests, 
this means you have to blow in a small tube, which is linked with a machine that shows us 
different numbers which tells us about how well your lungs are working. This test is only 
done when you enter and when you leave the hospital. The test will take about 30 minutes. 
All these tests are not painful; they can be a bit unpleasant. All these test will be repeated 
regularly while you are in the hospital. 
Can something bad happen to me? 
We want to tell you about some things that might hurt or upset you if you are in the study.  
We don’t know yet what bad things can happen during the physiotherapy that you will get, 
but you can get some blue lips or nails and find it difficult to breathe. The physiotherapist is 
going to watch you really closely so he/she can immediately stop the therapy if something 
like that happens. And you can always tell him/her if you don’t feel good. Also the 
suctioning of the phlegm, what the nurses do, can be uncomfortable but it will only be 
done when it is really needed.  
You will need to do a lung function test at the start and the end of the study. You may feel a 
bit light in your head or a bit tired, but the test will not do anything bad to you. 
Can anything good happen to me? 
We don’t know if being in this research study will help you feel better or get well.  But we 
hope to learn something that will help other people someday. 
Do I have other choices?  
You can choose not to be in this study 
Will anyone know I am in the study?  
We won’t tell anyone you took part in this study. When we are done with the study, we will 
write a report about what we found out.  We won’t use your name in the report. The only 
person who knows you are in the study is the physiotherapist. 
What if I don’t want to be in the study? 
If you don’t want to be in this study, we will tell you about the other things we can do for 
you.  Even if you decide not to be in this study, we will still take care of you. 
You don’t have to be in this study.  It’s up to you.  If you say yes now, but you change your 
mind later, that’s okay too.  All you have to do is tell us. 
Who can I ask questions about the study? 
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You can always ask questions or tell us about your worries. 
The persons you can contact about this are: 
Lieselotte Corten      Brenda Morrow 
071 588 3729       021 658 5074 
crtlie001@myuct.ac.za       Brenda.Morrow@uct.ac.za 
 
PART II: certificate of assent  
If you want to be in this study, please sign or print your name.  
   Yes, I will be in this research study.     No, I don’t want to do this. 
 
__________________________            ___________________ ____________ 
Child’s name                      signature of the child  Date 
 
__________________________            ___________________ ____________ 
Person obtaining Assent      signature    Date 
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Appendix 12. PRISMA checklist for the systematic review on AD and AAD in children with CF 
Section/topic  # Checklist item  Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  P 141 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, 
and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
P VI 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  P 141 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
P 141 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
P 141 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
P 142 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
P 143 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  P 143 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the 
meta-analysis).  
P 143 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining 
and confirming data from investigators.  
P 144 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
P 143 
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Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
P 144-145 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  P 145 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2
) for 
each meta-analysis.  
P 146 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
P 146 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
P 147-148 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
P 147 +149-
152 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  P 152-158 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
P 158-165 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups 
(e.g., healthcare providers, users, and policy makers).  
P 166-167 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
P 167-168 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  P 168-169 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
P ii 
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Appendix 13. Search terms for the systematic review on AD and AAD in children with CF 
Intervention Control Population Condition 
autogenic drainage chest physiotherapy Child* cystic fibrosis 
assisted autogenic drainage chest physical therapy infant* CF 
passive autogenic drainage respiratory physiotherapy baby mucoviscidosis 
AD  respiratory physical therapy babies  
AAD airway clearance techniques toddler*  
 airway clearance therapy paediatric*  
 breathing therapy pediatric*  
 conventional physiotherapy   
 conventional airway clearance therapy   
 conventional airway clearance technique   
 postural drainage   
 modified postural drainage   
 percussions   
 clapping   
 vibrations   
 chest wall shaking   
 coughing   
 active cycle of breathing technique OR ACBT   
 Forced expiratory therapy OR FET   
 Positive expiratory pressure therapy OR PEP   
 Oscillating PEP   
 High pressure PEP   
 Rib cage compressions   
 Thoracic squeezing   
 Flutter   
 Acapella   
 Intrapulmonary vibrations OR IPV   
 Quake   
Search terms between columns were combined with ‘AND’ 
Search terms within one column were combined with ‘OR’ 
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Appendix 14. Interview guideline for preference and adherence 
 
1) Which technique(s) did you use during the study to ‘clear your lungs’? 
 AAD (the new technique) 
 Flutter (device with ball that vibrates when breathing/blowing in the 
device) 
 Percussions (clapping on the chest and back by parent) 
 Vibrations 
 Active cycle of breathing (deep breathing exercises without a device) 
 Active play 
 Other: ………………………………………………………………… 
 
2) How often did you do this treatment per day? If not daily, how often did you do it 
per week? When more than 1 technique was used, please specify per technique 
how frequently it was used. 
 
 
 
 
 
3) How much time did you spend on 1 treatment session (specify per technique if 
possible)? 
 
 
 
 
 
4) What did you like about the technique (for each technique separately)? 
 
 
 
 
5) What did you dislike about the technique (for each technique separately)? 
 
 
 
 
 
6) What is the reason you were unable to perform the treatment twice a day? 
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Appendix 15. Approval documents for the study on the use of AAD in children with CF 
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Appendix 16. Informed consent and assent forms for the study on AAD in children with CF 
Informed Consent Form for the parent(s)/guardian(s) of children between the ages of 0 
and 8 years with cystic fibrosis, receiving a home-program and being followed up in Red 
Cross Children’s hospital, Cape Town. 
This Informed Consent Form has two parts: 
 Part I: Information Sheet (to share information about the study with you) 
 Part II: Certificate of Consent (for signatures if you agree that your child may 
participate) 
You will be given a copy of the full Informed Consent Form 
PART I: Information sheet 
I, Lieselotte Corten (PhD- student at the University of Cape Town) am doing research within 
breathing techniques in children with different diseases. One of my research topics is the 
use of “Assisted Autogenic Drainage” in children receiving a home-program for cystic 
fibrosis. 
What is the reason for the study and how will it be done? 
Cystic fibrosis is a disease that affects the whole body, and therefore also the lungs. 
Physiotherapy is part of the treatment for this disease. The current physiotherapy 
treatment consists of positioning, percussion (clapping) and breathing exercises. There is a 
new chest physiotherapy technique developed, Assisted Autogenic Drainage, which uses 
deepening of breathing to loosen up and evacuate the phlegm from the lungs. We selected 
this technique as children do not have to actively help during the treatment and therefore 
it might be a useful tool in young children. The aim of this research is to test this new 
technique to see if it helps the children better than the current therapy. We selected this 
technique because children do not have to actively help during the treatment and therefore 
it can be a useful tool for young children. We cannot assume that this technique will be 
effective in young children with cystic fibrosis unless we test it on this disease. We invite 
your child to take part in this research because he/she has cystic fibrosis and is less than 8 
years old. 
What does the study mean for your child? 
The children participating in this research will receive a home-program consisting of chest 
physiotherapy twice a day (performed by you), either the standard physiotherapy or the 
new treatment for 10 to 30 minutes, depending on the physician’s and physiotherapist’s 
decision and how your child responds. As we do not know if the new treatment is better 
than the standard treatment we need to make a comparison. Children taking part in this 
research will be put in one of the two groups by chance. This is like flipping a coin, with 
heads is the child participating in group 1 and tails in group 2. Only the physiotherapist 
knows which treatment is given during this home-program. It is important not to tell the 
doctors which treatment your child is getting.  This is the best way to test treatments 
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without being influenced by what we think or hope might happen. We will then compare 
which of the two treatments has the best results.  
We will collect some information of your child during one year, like how many times they 
need to be hospitalised or how many days they need antibiotics. We will collect this 
information from your child’s medical file. We will also ask you (and your child) to fill in a 
questionnaire concerning your child’s well-being at the beginning and end of the study 
period. You will have to mark which answer best describes your child’s health at that time. 
This questionnaire will take about 10 minutes to complete. We will also do a test to see 
how your child’s development is going. This test is not painful, it is a test where the child 
can do some playing activities and we will observe how he/she is performing these tasks. 
This test can take up to 30 minutes. Also your child’s height and weight will be measured 
every time you come to the clinic. Once a year a chest X-rays is taken, this is standard 
practice for managing children with CF. We will use these X-rays to look for changes. Also, if 
your child is older than five years of age, lung function tests are done annually, as part of 
the standard practice. This means that your child will be asked to do some breathing 
exercises while breathing through a small tube into a machine, which gives us an idea of 
how well your child’s lungs are working. Again we will use these results to look for 
differences. If your child is in the group receiving assisted autogenic drainage, we will also 
ask you to fill in an extra questionnaire on which treatment you preferred. We will ask you 
to fill in this questionnaire during the first follow-up visit and at the end of the study, and 
will not take more than 5 minutes. Again you are asked to indicate which answer suits you 
the best. 
During the first CF-clinic, you will be asked to spend about two hours more in hospital, 
because we need to get some more information about your child, we will have to do the 
test for your child’s development. We will try and do most of this while you are waiting to 
see the doctor. During this test, you can fill in the questionnaire we ask you to fill in. You 
will also be taught the treatment that needs to be given to your child and we will explain 
how to fill in the diary. The following visits won’t take much more time than usually. The 
last visit during the study period will again take more time, about 40 minutes, because we 
need again to test your child’s development and you will be asked again to fill in the 
different questionnaires. 
What does this study mean for you? 
As parent or legal guardian of your child, you will be asked to perform the chest 
physiotherapy at home, twice a day and fill in a diary on these treatments. We will teach 
you how to do the treatments by showing you an animated video to explain what cystic 
fibrosis is and why physiotherapy is important in this disease. Afterwards the 
physiotherapist will explain the treatment to you, he/she will demonstrate how to perform 
the treatment and then you will do it together with the physiotherapist. You can ask 
questions at any time. We will assess if you perform the technique correctly by asking you 
to show us how to do the technique on your child. We will not give feedback at the time 
you are performing the technique. Every time your child comes to the CF-clinic, you will be 
asked to perform the technique, to make sure it is executed as it should. This is not to 
criticise you, but to make sure that we receive the best results for our study and that your 
child receives the best treatment at home. 
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What are the possible benefits and/or risks to your child? 
It is unknown which risks/benefits are related to different chest physiotherapy techniques 
in children with cystic fibrosis. Conventional chest physiotherapy has been shown to 
improve lung function in children with cystic fibrosis if continued for a long period of time. 
Risks of postural drainage and percussion (standard chest physiotherapy) are a decrease in 
oxygen levels in the blood (your child can have dizziness), discomfort/pain and/or gastro-
oesophageal reflux, which means that your child may be nauseous or vomit. We will try to 
limit these risks by giving clear instructions on what you need to pay attention for during 
your treatment: is your child getting tired, does his/her lips or nails become blue, is he/she 
starting to get a weak cry, is his/her head starting to wobble, is he/she breathing with a 
widened nose or do you see the muscles in his/her neck retract. We do not know which 
complications are associated with Assisted Autogenic Drainage, but the technique is 
adapted to the child’s tolerance. The tests used in this study are not harmful in any way. 
We do not know the benefits of Assisted Autogenic Drainage, but Autogenic Drainage 
which is used in older children and adults works well in clearing the lungs. We do not know 
if the children who receive the new technique will have more benefits than the children 
who receive the standard chest physiotherapy. Therefore, there are no direct benefits to 
participate in the study. 
Voluntary participation 
Your decision to have your child participate in this study is entirely voluntary. It is your 
choice whether to have your child participate or not. If you choose not to consent, all the 
services you and your child receive at this clinic will continue and nothing will change, 
except your child will definitely not receive Assisted Autogenic Drainage. You may also 
choose to change your mind later and stop participating, even if you agreed earlier. The 
services you and/or your child receive at the clinic will continue as before. 
Confidentiality 
The information that we collect from this research project will be kept confidential. Any 
information about your child will have a number on it instead of his/her name. Only the 
physiotherapist will know what information belongs to your child. Participation in this 
research does not involve extra costs for you. No compensations for travel costs will be 
given. 
Insurance 
If you took part in study procedures exactly as the investigator told you to and as a result 
you become ill or are injured as part of the research, you may need to receive medical 
treatment. If this happens, the costs of any reasonable and necessary medical treatment 
will be covered by insurance held by the University of Cape Town through its no fault 
insurance policy, which covers this study, provided you have followed the directions of the 
investigator and her staff. You are not giving up any of your legal rights by participating in 
this study. When you sign this form, you only indicate that your study investigator has 
informed you about this research study and that you agree to take part in it. 
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Contact 
If you have any questions or worries after reading this form or at any other time during or 
after the study, please do not hesitate to contact us. You may contact the University of 
Cape Town Faculty of Health Sciences Human Research Ethics Committee (HREC) if you 
have any questions or concerns regarding your child’s rights or welfare as research 
participants. 
Lieselotte Corten      Brenda Morrow   
071 588 3729       021 658 5074 
crtlie001@myuct.ac.za    Brenda.Morrow@uct.ac.za   
Human Research Ethic Committee (HREC)  
Prof Marc Blockman, Chair   
Old Main Building, Groote Schuur Hospital    
021 406 6338  
Marc.Blockman@uct.ac.za 
 
PART II: Certificate of consent 
If you consent, we ask you to sign this letter. 
I have read the above information, or it has been read to me. I have had the opportunity to 
ask questions about it and any questions that I have asked have been answered to my 
satisfaction. I consent voluntarily for my child to participate as a participant in this study. 
Print Name of Participant__________________ 
Print Name of Parent or Guardian_______________      
Signature of Parent or Guardian ___________________ 
Date ___________________________  
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Assent form for children older than 5 years of age with cystic fibrosis. 
PART I: Information sheet 
My name is Lieselotte Corten and I am studying at the University of Cape Town. I am doing 
an investigation into the use of physiotherapy in children with cystic fibrosis. 
I am trying to find out more about the use of a new physiotherapy technique compared to 
the physiotherapy techniques you use now. You are being asked to join this study because 
you have cystic fibrosis and because you are younger than 8 years of age. You can be put in 
the group of children who keep using the physiotherapy you already use, or you can be put 
in the group of children who will get the new physiotherapy treatment. We don’t know yet 
in which group you will be placed in. 
But if you decide you want to be in this study, this is what will happen: 
Your mum or dad is going to give you physiotherapy twice a day, once in the morning and 
once in the afternoon or evening. The therapy will not take more than 30 minutes. We will 
follow you up during one year. 
If you are in the group that keeps doing the physiotherapy you already do, not much will 
change. We will teach your mum or dad how to do the physiotherapy with you. We will 
teach them in which position you need to be to do the therapy and how you need to 
breathe. Maybe they also need to tap you on the chest during the techniques. Sometimes 
we also give you a small device, called PEP-device of Flutter, through which you need to 
breathe. 
If you are in the group that gets the new physiotherapy treatment, you will sit in front of 
your mum or dad and your mum or dad will place his/her hands on your chest and will give 
some pressure. This does not hurt but it is necessary to perform the treatment correct. You 
don’t have to do anything. Your mum or dad will have to do everything. So he/she will give 
some pressure so you will not be able to take a deep breath. He/she will do this until 
he/she feels or hears you phlegm. If he/she hears or feels them, your mum or dad will hold 
the pressure on your chest until the phlegm is gone. Then he/she will let go the pressure a 
little bit until he/she feels or hears the phlegm again. Then he/she will hold the pressure 
again until the phlegm is gone. This is repeated three times. Eventually your mum or dad is 
going to let go of your chest so you can take a deep breath and maybe cough the phlegm 
out. Your mum or dad is going to repeat this a few times. 
We will also have to do get some information from you and your parents. We will see how 
many times you will be in hospital this year and how many times you need medicine. This 
information we will get from your doctor’s file. You and your mum or dad need to fill in a 
questionnaire about how you feel at the start of the study and at the end. This 
questionnaire will only take about 10 minutes to fill in. You need to point out which 
sentence you and your mum find the best to explain how you feel. We will also test how 
 328 
 
well you are developing, you will play some games for about 30 minutes and we are going 
to watch how you do this. Every year an X-ray is taken, this is normal in children with CF. 
We will look at these X-rays to see if we can find some changes. Every year you also need to 
do a lung test, this means you have to blow in a small tube, which is linked with a machine 
that shows us different numbers which tells us about how well your lungs are working. We 
will use these numbers to look for differences.  And finally we will also measure your height 
and weight every time you come to the CF-clinic. If you have been getting the new 
technique, we will also ask you and your parents to fill in an extra questionnaire on which 
treatment you like the most. This questionnaire will only take 5 minutes and again you 
need to point out which sentence explains the best how you feel. 
Can something bad happen to me? 
We want to tell you about some things that might hurt or upset you if you are in the study.  
If you get the standard physiotherapy, the therapy you are currently getting, it is possible 
that you feel nausea or maybe you have to vomit. The oxygen level in your body can go 
down so you may feel a bit dizzy or it can hurt you a bit. We don’t know yet what bad things 
can happen during the new physiotherapy technique, but you can get some blue lips or 
nails or find breathing more difficult. We are going to teach your parents how to see these 
things so they can immediately stop the therapy if something like that happens. And you 
can always tell him/her if you don’t feel good.  The tests we will do, will not do anything 
bad to you. 
Can anything good happen to me? 
We don’t know if being in this research study will help you feel better or get well.  But we 
hope to learn something that will help other people someday. 
Do I have other choices?  
You can choose not to be in this study 
Will anyone know I am in the study?  
We won’t tell anyone you took part in this study. When we are done with the study, we will 
write a report about what we found out.  We won’t use your name in the report. The only 
person who knows you are in the study is the physiotherapist. 
What if I don’t want to be in the study? 
If you don’t want to be in this study, we will tell you about the other things we can do for 
you.  Even if you decide not to be in this study, we will still take care of you. 
You don’t have to be in this study.  It’s up to you.  If you say yes now, but you change your 
mind later, that’s okay too.  All you have to do is tell us. 
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Who can I ask questions about the study? 
You can always ask questions or tell us about your worries. 
The persons you can contact about this are: 
Lieselotte Corten      Brenda Morrow   
071 588 3729       021 658 5074 
crtlie001@myuct.ac.za    Brenda.Morrow@uct.ac.za 
 
PART II: certificate of assent 
If you want to be in this study, please sign or print your name.  
   Yes, I will be in this research study.     No, I don’t want to do this. 
__________________________            ___________________ ____________ 
Child’s name                       signature of the child  Date 
__________________________            ___________________ ____________ 
Person obtaining Assent      signature   Date 
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Appendix 17. Data collection forms for the study on AAD in children with CF 
Recruitment form CF: Subjective assessment 
1) Name:     ……………………………………………….. 
 
2) Date of birth:    …../.…./…… 
 
3) Date of recruitment:   …../…../…… 
 
4) Age at recruitment:   ……………. 
 
5) Gender:    M F 
 
6) Age at diagnosis:   …………… 
Age started physio:   …………… 
 
7) Prematurity:    Y N 
Gestational age?   …………….. 
 
8) Acute TB:    Y N 
If yes, since when medication?  ……………. 
Which medication?   …………………………………… 
 
9) History of TB:    Y N 
If yes, when?    ……………… 
 
10) HIV-infected:    Y N 
If yes, when diagnosed?   ………………. 
If yes, since when HAART?  ………………. 
 
11) HIV-exposed:    Y N 
 
12) Asthma:    Y N 
If yes, since when medication:  ……………………….. 
Which medication?   ……………………….. 
 
13) On lung/heart transplant list:  Y N 
 
14) Neuromuscular disorder:  Y N 
Type of NMD?    …………………………………………. 
 
15) Severe kyphosis:   Y N 
Severe scoliosis:   Y N 
Other chest deformity?   Y N Which one? …………………… 
 
16) Recent pneumothorax (≤3m):  Y N 
 
17) Thoracic or abdominal surgery:  Y N 
(≤6m) 
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18) Osteoporosis:    Y N 
 
19) Ephysema:    Y N 
 
20) Active sarcoidosis:   Y N 
 
21) Developmental delay:   Y N 
If yes,IQ/developmental age?  ………………………….. 
 
22) Pancreas:    sufficient insufficient 
Medical record at commencement of the study CF 
1) Genotype    ……………………. 
 
2) X-ray score:    ……………………. 
 
3) Colonised with:    
 Pseudomonas aeruginosa 
 Staphylococcus aureus 
 MRSA 
 Haemophilus influenza 
 RSV 
 Adenoviruses 
 Viral influenzae 
 Aspergillosis 
 Other: ……………………………………….. 
 Nothing 
 
4) First isolation:    ………………………………….. 
 
5) Medication: 
 Eradication regimen 
 Chronic inhaled gentamicin 
 Chronic inhaled colistin 
 Azimothrycin 
 Others: …………………………………… 
 None 
 
6) Osteoporosis on X-ray:  Y N   Score? ……. 
 
7) EQ-5D-Y score:    ……………………………………. 
 
8) Neurodevelopmental test:  PDMS-2 Mov. ABC 
score:     ……………………………………… 
 
9) Weight:    …………………. 
 
10) Height:     ………………….. 
 
 332 
 
11) Weight for height ratio:   ………………….. 
 
Medical record at the end of the study CF 
1) X-ray score:    …………………………………….. 
 
2) During study period, infected with or colonised with:    
 Pseudomonas aeruginosa 
 Staphylococcus aureus 
 MRSA 
 Haemophilus influenza 
 RSV 
 Adenoviruses 
 Viral influenzae 
 Aspergillosis 
 Other: ……………………………………….. 
 Nothing 
 
3) First isolation:    …………………………………… 
 
4) Medication: 
 Eradication regimen 
 Chronic inhaled gentamicin 
 Chronic inhaled colistin 
 Azimothrycin 
 Others: …………………………………… 
 None  
 
5) EQ-5D-Y score:    ……………………………………. 
 
6) MABC/PDMS score:   ……………………………………… 
 
7) Number of hospitalisations  ………………………………………. 
Days of hospitalisations   …………………………………….. 
 
8) Number of exacerbations  …………………………………… 
Days of antibiotic usage   …………………………………… 
 
9) Weight:    …………………. 
 
10) Height:     ………………….. 
 
11) BMI-for age z-score:   ………………….. 
 
